: The AMEDEO Literature Guide

Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Bladder Cancer, January 2026
Free Subscription

Abstracts
Retrieve all available abstracts of the following 2245 articles:
HTML format

Single Articles

YANG CY, Ho SC, Chiu YW, Weng YH, et al
Risk of death from bladder cancer in relation to long-term exposure to fine particulate air pollution in Taiwan.
J Toxicol Environ Health A. 2026 Jan 2:1-10. doi: 10.1080/15287394.2025.2611423.
Abstract

YAMAMOTO H, Oura S
Possible Differentiation Between Recurrent Lymph Nodes of Bladder Cancer and Malignant Lymphoma on Ultrasound: A Case Report.
Cureus. 2025;17:e98260.
Abstract

SIKDER RK, Ellithi M, Uzzo RN, Weader DJ, et al
Editor's Note: Differential Effects of Clinically Relevant N- versus C-Terminal Truncating CDKN1A Mutations on Cisplatin Sensitivity in Bladder Cancer.
Mol Cancer Res. 2026;24:84.
Abstract

ANWAR I, Pandith AA, Rasool SUA, Manzoor U, et al
Promoter hypermethylation drives a paradoxical up regulation of hTERT with prognostic implications in bladder cancer.
Urol Oncol. 2025 Dec 31:110963. doi: 10.1016/j.urolonc.2025.
Abstract

SORIA F, Liedberg F, Stahl E, Dominguez-Escrig JL, et al
Perioperative and Oncological Outcomes of Distal Ureterectomy for Upper Tract Urothelial Carcinoma (UTUC): A Multicentre Study from the European Association of Urology Non-muscle-invasive Bladder Cancer/UTUC Guidelines Panels with a Focus on Survival
Eur Urol Oncol. 2025 Dec 31:S2588-9311(25)00328.
Abstract

LEE J, Jung H, Kim EG, Ahn J, et al
Phenotypic discovery and therapeutic evaluation of an ITGA3B1-targeting antibody-drug conjugate for bladder cancer.
Sci Adv. 2026;12:eady0041.
Abstract

JURCZOK N, Dernbach G, Ebner B, Plage H, et al
Multiregional Immune Profiling Reveals Prognostic Patterns in Bladder Cancer.
Eur Urol Oncol. 2025 Dec 30:S2588-9311(25)00333.
Abstract

BIDI S, Nerli RB, Rangrez S, Ghagane SC, et al
Association of SLC14A1C/T Polymorphisms in Patients with Bladder Cancer in Comparison with Healthy Controls.
South Asian J Cancer. 2025;14:810-814.
Abstract

SPITZER A, Aupperle-Lellbach H, Spitzer M, Weidle S, et al
DAXX and ATRX Expression in Canine Prostate and Bladder Cancer Identified by Immunohistochemistry-A Digital Quantitative Pilot Study.
Vet Sci. 2025;12:1209.
Abstract

WOLF I, Giess N, Roider C, Schultze-Seemann S, et al
Exploring EGFR, Nectin-4, and TROP-2 as Therapeutic Targets for Bladder Cancer Photoimmunotherapy.
Molecules. 2025;30:4802.
Abstract

KAYER A, Ozen A, Dinleyici EC
Urinary Microbiota Composition in Treatment-Naive Bladder Cancer: A Case-Control Study with Tumor Invasiveness Stratification.
Medicina (Kaunas). 2025;61:2240.
Abstract

SONG B, Lee H, Lee S, Hong SK, et al
Preoperative serum albumin level is associated with postoperative short- and long-term renal function deterioration in patients who underwent radical cystectomy for bladder cancer.
Investig Clin Urol. 2026;67:24-31.
Abstract

CERRATO C, Pandolfo SD, Kraft P, Ko DSC, et al
Opportunistic salpingectomy during radical cystectomy for bladder cancer: A systematic review of the literature.
Asian J Urol. 2025;12:471-477.
Abstract

ANIS O, Bar V, Zundelevich A, Anil SM, et al
Targeting bladder cancer: Potent anti-cancer effects of cannabichromene and delta-9-tetrahydrocannabinol-rich Cannabis sativa strains.
Asian J Urol. 2025;12:534-543.
Abstract

LAYMON M, Elsawy AA, Elsorougy A, Hashem A, et al
Clinically lymph node-positive urothelial bladder cancer treated with upfront radical cystectomy: Diagnostic accuracy of MRI and long-term oncologic outcomes.
Asian J Urol. 2025;12:520-528.
Abstract

SONG M, Ren H, Wang L, Zhou Y, et al
Beyond VI-RADS Uncertainty: Leveraging Spatiotemporal DCE-MRI to Predict Bladder Cancer Muscle Invasion.
Bioengineering (Basel). 2025;12:1338.
Abstract

CIGLIOLA A, Maiorano BA, Dengur D, Tateo V, et al
The Management of Muscle Invasive Bladder Cancer: State of the Art and Future Perspectives.
Cancers (Basel). 2025;17:4017.
Abstract

PLAGE H, Biernath N, Furlano K, Weinberger S, et al
Differential Androgen Receptor Expression Across Bladder Cancer Stages and Its Link to Poor Outcomes.
Cancers (Basel). 2025;17:3990.
Abstract

HOSHI S, Meguro S, Makabe S, Onagi A, et al
Immunosuppressive Role of Integrin beta8 in Recurrence After Bacillus Calmette-Guerin (BCG) Therapy for Non-Muscle Invasive Bladder Cancer.
Cancers (Basel). 2025;17:3964.
Abstract

XIAO B, Zeng Q, Peng X, He Q, et al
An interpretable machine learning model based on CT imaging for predicting lymphovascular invasion and survival in bladder urothelial carcinoma: a multicenter study.
BMC Med Imaging. 2025;25:513.
Abstract

LI C, Meng F, Lu C, Li A, et al
A smart amphiphilic nanoplatform amplifies ROS-mediated immunogenic cell death to suppress bladder cancer growth and metastasis.
J Nanobiotechnology. 2025 Dec 29. doi: 10.1186/s12951-025-03935.
Abstract

YANG CW, Yen CH, Chien TM, Yu SY, et al
Excavatolide E triggers oxidative stress-associated apoptosis and DNA damage to inhibit bladder cancer cell proliferation.
Mol Biol Rep. 2025;53:234.
Abstract

LI L, Ren F, Liu Z, Tian X, et al
Urothelial carcinoma following kidney transplantation: a narrative review of Chinese insights and challenges from pathogenesis to precision diagnosis and treatment.
Front Immunol. 2025;16:1668356.
Abstract

HO PARK J, Lee H, Lee S, Hong SK, et al
Effect of early detubularization on urethro-intestinal anastomosis during robot-assisted radical cystectomy and intracorporeal neobladder among bladder cancer patients.
Front Oncol. 2025;15:1680595.
Abstract

KANEMOTO S, Yamamoto S, Hino K, Tsuboi K, et al
Multiple Bone Metastases From Non-Muscle Invasive Bladder Cancer Responding to Combination Therapy With Enfortumab Vedotin and Pembrolizumab: A Case Report.
IJU Case Rep. 2025;9:e70119.
Abstract

PENUNURI A, Greenberg E, Phillips J, Katims AB, et al
The Emerging Role of B Cells and Tertiary Lymphoid Structures in Bladder Cancer.
Curr Urol Rep. 2025;27:3.
Abstract

XU M, Yue S, Chen Z, Li R, et al
hsa-miR-145-3p defines a fibro-inflammatory bladder cancer subtype with distinct therapeutic vulnerabilities.
Discov Oncol. 2025 Dec 28. doi: 10.1007/s12672-025-04355.
Abstract

WANG Y, Xue H, Xu S, Qin Y, et al
Network toxicology analysis of hair dye components and their association with breast and bladder cancers.
Afr J Reprod Health. 2025;29:204-216.
Abstract

AHMADI SP, Sadabadi F, Khoshbin B, Sheikhi Z, et al
Serum PSA levels fluctuations in patients with non-muscle-invasive bladder cancer (NMIBC) undergoing BCG therapy: a prospective study.
BMC Urol. 2025 Dec 28. doi: 10.1186/s12894-025-02006.
Abstract

MOUSA MMA, Abou-Dobara MI, El-Zahed MM, El-Sherif ME, et al
Molecular detection and ultrastructure characterization of some drug-resistant Gram-negative bacteria isolated from bladder cancer patients.
BMC Microbiol. 2025 Dec 27. doi: 10.1186/s12866-025-04572.
Abstract

ZHONG MY, Zou XC, Chen PH
Explainable machine learning predicts overall survival in female bladder cancer patients after radical cystectomy.
Discov Oncol. 2025 Dec 27. doi: 10.1007/s12672-025-04275.
Abstract

ZHANG M, Chen C, Zeng X, Zhao Q, et al
Application of computed diffusion-weighted imaging in vesical imaging reporting and data system assessment for bladder cancer.
Abdom Radiol (NY). 2025 Dec 27. doi: 10.1007/s00261-025-05358.
Abstract

TAN J, Wang Y, Huang J, Dong B, et al
Exploration of the Prognostic Value of PANoptosis-Related Genes in Bladder Cancer.
Am J Mens Health. 2025;19:15579883251404985.
Abstract

HU Z, Zeng D, Zhao X, Luo Y, et al
Global Disparities and Temporal Trends in Prostate, Bladder, and Kidney Cancer Burden Among Men: A Systematic Analysis of 204 Countries (1990-2021).
Cancer Control. 2025;32:10732748251411011.
Abstract

HUANG J, Chen D, Ji G, Ma J, et al
ERO1A promotes the proliferation, migration and invasion of bladder cancer through ALOX5 mediated activation of JAK-STAT signaling pathway.
J Transl Med. 2025;23:1427.
Abstract

NAIR MS, Scarborough J, Reddy CA, Bommireddy AR, et al
Trimodality Therapy for Bladder Cancer: A Single Institution Retrospective Analysis of Factors Associated With Outcomes for High-Risk Patients Undergoing Organ-Sparing Therapy.
Clin Genitourin Cancer. 2025;24:102477.
Abstract

OLUMOYIN K, El Naqa L, Rejniak K
Learning Model Parameter Dynamics in a Combination Therapy for Bladder Cancer from Sparse Biological Data.
ArXiv [Preprint]. 2025 Dec 17:arXiv:2512.15706.
Abstract

HANLON T, D'Andrea VD, Stelter I, Bekele R, et al
Orthotopic bladder cancer preclinical models: Comprehensive review and technique optimization.
Bladder Cancer. 2025;11:23523735251409720.
Abstract

XUE Z, Qie Y, Shen C, Wu Z, et al
Urinary Tumor DNA to Identify Candidates for Repeat Transurethral Resection in Non-Muscle-Invasive Bladder Cancer.
Cancer Sci. 2025 Dec 24. doi: 10.1111/cas.70311.
Abstract

LV J, Li K, Zhou J, Yu R, et al
Histone deacetylase HDAC7 restricts CD8 + T cell tumor infiltration and limits immunotherapy sensitivity in bladder cancer: reversal by pinocembrin.
J Exp Clin Cancer Res. 2025;44:324.
Abstract

ROESSLER N, Miszczyk M, Gontero P, Miyajima K, et al
Assessing clinical complete response after neoadjuvant systemic therapy in muscle-invasive bladder cancer: a systematic review.
World J Urol. 2025;44:65.
Abstract

LIU S, Liu T, Yang C, Mou Z, et al
Cytoskeletal protein KRT14 governs cisplatin resistance by modulating eIF4H-dependent ACOX2 translation and lipid metabolism in bladder cancer.
Cell Death Dis. 2025 Dec 24. doi: 10.1038/s41419-025-08369.
Abstract

LIU H, Jiang X, Wang T, Zhang G, et al
Low-dose corticomedullary phase CT urography with artificial intelligence iterative reconstruction for bladder cancer evaluation.
Br J Radiol. 2025 Dec 24:tqaf315. doi: 10.1093.
Abstract

PEKER P
Correspondence regarding "Epidemiology, treatment patterns and effectiveness of adherence to Bacillus Calmette-Guerin therapy in intermediate and high-risk non-muscle-invasive bladder cancer patients: a retrospective cohort analysis using German healt
World J Urol. 2025;44:64.
Abstract

VANTAGGIATO L, Frisenda M, Shaba E, Splendore C, et al
Proteomic Profiling of Non-Muscle Invasive Bladder Cancer Reveals Stage-Specific Molecular Signatures and Prognostic Biomarkers.
Proteomes. 2025;13:65.
Abstract

SILVANI C, Santangelo A, Considine J, Tylecki A, et al
Incarcerated Patients Present with More Advanced Bladder Cancer Stage: A Statewide Analysis.
Urol Pract. 2025 Dec 24:101097UPJ0000000000000961.
Abstract

CARROLL TF, Bardot JP, David J, Zucker M, et al
Compliance with Intravesical BCG Therapy for Non-Muscle Invasive Bladder Cancer.
Urol Pract. 2025 Dec 24:101097UPJ0000000000000962.
Abstract

OZGUN G, Alexander A, Arbour G, Kollmannsberger C, et al
Bladder Preservation in Muscle-Invasive Bladder Cancer: A Population-Based Analysis from British Columbia.
Curr Oncol. 2025;32:699.
Abstract

HU K, Ma X, Luo L, Li P, et al
FGL1 as an Immune Checkpoint in the Immune Microenvironment of Bladder Cancer.
J Immunother. 2025 Dec 26. doi: 10.1097/CJI.0000000000000595.
Abstract

MIYAJIMA K, Matsukawa A, Yanagisawa T, Miszczyk M, et al
Neoadjuvant Chemotherapy Prior to Trimodality Therapy for Muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis.
Eur Urol Open Sci. 2025;83:54-63.
Abstract

JALAL H, Kang SK, Alarid-Escudero F, Chrysanthopoulou SA, et al
Bladder Cancer Burden in the USA: Population Scenarios for 2040.
Eur Urol Open Sci. 2025;83:99-108.
Abstract

ZHUANG J, Yu H, Cao Q, Bai R, et al
Consolidative Radical Cystectomy Following Neoadjuvant Tislelizumab Plus Gemcitabine and Cisplatin in Clinically Lymph Node-positive Bladder Cancer: A Prospective Study.
Eur Urol Open Sci. 2025;83:36-45.
Abstract

XIANG J, Luo Y, Zhang B, Ke K, et al
Molecular mechanisms and translational advances in bladder cancer: from driver genes to precision therapy.
Front Oncol. 2025;15:1670574.
Abstract

ZHANG J, Wang Y, Yan Q, Wang H, et al
SWI/SNF complex alterations predict immunotherapy response in bladder cancer.
Front Immunol. 2025;16:1708324.
Abstract

HAN Y, Peng J, Yan W, Wu Z, et al
FLLL31 Induces Apoptosis via the FOXO4/BCL6 Axis to Inhibit Bladder Cancer Progression.
Hum Mutat. 2025;2025:5947612.
Abstract

CHEN J, Fu Y, Zhang Z, Zhao J, et al
Nanomaterial-Enhanced Immunotherapy: Advancing T-Cell-Based Treatments for Bladder Cancer.
Int J Nanomedicine. 2025;20:15235-15275.
Abstract

GONG J, Sun D, Zheng Y, Mao C, et al
Dauricine Inhibits Macrophages M2 Polarization and Regulates the Progression and Ferroptosis via HCK/IDO1 in Urinary Bladder Cancer.
Food Sci Nutr. 2025;13:e71341.
Abstract

CHEN D, Li Z, Sui Y, Zeng Y, et al
The efficacy and safety of interval and post-reTURBT intravesical therapy for bladder cancer.
iScience. 2025;28:114152.
Abstract

LI Q, Chen QF, Liao NQ
Graph Neural Network-Based Multi-Scale Whole Slide Image Fusion for pT Staging of Muscle-Invasive Bladder Cancer.
Cancer Sci. 2025 Dec 23. doi: 10.1111/cas.70292.
Abstract

LI M, Liu T, Shi J, Zhou F, et al
USP43 promotes gemcitabine resistance by regulating cholesterol homeostasis through E2F1 stabilization in bladder cancer.
J Exp Clin Cancer Res. 2025 Dec 23. doi: 10.1186/s13046-025-03621.
Abstract

ZHI L, Yuan L
Alantolactone curbs the malignant progression of bladder cancer partly via the HSP90AB1/LRP5/beta-catenin axis.
Mamm Genome. 2025;37:20.
Abstract

GOUHIZOUN O, Pattou M, Guena F, Khaddad A, et al
Diagnostic accuracy of [18F]-FDG-PET/CT for lymph node staging in bladder cancer prior to radical cystectomy.
World J Urol. 2025;44:59.
Abstract

D'ALESSIO I, Siloche D, Civilini E, Bissacco D, et al
Aortic complications after treatment with bacillus Calmette-Guerin: a tertiary hospital experience and an update of the literature.
J Cardiovasc Surg (Torino). 2025;66:532-542.
Abstract

DONG W, Bi J, Liu H, Yan D, et al
Correction: Circular RNA ACVR2A suppresses bladder cancer cells proliferation and metastasis through miR-626/EYA4 axis.
Mol Cancer. 2025;24:309.
Abstract

WANG C, Li K, Wan S, Chen S, et al
TPI1 enhances gemcitabine resistance in bladder cancer by promoting autophagy through activating Beclin-1.
Cell Death Dis. 2025;16:923.
Abstract

YANG H, Liu X, Nie J, Wu S, et al
USP7 promotes chemotherapy resistance and DNA damage response through stabilizing and deubiquitinating KDM4A in bladder cancer.
Cell Death Dis. 2025 Dec 23. doi: 10.1038/s41419-025-08297.
Abstract

ZHAO X, Liu H, Wang C, Guo F, et al
Development of a prognostic model related to mitochondria and programmed cell death-related genes in bladder cancer.
Front Genet. 2025;16:1615167.
Abstract

LING Z, He S, Li T, Zhang J, et al
Stem Cell-Related Gene CALR as a Novel Prognostic Factor for Bladder Cancer: Implications for Immunotherapy.
Hum Mutat. 2025;2025:5569005.
Abstract

WENG R, Phung TAT, Bell R, Dyrskjot L, et al
Long non-coding RNAs define favourable biology in high-risk non-muscle-invasive bladder cancer.
BJUI Compass. 2025;6:e70131.
Abstract

MARTEL A, Raue L, Avogbe PH, Raisch J, et al
Urinary biomarkers in multicentric studies: Shaping the future of bladder cancer diagnosis and follow-up.
BJUI Compass. 2025;6:e70124.
Abstract

LI C, Lv G, Xiong Z, Wang Z, et al
Ginsenoside Rh2 Suppresses the Fanconi Anemia Pathway by Inhibiting NF-kappaB-Mediated FANCL Transcription in Bladder Cancer.
Dose Response. 2025;23:15593258251411761.
Abstract

DI SPIRITO A, Zuccolotto G, Tosi A, Balkhi S, et al
Evolving frontiers in bladder cancer immunotherapy: integrating BCG, immune checkpoints, viral vectors, nanotechnology, and CAR-based therapies.
Front Cell Dev Biol. 2025;13:1719978.
Abstract

WANG JM, Xie HY, Zhang FH, Shu X, et al
Aberrant KIF26B expression promotes bladder cancer progression through driving NSUN2 nuclear localization.
J Hematol Oncol. 2025;18:110.
Abstract

JANENZ J, Leipe A, Urban N, Schaefer M, et al
Activation of TRPV3 channels in bladder cancer cells stimulates ATP release.
Mol Pharmacol. 2025;108:100096.
Abstract

LI G, Tatarano S, Yoshino H, Saito S, et al
Therapeutic strategies for MMAE-resistant bladder cancer through DPP4 inhibition.
Mol Oncol. 2025 Dec 21. doi: 10.1002/1878-0261.70187.
Abstract

JAZAYERI SB, DiNatale RG, Guske C, Harrs C, et al
Bacillus Calmette-Guerin-exposed Non-muscle-invasive Bladder Cancer: Survival Benchmarks, Bladder-sparing Strategies, and Implications for Trial Design.
Eur Urol Focus. 2025 Dec 19:S2405-4569(25)00367.
Abstract

JIANG L, Ge W, Feng R, Ji L, et al
Innovative AI model for bladder cancer diagnosis.
Discov Oncol. 2025 Dec 20. doi: 10.1007/s12672-025-04278.
Abstract

SHI C, Xu J, Chen Q, Gao X, et al
Novel DNA methylation biomarkers in urine for non-invasive diagnosis of bladder urothelial carcinoma.
Clin Epigenetics. 2025;17:204.
Abstract

XU C, Ying W, He Y, Wu Y, et al
Vitamin C enhances cisplatin sensitivity in bladder cancer via 5hmC-mediated epigenetic modulation of ATF4.
Clin Epigenetics. 2025;17:203.
Abstract

JIANG Y, Xu C, He W, Zhang C, et al
First-line therapies analysis in advanced/metastatic urothelial carcinoma: prognostic insights in ADCs combined therapy with propensity score analysis and RNA-Seq.
Int Immunopharmacol. 2026;169:116060.
Abstract

MAIORANO BA, Cigliola A, Tateo V, Mercinelli C, et al
Outcomes of immune checkpoint inhibitor rechallenge in advanced urothelial carcinoma: results from a global real-world evidence study.
ESMO Open. 2025;10:105862.
Abstract

GALSKY MD, Gschwend JE, Milowsky MI, Schenker M, et al
Adjuvant nivolumab versus placebo for high-risk muscle-invasive urothelial carcinoma: 5-year efficacy and ctDNA results from CheckMate 274.
Ann Oncol. 2026;37:69-78.
Abstract

CAINI S, Cosma C, Aprea MC, Saieva C, et al
Heavy metals levels in pre-diagnostic serum of nonsmokers with cancer of the lung, bladder and prostate, and paired individuals.
Arch Environ Occup Health. 2025;80:303-307.
Abstract

SHAMSEDDINE A, Abbas N, Temraz S, Al Darazi M, et al
Tetra-modality bladder preservation with avelumab for muscle-invasive urothelial cancer: a phase II trial (TRIUMPH-B01).
Future Oncol. 2025;21:3873-3884.
Abstract

PANER GP, Al-Ahmadie H, Gaisa NT, Lopez-Beltran A, et al
The Dublin International Society of Urological Pathology (ISUP) Consensus Conference on Best Practice Recommendations on the Pathology of Glandular Lesions of the Urinary Bladder.
Adv Anat Pathol. 2026;33:1-16.
Abstract

WAI R, Sheahen B, Thomas B
Severe itch from miliaria managed with propantheline: a case report.
BMJ Support Palliat Care. 2025;16:85-87.
Abstract

HARSANYI S, Novakova ZV, Neuschlova L, Galbavy S, et al
Optimizing Ki-67 and E-Cadherin Thresholds for Improved Grade and Stage Classification in Urothelial Bladder Cancer.
J Clin Med. 2026;15:338.
Abstract

TRILLA-FUERTES L, Pedregosa-Barbas J, Garcia-Fernandez E, Zambrana F, et al
Identification of a Muscle-Invasive Bladder Carcinoma Molecular Subtype of Poor Responders to Neoadjuvant Chemotherapy and High Expression of Targetable Biomarkers.
Int J Mol Sci. 2026;27:476.
Abstract

NAKAGAWA Y, Yamamoto C, Kawajiri H, Watanabe M, et al
Whole Genome Sequencing of Clinical Mycobacterium bovis BCG in Disseminated Infection with Mycotic Aneurysm and ARDS After Intravesical Therapy: A Case Report.
Int J Mol Sci. 2025;27:238.
Abstract

JAIN M, Tivtikyan A, Kislyakov D, Rakhmatullin T, et al
The Diagnostic Performance of a Four-Gene Digital Droplet PCR Panel for Urine Liquid Biopsy in Urothelial Bladder Cancer.
Diagnostics (Basel). 2025;16:69.
Abstract

JAROMIN M, Kutwin P, Konecki T, Popiela D, et al
Inflammation Indices as Predictive Markers of Muscle-Invasive Bladder Cancer.
Cancers (Basel). 2025;18:136.
Abstract

WU Z, Zeng J, Feng L, Zhu X, et al
Tumor-homing cerium nanozyme platform enables coordinated drug release and STING activation for bladder cancer treatment.
J Nanobiotechnology. 2026 Jan 10. doi: 10.1186/s12951-025-03955.
Abstract

ADMIRE K, Gegick S
Transvascular endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) to confirm urothelial carcinoma metastasis to the pulmonary artery.
BMJ Case Rep. 2026;19:e268157.
Abstract

RAGHAVAN D
Sad But True: Inconsistent Care for Invasive Bladder Cancer.
JCO Oncol Pract. 2026 Jan 9:OP2501254. doi: 10.1200/OP-25-01254.
Abstract

YANG FH, Zhang W, Wang R, Mao S, et al
Pseudomonas aeruginosa exacerbates bladder cancer progression by activating cancer-driven immunosuppression.
Cancer Immunol Res. 2026 Jan 9. doi: 10.1158/2326-6066.CIR-25-0873.
Abstract

GATELLIER L, Nakata K
Age-standardized mortality-to-incidence ratio for bladder cancer in the world.
Jpn J Clin Oncol. 2026;56:115-116.
Abstract

ABOU CHAKRA M, Boormans JL, Hayne D, O'Donnell MA, et al
Strategic sequencing of bladder-sparing therapies in the management of BCG-unresponsive non-muscle invasive bladder cancer.
Ann Med. 2026;58:2612387.
Abstract

SHAO YQ, Sheng DY, Guan YJ, Mi EX, et al
[Mechanism of periplogenin in promoting Nrf2 degradation and inducing ferroptosis to inhibit bladder cancer].
Zhongguo Zhong Yao Za Zhi. 2025;50:5790-5799.
Abstract

REMMELINK MJ, El Awadly N, Arbeel-Weening B, Nadorp S, et al
Correction: Impact of chemoradiotherapy for bladder cancer on pre-existing hydronephrosis and development of new hydronephrosis.
Radiat Oncol. 2026;21:8.
Abstract

XU D, Jacob JJ, Wieczorek K, Wang L, et al
Modeling primary immunotherapy resistance in metastatic bladder cancer: a syngeneic, bioluminescent mouse model.
Cancer Cell Int. 2026 Jan 8. doi: 10.1186/s12935-025-04117.
Abstract

WANG H, Xiong Y, He T, He M, et al
MXRA8, a key palmitoylation-related gene, promotes bladder cancer progression via remodeling tumor microenvironment and predicts poor prognosis.
BMC Urol. 2026 Jan 8. doi: 10.1186/s12894-026-02046.
Abstract

WANG J, Lu Q, Jiao P, Jian J, et al
Machine Learning Integration Framework Constructs a Lactylation-Associated Gene Signature to Improve Prognosis in Bladder Cancer.
Cancer Med. 2026;15:e71477.
Abstract

HESSE M, Iltzsche M, Nahhas D, Thomas C, et al
Type I-interferon beta induces a strong anti-tumour response in bladder cancer cells.
J Cancer Res Clin Oncol. 2026;152:35.
Abstract

JIN Z, Yang W, Peng Y, Ma L, et al
HOXB4 Promotes Bladder Cancer Progression in Part Through Transcriptional Activation of Smoothened.
FASEB J. 2026;40:e71388.
Abstract

BAI R, Cai L, Jiang M, Wang C, et al
Development and validation of MRI-based models to predict lymph node metastasis in bladder cancer: a multi-center study.
Cancer Imaging. 2026 Jan 7. doi: 10.1186/s40644-025-00984.
Abstract

DAI P, Chen L, Dong Z, Wang H, et al
LncRNA FRMD6-AS2 inhibits the malignant progression of bladder cancer by targeting miR-1260a.
World J Surg Oncol. 2026 Jan 7. doi: 10.1186/s12957-025-04171.
Abstract

SINGH P, D'Rozario R, Chakraborty B, Meher S, et al
Loss of KDM6A-mediated genomic instability and metabolic reprogramming regulates response to therapeutic perturbations in bladder cancer.
Nat Commun. 2026 Jan 7. doi: 10.1038/s41467-025-68132.
Abstract

SAOULI A, Contieri R, Quhal F, Hurle R, et al
Efficacy and safety of active surveillance and chemoablation in the management of non-muscle invasive bladder cancer (NMIBC): Systematic review and pooled analysis by the European Association of Urology-Young Academic Urologists: Urothelial Carcinoma
Actas Urol Esp (Engl Ed). 2026 Jan 5:501917. doi: 10.1016/j.acuroe.2026.501917.
Abstract

LI X, Xie J, Song SJ, Ahlquist CSE, et al
Sialic Acid Binding Liposome Nanoparticles for Targeted Bladder Cancer Therapy.
ACS Biomater Sci Eng. 2026 Jan 7. doi: 10.1021/acsbiomaterials.5c01546.
Abstract

CELLULAR LONGEVITY OMA
RETRACTION: lncRNA OTUD6B-AS1 Exacerbates As(2)O(3)-Induced Oxidative Damage in Bladder Cancer via miR-6734-5p-Mediated Functional Inhibition of IDH2.
Oxid Med Cell Longev. 2025;2025:9894089.
Abstract

PIZZI JR, Adhikari I, Prakash P, Miyamoto H, et al
Machine-learning-based determination of sex-related bladder cancer biomarkers.
bioRxiv [Preprint]. 2025 Dec 23:2025.12.20.695175.
Abstract

FALABELLA R, Porreca A, Foschi N, Salvaggio A, et al
Robotic bladder diverticulectomy in patients with bladder diverticulum neoplasia: a single-center study.
Arch Ital Urol Androl. 2025;97:14467.
Abstract

BUZOIANU M, Buhas BA, Abou Chakra M, Ionutas E, et al
A national perspective on the management of high-risk BCG-unresponsive non-muscle-invasive bladder cancer in Romania.
Arch Ital Urol Androl. 2025;97:14596.
Abstract

SHI G, Zhou X, Yang F, Wang T, et al
Harnessing Ubiquitin-Proteasome System-Related Genes to Identify Subtypes of Bladder Cancer and Reveal Immune Landscape.
Am J Mens Health. 2026;20:15579883251410519.
Abstract

PATTOU M, Robert G, Gouhizoun O, Guena F, et al
Persistent lymph node uptake on [18 F]-FDG PET-CT after neoadjuvant chemotherapy: a major predictive factor of disease-free survival in MIBC.
World J Urol. 2026;44:77.
Abstract

YUAN J, Yu S, Zheng J
Epidemiological trends and future projections of bladder and kidney cancer burden in China, 1990-2041: an ecological study.
Chin Clin Oncol. 2025;14:71.
Abstract

FU Q, Yan F, Sun Z, Yao Z, et al
Analysis of Urinary Continence, Complications, and Urodynamic Characteristics Following Orthotopic Ileocaecal Neobladder Reconstruction: A Preliminary Study on Safety and Feasibility.
Arch Esp Urol. 2025;78:1493-1500.
Abstract

ILKTAC A, Ersoz C, Kalkan S, Dogan B, et al
Bleeding Risks in Urologic Surgery: A Prospective Analysis of Anticoagulant and Antiaggregant Use in Transurethral Resection of Prostate, Transurethral Resection of Bladder Tumour and Open Prostatectomy.
Arch Esp Urol. 2025;78:1392-1400.
Abstract

ST-LAURENT MP, Nikkola J, Tomiyama E, Black PC, et al
Advances in the management of localized bladder cancers.
Nat Rev Clin Oncol. 2026 Jan 5. doi: 10.1038/s41571-025-01104.
Abstract

ROESSLER N, Maiorano BA, Miszczyk M, Miyajima K, et al
First-line treatments for BCG-naive non-muscle invasive bladder cancer: a systematic review and meta-analysis.
World J Urol. 2026;44:76.
Abstract

[Clinical pathological expert consensus on HER2 immunohistochemical testing in urothelial carcinoma(2026 version)].
Zhonghua Bing Li Xue Za Zhi. 2026;55:7-15.
Abstract

HE K, Lin C, Wang H, Wu H, et al
The circ-GLG1/miR-346/KCNJ9 axis drives malignant progression of bladder cancer by modulating KCNJ9 expression.
Exp Cell Res. 2026;455:114885.
Abstract

MINATO A, Jojima K, Watanabe S, Sugita Y, et al
Recurrence of Low-risk Non-muscle-invasive Bladder Cancer in Patients Who Did Not Receive Immediate Intravesical Chemotherapy.
Cancer Diagn Progn. 2026;6:135-143.
Abstract

ORAKZAI FK, Mirza W, Khan ME, Iqbal H, et al
Robot-assisted versus open radical cystectomy with extracorporeal urinary diversion for bladder cancer: a GRADE-assessed systematic review and meta-analysis of randomized controlled trials with subgroup analyses by orthotopic neobladder utilisation.
J Robot Surg. 2026;20:151.
Abstract

CHIANG Y, Tsai YC, Wang CC, Hsueh FJ, et al
High-CD14-expressing urothelial cancer cells foster a neutrophil-rich tumor microenvironment that increases the risk of radiation-promoted distant metastasis.
J Biomed Sci. 2026;33:2.
Abstract

MAY M, Wolff I, Brookman-May S, Burger M, et al
Re: Paramananthan Mariappan, Jasmin Hart-Brooke, Rebecca Sparks, Tanya Lord-McKenzie. Bladder EpiCheck Triggered Photodynamic Diagnosis Biopsies Detect High-grade Bladder Cancer Recurrences Missed by White Light Cystoscopy. Eur Urol Oncol. In press. h
Eur Urol Oncol. 2026 Jan 3:S2588-9311(25)00341-4. doi: 10.1016/j.euo.2025.
Abstract

SAITO M, Kakoi N, Izumi M, Aoki H, et al
[A Case of Verrucous Carcinoma of the Bladder in a Patient with Cerebral Palsy].
Hinyokika Kiyo. 2025;71:425-428.
Abstract

WANG Y, Liu H, Wang T, Yang Y, et al
GLRX5 is a prognostic marker in bladder cancer and correlates with activation of cancer-associated fibroblasts in the tumor microenvironment.
Exp Cell Res. 2026;455:114884.
Abstract

GUO C, Zhou Y, Liu X, Gao K, et al
Analysis of the care needs of family caregivers of patients with bladder cancer undergoing urostomy: a cross-sectional study.
Sci Rep. 2026 Jan 3. doi: 10.1038/s41598-025-34339.
Abstract

LI Y, Zhao B, Gao W, Wu Y, et al
Correction: LDB2 is a novel diagnostic and prognostic biomarker and inhibits bladder cancer metastasis by activating p38 MAPK/ERK1/2/JNK signaling pathway.
Clin Exp Med. 2026;26:62.
Abstract

BASU M, Chatterjee A, Chakraborty B, Chatterjee E, et al
Retraction Note: High nuclear expression of HIF1alpha, synergizing with inactivation of LIMD1 and VHL, portray worst prognosis among the bladder cancer patients: association with arsenic prevalence.
J Cancer Res Clin Oncol. 2026;152:26.
Abstract

STURDIVANT MS, Truong AS, Zhou M, Toomer ED, et al
APOBEC3 promotes squamous differentiation via IL-1A/AP-1 signaling.
Nat Commun. 2025;17:334.
Abstract

LIU P, Zhang L, Zhou Q, Fu Z, et al
STIM1 N-linked glycosylation promotes arsenic-induced malignant phenotype by activating SOCE in bladder epithelial cells.
Chem Biol Interact. 2026;424:111866.
Abstract

YE Y, Chen Q, Huang Z, Huang Q, et al
Preferred surgical strategies for bladder diverticular carcinoma.
Sci Rep. 2025;16:917.
Abstract

PEREIRA JA, Vieira-Brito D, Ferreira AM, Marques R, et al
Hyperthermic vs normothermic mitomycin C for intermediate-risk NMIBC: a real-world retrospective cohort study.
Arch Ital Urol Androl. 2025;97:14167.
Abstract

YU EM, Linville L, Hwang MW, Kim Y, et al
Harnessing genomic profiling for improved urothelial cancer outcomes.
Expert Rev Anticancer Ther. 2026;26:93-104.
Abstract

ZHANG T, Zhang X, Qian L, Hu C, et al
Molecular and immune characteristics of neuroendocrine bladder carcinoma - Implications for diagnosis, prognosis, and therapy: A review.
Biomol Biomed. 2025;26:711-719.
Abstract

DIANA P, Gallioli A, Uleri A, Mas L, et al
Attendings versus supervised residents: Educational results and future perspective in transurethral resection of bladder tumors.
Actas Urol Esp (Engl Ed). 2026;50:501830.
Abstract

CHENG AV, Bardell J, Sangoi AR
Collision of Presumed Primary Urinary Bladder Malignant Melanoma and Invasive Urothelial Carcinoma: A Case Report.
Int J Surg Pathol. 2026;34:201-206.
Abstract

HISANAGA E, Sano T, Yokoo H
Four Metachronous Cancers: Mutation Profiling Can Be Used to Distinguish Multiple Primary Cancers from Metastases.
Intern Med. 2026;65:183-186.
Abstract

KAYAR K, Dogan MB, Karabay E
A Rare Presentation of Alveolar Soft Part Sarcoma in the Bladder.
Int J Surg Pathol. 2026;34:158-161.
Abstract

KASUKAWA S, Kametaka H, Makino H, Fukada T, et al
[A Case of Pelvic Abscess Treated with Transperineal Drainage for Lower Gastrointestinal Perforation in Terminal Cancer].
Gan To Kagaku Ryoho. 2025;52:1189-1191.
Abstract

HATAKEYAMA T, Maeda T, Ide S
[A Case of Synchronous Primary Cancers of the Rectum and Bladder].
Gan To Kagaku Ryoho. 2025;52:1129-1130.
Abstract

SALZANO G, Digiacomo A, Dello Stritto G, Orsini A, et al
Artificial intelligence in bladder cancer management: a narrative review of diagnostic and surgical advances and current limitations.
Expert Rev Anticancer Ther. 2026 Jan 16. doi: 10.1080/14737140.2026.2619018.
Abstract

CHENG YT, Lu KH, Hong SY, Chen CH, et al
Particulate matter 2.5 promotes bladder cancer cell migration and invasion through the crosstalk between integrin-mediated MAPK/ERK and Wnt/beta-catenin pathways.
Part Fibre Toxicol. 2026 Jan 16. doi: 10.1186/s12989-025-00656.
Abstract

YANG J, Li X, Xie H, Guo J, et al
From mechanisms to therapy: the role of tertiary lymphoid structures in bladder cancer.
World J Surg Oncol. 2026 Jan 17. doi: 10.1186/s12957-026-04196.
Abstract

KHAN JS, Lonergan PE, McLoughlin LC
Adherence to Bacille Calmette-Guerin protocol in the management of non-muscle invasive bladder cancer at St James's Hospital.
Ir J Med Sci. 2026 Jan 17. doi: 10.1007/s11845-025-04260.
Abstract

HAJIME T, Shiota M, Fukuchi G, Mutaguchi J, et al
Tumor Laterality Predicts Pelvic Lymph Node Metastasis Patterns in Bladder Cancer.
Ann Surg Oncol. 2026 Jan 16. doi: 10.1245/s10434-026-19088.
Abstract

SASAKI Y, Izumi K, Fukuta K, Kadoriku F, et al
Robot-Assisted Radical Cystectomy in the Very Elderly: A Propensity Score-Matched Comparison of Outcomes Between Patients Aged >/= 85 Versus 75-84 Years.
Geriatr Gerontol Int. 2026;26:e70346.
Abstract

MARAMI S, Tavakoli MH, Pashaki AS, Nikzad S, et al
Computational analysis of the impact of urine volume on magnetic nanoparticle hyperthermia in the treatment of non-muscle-invasive bladder cancer.
Eur J Pharm Biopharm. 2026 Jan 14:114992. doi: 10.1016/j.ejpb.2026.114992.
Abstract

DYRSKJOT L, Birkenkamp-Demtroder K, Nordentoft I, Strandgaard T, et al
ctDNA-Guided Immunotherapy following Radical Cystectomy for Muscle-Invasive Bladder Cancer: Results from the TOMBOLA Trial.
Ann Oncol. 2026 Jan 14:S0923-7534(26)00011-6. doi: 10.1016/j.annonc.2025.
Abstract

ZHANG Q, Zhang B, Niu J, Sun S, et al
POSTN+ cancer-associated fibroblasts promote bladder cancer progression via angiogenesis and immune modulation: an analysis based on single-cell Transcriptomics.
Integr Biol (Camb). 2026;18:zyag001.
Abstract

KAWAI T, Miki J, Taoka R, Saito R, et al
Age-stratified outcomes of radical cystectomy for muscle-invasive bladder cancer: a nationwide multicenter study of 1867 patients in Japan.
Jpn J Clin Oncol. 2026 Jan 16:hyaf218. doi: 10.1093.
Abstract

LAERT J, Lupi Manso N, Franca de Santana T, Santos PO, et al
Pitfalls and Limitations of the Vesical Imaging-Reporting and Data System (VI-RADS): Challenges in the Multiparametric Magnetic Resonance Imaging (mpMRI) Assessment of Bladder Cancer.
Cureus. 2025;17:e99197.
Abstract

OKA R, Goto Y, Mikami K, Kato H, et al
Renal Granuloma Distinct From the Renal Pelvis Following Bacillus Calmette-Guerin Treatment for Bladder Cancer: A Case Report.
IJU Case Rep. 2026;9:e70141.
Abstract

DAI Y, Zhang X, Lin Q, Gu X, et al
Best evidence summary on gastrointestinal function recovery after radical cystectomy for bladder cancer.
Asia Pac J Oncol Nurs. 2025;13:100824.
Abstract

REYNARD M, Grobet-Jeandin E, Windisch O, Sebe P, et al
[Urology. Quality of life and safety : the new promises].
Rev Med Suisse. 2026;22:79-82.
Abstract

ZHANG J, Zheng L, Yu Z, Chen Y, et al
Single-cell and Bulk RNA-Seq Analyses Reveal TOMM7-mediated Multi-cell Death Mechanisms Driving Muscle-invasive Bladder Cancer Progression.
Recent Pat Anticancer Drug Discov. 2026.
Abstract

FULORIA NK, Narain K, Biswas A, Gnanam P, et al
Tissue polypeptide antigen as a non-invasive bladder Cancer biomarker.
Clin Chim Acta. 2026 Jan 13:120843. doi: 10.1016/j.cca.2026.120843.
Abstract

CONTIERI R, Mollica V, Shariat SF, Pradere B, et al
Comment to: ALBAN (GETUG-AFU 37): A phase 3, randomized, open-label, international trial of intravenous atezolizumab and intravesical Bacillus Calmette-Guerin (BCG) versus BCG alone in BCG-naive high-risk, non-muscle invasive bladder cancer (NMIBC).
Ann Oncol. 2026 Jan 13:S0923-7534(26)00012-8. doi: 10.1016/j.annonc.2026.
Abstract

SQUIRES P, Coutinho F, Tepsick JG, Rogiers A, et al
Real-world treatment patterns, recurrence, and overall survival of patients with muscle-invasive bladder cancer undergoing radical cystectomy in U.S. oncology practice.
Urol Oncol. 2026;44:110982.
Abstract

ILKI FY, Bulbul E, Topcu YK, Cinar O, et al
Comparison of intravesical Bacillus Calmette-Guerin and chemohyperthermia with mitomycin C in with high-risk non-muscle-invasive bladder cancer: a critical assesment focusing on the quality of life and adverse events.
BMC Urol. 2026 Jan 14. doi: 10.1186/s12894-025-02040.
Abstract

AL-SATTAR H, Ding H, Okoli O, Okoli S, et al
A multi-modal approach for decision making in bladder cancer.
Nat Rev Urol. 2026 Jan 14. doi: 10.1038/s41585-025-01122.
Abstract

MARIAPPAN P, Hart-Brooke J, Sparks R, Lord-McKenzie T, et al
Reply to Matthias May, Ingmar Wolff, Sabine Brookman-May, and Maximilian Burger's Letter to the Editor re: Paramananthan Mariappan, Jasmin Hart-Brooke, Rebecca Sparks, Tanya Lord-McKenzie. Bladder EpiCheck Triggered Photodynamic Diagnosis Biopsies Det
Eur Urol Oncol. 2026 Jan 13:S2588-9311(25)00344.
Abstract

ZHU M, Liu Y, Jia Y, Ren L, et al
Jujuboside A induces bladder cancer cell apoptosis by inhibiting ATP1A2-mediated mitochondrial energy metabolism regulation.
Cancer Biol Ther. 2026;27:2615418.
Abstract

CAO N, Cheng F
TSTA3 promotes the malignant progression of bladder cancer by regulating LAMP2 and MAPK signaling pathway-mediated epithelial-mesenchymal transition.
Genes Genomics. 2026 Jan 14. doi: 10.1007/s13258-025-01724.
Abstract

ARON S, Meagher M, Azari S, Baker B, et al
Beyond Sterility: the Urinary Microbiome in Bladder Cancer Carcinogenesis and Treatment.
Curr Urol Rep. 2026;27:8.
Abstract

DENIAUD C, Mesnard B, Bobet S, Perrouin-Verbe MA, et al
Morbi-mortality of robot-assisted radical cystectomy for bladder carcinoma by urinary diversion type.
J Robot Surg. 2026;20:173.
Abstract

GE T, Liu F, Cai M, Wu J, et al
Using transcriptomics and molecular docking to uncover the pharmacological targets and its associated biological mechanisms of paeoniflorigenone in treating bladder cancer.
Discov Oncol. 2026 Jan 14. doi: 10.1007/s12672-026-04404.
Abstract

CHEN J, Liu X, Ren R, Yi R, et al
Single-cell and immune-context integration identifies basement-membrane/metastasis signatures that sharpen bladder-cancer diagnosis and prognosis.
Discov Oncol. 2026 Jan 14. doi: 10.1007/s12672-026-04440.
Abstract

DENIAUD C, Mesnard B, Bobet S, Perrouin-Verbe MA, et al
Oncologic outcomes of robot-assisted radical cystectomy for bladder carcinoma by urinary diversion type.
World J Urol. 2026;44:93.
Abstract

WU X, Zhou Y, Chen J, Zhang H, et al
A high-throughput photothermal aptasensing platform using MnO(2)@CuS nanoprobes for noninvasive detection of bladder cancer cells in simulated liquid biopsy.
Mikrochim Acta. 2026;193:88.
Abstract

INUI S, Ito S, Ueda T, Shiraishi T, et al
Efficacy and safety of cryoablation procedures using mouse models of bladder cancer.
Sci Rep. 2026 Jan 13. doi: 10.1038/s41598-026-35571.
Abstract

DADABHOY A, Doshi C, Zahir M, Ladi-Seyedian S, et al
Alopecia following single-dose postoperative intravesical gemcitabine in nonmuscle-invasive bladder cancer: A multi-institutional case series.
Urol Oncol. 2026;44:110984.
Abstract

MAN X, Zhang X, Dong A, He J, et al
Isolated Vaginal Recurrence of Urothelial Bladder Cancer on FDG PET/CT.
Clin Nucl Med. 2026 Jan 6. doi: 10.1097/RLU.0000000000006294.
Abstract

MJAESS G, Quackels T, Fantoni JC, Tricard T, et al
Surgical outcomes after neoadjuvant avelumab with or without chemotherapy for Muscle-Invasive bladder cancer: a Post-Hoc analysis of the aura trial (Oncodistinct-004).
World J Urol. 2026;44:90.
Abstract

PEREZ-LONDONO A, Kaul S, Fleishman A, Korets R, et al
Repeat transurethral resection and contemporary oncologic outcomes among patients with non-muscle invasive urothelial carcinoma of the bladder.
World J Urol. 2026;44:91.
Abstract

ZHOU H, Peng S, Ling Z, Cai J, et al
Multi-omics analysis identifies BUB1B as a cell cycle-related driver of bladder cancer progression.
World J Surg Oncol. 2026 Jan 12. doi: 10.1186/s12957-025-04175.
Abstract

AYDIN ME, Aykac A, Kaya C, Sungur M, et al
Comparative analysis of EAU, AUA, and NCCN guidelines for the management of non-muscle invasive bladder cancer.
BMC Urol. 2026 Jan 12. doi: 10.1186/s12894-026-02045.
Abstract

REGNIER S, Gabriel PE, Ouzaid I, Moschini M, et al
Second-look transurethral resection in high-grade Ta non-muscle invasive bladder cancer.
World J Urol. 2026;44:84.
Abstract

SUNGUR U, Bitkin A, Eksi M, Polat H, et al
Machine learning methods for predicting early recurrence in Ta stage bladder cancer and comparison with conventional statistical methods.
Minerva Urol Nephrol. 2026 Jan 12. doi: 10.23736/S2724-6051.25.06385.
Abstract

ZHANG F, Yang Y, Zhang R, Hu H, et al
Curcumol overcomes cisplatin resistance and rewires glycolysis-H3K9la-ORC6 axis to trigger ferroptosis in bladder cancer.
Chin J Cancer Res. 2025;37:1034-1057.
Abstract

Expression of miR-149-3p inhibits proliferation, migration, and invasion of bladder cancer by targeting S100A4 [Retraction].
Am J Cancer Res. 2025;15:5395.
Abstract

HUANG H, Ye F, Liu T, Hong J, et al
Nano-Immunotherapy Synergizing Ferroptosis and STING Activation in Metastatic Bladder Cancer.
Cyborg Bionic Syst. 2026;7:0458.
Abstract

DE ALMEIDA MF, Rosa BG, Delechiave D, Annequin LF, et al
rBCG-LTAK63 Outperforms BCG in Bladder Cancer Immunotherapy: Dendritic and T Cell Coordination Drives Superior Tumor Control in a Mouse Model.
Int J Biol Sci. 2026;22:713-730.
Abstract

SCILIPOTI P, Zaurito P, Longoni M, Tremolada G, et al
Real-world outcomes of bladder-sparing strategies for BCG-unresponsive non-muscle-invasive bladder cancer: a multicenter study.
World J Urol. 2026;44:82.
Abstract

CHEN L, Jin C, Guo E, Liu F, et al
The Performance of MR Cytometry Imaging in Differentiating High- and Low-Grade Bladder Cancer.
J Magn Reson Imaging. 2026 Jan 11. doi: 10.1002/jmri.70232.
Abstract

MUMUNI AN
Editorial for "The Performance of MR Cytometry Imaging in Differentiating High- and Low-Grade Bladder Cancer".
J Magn Reson Imaging. 2026 Jan 11. doi: 10.1002/jmri.70238.
Abstract

CHENG LH, Hsu CW, Yang PM, Liao TY, et al
Chemotherapy resistance of urinary bladder cancer mediated by a Notch and Wnt co-regulatory module of stemness.
Stem Cells. 2026 Jan 10:sxag002. doi: 10.1093.
Abstract

SYNESI G, Lewis R, Kilburn L, Bliss J, et al
Reviewing inclusivity of the UK bladder and head and neck oncology trial portfolio through eligibility criteria: a scoping review.
Trials. 2026;27:19.
Abstract

KAYRAKLIOGLU N, Zhang L, Cornelia Ding CK, Greenland NY, et al
Correlation of lymphocytic infiltration and degree of pleomorphism with tumor mutation burden in high-grade urothelial carcinoma.
Hum Pathol. 2026;167:106005.
Abstract

FERNANDEZ O, Molina A, Anido-Herranz U, Alvarez C, et al
Real-world data on avelumab in first-line maintenance therapy for advanced or metastatic urothelial carcinoma: the SOGUG-AVELUMAB RWD study.
Clin Transl Oncol. 2026;28:254-264.
Abstract

FERNANDEZ RODRIGUEZ P, Castillo Gazquez L, Tomas Alvarez S, Casals Seoane F, et al
Abdominal BCGitis with hepatosplenic and lymphatic involvement following intravesical therapy: a rare complication.
Rev Esp Enferm Dig. 2025;117:797-799.
Abstract

PARK I, Lee JL, Yoon S, Shin SJ, et al
A Multicenter Phase II Study of Modified FOLFIRINOX for First-Line Treatment for Advanced Urachal Cancer (ULTIMA; KCSG GU20-03).
Cancer Res Treat. 2026;58:284-291.
Abstract

MEZEPO G, Khene ZE, Boustani J, Kleinclauss F, et al
Oncological Outcomes of Trimodal Therapy in Primary Versus Secondary Muscle-invasive Bladder Cancer: A Multicenter Retrospective Study.
Eur Urol Oncol. 2026 Jan 22:S2588-9311(25)00343.
Abstract

GABRIEL PE, Xylinas E
The Future of Non-muscle-invasive Bladder Cancer: Towards a Molecular-Digital Paradigm for Personalized Management.
Eur Urol Focus. 2026 Jan 22:S2405-4569(26)00004.
Abstract

REIS LO
Bladder Cancer Immunotherapy in 2025: ALBAN, CREST, POTOMAC, and the Winner Is BCG!
Int Braz J Urol. 2026;52:e20259921.
Abstract

SUGAWARA D, Hatakeyama K, Konno M, Tozawa T, et al
Decision tree models combining Bi-parametric vesical imaging reporting and data system and apparent diffusion coefficient metrics for predicting muscle-invasive bladder cancer.
Abdom Radiol (NY). 2026 Jan 23. doi: 10.1007/s00261-026-05389.
Abstract

ZHAO Q, Gao S, Du Q, Liu Y, et al
[Expression of Concern] Long non?coding RNA SNHG20 promotes bladder cancer via activating the Wnt/beta?catenin signalling pathway.
Int J Mol Med. 2026;57:66.
Abstract

KUO WT, Pan CC, Liu YW, Chow NH, et al
Autophagy Plays a Suppressive Role in Bladder Tumor Formation in an Orthotopic Mouse Model and Bladder Cancer Patient Specimens.
Kaohsiung J Med Sci. 2026 Jan 23:e70179. doi: 10.1002/kjm2.70179.
Abstract

LIU L, Liang T, Huang G, Deng D, et al
Electroacupuncture in Combination with Bevacizumab Hydrogel Provides a Therapeutic Strategy for Bladder Cancer.
ACS Appl Mater Interfaces. 2026 Jan 22. doi: 10.1021/acsami.6c00404.
Abstract

Long-term impact of synchronous and metachronous bladder cancer on prognosis after radical nephroureterectomy for upper urinary tract urothelial carcinoma: results from a large population-based cohort in China: Erratum.
Int J Surg. 2026;112:2201.
Abstract

DYRSKJOT L
ctDNA-guided treatment decisions in muscle-invasive bladder cancer.
Nat Rev Urol. 2026 Jan 22. doi: 10.1038/s41585-026-01125.
Abstract

HUANG Y, Chen C, Su M, Ye W, et al
TMEM11 promotes cisplatin resistance by inhibiting BNIP3-mediated mitophagy in bladder cancer.
Cancer Lett. 2026;641:218271.
Abstract

DO NT, Nguyen Tung L, Nguyen Cong D, Do MT, et al
Tumor Morphology as a Risk Factor for Muscle Invasiveness in Newly Diagnosed Bladder Cancer: A Stratified Analysis.
Asian Pac J Cancer Prev. 2026;27:151-156.
Abstract

STROJNY Z, Kanikowska A, Sikora W, Lewandowska M, et al
First look at evaluation of serum angiopoietin-like 4 levels in bladder cancer: A pilot study.
J Physiol Pharmacol. 2026;76:673-680.
Abstract

NAGUMO Y, Ye X, Shi T, Mathis BJ, et al
Revealing intra-group immunotherapy response heterogeneity in metastatic urothelial carcinoma through interpretable feature extraction and spectral clustering.
Front Immunol. 2026;16:1629001.
Abstract

NUMATA Y, Ito H, Tatenuma T, Noguchi G, et al
[A CASE OF ACUTE EXACERBATION OF INTERSTITIAL PNEUMONIA AFTER ROBOT-ASSISTED TOTAL CYSTECTOMY].
Nihon Hinyokika Gakkai Zasshi. 2025;116:37-40.
Abstract

KURETAKE K, Minato A, Harada S, Fujimoto N, et al
[CLINICAL OUTCOMES OF NEUROENDOCRINE CARCINOMA OF THE URINARY BLADDER].
Nihon Hinyokika Gakkai Zasshi. 2025;116:10-16.
Abstract

YAMADA R, Hayakawa N, Kikuchi E
[PERIOPERATIVE INCIDENCE OF VENOUS THROMBOEMBOLISM IN BLADDER CANCER PATIENTS TREATED BY OPEN RADICAL CYSTECTOMY].
Nihon Hinyokika Gakkai Zasshi. 2025;116:1-9.
Abstract

HUSSEIN AA, Klugman Y, Carlson J, Bhat TA, et al
Does the urinary microbiome reflect the bladder-cancer-associated microbiome? Characterizing the microbiome in urine and cancer tissue in bladder cancer.
Urol Oncol. 2026;44:110978.
Abstract

CALOUDAS AB, Haltom TM, Taylor JM
"It's Killed My Sex Life": Veteran Bladder Cancer Survivors' Perspectives on Sexual Problems and Intimacy.
Arch Sex Behav. 2026 Jan 21. doi: 10.1007/s10508-025-03364.
Abstract

SONG S MSC, Yang W MSc, Gao C MD
Comment on "The role of adjuvant chemotherapy after radical surgery in patients with lymph node-positive bladder cancer or locally advanced (pT3, pT4a) bladder cancer: a meta-analysis and systematic review".
Int J Surg. 2026 Jan 20. doi: 10.1097/JS9.0000000000004892.
Abstract

LI M, Liu X, Xue Y, Lu Y, et al
Integrative bulk and single-cell transcriptomic analysis reveals COL1A2-driven ECM remodeling and focal adhesion signaling associated with the transition from non-muscle-invasive to muscle-invasive bladder cancer.
Front Oncol. 2026;15:1716324.
Abstract

YAN B, Hu W, Li Y, Feng T, et al
Hyperthermic intravesical chemotherapy with gemcitabine versus Bacillus Calmette-Guerin in intermediate- and high-risk non-muscle-invasive bladder cancer.
Front Oncol. 2026;15:1715762.
Abstract

SONG F, Su S, Zhang X, Cao Y, et al
Association between the red cell distribution width-to-albumin ratio and recurrence-free survival and overall survival in patients with non-muscle-invasive bladder cancer: a retrospective cohort study.
Front Oncol. 2026;15:1710047.
Abstract

REDDY N, Lau K, Naman J, Lu K, et al
Killing cancer takes guts: lessons learned from the manipulation of gut microbiome and immunotherapy for the future of urothelial carcinoma.
Oncoimmunology. 2026;15:2611458.
Abstract

FAN D, Meng R, Han Y, Zhai Z, et al
Conservative versus aggressive transurethral resection of bladder cancer for paraureteral bladder cancer: A comparison of postoperative ureteral stricture and cancer recurrence rates.
Medicine (Baltimore). 2026;105:e47176.
Abstract

CAI J, Jiao C, Xu Y, Zhang F, et al
Polarity protein Par3 deficiency promotes metastasis of bladder cancer via interaction of Ppp1r12c.
Biol Direct. 2026 Jan 20. doi: 10.1186/s13062-026-00727.
Abstract

LI Y, Zhou Z, Liu J, Cheng Z, et al
En bloc versus conventional transurethral resection for non-muscle-invasive bladder cancer: an expanded and updated systematic review and meta-analysis reconciling contemporary evidence on oncological, pathological, and safety outcomes.
World J Surg Oncol. 2026 Jan 20. doi: 10.1186/s12957-025-04172.
Abstract

JIANG M, Chen S, Ma H, Shi Y, et al
Intratumoral and Peritumoral Fat CT?Based Radiomics for Predicting Recurrence Risk in Non-Muscle-Invasive Bladder Cancer: A Two-Center Study.
Ann Surg Oncol. 2026 Jan 20. doi: 10.1245/s10434-025-18981.
Abstract

HE W, Wen Y, Qin H
LncRNA NPSR1-AS1 affects the malignant biological behavior of bladder cancer through miR-199a-3p and the clinical value of urine-derived lncRNA NPSR1-AS1.
Urol Oncol. 2026;44:110980.
Abstract

SHANG LL, Hu TL, Xiong S, Xu S, et al
Design and synthesis of dual-activity biphenyl inhibitors against SARS-CoV-2 and bladder cancer.
Eur J Med Chem. 2026;306:118581.
Abstract

STUART J, Zhuleku E, Mevius A, Squires P, et al
Characteristics, Treatment Patterns, and Outcomes of Patients with Muscle-Invasive Bladder Cancer Undergoing Radical Cystectomy: A Retrospective Analysis of Health Insurance Claims Data in Germany.
Oncol Ther. 2026 Jan 20. doi: 10.1007/s40487-025-00413.
Abstract

HAYAKAWA N, Kikuchi E
[Current Landscape of Sequential Treatment Strategy in Metastatic Urothelial Carcinoma].
Gan To Kagaku Ryoho. 2026;53:21-24.
Abstract

KITA Y
[Current Development of Perioperative Immune Checkpoint Inhibitor Therapy for Muscle-Invasive Bladder Cancer].
Gan To Kagaku Ryoho. 2026;53:16-20.
Abstract

SHIGEHISA R, Fukata S, Inoue K
[Evolving Pharmacotherapy for Bladder Cancer-From Non-Muscle-Invasive to Metastatic Disease-Development of Novel Therapies for BCG-Unresponsive NMIBC].
Gan To Kagaku Ryoho. 2026;53:10-15.
Abstract

KAWAHARA T
[Recent Progress in Novel Therapies for Non-Muscle Invasive Bladder Cancer].
Gan To Kagaku Ryoho. 2026;53:7-9.
Abstract

ST-LAURENT MP, Nikkola J, Tomiyama E, Black PC, et al
Author Correction: Advances in the management of localized bladder cancers.
Nat Rev Clin Oncol. 2026 Jan 19. doi: 10.1038/s41571-026-01121.
Abstract

LONGONI M, Falkenbach F, Marmiroli A, Le QC, et al
Development and external validation of a nomogram predicting cancer-specific mortality-free survival after trimodal therapy in muscle-invasive bladder cancer.
World J Urol. 2026;44:111.
Abstract

ZHAO Z, Zhao Z, Bu X, Wang M, et al
Added value of synthetic MRI in refining biparametric MRI VI-RADS for predicting muscle-invasive bladder cancer.
Abdom Radiol (NY). 2026 Jan 19. doi: 10.1007/s00261-025-05365.
Abstract

EL MJABBER R, Alami R, Aouzah F, Bezzari W, et al
Integrated Boost vs. Sequential Scheme in Volumetric Modulated Arc Therapy (VMAT) for Trimodal Bladder Cancer Therapy: A Comparative Study.
Cureus. 2025;17:e99438.
Abstract

KAUFMANN E, Aeppli S, Affentranger A, Arnold N, et al
Interdisciplinary Swiss consensus recommendations for follow-up after radical cystectomy and trimodal treatment for muscle-invasive bladder cancer.
Bladder Cancer. 2026;12:23523735251410823.
Abstract

WU J, Jin S, Bai Q, Wang H, et al
Noninvasive Early Detection and Recurrence Monitoring for Non-Muscle-Invasive Bladder Cancer via Urine Tumor DNA: A Prospective Clinical Study.
MedComm (2020). 2026;7:e70592.
Abstract

YAMANAKA R, Miura K, Yamasaki N, Ogata S, et al
Angiotensin II type 1 receptor signaling promotes bladder cancer progression and its inhibition by Losartan.
Hypertens Res. 2026 Jan 19. doi: 10.1038/s41440-025-02535.
Abstract

LU L, Cheng H, Liu S, Tao Y, et al
TAK-901 targeted inhibition of EGFR activates transcription factor FOXO causing cell cycle arrest and apoptosis in bladder cancer.
Mol Cancer Ther. 2026 Jan 19. doi: 10.1158/1535-7163.MCT-25-0507.
Abstract

XU T, Wang K, Chen Y, Yu Y, et al
Adjuvant bacillus Calmette-Guerin (BCG) immunotherapy versus BCG combined with disitamab vedotin in BCG-naive high-risk non-muscle invasive bladder cancer with HER2 expression: A real-world study.
Int Immunopharmacol. 2026;172:116186.
Abstract

RICHTERS A, Franken MD, Meijer RP, van der Heijden AG, et al
Treatments and survival outcomes of patients with synchronous and metachronous metastatic bladder cancer: A population-based nationwide cohort study.
Cancer Treat Res Commun. 2026;46:101099.
Abstract

MOHAMED T, Bani Irshid BA, Elhashamy H, Deameh MG, et al
Optimal duration of perioperative antibiotics in radical cystectomy and urinary diversion: a systematic review and meta-analysis.
Langenbecks Arch Surg. 2026;411:58.
Abstract

RICCIARDI G, Tralongo P, Pierconti F, Zuccala V, et al
Urothelial Carcinoma In Situ: Advances in Diagnosis and Management.
Clin Genitourin Cancer. 2026;24:102478.
Abstract

KURIAN M, Mamtani R, Elghawy O, Nimgaonkar V, et al
Real-World Enfortumab Vedotin +/- Pembrolizumab Treatment-Based Toxicities and Associations With Survival in Advanced Urothelial Carcinoma.
Clin Genitourin Cancer. 2026;24:102474.
Abstract

WENG C, Deng H, Yang Z, Zeng X, et al
Regulation of drug resistance in bladder urothelial carcinoma by tumor aerobic glycolysis.
J Transl Med. 2025;24:85.
Abstract

CARVALHO D, Pinto S, Sarmento B
Modeling the human bladder tissue using three dimensional in vitro approaches as a tool for drug screening platforms.
Acta Biomater. 2026;210:296-313.
Abstract

REVERDY T, Izarn F, Allignet B, Roubaud G, et al
Impact of FGFR3 Alterations on First-Line Platinum Based Chemotherapy in Patients With Metastatic or Locally Advanced Urothelial Carcinoma: The Retrospective IFUCA Study.
Clin Genitourin Cancer. 2026;24:102465.
Abstract

COCA MEMBRIBES S, Szabados B, Powles T
Towards biomarker-driven therapies for urothelial carcinoma.
Nat Rev Clin Oncol. 2026;23:92-106.
Abstract

LITT HK, Mamtani R, Chow RD
Outcomes of enfortumab vedotin plus pembrolizumab in patients with advanced urothelial cancer and severe renal dysfunction.
Urol Oncol. 2026;44:118.
Abstract

DOGRA S, Lee J, Siriruchatanon M, Gu Z, et al
Incidental Bladder Lesions on Prostate Multiparametric MRI: Prevalence and Factors Associated with Bladder Carcinoma.
Acad Radiol. 2026;33:472-481.
Abstract

CHEVILLE JC, Orme JJ, Gupta S, Lucien-Matteoni F, et al
Defining NECTIN4 Amplification and Protein Expression in Urothelial Carcinoma and Histologic Subtypes.
Mod Pathol. 2026;39:100928.
Abstract

MAREI A, Hohls M, Touloumtzidis A, Katoh M, et al
Metastasis of an urothelial carcinoma as rare cause of an AV-graft dysfunction in a transgender patient.
J Vasc Access. 2026;27:326-331.
Abstract

RAHMADI R, Mudhia Arisa Putri U, Herman H, Rachman W, et al
Case Report: Radical urethrectomy with partial cystectomy and bladder outlet reconstruction in giant female urethral adenocarcinoma infiltrating the bladder: A rare case report.
F1000Res. 2026;14:741.
Abstract

ZHANG X, Zong R, Sun Y, Chen N, et al
The FN1-ITGB4 Axis Drives Acquired Chemoresistance in Bladder Cancer by Activating FAK Signaling.
Oncol Res. 2026;34:21.
Abstract

FENG R, Zhang J, Tao Y, Hou J, et al
Preoperative inflammation-based immune prognostic nomogram in bladder cancer: a multicenter study.
Front Oncol. 2026;15:1644747.
Abstract

CHEN ST, Chang KS, Hou CP, Lin WY, et al
WISP1 is the stromal-secreting oncoprotein via paracrine downregulation of NDRG1, KAI1, and Maspin in human bladder cancer cells.
Transl Oncol. 2026;65:102680.
Abstract

NEBIOGLU A, Basaranoglu M, Bozlu M, Tek M, et al
Effects of dutasteride with Bacillus Calmette-Guerin therapy on recurrence, progression, metastasis, and survival in non-muscle invasive bladder cancer: a retrospective single-center study.
BMC Urol. 2026 Jan 28. doi: 10.1186/s12894-026-02059.
Abstract

LU Q, Guo J, Xu Y, Cui Y, et al
RAD54B as a biomarker for prognosis and immunotherapy response in bladder cancer.
Discov Oncol. 2026 Jan 28. doi: 10.1007/s12672-026-04514.
Abstract

MARCQ G, Dahm P, Maisch P
En-bloc resection: Evidence and uncertainty Re: Comparative effectiveness of en-bloc resection techniques vs. conventional transurethral resection for non-muscle-invasive bladder cancer: A systematic review and meta-analysis.
Can Urol Assoc J. 2026;20:E80-E81.
Abstract

SHIH YC, Wu CY, Huang SW, Tsai CY, et al
Multimodal Large Language Models for Cystoscopic Image Interpretation and Bladder Lesion Classification: Comparative Study.
J Med Internet Res. 2026;28:e87193.
Abstract

SHI WY, Liu KJ, Esfahani MS, Mach KE, et al
Field-effect-informed urine liquid biopsy for bladder cancer.
Cell. 2026 Jan 27:S0092-8674(25)01503-X. doi: 10.1016/j.cell.2025.
Abstract

SCHERRER M, Brunaiova L, Furrer M, John H, et al
How safe is teaching radical cystectomy? : Results from the prospective Swiss society of urology database.
World J Urol. 2026;44:133.
Abstract

HE Y, Xie J, Zhong S, Zhan C, et al
A Deep Learning-Generated Mixed Tumor-Stroma Ratio for Prognostic Stratification and Multi-omics Profiling in Bladder Cancer.
Research (Wash D C). 2026;9:1053.
Abstract

HU H, Huang J, Ma L, Zhang S, et al
Hexaminolevulinate blue light cystoscopy improves bladder cancer detection in comparison to white light cystoscopy: a prospective, comparative, within-patient controlled multicenter phase III bridging study in China.
Front Urol. 2026;5:1713128.
Abstract

PAN S, Cui W, Lin J, Wang Z, et al
The infection-microbiome-immunity axis in bladder cancer: mechanistic insights and therapeutic perspectives.
Front Immunol. 2026;16:1716230.
Abstract

FRYD ND, Albertsen N, Bernth-Andersen S, Ernst A, et al
The GreenBladder Study: Early Detection of Bladder Cancer in Greenland Using a Urinary Biomarker.
J Clin Med. 2026;15:761.
Abstract

KLATTE T, Bold F, Dengler J, de Martino M, et al
Trends in the Management of Bladder Cancer with Emphasis on Frailty: A Nationwide Analysis of More Than 49,000 Patients from a German Hospital Network.
Life (Basel). 2026;16:169.
Abstract

ALQAISI O, Tai P, Storme G
Specialized Nursing-Led Interventions for Bladder Cancer Management: A Scoping Review of Evidence and Clinical Outcomes.
Medicina (Kaunas). 2026;62:185.
Abstract

NEBIOGLU A, Turhan A, Basaranoglu M, Bozlu M, et al
Prognostic Significance of Hemogram Parameters in Non-Muscle Invasive Bladder Cancer: A Comprehensive Retrospective Analysis.
Medicina (Kaunas). 2025;62:51.
Abstract

COJOCARU I, Guliciuc M, Cojocaru E, Serban C, et al
A Review of the Latest Evidence on Prognostic Factors in Locally Advanced and Metastatic Urothelial Carcinoma Treated with Immune Checkpoint Inhibitors.
Medicina (Kaunas). 2025;62:46.
Abstract

JIANG H, Chen Y, Zeng X, Yang R, et al
The Role of Natural Compounds in Bladder Urothelial Carcinoma Treatment.
Int J Mol Sci. 2026;27:596.
Abstract

MOHAMED AA, AbdulAzeem Y, Almudaifer AI, ZainEldin H, et al
Explainable Computational Imaging for Precision Oncology: An Interpretable Deep Learning Framework for Bladder Cancer Histopathology Diagnosis.
Bioengineering (Basel). 2025;13:4.
Abstract

NAN Z, Zhao W, Li S, Yue C, et al
Unequal Progress in Early-Onset Bladder Cancer Control: Global Trends, Socioeconomic Disparities, and Policy Efficiency from 1990 to 2021.
Healthcare (Basel). 2026;14:193.
Abstract

CERIA F, Muhammad G, Del Giudice F, Ibrahim Y, et al
Unveiling the Female Factor: Gender-Based Differences in Outcomes and Survival Following Radical Cystectomy for Bladder Cancer.
Cancers (Basel). 2026;18:308.
Abstract

PACKIAM VT, Ghodoussipour S, Konety BR, Ahmadi H, et al
Impact of Computational Histology AI Biomarkers on Clinical Management Decisions in Non-Muscle Invasive Bladder Cancer: A Multi-Center Real-World Study.
Cancers (Basel). 2026;18:249.
Abstract

PITOUT A, Mazeaud C, Blondeau A, Salleron J, et al
Sarcopenia Predicts Mortality in Bladder Cancer with Neoadjuvant Chemotherapy: A Multicenter Study.
Cancers (Basel). 2026;18:222.
Abstract

SANDHU K, Hopkins DT, Newton M, Sathianathen N, et al
Oligometastatic Bladder Cancer: Current Definitions, Diagnostic Challenges, and Evolving Therapeutic Strategies.
Cancers (Basel). 2026;18:189.
Abstract

PIRES I, Files R
Silent Threats: A Narrative Review of Urinary Bladder Cancer in Dogs and Cats-Epidemiology and Risk Factors.
Animals (Basel). 2026;16:217.
Abstract

MIKI J, Kimura S, Urabe F, Atsuta M, et al
Optimizing pelvic lymph node dissection in bladder cancer: obturator focus, pN1 prognosis, and sentinel node feasibility.
Int J Clin Oncol. 2026 Jan 27. doi: 10.1007/s10147-026-02969.
Abstract

SHEN L, Yu C, Wu Y, Chen H, et al
NFIB suppresses cell migration, invasion and EMT of bladder cancer through the PI3K-AKT signaling pathway.
Cytotechnology. 2026;78:33.
Abstract

QIU M, Zhang S, Liang J, Chen G, et al
Prolyl 4-Hydroxylase Beta Peptide Promotes Invasion, Migration, and Epithelial-Mesenchymal Transition through Activation of the Claudin-1/ AMPK/TGF-beta1 Pathway in Bladder Cancer Cells.
Protein Pept Lett. 2026 Jan 22. doi: 10.2174/0109298665418763251124051527.
Abstract

ZENG D, Liu B, Deng F, Wang Y, et al
Multidimensional liquid biopsy in bladder cancer: advances in circulating tumor cells, circulating tumor DNA, exosomes, and metabolomics.
Oncologist. 2026;31:oyaf409.
Abstract

SILVA TA, Viana LG, Carvalho VM, Bertolla RP, et al
Proteomic Profiling of Non-Muscle Invasive Bladder Cancer Reveals Potential Biomarkers for Recurrence and Progression Risk.
J Proteome Res. 2026 Jan 26. doi: 10.1021/acs.jproteome.5c00486.
Abstract

WANG X, Preston A, Aning J, Loizou M, et al
Early Detection of Bladder Cancer Using Advanced Feature Engineering and Swarm Intelligence Optimization on EHRs.
IEEE Trans Biomed Eng. 2026;PP.
Abstract

KARKEET RM, Sayed-Ahmed MM, Ghaly S, Farouk M, et al
Comprehensive Evaluation of Bacillus Calmette-Guerin therapy in Non-muscle invasive bladder cancer Egyptian patients: a retrospective cohort study.
J Egypt Natl Canc Inst. 2026;38:2.
Abstract

ZHANG WW, Qu HR, Du XS, Sun SJ, et al
SREBP2-RAB11A-ZDHHC20 axis orchestrates FGFR3 palmitoylation and membrane retention to drive bladder cancer progression.
Cell Oncol (Dordr). 2026;49:30.
Abstract

NAPPI A, Crocetto F, Conforti P, Sagliocchi S, et al
Cell-free RNA profiling uncovers non-canonical circulating D2 transcript elevation in Bladder Cancer plasma.
J Liq Biopsy. 2026;11:100454.
Abstract

WANG P, Deng J, Wu S
Modeling and validation of serum miR-18a and miR-122 levels as predictors of recurrence after laparoscopic radical cystectomy procedure for bladder cancer based on nomogram model.
Front Oncol. 2026;15:1579873.
Abstract

HARMON JF, Santos E, Johnson-Pais TL, Leach RJ, et al
Association of CCL2/CCR2 gene polymorphisms and bladder cancer risk in a hispanic-rich US population.
Bladder Cancer. 2026;12:23523735261417401.
Abstract

SU X, Yu H, Zhang M, Zeng K, et al
A novel prognostic model based on epithelial cell progression genes identifies OAS1 as a suppressor of bladder cancer aggressiveness.
Front Mol Biosci. 2026;12:1716130.
Abstract

YUAN Z, Situ M, Ye Y, Zhang J, et al
Dissecting the role of KLF5: from tumor progression to immune interactions with emphasis on glioma and bladder cancer.
Front Immunol. 2026;16:1730356.
Abstract

CHAN CC, Lee MJ, Su J, Su JJ, et al
Exploring Pembrolizumab-Induced IM3OS in a Patient With Bladder Cancer.
Pharmacol Res Perspect. 2026;14:e70212.
Abstract

CHEN Y, Lao M, Shen M, Wang Z, et al
TMIGD2 in Bladder Cancer: A Bioinformatics and Experimental Approach to Understanding its Prognostic and Therapeutic Potential.
Curr Top Med Chem. 2026 Jan 15. doi: 10.2174/0115680266414071251126071447.
Abstract

CHEN Y, Zhu H, Lao M, Ding G, et al
Exploring ZPLD1 as a Prognostic Indicator and Therapeutic Target in Bladder Cancer.
Curr Med Chem. 2026 Jan 15. doi: 10.2174/0109298673413898251122184011.
Abstract

FANG Q, You C, Xiao X, Yang W, et al
Targeting the WWP2-ASPP2 axis overcomes cisplatin resistance by inhibiting the mevalonate pathway in TP53-mutant bladder cancer.
Int J Biol Macromol. 2026;343.
Abstract

LUTY M, Szydlak R, Pabijan J, Ovreeide IH, et al
Identification of glycosylation-related changes in migratory and mechanical properties of bladder cancer cells.
Biosens Bioelectron. 2026;298:118410.
Abstract

CHEN M, Zheng L, Huang D, Wang S, et al
RBM15/IGF2BP3 promotes immune escape in bladder cancer by enhancing m6A modification of PFKFB4.
Int J Biol Macromol. 2026 Jan 22:150142. doi: 10.1016/j.ijbiomac.2026.150142.
Abstract

CHEN Q, Wu R, Zhang C, Xie J, et al
Efficacy and safety of tislelizumab plus intravesical chemotherapy in recurrent high-risk non-muscle-invasive bladder cancer: A retrospective single-center real-world study.
Urol Oncol. 2026;44:110988.
Abstract

KLUTH M, Plage H, Furlano K, Hofbauer S, et al
PTEN Deletions Are Associated With Tumor Progression But Unrelated to Patient Prognosis in Muscle-Invasive Urothelial Bladder Carcinomas: A Large Multi-Center Validation Study on 2710 Urothelial Bladder Carcinomas.
Genes Chromosomes Cancer. 2026;65:e70105.
Abstract

CHEN WW, Wu B, Wen X
Causal association between socioeconomic disparities and tumors of the urinary system: A Mendelian randomization study.
Medicine (Baltimore). 2026;105:e47216.
Abstract

WANG Y, Bhandary P, Moore JH, Li X, et al
Integrative microRNA and transcriptome analysis reveals sex-specific molecular divergence in human bladder cancer.
Biol Sex Differ. 2026 Jan 23. doi: 10.1186/s13293-026-00829.
Abstract

BENTSEN L, Lund-Jacobsen T, Jakobsen CB, Larsen FM, et al
Shared Decision-Making in Curative Uro-Oncology: A Systematic Review.
Semin Oncol Nurs. 2026;42:152116.
Abstract

SONG T, He W, Yuan Q, Xia S, et al
ADAM12-programmed ECM-CAF remodeling activates PI3K-AKT and enforces an immune-excluded microenvironment to drive bladder cancer progression and therapy resistance.
Cell Signal. 2026 Feb 4:112398. doi: 10.1016/j.cellsig.2026.112398.
Abstract

LABROY M, Chabaud S, Durand M, Fourquaux I, et al
Improving photodynamic therapy efficacy in bladder cancer using polymer micelle-encapsulated pheophorbide a.
Transl Oncol. 2026;65:102687.
Abstract

WANG Y, Ni H, Dong S, Shang Y, et al
Environmental Dose MEOHP Promotes Bladder Cancer Progress through Hybrid EMT Mechanism: Based on the Adverse Outcome Pathway.
Environ Sci Technol. 2026 Feb 6. doi: 10.1021/acs.est.5c08003.
Abstract

JIANG M, Sun C, Wang B, Huang Q, et al
Analysis of the molecular mechanism underlying di(2-ethylhexyl) phthalate-induced bladder carcinogenesis via network toxicology and molecular docking approaches: An observational study.
Medicine (Baltimore). 2026;105:e47378.
Abstract

TAKADA H, Ikeda M, Tanaka R, Samejima N, et al
Prognostic effect of preoperative albumin-to-globulin ratio in patients with non-metastatic bladder cancer undergoing radical cystectomy.
Oncology. 2026 Feb 6:1-20. doi: 10.1159/000550892.
Abstract

MEHMUD I, Zhang Y, Wu S, Zhang S, et al
Oncological Safety of Bladder Preservation in Elderly Patients with Muscle-Invasive Bladder Cancer.
Ann Surg Oncol. 2026 Feb 6. doi: 10.1245/s10434-025-19064.
Abstract

BOLENZ C, Zengerling F, Kubler H, Hahn O, et al
[Neoadjuvant therapy and complete response of muscle-invasive bladder cancer: may the urinary bladder be preserved?].
Urologie. 2026 Feb 6. doi: 10.1007/s00120-026-02774.
Abstract

MOJICA W, Izydorczak A, Wood T, Hsu J, et al
A Novel Method to Generate Analyte-Specific Specimens for Multi-Omic Studies of Primary Bladder Cancer.
Biopreserv Biobank. 2026 Feb 6:19475535251394594. doi: 10.1177/19475535251394594
Abstract

NING W, Chang P, Zheng J, Chen W, et al
Advances in immunotherapy for bladder cancer and clinical practice of next-generation sequencing.
Front Immunol. 2026;16:1684597.
Abstract

GALSKY MD, Izadmehr S, Yu M, Curtis SD, et al
Monitoring of plasma and urine tumor-derived DNA to inform bladder-sparing approaches for patients with muscle-invasive bladder cancer.
medRxiv [Preprint]. 2026 Jan 16:2026.01.14.26344033.
Abstract

JALAL H, Kang SK, Alarid-Escudero F, Chrysanthopoulou SA, et al
Understanding Bladder Cancer Screening Limits Through Comparative Modeling: The Maximum Clinical Incidence Reduction (MCLIR) Methodology.
medRxiv [Preprint]. 2026 Jan 30:2026.01.27.26344939.
Abstract

MAK KS, Efstathiou JA
Tipping the Scales for Bladder Cancer: Weighing Differences in Quality of Life After Cystectomy Versus Trimodality Therapy.
Int J Radiat Oncol Biol Phys. 2026;124:651-653.
Abstract

NABIYOUNI F, Chiou PZ
Enhancing urine cytopathology with artificial intelligence: a systematic review.
Am J Clin Pathol. 2026;165:aqaf135.
Abstract

LIU N, Xing L, Chen H, Chen S, et al
Sequential dilatation of two balloons and double D-J stents for therapy of ureteroenteral anastomotic stricture in patients following radical cystectomy and Bricker urinary diversion.
Afr Health Sci. 2025;25:334-342.
Abstract

CHEN K, Su H, Pei F, Chen X, et al
KNTC1 initiates a KNTC1/E2F8/MYC positive feedback loop to facilitate tumorigenesis and enhance chemoresistance in bladder cancer.
J Exp Clin Cancer Res. 2026 Feb 4. doi: 10.1186/s13046-026-03651.
Abstract

HSIEH YC, Li CF, Ho CH, Huang SK, et al
Evaluation of Clinical and Prognostic Roles of CCL8 in Urinary Bladder Cancer and Upper Tract Urothelial Carcinoma.
Appl Immunohistochem Mol Morphol. 2026 Feb 5. doi: 10.1097/PAI.0000000000001307.
Abstract

JIN H
Comment on "adjuvant bacillus Calmette-Gu'erin (BCG) immunotherapy versus BCG combined with disitamab vedotin in BCG-naive high-risk non-muscle invasive bladder cancer with HER2 expression: A real-world study".
Int Immunopharmacol. 2026;173:116312.
Abstract

XU G, Li Y, Peng S, Zhao W, et al
Delactylation of the tumor suppressor ARHGDIB drives metastasis and chemoresistance in bladder cancer.
Cell Rep. 2026;45:116941.
Abstract

LIU Q, Lu X, He C, Chen J, et al
A Novel Model for Muscle-Invasive Bladder Cancer Diagnosis Using Contrast-Enhanced Ultrasound.
Ann Surg Oncol. 2026 Feb 4. doi: 10.1245/s10434-026-19122.
Abstract

WANG Y, Guo S, Zeng J, Feng W, et al
Prognostic Significance of Lymph Node Ratio for Overall Survival in Patients with Lymph Node-Positive Bladder Cancer Post-Radical Cystectomy and Chemotherapy: A Multicenter Cohort Analysis.
Ann Surg Oncol. 2026 Feb 4. doi: 10.1245/s10434-026-19090.
Abstract

DE FELICE M, Tammaro M, Caterino M, Nacca V, et al
Fulminant Fournier gangrene in bladder cancer: case report and review of the literature.
Eur Rev Med Pharmacol Sci. 2026;30:46-50.
Abstract

OZTURK YUZDEMIR K, User IR, Ozcan HN, Orhan D, et al
Pediatric inflammatory myofibroblastic tumor of the urinary bladder: a rare case report and treatment approach.
Turk J Pediatr. 2025;67:920-926.
Abstract

SOMA T, Takemura K, Toide M, Ito M, et al
Bladder-sparing strategies for non-muscle-invasive bladder cancer after bacillus Calmette-Guerin failure: a systematic review.
BMJ Oncol. 2026;5:e000753.
Abstract

YIN Y, Qin Z, Zhou H, Wu Y, et al
Ultrasound Responsive Mn/Se-Nanozyme as PANoptosis Initiators for Bladder Cancer Immunotherapy.
Adv Healthc Mater. 2026 Feb 3:e04808. doi: 10.1002/adhm.202504808.
Abstract

HAJIME T, Shiota M, Matsumoto T, Mutaguchi J, et al
ASO Author Reflections: Tumor Laterality as a Key Determinant of Pelvic Lymph Node Dissection Strategy in Bladder Cancer.
Ann Surg Oncol. 2026 Feb 3. doi: 10.1245/s10434-026-19200.
Abstract

TANG X, Liu L, Gao M, Duan P, et al
Single-cell transcriptomics identifies fibroblast associated immune heterogeneity and prognostic signatures in bladder cancer.
Sci Rep. 2026 Feb 3. doi: 10.1038/s41598-026-38219.
Abstract

SHEN C, Liu C, Hu D, Ge H, et al
Targeting RRBP1 reverses immune evasion and enhances immunotherapy efficacy via the CXCL10-CXCR3 axis in bladder cancer.
J Immunother Cancer. 2026;14:e013809.
Abstract

ZHANG H, Liu Y, Huang W, Li Y, et al
Mediator complex subunit 8 promotes bladder cancer progression via Stearoyl-CoA desaturase.
Cell Mol Life Sci. 2026 Feb 3. doi: 10.1007/s00018-026-06083.
Abstract

WANG Z, He W, Wang M, Hua M, et al
Integrated multicenter single-cell atlas of bladder cancer reveals tumor heterogeneity associated with immunotherapy.
Int J Surg. 2026 Feb 3. doi: 10.1097/JS9.0000000000003830.
Abstract

MIKHAIL AS, Gurram S, Valera VA, Haemmerich D, et al
Heat-activated intravenous liposomal doxorubicin combined with mitomycin C hyperthermic intravesical chemotherapy (HIVEC) for treatment of bladder cancer.
Int J Hyperthermia. 2026;43:2615462.
Abstract

VAN DE MERBEL AF, van der Mark MH, Hensen LCM, van den Wollenberg DJM, et al
Improved oncolytic and immunostimulatory activity of the spontaneous jin-3 reovirus mutant in preclinical bladder cancer models.
Mol Ther Oncol. 2026;34:201128.
Abstract

YOUSSEF M, Nasseredine B, Amine Z, Amine S, et al
Psoas metastasis mimicking abscess in untreated muscle-invasive bladder cancer: A diagnostic pitfall.
Radiol Case Rep. 2026;21:1554-1558.
Abstract

MENG X, Su CY, Yang Z
Editorial Comment on: "Enhanced Artificial Intelligence in Bladder Cancer Management: A Comparative Analysis and Optimization Study of Multiple Large Language Models" by Li et al.
J Endourol. 2026 Feb 2:8927790251387369. doi: 10.1177/08927790251387369.
Abstract

YAMAMOTO S, Fukata S, Shimasaki S, Kurano Y, et al
Clinical Outcomes Following Transurethral Laser Ablation with Topical Versus General or Spinal Anesthesia for Non-Muscle-Invasive Bladder Cancer: A Japanese Single-Center Pilot Study.
Photodiagnosis Photodyn Ther. 2026 Jan 31:105376.
Abstract

YOKOYAMA T, Kobayashi H, Horiguchi A, Miyai K, et al
A Case of Primary Bladder Neuroendocrine Carcinoma With Urethral Invasion Following Radical Prostatectomy.
Asian J Endosc Surg. 2026;19:e70251.
Abstract

ZHANG M, Zhou Y
Sexual distress in patients after radical cystectomy for bladder cancer: a qualitative study.
Support Care Cancer. 2026;34:151.
Abstract

WANG X, Jin L, Zou X, Zhu A, et al
ERBB2 mutations promote recurrence and metastasis in non-muscle-invasive bladder cancer via HIF-1 phosphorylation: Insights from whole exome sequencing.
J Pharm Anal. 2026;16:101519.
Abstract

LIU Z, Zhou C, Xu W, Zhang D, et al
Polyarginine Peptide R11-Actin Interaction Induces a Domino Effect on Cytoskeleton Remodeling to Suppress Bladder Cancer Metastasis.
Research (Wash D C). 2026;9:1109.
Abstract

ZHANG M, Lin L, Xu H, Su X, et al
A novel tumor-progressing fibroblast signature derived from single-cell RNA sequencing enables prognostic stratification and reveals RNF11 as a functional regulator in bladder cancer.
Front Mol Biosci. 2026;12:1722809.
Abstract

EL OMRI G, Houssaini OI, Rachid M, Houry Y, et al
Non-functional bladder paraganglioma in a young patient: conservative management by transurethral resection and diagnostic challenges.
Pan Afr Med J. 2025;52:105.
Abstract

WANG Y, Yuan H, Zhang Y, Zhang Y, et al
Intravesical folate-conjugated hydroxyethyl starch micelles for pH-triggered co-delivery of epirubicin and TLR7 agonist toward synergistic chemoimmunotherapy of bladder cancer.
Mater Today Bio. 2026;37:102835.
Abstract

YU K, Sun J, Zhang J, Shi Y, et al
Lactylation enhances YTHDF3 stability to promote cisplatin resistance via m6A-dependent KDM6B decay in bladder cancer.
Cancer Lett. 2026;642:218282.
Abstract

ZHAO J, Zhao J, Huang W, Lin W, et al
Decoding metabolic reprogramming heterogeneity across bladder cancer stages using single-cell and spatial multi-omics approaches.
Comput Methods Programs Biomed. 2026;277:109261.
Abstract

LI D, Lu J, Zhu R, Sun X, et al
Ad-VT oncolytic adenovirus suppresses bladder cancer via cAMP-dependent AMPK-Raptor activation and G2/M arrest.
Tumour Virus Res. 2026;21:200337.
Abstract

CHEN Z, Chen X, Xie R, Huang M, et al
DANCR Promotes Metastasis and Proliferation in Bladder Cancer Cells by Enhancing IL-11-STAT3 Signaling and CCND1 Expression.
Mol Ther. 2026 Jan 30:S1525-0016(26)00036-5. doi: 10.1016/j.ymthe.2026.
Abstract

DU A, Zhou Y, Deng X, Yuan D, et al
DCLK1 drives malignant progression and chemoresistance of bladder cancer by deubiquitinating HDAC6.
Mol Cancer. 2026 Jan 30. doi: 10.1186/s12943-025-02560.
Abstract

DAY E, Bizzarri FP, Mackenzie C, Szabados B, et al
Management of surgical menopause in female patients with bladder cancer undergoing radical cystectomy.
Nat Rev Urol. 2026 Jan 30. doi: 10.1038/s41585-026-01124.
Abstract

MORIKAWA T, Hamamoto S, Tasaki Y, Ishikawa D, et al
Evaluation of the Safety of Robot-Assisted Radical Cystectomy for Bladder Cancer in Octogenarians.
Asian J Endosc Surg. 2026;19:e70248.
Abstract

ZHOU J, Jiang X, Liu Q, Xia HA, et al
PD-L1 subpopulations of metastatic urothelial carcinoma demonstrate heterogeneity to chemotherapy: an integrated analysis of digitized trial results.
Cancer Metastasis Rev. 2026;45:7.
Abstract

BOURGI A, Rusch E, Bruyere F
Water-Related Exposures And Bladder Cancer Risk: A Comprehensive Epidemiological Review.
Cancer Epidemiol Biomarkers Prev. 2026.
Abstract

AY A, Alkanli N, Atli E, Gurkan H, et al
Investigation of the Correlation Between Selected miRNAs, Proinflammatory Cytokines, and Serum Trace Elements in Bladder Cancer Development and Progression.
Curr Issues Mol Biol. 2025;48:53.
Abstract

RIAZ IB, Humayun MA, Khaki AR, Hussain SA, et al
Treatment Sequencing in Advanced Urothelial Cancer.
Drugs. 2026;86:203-215.
Abstract

ZARZYCKA M, Kotula-Balak M, Gil D
Inhibiting autophagy enhances anti-cancer properties of sulforaphane.
Sci Rep. 2026;16:5296.
Abstract

KIELBIK A, Hellwich E, Bahlinger V, Sowa P, et al
Nanosecond pulsed electric fields induce cell-size-dependent selective permeabilization of urothelial cancer cells.
Commun Biol. 2025;9:153.
Abstract

KATSUMATA Y, Yamamoto S, Iwata H, Kuroiwa H, et al
Agent-specific differences in sustained intraoperative hypotension during oral 5-Aminolevulinic acid-guided transurethral resection of bladder tumor: A retrospective observational study.
Photodiagnosis Photodyn Ther. 2026;57:105319.
Abstract

MANOHARAN M, Raja Iyub MJ, Zhang Y, Prabhakar P, et al
Development of a Multivariable Machine Learning Model for the Prediction of Postoperative Ileus After Radical Cystectomy.
J Surg Oncol. 2026;133:226-232.
Abstract

WANG J, Zhao X, Jiang XL, Liu G, et al
Construction and Validation of a Prognostic Survival Prediction Model for NMIBC Patients Undergoing Radical Cystectomy.
Cancer Invest. 2026;44:156-173.
Abstract

NIHARIKA, Tripathi S, Singhai A, Goel A, et al
Clinical correlates of key autophagic markers, ATG4B, LC3 and p62 in urothelial carcinoma of bladder patients.
Tissue Cell. 2026;99:103240.
Abstract

TEOH JY, Bracco FM, Wong JH, Liu AQ, et al
A Novel Transurethral Robotic Platform for Performing En Bloc Resection of Bladder Tumour: Results from the First Phase of the VIABLE Trial.
Eur Urol Oncol. 2026;9:111-115.
Abstract

KONG L, Yang G, Weng B, Wen Z, et al
Early Detection of Chemotherapy-Induced Glucose Metabolic Alterations in Bladder Carcinoma Using Deuterium ((2)H) Metabolic Imaging: in Vitro and in Vivo Assessments.
Adv Sci (Weinh). 2026;13:e14614.
Abstract

RAGGI D, Crupi E, Pederzoli F, Martini A, et al
HER2 and urothelial carcinoma: current understanding and future directions.
Nat Rev Urol. 2026;23:110-132.
Abstract

HARLE V, Agrawal YO
Development of Novel Intravesical Formulation for Bladder Retention Targeting Bladder Disorders.
Curr Drug Targets. 2025;26:903-920.
Abstract

FILON M, Schmidt B
The Future of Novel Antibody-drug Conjugates in Localized Urothelial Cancer.
Eur Urol Focus. 2026;12:34-37.
Abstract

CHATZKEL J, Linscott J, Daniel Grass G, Li R, et al
Urothelial Cancer: Leveraging Circulating Tumor DNA To Avoid Unnecessary Bladder-directed and Systemic Therapies.
Eur Urol Focus. 2026;12:38-40.
Abstract

WU K, Liu X, Zhang J, Wang X, et al
Mechanisms and implications of epithelial cell plasticity in the bladder.
Nat Rev Urol. 2026;23:70-88.
Abstract

PYRGIDIS N, Schulz GB, Scilipoti P, Pellegrino F, et al
The Role of Salvage Cystectomy After Prior Trimodality Therapy: A Multinational Match-paired Analysis.
Eur Urol Focus. 2026;12:88-95.
Abstract

ROBBRECHT DGJ, Salhi Y, Martens JWM, Aarts MJB, et al
Novel Molecular Biomarkers to Guide Treatment Decision-making in Metastatic Urothelial Cancer-A Patient Cohort Analysis.
Eur Urol Oncol. 2026;9:7-11.
Abstract

CHEN J, Fu S, Yu J, Tang Q, et al
Modified Glasgow prognostic score as a marker for predicting outcomes in patients with either bladder and prostate cancer : A systematic review and meta-analysis.
Oncology. 2025 Mar 28:1-20. doi: 10.1159/000545001.
Abstract

HILSER T, Darr C, Bedke J, Ivanyi P, et al
Treatment of Advanced or Metastatic Urothelial Cancer.
Oncol Res Treat. 2026;49.
Abstract

DOMIAN N, Mlynarczyk G, Kasacka I
Analysis of CacyBP/SIP, ERK1/2, and p38 Expression in Low- and High-Grade Papillary Urothelial Carcinoma.
Cancer Med. 2026;15:e71649.
Abstract

RYOO SW, Choi BY, Son SY, Lee JH, et al
Occupational Exposure to Welding Fumes and the Risk of Bladder Cancer: A Systematic Review and Meta-Analysis.
Am J Ind Med. 2026 Feb 15. doi: 10.1002/ajim.70062.
Abstract

TUNCEKIN A, Aktas Y
The role of systemic inflammatory and prognostic indices in diabetic patients with non-muscle invasive bladder cancer receiving BCG therapy.
Actas Urol Esp (Engl Ed). 2026 Feb 12:501925. doi: 10.1016/j.acuroe.2026.501925.
Abstract

MICHALET M, Ronchin P, Reynaud T, Demogeot N, et al
Radiotherapy with twice weekly Gemcitabine and Cisplatin compared to Cisplatin alone for organ preservation in muscle-invasive bladder cancer: results of the GETUG V04 randomized phase II trial.
Radiother Oncol. 2026;217:111443.
Abstract

GAO M, Li C, Li W, Xie J, et al
White-to-brown adipose switching promotes bladder cancer progression.
Neoplasia. 2026;73:101282.
Abstract

SCILIPOTI P, Rosiello G, Santangelo A, Viti A, et al
Optimizing oncological outcomes in high-grade non-muscle invasive bladder cancer: The impact of a surgeon-led treatment pathway.
Urol Oncol. 2026;44:111007.
Abstract

ELSAWY AA, Laymon M, Ezzat O, Mansour I, et al
Optimal adjuvant intravesical therapy for intermediate risk non-muscle invasive bladder cancer; oncological and patient-reported outcomes of randomized controlled trial.
Urol Oncol. 2026;44:111006.
Abstract

SONG YX, Xia XL, Wu ZM, Yao Y, et al
Integration of bulk and single-cell transcriptomic sequencing reveals the neutrophil heterogeneity in bladder cancer and establishes a prognostic model.
Discov Oncol. 2026 Feb 14. doi: 10.1007/s12672-026-04559.
Abstract

DINCER E, Ozkaptan O, Canakci C, Ipek OM, et al
The Modified Frailty Index-5 as a Predictor of Postoperative Complications Following Radical Cystectomy.
J Coll Physicians Surg Pak. 2026;36:258-262.
Abstract

LIU Y, Duan L, Zhu M, Zhou Z, et al
Exploring the underlying mechanisms of Hedyotis diffusa and Scutellaria Barbata herb pair on the prognosis and treatment efficacy of bladder cancer patients: an integrated approach of network pharmacology and bioinformatics analysis.
BMC Complement Med Ther. 2026 Feb 13. doi: 10.1186/s12906-026-05279.
Abstract

WAN E, Wade C, Sathe A, Ferguson JE 3rd, et al
Contemporary Role for Blue Light Cystoscopy Across the Bladder Cancer Disease Spectrum.
Curr Urol Rep. 2026;27:13.
Abstract

SJODAHL G, Eriksson P, Hoglund M
Re: Joshua J. Meeks. Urothelial Cancer: What Is the Role of Expression-based Subtypes to Guide Neoadjuvant Therapy in Muscle-invasive Bladder Cancer? Eur Urol Focus. In press. https://doi.org/10.1016/j.euf.2025.11.014.
Eur Urol Focus. 2026 Feb 12:S2405-4569(26)00012.
Abstract

LIU J, Luo Y, Chen L, Xiong W, et al
Urinary microbiome and metabolomic profiling reveal propionic acid as an enhancer of BCG immunotherapy in bladder cancer.
Biochim Biophys Acta Mol Basis Dis. 2026;1872:168192.
Abstract

HUANG X, Chen R, Guo Z, Song C, et al
Intensive nursing interventions for post-treatment anxiety and depression in bladder cancer: A systematic review and meta-analysis.
Support Care Cancer. 2026;34:195.
Abstract

LIU ZX, Shi YY, Zhou DS, Chen SN, et al
Role of MED15 in Enhancing EMT and Metastasis in Bladder Cancer Through YAP1 Stabilization.
FASEB J. 2026;40:e71558.
Abstract

LI A, Zhao K, Wang T, Shi G, et al
Transcriptome and single-cell RNA sequencing analysis with 101 machine learning combinations and experimental verification reveals the mechanism of action of mannose metabolism in bladder cancer.
Front Immunol. 2026;17:1710823.
Abstract

ZHANG G, Wang L, Zhao G, Huang Y, et al
Hypoxia-Induced TGFBI Promotes Bladder Cancer Progression by Creating a Stemness Regulation Loop through Stabilizing the Disulfide Bonds of GDF15.
Research (Wash D C). 2026;9:1134.
Abstract

SHANGGUAN W, Li W, Huang W, Wu J, et al
FomA-Containing Outer Membrane Vesicles of Fusobacterium Nucleatum Facilitate Bladder Cancer Lymphatic Metastasis via IL-6-Dependent M2b Macrophage Polarization.
Adv Sci (Weinh). 2026 Feb 13:e23256. doi: 10.1002/advs.202523256.
Abstract

BUTT UA, De Biase D
Correction: Butt, U.A.; De Biase, D. The Urinary Microbiota and the Gut-Bladder Axis in Bladder Cancer. Int. J. Mol. Sci. 2025, 26, 10558.
Int J Mol Sci. 2026;27:1521.
Abstract

RUTZ J, Grein T, Laqua M, Benhassine K, et al
Natural Isothiocyanates Block Adhesion and Invasion of Gemcitabine- and Cisplatin-Resistant Bladder Cancer Cell Lines.
Molecules. 2026;31:555.
Abstract

KOCAK T, Ozbek YD, Bodur M, Yesil S, et al
Intersection of Precision Nutrition and Bladder Cancer: A Narrative State-of-the-Art Review of Potential Applications and Challenges.
J Clin Med. 2026;15:1247.
Abstract

PENG Y, Wang H, Chen H, Jin Z, et al
SAPCD2 Drives Bladder Cancer Progression by Stabilizing TANK and Engaging a CREB-PLAGL2 Feedback Loop to Sustain MAPK Signaling.
Cancers (Basel). 2026;18:535.
Abstract

DEL GIUDICE F, Santarelli V, Khan A, Gad M, et al
Survival Outcomes of BCG Only, BCG Plus EMDA-MMC or Upfront Radical Cystectomy in High-Risk Non-Muscle Invasive Bladder Cancers (NMIBCs): A Multicentre, International, Collaborative Study from Tertiary Referral Institutions.
Cancers (Basel). 2026;18:500.
Abstract

WANG X, Guo J, Zhang R, Dong Y, et al
Hypoxia-inducible factor 1alpha exerts dual roles in bladder cancer progression through TIMP3-mediated regulation of angiogenesis and invasion.
Sci Rep. 2026 Feb 12. doi: 10.1038/s41598-026-39635.
Abstract

KUANG J, An Y, Zhang X, He Z, et al
Analysis of bladder cancer therapeutic drug clinical trials in mainland China and globally.
Biochim Biophys Acta Rev Cancer. 2026 Feb 10:189558.
Abstract

YUTKIN V, Maalouf N, Gur C, Zini A, et al
Targeting Bladder Cancer with Inactivated Uropathogenic E. coli: A Novel Alternative to BCG Immunotherapy.
Cells. 2026;15:229.
Abstract

YANG Y, Wang F, Ning W, Ding Y, et al
CircRNA_103809/miR-516a/FBXL18 contributes to stemness and gemcitabine resistance of bladder cancer cells.
Arch Med Sci. 2025;21:2766-2782.
Abstract

XU X, Gu W, Zakeri MA, Chen YH, et al
No genetic causal links detected between antihypertensive medications and bladder cancer: insights from a trans-ancestry, drug-target Mendelian randomization analysis.
Arch Med Sci. 2025;21:2856-2863.
Abstract

KUMAR P, Alarid-Escudero F, Chiddarwar TV, Garibay-Trevino DU, et al
Differences in Bladder Cancer Diagnosis by Demographic Factors: A Simulation Modeling Analysis.
medRxiv [Preprint]. 2026 Feb 2:2026.01.30.26344972.
Abstract

LOCATELLI I, Lorenzoni M, Venegoni C, Di Coste A, et al
PD1-IL2v expands and induces effector CD8(+) TILs, but not Tregs, in the BCG treated orthotopic non-muscle invasive bladder cancer model.
J Exp Clin Cancer Res. 2026 Feb 11. doi: 10.1186/s13046-026-03667.
Abstract

UTLU A, Aksakalli T, Celik F, Cinislioglu AE, et al
HALP score as an independent prognostic biomarker for recurrence and progression in non-muscle-invasive bladder cancer: A retrospective cohort study.
Surg Oncol. 2026;65:102357.
Abstract

Standard or Extended Lymphadenectomy for Muscle-Invasive Bladder Cancer.
N Engl J Med. 2026;394:728.
Abstract

KUNG TC, Jiang YH, Kuo HC
Prognostic factors for the recurrence, progression, and multiple recurrences of non-muscle-invasive bladder cancer in Eastern Taiwan.
Tzu Chi Med J. 2025;38:83-89.
Abstract

LI L, Li Q, Liu J, Wang Y, et al
Integrated single-cell and spatial transcriptomics combined with whole-exome sequencing reveal key hub genes and epithelial heterogeneity in bladder cancer.
Front Oncol. 2026;15:1748105.
Abstract

CASALE P, Hurle R, Buffi NM, Lughezzani G, et al
Efficacy of early intravesical instillation of hyaluronic acid after transurethral resection of non-muscle-invasive bladder cancers: An open-label, prospective, single-center, randomized, controlled and parallel-group pilot study.
Curr Urol. 2026;20:117-124.
Abstract

SUN X, Jia D, Song X, Jiang Y, et al
Revealing the function and mechanism of piRNA-related genes in bladder cancer through single-cell sequencing and methylation analyses and construction of prognostic features based on consensus clustering.
Curr Urol. 2026;20:101-116.
Abstract

HARLAND N, Reitnauer LE, Amend B, Bahlinger V, et al
Significant differences in CD276 (B7H3) expression between female and male bladder cancer tissue samples: An exploratory study.
Curr Urol. 2026;20:125-126.
Abstract

LIN N, Chen L, Zhang Y, Yang Y, et al
Retraction Note: KIF4A promotes tumor progression of bladder cancer via CXCL5 dependent myeloid-derived suppressor cells recruitment.
Sci Rep. 2026;16:5741.
Abstract

AYDOGDU C, McSweeney ST, Packiam VT, Bukavina L, et al
ASO Practice Guidelines Series: Surgical Management of Bladder Cancer Relapse.
Ann Surg Oncol. 2026 Feb 10. doi: 10.1245/s10434-026-19129.
Abstract

SORENSEN EE, Frydendahl A, Rasmussen MH, Nordentoft I, et al
Molecular residual disease assessment in colorectal and bladder cancer by somatic structural variant analysis of cell-free DNA whole-genome sequencing data.
J Transl Med. 2026 Feb 9. doi: 10.1186/s12967-026-07762.
Abstract

TAO L, Zhao T, Xu Y, Chen W, et al
Integrative multi-cohort analysis identifies urinary microbiota as non-invasive biomarkers of bladder cancer.
BMC Microbiol. 2026 Feb 9. doi: 10.1186/s12866-026-04829.
Abstract

LIN Z, Zhao K, Wang S, Liu J, et al
Oncogenic and immunological roles of LAMP5 across cancers and its potential utility in bladder cancer.
Apoptosis. 2026;31:65.
Abstract

FUKUSHIMA H, Yoshida S, Yajima S, Chen W, et al
A multi?criteria decision analysis comparing robot?assisted, laparoscopic, and open radical cystectomy using large-scale Japanese nationwide databases.
J Robot Surg. 2026;20:230.
Abstract

LEEDER M, Leucht K, Marx M, Grimm MO, et al
[Treatment of non-muscle-invasive bladder cancer].
Urologie. 2026 Feb 9. doi: 10.1007/s00120-026-02781.
Abstract

GAO C, Cao X, Miao L, Chen W, et al
lncRNA FENDRR as a Prognostic Biomarker and Regulator of Bladder Cancer Progression via the miR-18a-5p/ESR1 Axis.
J Environ Pathol Toxicol Oncol. 2026;45:1-12.
Abstract

LIU Q, Huang J
ASO Author Reflections: Augmenting Contrast-Enhanced Ultrasound: A Quantitative Approach to Predict Muscle-Invasive Bladder Cancer.
Ann Surg Oncol. 2026 Feb 9. doi: 10.1245/s10434-026-19236.
Abstract

MANIVASAGAM SS, Kassim A, Raman JD
Diagnosis, evaluation, and management of patients with non-muscle invasive bladder cancer.
Future Sci OA. 2026;12:2622297.
Abstract

SHIBEL PE, Elyamany AM, El Shorbagy G, Abd Elmaogod EA, et al
Exploring the Role Of CD155 in Urothelial Carcinoma of the Urinary Bladder: An Immunohistochemical Study & Its Correlation With PD-L1.
Asian Pac J Cancer Prev. 2026;27:667-675.
Abstract

ABDEL-HAKEEM SS, Abdel-Hakeem SS, Kamal FMM
Crosstalk between ZEB1 expression and CD163+ Tumor-Associated Macrophages in Muscle-Invasive Urothelial Carcinoma.
Asian Pac J Cancer Prev. 2026;27:499-507.
Abstract

CARAPITO A, Sousa TV, Teixeira-Marques A, Henrique R, et al
Urinary Metabolomics Identifies Lactate as a Biomarker for Bladder Cancer Detection and Progression.
Mol Omics. 2026 Feb 9:aaiag004. doi: 10.1093.
Abstract

ROLLIN P, Pluskwa B, Artru E, Le Vaslot T, et al
BCG immunotherapy for bladder cancer triggers systemic and local BCG-specific CD4(+) Th1 responses.
iScience. 2026;29:114676.
Abstract

LONCA L, Beniac P, Necsulescu A, Teixeira-Guerra D, et al
Robot-Assisted Cystoprostatectomy for Muscle-Invasive Bladder Cancer in a Patient With a Prior Simultaneous Pancreas-Kidney Transplantation.
Case Rep Transplant. 2026;2026:9534770.
Abstract

ZHANG X, Su S, Liu L, Song F, et al
Preoperative fibrinogen-to-lymphocyte ratio as a prognostic biomarker for non-muscle-invasive bladder cancer.
Front Oncol. 2026;16:1707696.
Abstract

SOOD A, Martini A, Rudzinski JK, Tholomier C, et al
Combination Treatment with Intravesical Interferon-Alpha Gene Therapy and Oral Pan-ErbB Receptor Family Blocker Improves Survival in Mice with Bladder Cancer.
bioRxiv [Preprint]. 2026 Jan 26:2026.01.23.701130.
Abstract

JIA B, Rao B, Chen R, Cui K, et al
Overview of tumor-resident intratumoral microbiota in human bladder cancer.
Transl Androl Urol. 2026;15:19.
Abstract

ZHOU H, Ge Z, Lin S, Wu Y, et al
Application of serum miRNA panel in bladder cancer detection.
Transl Androl Urol. 2026;15:23.
Abstract

ZHAO L, Yang JW, Chen SY, Wang L, et al
Immune checkpoint inhibitors in BCG-unresponsive non-muscle-invasive bladder cancer: a narrative review of evidence and future directions.
Transl Androl Urol. 2026;15:29.
Abstract

ZHANG X, Fu Y, Du Y, Xiong W, et al
CCT5 as a candidate biomarker in bladder cancer: functional validation and mechanistic clues.
Am J Cancer Res. 2026;16:51-69.
Abstract

RANJITH N, Khan PA, Koppolu S, Pavani S, et al
Impact of lifestyle factors on recurrence rates in non-muscle invasive bladder cancer: A case-control study.
Bioinformation. 2025;21:4025-4027.
Abstract

WANG Y, Liu L, Li M
Toxic epidermal necrolysis associated with immune checkpoint inhibitors for bladder cancer: A case report.
Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2025;50:2031-2037.
Abstract

ABU-GHANEM Y, Laszkiewicz J, Chan HT, Krajewski W, et al
Impact of pelvic lymph node dissection on oncological outcomes in patients with clinically staged non-muscle-invasive bladder cancer undergoing radical cystectomy: A systematic review.
Crit Rev Oncol Hematol. 2026;220:105192.
Abstract

KLINGLMAIR G, Lutz M, Telia T, van Creij NCH, et al
Sarcopenia and recurrence risk in high-risk non-muscle-invasive bladder cancer: a nonlinear modeling approach.
J Nutr Health Aging. 2026;30:100805.
Abstract

XIE H, Liao T, Tang H, Ban C, et al
The GFPT2/O-GlcNAcylation/c-Myc axis promotes bladder cancer progression.
J Transl Med. 2026 Feb 7. doi: 10.1186/s12967-026-07811.
Abstract

CONTIERI R, Paciotti M, Uleri A, Saita A, et al
Second Transurethral Resection of Bladder Tumor Can Be Safely Omitted in Selected Patients with T1 Non-muscle-invasive Bladder Cancer: Results from the Prospective HuNIRe Trial.
Eur Urol Oncol. 2026 Feb 6:S2588-9311(26)00031-3. doi: 10.1016/j.euo.2026.
Abstract

DEMIGNE JB, Ferber E, Rodrigues M, Flippot R, et al
[Perioperative durvalumab with neoadjuvant cisplatine-gemcitabine chemotherapy in localized muscle-invasive bladder cancer].
Bull Cancer. 2026 Feb 6:S0007-4551(26)00056-1. doi: 10.1016/j.bulcan.2025.
Abstract

GARG T, Negron-Candelario S, Miller H, Demirsoy S, et al
Adapting patient priorities care for older adults with non-muscle-invasive bladder cancer: A qualitative inquiry.
Urol Oncol. 2026;44:110996.
Abstract

QIN M, Xie G, Xie H, Lin B, et al
Development and validation of a novel senescence-associated gene signature for prediction of survival and endocrine-disrupting chemicals in bladder cancer.
Discov Oncol. 2026 Feb 7. doi: 10.1007/s12672-026-04611.
Abstract

CHEN H, Peng Y, Ji Z, Dong J, et al
SPP1(+) Macrophage-POSTN(+) Fibroblast-Endothelial Triad Dictates Immunotherapy Response in Bladder Cancer.
FASEB J. 2026;40:e71546.
Abstract

KONG Y, Li Y, An M, Luo Y, et al
Correction: ZEB1-mediated biogenesis of circnipbl sustains the metastasis of bladder cancer via Wnt/beta-catenin pathway.
J Exp Clin Cancer Res. 2026;45:39.
Abstract

ZHANG Q, Guo Y, Lin F, Zuo Y, et al
?CT image-derived radiomics predicts molecular subtypes in bladder urothelial carcinoma: validation of a non-invasive classification strategy.
Sci Rep. 2026;16:6016.
Abstract

HERCZEG BT, Sudar A, Ortutay R, Agoston P, et al
Risk estimations of radiation induced malignancies in rectum and bladder following radiotherapy of prostate carcinoma.
Phys Med. 2026;142:105714.
Abstract

JENDEBERG J, Bjorkman A, Dahlman P, Eklof H, et al
Computed tomography urography in macroscopic hematuria: a retrospective study with implications for standard care pathway.
Acta Radiol. 2026;67:227-236.
Abstract

ZHU Y, Jiang S, Shi Y, Wang S, et al
Sacituzumab tirumotecan in participants with advanced or metastatic urothelial carcinoma and disease progression after chemotherapy and immune checkpoint inhibitors.
Ann Oncol. 2026;37:378-387.
Abstract

IWATANI K, Urabe F, Mori K, Nakano J, et al
Safety profile of enfortumab vedotin plus pembrolizumab in locally advanced or metastatic urothelial carcinoma: a multicenter Japanese cohort study.
Jpn J Clin Oncol. 2026;56:234-240.
Abstract

YAJIMA S, Yoshida S, Chen W, Hirose K, et al
Bayesian reanalysis of avelumab maintenance therapy in Asian and Japanese patients with advanced urothelial carcinoma: evidence from the JAVELIN Bladder 100 trial.
Jpn J Clin Oncol. 2026;56:216-220.
Abstract

ESCOBAR D, Doshi C, Zahir M, Daneshmand S, et al
Modern management of BCG-refractory non-muscle-invasive urothelial carcinoma of the urinary bladder.
Urologie. 2026;65:162-170.
Abstract

BAHLBURG H, Rausch P, Tully KH, Berg S, et al
Psychosocial distress after radical prostatectomy, radical cystectomy, or (partial) nephrectomy - a comprehensive analysis of 4,290 German cancer patients during the COVID-19 pandemic.
J Cancer Surviv. 2026;20:181-188.
Abstract

LONGONI M, Scilipoti P, De Angelis M, Zaurito P, et al
Real-world Adherence to European Association of Urology-recommended Non-muscle-invasive Bladder Cancer Management: From Evidence-based Practice to Oncological Outcomes.
Eur Urol Oncol. 2026 Feb 19:S2588-9311(26)00042.
Abstract

GAO J, Pan Y, Cheng Q, Wang S, et al
USP43 promotes lymphatic metastasis of bladder cancer by regulation of ZBTB7A.
Cell Signal. 2026 Feb 18:112433. doi: 10.1016/j.cellsig.2026.112433.
Abstract

JONAS K, Moser T, Heitzer E
Listening to the bladder field: Urine liquid biopsies reveal differential treatment responses in NMIBC.
Cell. 2026;189:995-997.
Abstract

ZHANG H, Han S, Su Z, Zheng Z, et al
Single-cell transcriptomic analysis and machine learning identify ATAD3A as a key gene that stabilizes mitochondrial-endoplasmic reticulum membranes, promoting bladder cancer progression.
J Transl Med. 2026 Feb 20. doi: 10.1186/s12967-026-07857.
Abstract

KWON J, Jeon J, Lee HS, Jeon S, et al
Effects of Radiation Therapy on the Incidence of Bladder Cancer and Rectal Cancer in Patients with Prostate Cancer: A Nationwide Nested Case-Control Study in Korean Population.
World J Mens Health. 2026 Jan 15. doi: 10.5534/wjmh.250298.
Abstract

LAHIRI A, Chowdhury S, Goel S, Assif Iqbal S, et al
Neoadjuvant therapy in gall bladder cancer improves resectability and survival: a prospective study.
HPB (Oxford). 2026 Feb 2:S1365-182X(26)00016-X. doi: 10.1016/j.hpb.2026.
Abstract

CAUSIO FA, De Vita V, Nappi A, Sawaya M, et al
Survival Prediction in Patients With Bladder Cancer Undergoing Radical Cystectomy Using a Machine Learning Algorithm: Retrospective Single-Center Study.
JMIR Perioper Med. 2026;9:e86666.
Abstract

KATO M, Matsue T, Yamamoto S, Yukimatsu N, et al
Clinical impact of carboplatin-based neoadjuvant chemotherapy: lack of benefit and surgical delay in muscle-invasive bladder cancer.
Jpn J Clin Oncol. 2026 Feb 19:hyag027. doi: 10.1093.
Abstract

ZHANG P, Xiong W, Wang K, Zhao X, et al
Copper-based architectures for bladder cancer therapy: mechanistic insights, progress and prospects.
Nanoscale. 2026 Feb 19. doi: 10.1039/d5nr04072.
Abstract

LIU X, Chen Z, Lu Y, Wu Y, et al
Fecal microbiota transplantation: a novel strategy and challenges in the adjuvant treatment of bladder Cancer.
Front Microbiol. 2026;17:1756107.
Abstract

OKADA N, Kimura H, Ozaki M, Tamura M, et al
Risk Factor of Persistent Hypotension Associated with 5-Aminolevulinic Acid: A Single-Institution Retrospective Study.
Biol Pharm Bull. 2026;49:335-340.
Abstract

SUN Y, Tong H, Zhao G, Wu L, et al
Nutrient Deprivation Promotes Bladder Cancer Metastasis through Beclin-1 Deacetylation-Mediated Autophagy Activation.
Cancer Lett. 2026 Feb 16:218337. doi: 10.1016/j.canlet.2026.218337.
Abstract

VULSTEKE C, Adra N, Danchaivijitr P, Sabadash M, et al
Perioperative Enfortumab Vedotin and Pembrolizumab in Bladder Cancer.
N Engl J Med. 2026 Feb 18. doi: 10.1056/NEJMoa2511674.
Abstract

XU C, Dong Y, Li J, Liao X, et al
Integrating machine learning and mendelian randomization for identifying genetic biomarkers in bladder cancer: implications for early diagnosis and targeted therapies.
Int J Surg. 2025 Dec 3. doi: 10.1097/JS9.0000000000003833.
Abstract

HU J, Zhu Y, Wang G, Dai H, et al
SNW1 promotes lymphatic metastasis in bladder cancer by modulating SRPK1 splicing.
iScience. 2026;29:114811.
Abstract

HUANG X, Meng Y, Song J, Zhu Y, et al
KNSTRN knockdown impairs autophagy flux to inhibit bladder cancer progression.
iScience. 2026;29:114734.
Abstract

ZHANG J, Wang J, Hu X, Jia W, et al
Biomimetic hydrogel for the construction of patient-derived bladder cancer organoids with aggressive growth.
iScience. 2026;29:114786.
Abstract

HINLEY J, Baker SC, Mason AS, Kyriazis G, et al
Connexin 32 constrains a mesenchymal-like switch in differentiated urothelium and luminal cancers.
Life Sci Alliance. 2026;9:e202503427.
Abstract

KOHLER J, Buck L, Hugelmann K, Incesu RB, et al
Chronological and biological age stratify survival after robot-assisted radical cystectomy for bladder cancer: a pragmatic age-ECOG risk score.
World J Urol. 2026;44:178.
Abstract

ACCETTO T, Strasek Smrdel K, Taskovska M, Starcic Erjavec M, et al
Negative-control-anchored urinary microbiome profiling with absolute 16S quantification: a pilot study in newly diagnosed, treatment-naive bladder cancer and healthy individuals.
FEMS Microbiol Lett. 2026 Feb 17:fnag020. doi: 10.1093.
Abstract

LIU Q, Lu X, He C, Chen J, et al
Correction: A Novel Model for Muscle-Invasive Bladder Cancer Diagnosis Using Contrast-Enhanced Ultrasound.
Ann Surg Oncol. 2026 Feb 16. doi: 10.1245/s10434-026-19331.
Abstract

LI H, Long G, Hu L, Wang Q, et al
Intravesical hematoporphyrin photodynamic therapy combined with pirarubicin for intermediate and high-risk non-muscle-invasive bladder cancer: a multicenter, prospective single-arm cohort.
Photodiagnosis Photodyn Ther. 2026 Feb 14:105396.
Abstract

CRESTANI B, Tamborrino V, Bertolo R, Antonelli A, et al
Balancing maternal and fetal safety in non-muscle-invasive bladder cancer: report of our experience.
Minerva Urol Nephrol. 2026;78:155-157.
Abstract

LAMBERTINI L, Saladino M, DI Maida F, Grosso AA, et al
Oncologic outcomes after robot assisted radical cystectomy in patients with clinically positive lymph nodes (cN1): a tertiary referral center experience.
Minerva Urol Nephrol. 2026;78:118-126.
Abstract

CHEN KY, Jones MK, Ghosal S, Ignozzi GP, et al
Predictors of adherence to surveillance cystoscopy for patients with non-muscle invasive bladder cancer.
BJUI Compass. 2026;7:e70135.
Abstract

FUKUHARA H, Shigehisa R, Yamamoto S, Fukata S, et al
Effect of extending the oral administration period of 5-aminolevulinic acid on diagnostic accuracy and treatment outcomes for non-muscle-invasive bladder cancer.
BJUI Compass. 2026;7:e70173.
Abstract

INDRASWARI MT, Rahman F, Hamid ARAH, Mochtar CA, et al
Psychological distress among bladder cancer patients: A systematic review.
Urol Ann. 2026;18:10-17.
Abstract

SONG F, Su S, Zhang X, Cao Y, et al
A nomogram based on the red cell distribution width to lymphocyte ratio as a prognostic tool for non-muscle-invasive bladder cancer: a retrospective study.
Front Oncol. 2026;16:1728821.
Abstract

PAN S, Zhu H, Yin R, Lin J, et al
Carcinogen metabolism and bladder cancer: role of gut microbiota in disease and prevention.
Front Cell Infect Microbiol. 2026;15:1727550.
Abstract

BASAR M, Yol C, Chen JF, Al-Ahmadie H, et al
Micropapillary Urothelial Carcinoma: A Review and Update.
Adv Anat Pathol. 2026;33:e1-e8.
Abstract

DAS M, Rath S, Gorepatti R, Dash R, et al
Microbiome-linked transcriptomic signatures in NMIBC: Toward personalized uro-oncology.
Urol Oncol. 2026;44:110977.
Abstract

QU M, Wei J, Mo J, Chen J, et al
Disitamab vedotin with or without PD-1 inhibitors in pretreated patients with locally advanced or metastatic urothelial carcinoma: Identifying patients who derive additional benefit from immune combination therapy.
Urol Oncol. 2026;44:110970.
Abstract

WEIR S, Murgas KA, Froehlich M, Nash M, et al
Urothelial cell carcinoma of the bladder in pediatric patients: A comparison with adults from the National Cancer Database.
J Pediatr Urol. 2026;22:105677.
Abstract

WEBER TD, Gershman B, Wang L, Rosen S, et al
Rapid evaluation of muscularis propria in transurethral resection of bladder tumour specimens using non-linear microscopy (NLM).
J Clin Pathol. 2026;79:186-191.
Abstract

LANGE F, Gaisa NT, Bolenz C, Klumper N, et al
[Pathological Risk Stratification of Non-Muscle-Invasive and Muscle-Invasive Urothelial Carcinoma for Optimal Therapeutic Decision-Making].
Aktuelle Urol. 2026;57:52-59.
Abstract

NIEGISCH G, Zschabitz S, Klumper N, Eckstein M, et al
[Current and future treatment stratification of metastatic urothelial carcinoma: a great opportunity for true precision oncology].
Aktuelle Urol. 2026;57:46-51.
Abstract

WALLERSON J, Rostampour S, Teng S, Kidane D, et al
Dysregulated Peroxiredoxins in Bladder Cancer Are Associated With an Altered Tumour Immune Microenvironment.
J Cell Mol Med. 2026;30:e71064.
Abstract

MELLEMA JJ, Stockem CF, Herberts C, Cheung SK, et al
Ipilimumab and nivolumab followed by chemoradiotherapy as bladder-sparing treatment in muscle-invasive bladder cancer: a phase 2 trial.
Nat Med. 2026 Feb 27. doi: 10.1038/s41591-026-04271.
Abstract

SHENG Y, Fan L, Zhu S, Wang Y, et al
Combined and individual effects of neoadjuvant chemotherapy and lymph node dissection on survival in non-muscle-invasive bladder cancer undergoing radical cystectomy.
Urol Oncol. 2026;44:111039.
Abstract

DENG Z, Yan Z, Chen Z
Post-translational modifications: Principal regulators of bladder cancer.
Mol Biol Rep. 2026;53:446.
Abstract

LI Y, Ma Y, Lai J, Wan Q, et al
Exploring the potential mechanisms of hydroquinone on bladder cancer using network toxicology, Mendelian randomization analysis, molecular docking, and molecular dynamics simulations.
Discov Oncol. 2026 Feb 27. doi: 10.1007/s12672-025-04114.
Abstract

BENIJTS R, Akand M, Tipirdamaz M, Mennes J, et al
External validation and comparison of nomograms for prediction of long-term disease recurrence and survival for bladder cancer patients who undergo radical cystectomy.
Minerva Urol Nephrol. 2026 Feb 27. doi: 10.23736/S2724-6051.25.06600.
Abstract

YING X, Huang Y, Huang J, Cai Q, et al
m(5)C-Modified tRF3b-Cys(GCA)-23 Suppresses Bladder Cancer Malignancy by Repressing H3K18 Lactylation via Stabilizing RBM4.
Adv Sci (Weinh). 2026 Feb 27:e22294. doi: 10.1002/advs.202522294.
Abstract

MATSUO T, Mori S, Honda H, Kakita S, et al
Preoperative Gamma-Glutamyltransferase-to-Lymphocyte Ratio as an Independent Prognostic Biomarker in Patients Undergoing Radical Cystectomy for Bladder Cancer.
Medicina (Kaunas). 2026;62:343.
Abstract

PEREIRA M, Vale N
Gene Expression-Guided Drug Repurposing in Oncology: Insights from Antiretroviral Agents in Prostate and Bladder Cancer.
Genes (Basel). 2026;17:184.
Abstract

SCHITCU VH, Munteanu VC, Borz MB, Cojocaru I, et al
Genomic Subtypes and Computational Biomarkers in Non-Muscle-Invasive Bladder Cancer Guiding Optimal Timing of Radical Cystectomy and BCG Response Prediction.
Genes (Basel). 2026;17:153.
Abstract

CAN VG
Molecular Characterization of Muscle-Invasive Bladder Cancer: Key MicroRNAs, Transcription Factors, and Differentially Expressed Genes.
Genes (Basel). 2026;17:122.
Abstract

OZYURT N, Turhan A
Prognostic Impact of the Gustave Roussy Immune Score on Cancer-Specific Survival and Treatment Completion in Patients with Bladder Cancer.
Diagnostics (Basel). 2026;16:574.
Abstract

PARADA D, Onoiu AI, Iftimie S, Camps J, et al
A Pilot Study Exploring Paraoxonase-1 Tissue Protein Expression and Circulating Levels in Bladder Cancer.
Antioxidants (Basel). 2026;15:198.
Abstract

BEKESCHUS S, Berner J, Edelmann J, Wolff CM, et al
Synergistic Toxicity of Cold Gas Plasma and Cisplatin in Bladder Cancer Cells.
Cancers (Basel). 2026;18:675.
Abstract

GRIER AL, Zhong JY, Basourakos S, Calaway A, et al
Recent Advances in Immunotherapy for Non-Muscle-Invasive Bladder Cancer.
Cancers (Basel). 2026;18:623.
Abstract

RIBEIRO E, Vale N
Personalized Combination Therapy in Bladder Cancer: cAMP Modulators Synergize with 5-FU and Modulate Redox Programs.
Cancers (Basel). 2026;18:562.
Abstract

ZENG S, Xu Z, Xing S, Zhang Y, et al
Exploratory study of olaparib combined with intravesical perfusion in the treatment of secondary bladder cancer after kidney transplantation: preliminary observations and discussion.
Eur J Med Res. 2026 Feb 26. doi: 10.1186/s40001-026-04029.
Abstract

BAEK SW, Byun YJ, Piao XM, Seo JW, et al
Transcriptome-based high-frequency recurrence index predicts frequent recurrence in non-muscle-invasive bladder cancer after Bacillus Calmette-Guerin therapy.
BMC Med. 2026 Feb 27. doi: 10.1186/s12916-026-04745.
Abstract

HUANG GK, Zhang XX, Huang LY, Un HC, et al
Tumor-infiltrating lymphocytes demonstrate potent anti-tumor efficacy and synergize with PD-1 blockade in bladder cancer.
J Transl Med. 2026 Feb 26. doi: 10.1186/s12967-026-07924.
Abstract

REN S, Dai R, Zheng Z, Liu Q, et al
Corrigendum to "A novel bidirectional perfusion-like administered system for NIR-II fluorescence imaging precision diagnosis of bladder cancer" [Nanomed Nanotechnol Biol Med 49 (April 2023) 102661].
Nanomedicine. 2026 Feb 25:102916. doi: 10.1016/j.nano.2026.102916.
Abstract

SCHMID SC, Jahnen M, Schiller K, Sauter A, et al
Radiation Therapy Combined with Immunotherapy Before Radical Cystectomy in Locally Advanced Bladder Cancer: A Prospective, Single-arm, Multicenter, Phase 2 Trial (RACE-IT).
Eur Urol Oncol. 2026 Feb 25:S2588-9311(26)00056.
Abstract

TRAN MA, Cho BA, Izadmehr S, Yoo SK, et al
A tumor-promoting inflammatory SPP1+ macrophage-IL-6-CRP axis drives immune dysfunction in bladder cancer.
Cancer Discov. 2026 Feb 27. doi: 10.1158/2159-8290.CD-25-1774.
Abstract

KATONGTUNG P, Shiangjen K, Cholamjiak W, Naravejsakul K, et al
MRI-Based Bladder Cancer Staging via YOLOv11 Segmentation and Deep Learning Classification.
Diseases. 2026;14:45.
Abstract

PAVALEAN MI, Lambrescu IM, Gaina G, Madan VL, et al
CD36 rs1761667 Polymorphism and Its Impact on Molecular Signatures in Bladder Cancer.
Diseases. 2026;14:44.
Abstract

BUONERBA C, Baio R, Crocetto F, Bruzzese D, et al
BLOSSOM Dietary Habits and 1-Year Intravesical Recurrence in High-Risk Non-Muscle-Invasive Bladder Cancer Treated with BCG.
Curr Oncol. 2026;33:128.
Abstract

ZHANG X, Su S, Liu L, Song F, et al
Preoperative gamma-glutamyl transferase to lymphocyte ratio predicts recurrence in non-muscle-invasive bladder cancer.
Front Oncol. 2026;16:1724968.
Abstract

NIU S, Li L, Jia W, Feng H, et al
Quantitative proteomic analysis reveals different characteristics of bladder cancer cells after exposure to bisphenol A.
FEBS Open Bio. 2026 Feb 25. doi: 10.1002/2211-5463.70221.
Abstract

HABICHER M, Swoboda C, Hauptmann A, Koch C, et al
Enhanced recovery after radical cystectomy for bladder cancer: a prospective observational case -control study.
BMC Urol. 2026 Feb 25. doi: 10.1186/s12894-026-02093.
Abstract

LEE TJ, Qiu L, Long J, Mach KE, et al
CystoDS: a multiclass endoscopy image dataset for artificial intelligence-assisted bladder cancer detection.
Sci Data. 2026 Feb 26. doi: 10.1038/s41597-026-06887.
Abstract

TAKEUCHI M, Tamada T
Current Status and Future Perspective for Bladder Cancer MR Imaging and the Vesical Imaging-Reporting and Data System (VI-RADS) in Japan: Challenges and Solutions.
Magn Reson Med Sci. 2026 Feb 26. doi: 10.2463/mrms.rev.2025-0213.
Abstract

GUERRERO-RAMOS F
BCG and Systemic Immunotherapy for High-Risk Non-Muscle-Invasive Bladder Cancer: Lights and Shadows.
Actas Urol Esp (Engl Ed). 2026 Feb 23:501936. doi: 10.1016/j.acuroe.2026.501936.
Abstract

WEI X, Cai L, Li N, Fang Y, et al
High-throughput screening of bladder cancer exosome biomarkers by barcodes integrated herringbone microfluidics.
Biosens Bioelectron. 2026;302:118545.
Abstract

TRATNJEK L, Janev A, Kuret T, Jerman UD, et al
The interplay of dietary sugar, chronic inflammation, and bladder cancer: mechanistic insights, evidence, and prevention strategies.
Front Immunol. 2026;17:1731784.
Abstract

WANG Y, Wu N, Zhang S
Ferroptosis-autophagy crosstalk in bladder cancer: mechanisms and therapeutic implications.
Mol Cancer. 2026 Feb 24. doi: 10.1186/s12943-026-02608.
Abstract

ADIB E, Nassar AH, Alaiwi SA, Baca SC, et al
Epigenetic Atlas of Bladder Cancer Reveals Master Transcription Factors and Risk-Associated Regulatory Elements in Luminal and Basal-Squamous Molecular Subtypes.
Mol Cancer Res. 2026 Feb 24. doi: 10.1158/1541-7786.MCR-25-1385.
Abstract

GOEL V, Jain A, Basu D, Patnaik N, et al
Comparative Efficacy and Toxicity of Gemcitabine-Cisplatin vs. Gemcitabine-Carboplatin in Metastatic Carcinoma of the Urinary Bladder: A Retrospective Review.
Gulf J Oncolog. 2025;1:60-66.
Abstract

SHAN M, Wang X, Wang Z, Xu C, et al
NIR-II aggregation-induced emission sonosensitizer for pyroptosis induction in bladder cancer.
Bioact Mater. 2026;61:229-242.
Abstract

HONG X, Wang G, Hong T, Liu X, et al
Glycolysis-related genes for bladder cancer: A Mendelian randomization analysis.
Biochem Biophys Rep. 2026;45:102501.
Abstract

PEYROTTES A, Masson-Lecomte A, Aregui A, Meria P, et al
[Specificities of oncologic surgery in elder patients].
Rev Prat. 2026;76:60-65.
Abstract

ZHANG L, Zhong Y, Yang G, Huang L, et al
Artificial intelligence-assisted diagnosis and histopathological grading of bladder cancer: current status, challenges, and future directions.
Front Digit Health. 2026;8:1708289.
Abstract

ZHANG L, Gong Y, Chen J, Li M, et al
Prognostic significance of calcium signaling-related genes in bladder cancer and the role of ATP2B4 in regulating mitochondrial calcium ion levels via the VDAC1/MCU pathway.
Front Immunol. 2026;17:1561666.
Abstract

KUCAN BRLIC P, Bellulovich E, Golemac M, Jaksic A, et al
High PVR protein expression marks clear cell renal cell carcinoma with metastatic spread.
Front Immunol. 2026;17:1754848.
Abstract

MUNERA-MARAVILLA E, Perez-Escavy M, Rubio C, Segovia C, et al
Cell-of-origin and genetic drivers define advanced bladder cancer subtypes and potential therapeutic response in mouse models.
J Exp Clin Cancer Res. 2026 Feb 23. doi: 10.1186/s13046-026-03677.
Abstract

CUI J, Chen S, Liu X, Jiang X, et al
PRDM1 restricts bladder cancer progression and enhances chemosensitivity by suppressing OTUD6A-mediated deubiquitination of CDC6.
Cell Death Dis. 2026 Feb 23. doi: 10.1038/s41419-026-08498.
Abstract

SEO J, Park JM, Park DJ, Seo I, et al
Exploration of the Tumor Transcriptomic and Immune Landscape Following Repeated Transurethral Resection in Non-Muscle-Invasive Bladder Cancer.
Clin Genitourin Cancer. 2026 Jan 23:102513. doi: 10.1016/j.clgc.2026.102513.
Abstract

XU L, Lin Y, Shi G, Zhang L, et al
Single-Cell Insights into Cisplatin Resistance Mechanisms in Bladder Cancer Tumor Microenvironment.
J Biol Chem. 2026 Feb 20:111304. doi: 10.1016/j.jbc.2026.111304.
Abstract

MISURKA J, Berjaoui MB, Lajkosz K, Cockburn J, et al
PA- versus urologist-performed flexible cystoscopy: A comparative study.
JAAPA. 2026;39:34-36.
Abstract

LUO C, Kuang X, Dai Y, Cai Z, et al
DNA methylation-mediated silencing of HNF1B promotes bladder cancer progression.
Clin Epigenetics. 2026 Feb 21. doi: 10.1186/s13148-026-02079.
Abstract

XU DM, Chen J, Lin SB, Xu TY, et al
ATIC facilitates the malignant progression of bladder cancer by modulating AMPK-mTOR-S6K1 axis under folate reprogramming.
J Transl Med. 2026 Feb 21. doi: 10.1186/s12967-026-07830.
Abstract

CHEN Q, Wu K, Cai B, Yu X, et al
LncRNA miR17HG promotes tumor progression through AXIN2 by sponging miR-144-3p in bladder cancer.
World J Surg Oncol. 2026 Feb 21. doi: 10.1186/s12957-026-04246.
Abstract

FALQUET M, El Ahanidi H, Gomez-Cadena A, Su Z, et al
Mast-cell derived nerve growth factor drives ILC2 pro-tumoral functions in bladder cancer.
Nat Commun. 2026 Feb 21. doi: 10.1038/s41467-026-69841.
Abstract

STEMPEL MH, Quezada JP, Belz B, Sun F, et al
Implications of hemoglobin, albumin, lymphocyte, platelet (HALP) score as a predictor of neoadjuvant chemotherapy response in bladder cancer patients.
Urol Oncol. 2026 Feb 20:111005. doi: 10.1016/j.urolonc.2026.111005.
Abstract

DI LORENZO G, Di Maio M, Buonerba C
Neoadjuvant Therapy in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer: Recent Progress, Challenges, and Future Directions in the Era of TAR-200 and Enfortumab Vedotin Plus Pembrolizumab.
Oncol Ther. 2026 Feb 21. doi: 10.1007/s40487-026-00417.
Abstract

CHEN C, Yang Y, Niu H, Tang Y, et al
Interfacial Electric Locking of the Aptamer Conformation for Accurate Liquid Biopsy Detection.
Nano Lett. 2026;26:2371-2380.
Abstract

SAKTHIVEL DK, Prabhakar P, Iyub MJR, Garje R, et al
Comparative Analysis of Signet Ring and Non-Signet Ring Urachal Adenocarcinomas: A National Cancer Database Study.
Clin Genitourin Cancer. 2026;24:102495.
Abstract

TAWAGI K, Khaki AR, Chablani PV, Hoffman-Censits J, et al
Preferred Treatment Sequencing for Metastatic Urothelial Carcinoma (mUC) in the Era of Perioperative and First-Line (1L) Checkpoint Inhibitor: Results From a National Survey of Genitourinary Oncologists.
Clin Genitourin Cancer. 2026;24:102487.
Abstract

SAHIN KC, Simsekoglu MF, Ozden SB, Ercili B, et al
Histologic subtypes and divergent differentiations of urothelial carcinoma: Prognostic implications and clinical insights.
Surg Oncol. 2026;64:102344.
Abstract

HUNDEBOLL JH, Olesen AF, Wessel I, Magkos F, et al
Not just about weight: Identifying hidden nutritional vulnerability after radical cystectomy.
Eur J Clin Nutr. 2025 Dec 10. doi: 10.1038/s41430-025-01694.
Abstract

PAN W, Xing J, Chen X, Xue R, et al
Urinary biomarkers in cancer detection: explorations, advancements, challenges, and future directions.
Int J Surg. 2026;112:4762-4788.
Abstract

WENG HW, Ting HK, Wang HH, Peng TJ, et al
Targeting neuropilin-1 and neutralizing interleukin-6 inhibits cancer stem cell formation in bladder cancer cells.
J Transl Med. 2026 Mar 4. doi: 10.1186/s12967-026-07943.
Abstract

ROUPRET M
Reply to Letter to the Editor: 'ALBAN (GETUG-AFU 37): a phase 3, randomized, open-label, international trial of intravenous atezolizumab and intravesical Bacillus Calmette-Guerin (BCG) versus BCG alone in BCG-naive high-risk, non-muscle invasive bladd
Ann Oncol. 2026 Mar 3:S0923-7534(26)00046-3. doi: 10.1016/j.annonc.2026.
Abstract

ZHOU M, Xue X, Li H, Chen Z, et al
Decoding the metabolic-immune axis for novel therapeutics in bladder cancer.
Biochim Biophys Acta Rev Cancer. 2026 Mar 2:189569.
Abstract

YANG M, Chai X, Ye D, Zhao A, et al
Budget impact model of nadofaragene firadenovec for the treatment of high-risk non-muscle-invasive bladder cancer that is unresponsive to Bacillus Calmette-Guerin immunotherapy.
J Med Econ. 2026;29:672-687.
Abstract

BANG S, Joo SM, Kim DK, Kwon JK, et al
Preoperative selective arterial embolization followed by transurethral resection of bladder tumor for large bladder tumors: Early clinical experiences.
Investig Clin Urol. 2026;67:162-169.
Abstract

YANG Q, Zhou D, Beasley A, Liu Y, et al
Identification of SLC3A2 as a Potential Therapeutic Target of Ferroptosis in Bladder Cancer.
Arch Esp Urol. 2026;79:36-48.
Abstract

MCKAY RR, Tipirneni A, Bangs R, Guercio BJ, et al
Neoadjuvant Systemic Therapy in Kidney and Bladder Cancer: Current Evidence and Emerging Paradigms.
Am Soc Clin Oncol Educ Book. 2026;46:e516902.
Abstract

GIRGIN R, Mungan NA
Turkish urologists' knowledge and attitudes on lifestyle advice for bladder cancer: a national survey.
Support Care Cancer. 2026;34:260.
Abstract

YAMADA S, Sato M, Osawa T, Harabayashi T, et al
Longitudinal Impact of Urinary Diversion on Health-Related Quality of Life After Radical Cystectomy: A Multicenter Study in Japan.
Cancer Sci. 2026;117:739-748.
Abstract

NOGUEIRA CM, Machado C, Santos RB, Faustino AS, et al
Infiltrated penile papules as a cutaneous manifestation of disseminated BCGitis: A rare dermatologic presentation.
Int J STD AIDS. 2026;37:444-446.
Abstract

STARRETT JH, Allen EL, Neal M, Iyer S, et al
Dabogratinib (TYRA-300), an FGFR3 Isoform-Selective Inhibitor: Preclinical and Initial Clinical Evidence of Antitumor Activity.
Mol Cancer Ther. 2026;25:408-415.
Abstract

SHUKLA A, Hiralal, Raj H, Surekha S, et al
Diagnostic accuracy and reliability of VI-RADS in assessing muscle invasion in bladder cancer: Insight from a prospective tertiary care study.
Urologia. 2026 Mar 13:3915603261429445. doi: 10.1177/03915603261429445.
Abstract

TAN K, Quan X, Tan M, Han Z, et al
Metachronous multiple primary cancers involving pulmonary non-Hodgkin lymphoma and bladder cancer: a case report.
Front Oncol. 2026;16:1734661.
Abstract

WANG X, Zhao J, Li Q, Chang J, et al
Disulfidptosis and androgenic cancers: from molecular mechanisms to clinical applications and future translational research.
Front Endocrinol (Lausanne). 2026;17:1783929.
Abstract

LI Z, Yu Y, Liu F, Wu Y, et al
Suppression of LTBP1 enhances the sensitivity of bladder cancer to cisplatin.
Sci Rep. 2026 Mar 13. doi: 10.1038/s41598-026-42815.
Abstract

HERMANN-VARADI M
[Prediction of immune checkpoint inhibitor therapy in urothelial carcinoma: integrated analysis of molecular patterns and clinical factors].
Magy Onkol. 2026;70:85-87.
Abstract

PULUGOR GD, Galdi A, Varga L, Jorgo K, et al
[Daily online adaptive irradiation of bladder tumors with individualized safety margin creation].
Magy Onkol. 2026;70:23-31.
Abstract

CERBONE L, Roviello G, Calabro F, Taha T, et al
Liver metastases in advanced urothelial carcinoma (ARON-2): do pembrolizumab and avelumab make a difference in a poor-prognosis scenario?
Front Immunol. 2026;17:1667155.
Abstract

HAO Z, Zhu L, Ding J, Jin Q, et al
bp-VI-RADS combined with normalized apparent diffusion coefficient enhances diagnostic efficacy for muscle-invasive bladder cancer.
Quant Imaging Med Surg. 2026;16:244.
Abstract

LIU W, Xiao J, Zou J, He Z, et al
Recurrence and prevention strategies for non-muscle-invasive bladder cancer: A comprehensive review.
Asian J Urol. 2026;13:11-23.
Abstract

LIU S, Wang M, Wang W
[Analysis of urine biomarkers in urothelial carcinoma based on untargeted metabolomics].
Se Pu. 2026;44:329-337.
Abstract

MANCIN S, Ferrara G, Palomares SM, Matteucci S, et al
Vitamin D and Bladder Cancer Risk: An Umbrella Review and Second Order Meta-Analysis.
Cancer Med. 2026;15:e71672.
Abstract

LODEWIJK I, Rubio C, Eriksson P, Reina IA, et al
CD44v6 is associated with tumor aggressiveness and chemoresistance in bladder cancer.
Sci Rep. 2026 Mar 11. doi: 10.1038/s41598-026-42566.
Abstract

BOLENZ C, Heidenreich A
[From limited options to individualized strategies: advances in the treatment of bladder cancer].
Urologie. 2026;65:239-241.
Abstract

JIANG Y, Li J, Yang Z, Ma M, et al
Multi-omics study on tumor-associated macrophages remodeling the tumor microenvironment via the CXCL5-CXCR2 axis to drive immune escape in bladder cancer.
Cancer Immunol Immunother. 2026;75:103.
Abstract

MASON B, Eccleston A, Ayala-Nunes L, Hauber B, et al
Incorporating the Patient Voice into Attribute and Level Selection for a Preference Study: A Qualitative Study in Non-Muscle Invasive Bladder Cancer.
Patient. 2026 Mar 11. doi: 10.1007/s40271-026-00804.
Abstract

ITO K, Yamashita R, Kasai S, Sakura Y, et al
A Case of Unexpected Peritoneal Carcinomatosis From Colon Cancer Detected After Robot-Assisted Radical Cystectomy for Advanced Bladder Cancer.
IJU Case Rep. 2026;9:e70155.
Abstract

FAN G, Luo X, Li K, Zhang Z, et al
Development and preclinical evaluation of a novel FGFR3-targeted antibody-drug conjugate in bladder cancer.
Asian J Pharm Sci. 2025;20:101095.
Abstract

LIANG S, Liu H, Su Q, Li X, et al
Machine learning identifies a DNA repair-related risk model for bladder cancer and functionally characterizes ZWINT as a potential oncogenic factor.
Transl Androl Urol. 2026;15:46.
Abstract

LIU J, Tang X, Cui Y, Yang X, et al
Development and validation of a gemcitabine sensitivity-related long noncoding RNA signature for predicting the prognosis and subtypes of bladder cancer.
Transl Androl Urol. 2026;15:60.
Abstract

WANG Q, Pei CS, Cao JY, Peng H, et al
Impact of Surgical Wait Time on Survival After Radical Cystectomy for Muscle-Invasive Bladder Cancer: A Retrospective Cohort Study.
Cancer Manag Res. 2026;18:583762.
Abstract

WISHAHI M
Gut microbiotas attributed to disorders and diseases of the gastrointestinal tract, colorectal cancer, bladder cancer: Geographical factors, inflammation, metabolic toxic.
World J Gastrointest Pharmacol Ther. 2026;17:115573.
Abstract

SU Y, Wu J, Deng Z, Luo Y, et al
In Vivo Target Drug Enrichment Based on Spatiotemporal Acoustic Node Modulation (STANM) for Bladder Cancer Treatment.
Adv Mater. 2026 Mar 10:e17740. doi: 10.1002/adma.202517740.
Abstract

GAO Y, Yang F, Yin L, Wang W, et al
A Redox-Responsive Selenium-Containing Nanomedicine Enables Dual Antioxidant System Inhibition to Overcome Platinum Resistance and Enhance Immunotherapy in Bladder Cancer.
ACS Nano. 2026 Mar 10. doi: 10.1021/acsnano.5c21831.
Abstract

VAN CREIJ NCH, Tymoszuk P, Handle F, Seeber A, et al
Multi-omic profiling defines three distinct molecular subtypes of urothelial carcinoma with implications for precision therapy.
Clin Transl Med. 2026;16:e70638.
Abstract

QIN S, Luo H, Hong Y, Fu C, et al
Evaluation of T1 and T2 mapping for non-invasive assessment of HER2 and PD-L1 expression in bladder cancer.
Abdom Radiol (NY). 2026 Mar 9. doi: 10.1007/s00261-026-05390.
Abstract

DONMEZ K, Yorulmaz EM, Candemir E, Ozcan S, et al
Unusual metastatic patterns of urologic malignancies: a case series and literature review.
Can J Urol. 2026;33:211-219.
Abstract

AKKAD A, Bruyere F, Bourgi A
Uretero-enteric strictures after cystectomy: revealing the modifiable risk factors.
Can J Urol. 2026;33:155-163.
Abstract

ZHAN M, Zhou Z, Zhang J, Wang X, et al
Artificial intelligence in urological malignancy diagnosis and prognosis: current status and future prospects.
Can J Urol. 2026;33:35-49.
Abstract

NIE Q, Jiang M, Wan S, Xi M, et al
Neuro-immune-related gene signatures define molecular subtypes and prognostic score in bladder cancer with SERPINE2 as a potential therapeutic target.
PeerJ. 2026;14:e20917.
Abstract

LI Z, Wang G, Tan S, Wang Y, et al
Expression of ribosomal S6 kinase 4 in bladder cancer and its correlation with clinicopathological features.
Front Oncol. 2026;16:1757293.
Abstract

FENG R, Zhang J, Tao Y, Hou J, et al
Correction: Preoperative inflammation-based immune prognostic nomogram in bladder cancer: a multicenter study.
Front Oncol. 2026;16:1787982.
Abstract

HUANG Z, Cao X, Yan Y, Li H, et al
Integrative analysis of the PSMA family identifies PSMA6 as an adverse prognostic biomarker promoting bladder cancer cell proliferation.
Int J Med Sci. 2026;23:986-1001.
Abstract

ISTAMULOV M, Eriksson H, Abuhasanein S
Standardized care pathway reshaped the diagnostic and therapeutic landscape of urinary bladder cancer. A 15-year population-based study.
BJUI Compass. 2026;7:e70179.
Abstract

MENGYAN J, Jun Q, Wen L, Tingting P, et al
Research Progress on Financial Toxicity in Bladder Cancer Patients.
J Surg Oncol. 2026 Mar 8. doi: 10.1002/jso.70201.
Abstract

ZHANG Y, Liu L, Yang B, Wu Q, et al
Electron transfer-driven ultrathin nanozyme synergizes with nucleic acid amplification for bladder cancer screening.
Biosens Bioelectron. 2026;303:118580.
Abstract

SONG YS, Liu CK, Jiang WS, Liu J, et al
Targeting GRB2 with Polyphyllin H overcomes PIKFYVE inhibitor resistance in bladder cancer by blocking Akt-SREBP1-SCD1 pathway.
Phytomedicine. 2026;154:158011.
Abstract

QIN Z, Zhou H, Hu Y, Xiong X, et al
Survival prediction for bladder cancer using multimodal data with quantum neural networks and transformer architectures.
Sci Rep. 2026 Mar 7. doi: 10.1038/s41598-026-42047.
Abstract

LIJNEN RAG, Ringia JB, Claps F, Vogel WV, et al
Diagnostic Value of Fluorine-18-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Staging Histological Subtypes of Invasive Bladder Cancer.
Eur Urol Oncol. 2026 Mar 6:S2588-9311(26)00046-5. doi: 10.1016/j.euo.2026.
Abstract

YAN H, Yin C, Xu F, Li R, et al
Unraveling the connection between PFOA and bladder cancer: A study integrating network toxicology, molecular docking, and experimental validation.
Toxicol Appl Pharmacol. 2026;511:117784.
Abstract

NUR BUDAYA T, Seputra KP, Susianti H, Aditya Hutama S, et al
Diagnostic Value of Rabbit-Derived 47 kDa Epitope-Based Antibodies as a Detection and Evaluation Method for Bladder Cancer.
Asian Pac J Cancer Prev. 2026;27:911-920.
Abstract

LI P, Li L, Li Z, Wang S, et al
Correction: Annexin A1 promotes the progression of bladder cancer via regulating EGFR signaling pathway.
Cancer Cell Int. 2026;26:119.
Abstract

LI J, He Y, Wu S
Predictors of Residual Tumour in Non-Muscle-Invasive Bladder Cancer Following Repeat Transurethral Resection: A Meta-Analysis.
J Coll Physicians Surg Pak. 2026;36:87-94.
Abstract

GUO X, Zhu C, Yin Z
A positive SPTBN2-FLI1 feedback axis promotes bladder cancer via PI3K/AKT activation.
Cell Signal. 2026 Mar 4:112471. doi: 10.1016/j.cellsig.2026.112471.
Abstract

QI T, Yang W, Liu R, Deng D, et al
SWI/SNF-associated molecular subtypes reshape tumor microenvironmental features and inform precision therapeutic strategies in bladder cancer.
Front Cell Infect Microbiol. 2026;16:1774929.
Abstract

CAO JY, Peng H, Wang GY, Chang PA, et al
IGF2BP3 promotes the muscle invasion of bladder cancer via PPARgamma dysregulation.
Discov Oncol. 2026 Mar 5. doi: 10.1007/s12672-026-04648.
Abstract

KHAN A, Alanazi FJ, Ahmed S, Alzahrani AR, et al
Glycoprotein biomarkers for bladder cancer detection.
Clin Chim Acta. 2026;586:120938.
Abstract

TANGUY M, Armelle P, Sheik E, Nicolas I, et al
Real-World Data on Neoadjuvant Chemotherapy for Localized Muscle-Invasive Bladder Cancer (2015-2024): A Single-Center Retrospective Study.
Fr J Urol. 2026 Mar 3:103093. doi: 10.1016/j.fjurol.2026.103093.
Abstract

ZHANG M, Wang K, Li G, Bao X, et al
Light-activated targeted degradation of VHL drug for selective tumor killing: A novel strategy for precision therapy of bladder cancer.
Eur J Med Chem. 2026;309:118736.
Abstract

GAO X, Liu J, Deng D, Xiao J, et al
The ZNF737-CXCL10 axis drives immune exclusion and resistance to anti-PD-1 therapy in bladder cancer.
Int Immunopharmacol. 2026;175:116443.
Abstract

AJALLI MM, Sansebli Y, Ekrami D, Alaeenejad F, et al
Immune checkpoint inhibitors in bladder cancer: from mechanistic insights to emerging combination frontlines.
Clin Exp Med. 2026 Mar 5. doi: 10.1007/s10238-026-02098.
Abstract

TIAN X, Liu Y, Mi Z, Liang Y, et al
CALR/HIF-1alpha Positive Feedback Loop Drives CALR Upregulation to Promote EMT-Mediated Bladder Cancer Progression via ROS/AKT Axis.
Cancer Sci. 2026 Mar 5. doi: 10.1111/cas.70354.
Abstract

Correction to "KIF20A Affects the Prognosis of Bladder Cancer by Promoting the Proliferation and Metastasis of Bladder Cancer Cells".
Dis Markers. 2026;2026:9804137.
Abstract

MALSHY K, Messing EM
Circulating tumor DNA-guided adjuvant immunotherapy in muscle-invasive bladder cancer.
Bladder Cancer. 2026;12:23523735261429862.
Abstract

HE J, Jiang Z, Peng S, Peng L, et al
Single-cell transcriptomic profiling combined with Mendelian randomization illuminates molecular drivers of bladder cancer.
Mol Genet Genomics. 2026;301:50.
Abstract

MIYAMOTO T, Miyake M, Nishimura N, Oda Y, et al
Immunogenic Tumor Cell Death Induced by Neoadjuvant Chemotherapy in Patients With Muscle-Invasive Bladder Cancer: An Immunohistochemical Analysis.
Cureus. 2026;18:e102672.
Abstract

HUANG J, Hu H, Sun M, Wu W, et al
A domain-adaptive deep contrastive network for magnetic resonance imaging-driven bladder cancer classification.
NPJ Digit Med. 2026 Mar 3. doi: 10.1038/s41746-026-02499.
Abstract

DOMANSKI P, Hanusz K, Zapala L, Shah P, et al
Efficacy and Safety of Intravesical Gemcitabine and Docetaxel Combination Therapy in Patients With Intermediate- and High-Risk Non-Muscle-Invasive Bladder Cancer: A Systematic Review and Meta-Analysis.
Clin Genitourin Cancer. 2026 Feb 11:102514. doi: 10.1016/j.clgc.2026.102514.
Abstract

MENA E, Lindenberg L, Heng S, Choyke PL, et al
Advances and challenges of PET imaging in bladder cancer-An update and future trends.
Semin Nucl Med. 2026 Mar 2:S0001-2998(26)00046.
Abstract

KUROBE M, Ogawa T, Satoh Y, Yamamoto M, et al
Near infrared ray-guided partial cystectomy using da Vinci Firefly((R)) technology and intraoperative cystoscopy for urachal cyst, suspected of urachal tumor.
Investig Clin Urol. 2026;67:178-185.
Abstract

YOON SG, Park TY, Jin HJ, Noh TI, et al
Long-term oncologic outcomes of robot-assisted radical cystectomy: Prognostic indicators and complication profiles from a high-volume single-surgeon series.
Investig Clin Urol. 2026;67:148-161.
Abstract

CHOI SY, Yang YJ, Min KC, Lee YS, et al
Diagnostic performance of narrow-band imaging and photodynamic diagnosis compared to white light cystoscopy for non-muscle invasive bladder cancer: A network meta-analysis of randomized trials.
Investig Clin Urol. 2026;67:131-139.
Abstract

AKIN Y, Yorulmaz EM, Gorgel SN, Ozcan S, et al
Who is Next? Impact of Systemic Immune-Inflammation Index and De Ritis Ratio for Predicting 90-Day Survival after Salvage Cystectomy in Advanced Bladder Cancer.
Arch Esp Urol. 2026;79:66-72.
Abstract

SARI H, Celik S, Yorukoglu K, Celebi I, et al
Ankaferd versus Immunotherapeutics and Chemotherapeutics in Bladder Cancer.
Arch Esp Urol. 2026;79:58-65.
Abstract

Strategy to Analyze Urine Tumor DNA Predicts Outcomes in Bladder Cancer.
Cancer Discov. 2026 Feb 11:OF1. doi: 10.1158/2159-8290.CD-RW2026.
Abstract

SIDAWAY P
Enfortumab vedotin plus pembrolizumab effective in patients with resectable bladder cancer.
Nat Rev Clin Oncol. 2026 Mar 2. doi: 10.1038/s41571-026-01139.
Abstract

BARLAK BSR, Iskender B
Proteomic Signatures of Cellular Reprogramming in Bladder Cancer: Insights into the Acquisition of Cancer Stem-like States and Phenotypic Plasticity.
Cancer Genomics Proteomics. 2026;23:300-321.
Abstract

NECCHI A, Maiorano BA, de Jong JJ, Proudfoot JA, et al
Neoadjuvant sacituzumab govitecan plus pembrolizumab, followed by adjuvant pembrolizumab, in patients with muscle-invasive bladder cancer (SURE-02): a single-arm, phase 2 study.
Lancet Oncol. 2026 Feb 27:S1470-2045(26)00050.
Abstract

WONG R, Matulewicz RS, Talwar R, Goldstein AO, et al
Temporal Association of US Tobacco Taxation on Smoking Attributable Bladder Cancer Mortality and Disability-Adjusted Life Years.
JCO Oncol Pract. 2026 Mar 2:OP2500780. doi: 10.1200/OP-25-00780.
Abstract

SUPERDOCK M, Wobker SE, Carmicheal I, Kim WY, et al
Computational pathology in bladder cancer: A scoping review.
Bladder Cancer. 2026;12:23523735251413333.
Abstract

BLUMENFELD P, Levy D, Hillman Y, Feldman J, et al
Daily artificial intelligence-assisted adaptive small margin radiotherapy during trimodal therapy of muscle-invasive bladder cancer.
Front Oncol. 2026;16:1729810.
Abstract

IMAI K, Masuda N, Hazama T, Hosomi T, et al
Invasive Bladder Cancer With Peritoneal Invasion and Rectal Involvement Causing Rectal, Bilateral Ureteral, and Common Bile Duct Obstruction Without a Retroperitoneal Mass: A Case Report.
IJU Case Rep. 2026;9:e70157.
Abstract

MEEKS JJ
The changing landscape of urothelial carcinoma: on the edge of a paradigm shift.
J Clin Invest. 2026;136:e202079.
Abstract

MOINARD-BUTOT F, Barbe-Richaud JB, Baudry E, Pierard L, et al
Real-world treatment sequences and overall survival in metastatic bladder cancer: The STATES-Bladder study.
Urol Oncol. 2026;44:111036.
Abstract

CUADRA JDP, Perez MA, Gonzalez-Peramato P, Sanz J, et al
PD-L1 expression across urothelial carcinoma subtypes: A multicenter comparison of 22C3 and SP142 for clinical decision-making in the immunotherapy era.
Pathol Res Pract. 2026;281:156372.
Abstract

THU PHUNG TA, Weng R, Black PC, Dyrskjot L, et al
A Long Noncoding RNA-based Classifier for Identifying More Aggressive Low-grade Ta Bladder Cancer with Elevated FGFR3 Activity.
Eur Urol Oncol. 2026 Feb 27:S2588-9311(26)00057.
Abstract

PRIETO MATIENZO L, Fischer-Straub A, Perera M, Babst C, et al
Follicular lymphoma of the urachus.
BMJ Case Rep. 2026;19:e267211.
Abstract

BENCINA G, Ruiz RA, Bencina B
Evaluating the economic burden of bladder cancer in 32 European countries using a value of a statistical life year framework.
J Cancer Policy. 2026;48:100728.
Abstract

HUANG J, Ojo A, Liaw B
Predictors of Response and Mechanisms of Resistance to Antibody Drug Conjugates in Urothelial Carcinoma.
Curr Oncol. 2026;33:103.
Abstract

BURTZ M, Boss MK, Leary D, Martin TW, et al
Radiation therapy as a treatment for urinary obstruction secondary to urothelial carcinoma in dogs.
J Vet Intern Med. 2026;40:aalaf093.
Abstract

SONG SH, Park JH, Lee S, Jeong SH, et al
Oncological outcomes of concurrent nephroureterectomy during radical cystectomy: A propensity score-matched analysis with multivariable adjustment from Korean multicenter database.
Surg Oncol. 2026;65:102362.
Abstract

GAISA NT, Reis H, Heidenreich A
[Diagnosis and treatment of urothelial carcinoma of the bladder with divergent histology].
Urologie. 2026;65:278-287.
Abstract

WEI G, Fan ZH, Huang RZ, Wei Y, et al
Design, synthesis and antitumor activity evaluation of 1,4-naphthoquinone-benzene sulfonamide hybrids.
Future Med Chem. 2026;18:637-648.
Abstract

ZHANG Q, Hong Y, He C, Guo R, et al
Oncogenic epigenetic factor EP300 is a potential therapeutic target for bladder carcinoma.
Biochim Biophys Acta Mol Basis Dis. 2026;1872:168182.
Abstract

KOHLER J, Rodler S, Andersson J, Juptner M, et al
[Innovative imaging techniques for urothelial carcinoma].
Urologie. 2026;65:242-249.
Abstract

KIMBALL J, Steele J, Vargas SO, Hirsch M, et al
BK Polyomavirus-Associated Kidney and Bladder Carcinomas Following Heart and Lung Transplantation in Childhood.
Pediatr Dev Pathol. 2026;29:128-135.
Abstract

NIEGISCH G, Zschabitz S, Eckstein M, Klumper N, et al
[From nontargeted to precision oncology: predictive biomarkers and targeted therapies in advanced urothelial carcinoma].
Urologie. 2026;65:271-277.
Abstract

ORDOBAZARI A, Nikfar R, Zhao X, Davaro E, et al
Evaluating the Performance of the Paris System in Neobladder Cytology: The Role of Cellularity and Volume Adequacy Criteria.
Diagn Cytopathol. 2026;54:299-306.
Abstract

FARTIYAL JS, Rao M, Elhence PA, Nalwa A, et al
Comparison of Conventional Sediment Smears and Liquid-Based Cytology and Utility of Cell Block Preparation in Urinary Cytology.
Diagn Cytopathol. 2026;54:285-292.
Abstract

MAN X, Dong C, Dong A, Song X, et al
FDG PET/CT in Primary Mucosa-associated Lymphoid Tissue Lymphoma of the Bladder.
Clin Nucl Med. 2026 Jan 6. doi: 10.1097/RLU.0000000000006295.
Abstract

FORTIER A, Mokadem S, Saadi A, Gillibert A, et al
Does ureteroileal anastomosis technique (Bricker versus Wallace) influence benign ureteroileal stricture occurrence on transileal diversion?
Fr J Urol. 2026;36:103078.
Abstract

SRETENOVIC M, Bumbasirevic U, Bojanic N, Durutovic O, et al
Prognostic Value of Preoperative Anemia on Survival and Recurrence in Patients with Bladder Carcinoma Treated by Radical Cystectomy.
Ann Surg Oncol. 2026;33:3743-3751.
Abstract

CHEN C, An M, Zheng H, Pang M, et al
B cells disrupt tertiary lymphoid structure formation and suppress anti-tumor immunity.
Cancer Cell. 2026;44:551-566.
Abstract

COLLINS K, Gupta S, Cheng L
Updates in bladder and prostate pathology: Diagnostic consensus and clinical relevance.
Hum Pathol. 2026;169:106018.
Abstract

WANG Y, Wu N, Zhang F, Zhang S, et al
The Comprehensive Complication Index for Assessing Short-Term Complications of Urothelial Carcinoma with Variant Histology: A Patient-Based Study.
Ann Surg Oncol. 2026;33:3688-3697.
Abstract

LONGONI M, Le QC, Falkenbach F, Marmiroli A, et al
The Effect of Pelvic Lymph Node Dissection on Cancer-Specific Mortality in Partial Cystectomy According to Eligibility Criteria.
Ann Surg Oncol. 2026;33:3680-3687.
Abstract

D'AGOSTINO E, Pirola M, Callegari V, Tonni E, et al
Future directions for antibody-drug conjugates in urothelial cancer.
Expert Rev Anticancer Ther. 2026;26:321-332.
Abstract

KEANE KG, Redfern A, Lim J, Hayne D, et al
The role of gemcitabine-docetaxel in the management of NMIBC: a scoping review of current status and future directions.
Expert Rev Anticancer Ther. 2026;26:333-344.
Abstract

KEANE KG, Redfern A, Lim J, Hayne D, et al
The role of immune checkpoint inhibitors in the management of NMIBC: a scoping review of current status and future direction.
Expert Rev Anticancer Ther. 2026;26:307-320.
Abstract

WOO S, Luk L, Muglia VF, Briganti A, et al
VI-RADS quality score: development and proposal of a scoring system by the American College of Radiology VI-RADS Steering Committee.
Eur Radiol. 2026;36:1093-1104.
Abstract

RIZKALLA CN, Tretiakova M, Williamson SR, Akgul M, et al
Overlapping Morphologic and Immunophenotypic Features of Plasmacytoid Urothelial Carcinoma and Urothelial Carcinoma With Osteoclast-Like Giant Cells.
Int J Surg Pathol. 2026;34:309-314.
Abstract

SCHNEIDEWIND L, Kiss B, Arnold N, Kranz J, et al
[Gender-specific differences in outcome and survival in early cystectomy : Systematic review].
Urologie. 2026;65:300-307.
Abstract

TUCKER J, Sharma V, Johnson M, Hibbert R, et al
Safety and Diagnostic Yield of Percutaneous Urinary Bladder Tumor Biopsy.
Abdom Radiol (NY). 2026;51:1444-1449.
Abstract

DENG Z, Li M, Li J, Jung M, et al
Disparities in Cancer and Cardiovascular Disease Mortality Among Asian Americans Diagnosed with Urologic Cancer.
J Racial Ethn Health Disparities. 2026;13:1555-1571.
Abstract

GONG Z, He Y, Mi X, Li C, et al
Complement and coagulation cascades pathway-related signature as a predictor of immunotherapy in metastatic urothelial cancer.
Aging (Albany NY). 2023;15:9479-9498.
Abstract

XU C, Zou W, Wang Y, Liu X, et al
Bladder-sparing treatment for muscle-invasive bladder carcinoma using immune checkpoint inhibitors.
Crit Rev Oncol Hematol. 2023;191:104137.
Abstract

GIESE M, Butea-Bocu M, Huber J, Groeben C, et al
[Prehabilitation prior to radical cystectomy].
Urologie. 2023;62:1034-1040.
Abstract

OEY O, Tiong SS, Wong SL, Navadgi S, et al
Triple synchronous malignancies of the stomach, bladder and thyroid in a previously treated prostate cancer patient: A Case Report.
Folia Med (Plovdiv). 2023;65:693-698.
Abstract

MENDES WEFELNBERG M, Reimer N, Baumann FT
[Exercise therapy in prehabilitation : Current findings in urology].
Urologie. 2023;62:1011-1016.
Abstract

ANDO K, Kurashina R, Motoi N, Iizuka T, et al
Positive regulatory loop of platelet-derived growth factor DD-induced STAT3 activation is associated with poor prognosis in advanced urothelial carcinoma.
Biochem Biophys Res Commun. 2023;676:165-170.
Abstract

ZHANG J, Guo F, Zhu J, He Z, et al
Ultrasensitive Electrochemiluminescence Immunosensor for Bladder Marker Human Complement Factor H-Related Protein Detection.
Anal Chem. 2023;95:11440-11448.
Abstract

PERUZZI V, Torresan S, Cortiula F, Fanelli M, et al
Unveiling the Potential of Venn Diagrams as a Helpful Tool for Clinical Reasoning: An Illustrative Case-based Discussion.
Curr Probl Diagn Radiol. 2023;52:478-481.
Abstract

LU S, Zhang X, Cai Z, Xi Z, et al
Identification of novel lncRNA prognostic biomarkers and their associated ceRNAs in bladder urothelial carcinoma.
J Biochem Mol Toxicol. 2023;37:e23441.
Abstract

YAMASHITA S, Wada T, Deguchi R, Mashima N, et al
Prognostic significance of pre-treatment albumin-bilirubin grade in metastatic urothelial carcinoma receiving pembrolizumab.
Jpn J Clin Oncol. 2023;53:845-850.
Abstract

DOUMANIDIS P, Tsagkozis P
Surgical Management of Bone Metastases in Bladder Cancer: A Single-Center Retrospective Study.
Cancer Rep (Hoboken). 2026;9:e70524.
Abstract

SLUSARCZYK A, Moschini M, Krajewski W, Scilipoti P, et al
Bladder Tumor Location Matters: Trigone and Bladder Neck Involvement Predict Worse Oncological Outcomes in High-Grade Non-Muscle-Invasive Bladder Cancer.
Ann Surg Oncol. 2026 Mar 20. doi: 10.1245/s10434-026-19476.
Abstract

DUQUESNE I, Epelbaum I, Prost D, Haberstich M, et al
Blood and Urine Circulating Tumor DNA in Urothelial Bladder Cancer: State of the Art and Clinical Perspective.
Eur Urol Oncol. 2026 Mar 19:S2588-9311(26)00065.
Abstract

XU X, Liang R, Zhao A, Zhang J, et al
Ferroptosis Induction by Fenbendazole Combined With Photothermal Therapy Triggers Dual-Immunotherapy Against Bladder Cancer.
Adv Sci (Weinh). 2026 Mar 20:e74876. doi: 10.1002/advs.74876.
Abstract

WU Q, Zhou Y, Ou Z, Fu H, et al
Peroxisomal activity drives aggressive bladder cancer phenotypes and reveals erythorbic acid as a potential therapeutic modulator.
Front Oncol. 2026;16:1734437.
Abstract

ICHAS M, Allard L, Harper L, Yacoub M, et al
Urothelial Carcinoma of the Bladder Following BK Virus Infection in a Pediatric Kidney Transplant Recipient.
Pediatr Transplant. 2026;30:e70303.
Abstract

PORRECA A, Marino F, De Marchi D, Giampaoli M, et al
Can we define the clinical variables predicting T0 after neoadjuvant systemic therapy in bladder cancer?
Cancer Treat Res Commun. 2026;47:101181.
Abstract

WANG Y, Zhang A, Che H, Gao J, et al
Coenzyme Q10 exerts anti-cancer effects in bladder cancer by inducing ROS-mediated apoptosis and autophagy.
J Bioenerg Biomembr. 2026 Mar 19. doi: 10.1007/s10863-026-10093.
Abstract

HU Z, Jiang N, Xie B, Zhou J, et al
CircBARD1 suppresses tumor progression driven by H3K18 lactylation-CCNA2 axis in human bladder cancer.
Cell Oncol (Dordr). 2026;49:58.
Abstract

EVANGELISTA L, Guglielmo P
From prostate to bladder cancer: current evidence and expanding horizons in nuclear medicine.
Q J Nucl Med Mol Imaging. 2026 Mar 19. doi: 10.23736/S1824-4785.26.03731.
Abstract

GUGLIELMO P, Perrone E, Librando M, Aghaee A, et al
Novel radiopharmaceuticals for bladder cancer evaluation.
Q J Nucl Med Mol Imaging. 2026 Mar 19. doi: 10.23736/S1824-4785.26.03706.
Abstract

GERSHMAN B, Perez-Londono A, Almohtasib J, Kaul S, et al
Voiding Dysfunction Among Older Adults With Non-Muscle Invasive Bladder Cancer: Incidence and Predictors of Treatment for Overactive Bladder.
Neurourol Urodyn. 2026 Mar 19. doi: 10.1002/nau.70269.
Abstract

YAO W, Shen W, Zhou H, Dai X, et al
Bioinspired IgM-Mimetic Polyvalent Aptamer-Albumin Nanoplatform for Targeted Intravesical Therapy of Bladder Cancer.
Small. 2026 Mar 19:e14393. doi: 10.1002/smll.202514393.
Abstract

LONG M, Peng Y, Gade S, Nicholson H, et al
Innovative In Vitro-In Silico Platform for Dose-Response Modeling in Canine Bladder Cancer: A 3D Organoid- and Mathematics-Based Approach.
AAPS J. 2026;28:74.
Abstract

WATANABE H, Takeuchi M, Higaki A, Kojima Y, et al
Histopathological Basis of Peritumoral Enhancement in Muscle-invasive Bladder Cancer.
Magn Reson Med Sci. 2026 Mar 19. doi: 10.2463/mrms.mp.2025-0211.
Abstract

CHENG H, Lu L, Gong Y, Liu S, et al
Targeting EGFR with sanguinarine chloride: a novel approach to bladder cancer therapy.
Biochem Pharmacol. 2026 Mar 16:117905. doi: 10.1016/j.bcp.2026.117905.
Abstract

CANO-VELASCO J, Luis-Cardo A, Moreno-Cortes JC, Carrasco-Loras L, et al
Impact of Intravesical BCG Therapy on Quality of Life in Non-Muscle-Invasive Bladder Cancer: A Prospective Evaluation Using The FACT-Bl Questionnaire.
Actas Urol Esp (Engl Ed). 2026 Mar 16:501937. doi: 10.1016/j.acuroe.2026.501937.
Abstract

FELTES BENITEZ N, Counago F, Paredes-Rubio S, Peleteiro Higuero P, et al
Prognostic Factors and Oncological Outcomes after Trimodality Bladder-Preserving Therapy for Muscle-Invasive Bladder Cancer: A Multicenter Real-World Study.
Actas Urol Esp (Engl Ed). 2026 Mar 16:501967. doi: 10.1016/j.acuroe.2026.501967.
Abstract

BAHAR P, Perez-Londono A, Kaul S, Efstathiou J, et al
Population-based outcomes of chemoradiation therapy for muscle-invasive bladder cancer in older adults.
J Geriatr Oncol. 2026;17:102939.
Abstract

VANEGAS CARDENAS SA, Cantor EJ, de Vries E
Incidence, mortality, and five-year survival of bladder cancer in six population-based cancer registries in Colombia, 2003-2018.
Cancer Epidemiol. 2026;102:103049.
Abstract

KITANO H, Watanabe E, Tadera K, Nakano Y, et al
Urine culture-guided antibiotic prophylaxis reduces febrile pyelonephritis after ureteral stent removal following radical cystectomy.
World J Urol. 2026;44:249.
Abstract

RIBEIRO CPS, Fernandes R, Lourenco LMO
Smart Macrocycles: Cyclodextrin-Porphyrin Photosensitizers for Photodynamic Therapy in Human Bladder Cancer Cells.
ACS Appl Bio Mater. 2026 Mar 18:XXX. doi: 10.1021/acsabm.6c00053.
Abstract

SUN L, Liu C, Yuan L
Evolving patterns of bladder cancer mortality in US adults: a two-decade analysis reveals persistent disparities despite overall progress (1999-2020).
Front Oncol. 2026;16:1713506.
Abstract

VARADI M, Magyar B, Szeles A, Korda S, et al
Prognostic and predictive factors of immune checkpoint inhibitor therapy in urinary bladder cancer.
Pathol Oncol Res. 2026;32:1612333.
Abstract

JIE J, Wang Q, Chen Z, Hu C, et al
Multi-omics analysis and preliminary experimental validation of acetyl tributyl citrate (ATBC) promoting bladder cancer progression via the AKR1B1/EMT axis.
Environ Pollut. 2026;397:127970.
Abstract

SAKATANI T, Tanaka S, Murakami K, Jinno C, et al
Development and validation of a tumor-derived CXCL1 qPCR assay to support patient selection for anti-CXCL1 therapeutics in bladder cancer.
Exp Mol Pathol. 2026;146:105039.
Abstract

LI J, Ballas L, Ghatalia P
Bladder Preservation Strategies in Muscle-Invasive Bladder Cancer.
Am Soc Clin Oncol Educ Book. 2026;46:e515984.
Abstract

TURAN S, Gezmis CT, Israfilov A, Aydin M, et al
Primary Mucinous Bladder Adenocarcinoma.
Prague Med Rep. 2026;127:44-47.
Abstract

ZHANG C, Cao S, Zeng G, Dong Y, et al
APR-246 drives ROS-dependent ferroptosis and apoptosis and enhances anti-PD-1 efficacy in bladder cancer.
Sci Rep. 2026 Mar 15. doi: 10.1038/s41598-026-44653.
Abstract

HUANG L, Sun X, Song T, Liu Z, et al
Squid tentacle-mimetic magnetically targeted nanomotors to overcome the bladder barrier for synergistic chemotherapy-immunotherapy of bladder cancer.
J Control Release. 2026;393:114808.
Abstract

DUNST J
[Cystectomy plus perioperative enfortumab vedotin/pembrolizumab in bladder cancer].
Strahlenther Onkol. 2026;202:448-450.
Abstract

ASSEL M, Vickers AJ
Letter: Incarcerated Patients Present With More Advanced Bladder Cancer Stage: A Statewide Analysis.
Urol Pract. 2026 Mar 16:101097UPJ0000000000000987.
Abstract

ALWABEL W, Almisfer A, Alsamaani I, Aljaafri B, et al
Intravesical therapy for bladder cancer causing disseminated tuberculosis and perforated viscus: a case report.
J Surg Case Rep. 2026;2026:rjag131.
Abstract

MAHDIPOUR S, Modarressi MH, Noruzinia M
Methylation and Expression Analysis of POU4F2, HOXA9, RBM46, and TSGA10 Genes in Bladder Cancer Using Methyl-Sensitive Restriction Enzyme PCR (MSRE-PCR).
Cancer Manag Res. 2026;18:557943.
Abstract

YU H, Lei Q, Yang W, Cao M, et al
FAM-related prognostic molecular subtype screening identified epithelial-derived MAOA-inhibiting bladder cancer.
Front Cell Dev Biol. 2026;14:1732999.
Abstract

HE J, Liu X, Li S, Xia Z, et al
A systematic characterization of amino acid metabolism-related genes reveals molecular subtypes and a prognostic signature in bladder cancer.
Front Oncol. 2026;16:1754912.
Abstract

MAHATI SG, Wu J, Walter FM, Zhou Y, et al
Defining recurrent urinary tract infections and quantifying bladder cancer risk in primary care in England: a nationwide case-control study.
Lancet Prim Care. 2026;2:None.
Abstract

BOUNOUAR O, El Moudane A, Andrea E, Jdaini A, et al
Urothelial Bladder Cancer With Cardiac Metastasis: A Case Report.
Cureus. 2026;18:e103414.
Abstract

LEASK J, Ibrahim I, Wilson B, Hendry J, et al
The Role of Socioeconomic Status in Influencing Stage at Presentation and Overall Survival in Bladder Cancer: Experience From the West of Scotland.
Cureus. 2026;18:e103399.
Abstract

HU X, Miao J, Huang Y, Yang Y, et al
Urinary Diversion-Specific Morbidity After Radical Cystectomy: A Ten-Year Institutional Experience.
Cancer Med. 2026;15:e71684.
Abstract

ZHAO K, Zhou Z, Ma X, Xiao X, et al
Progress and challenges in CAR-T cell therapy for bladder cancer.
Crit Rev Oncol Hematol. 2026;222:105275.
Abstract

HJORT PB, Jensen JE, Jensen JB, Ernst A, et al
Study of bladder cancer detection in standard white light versus AI-supported endoscopy-01 (RAISE-01) - Development and validation of an AI-based support tool.
Int J Med Inform. 2026;213:106390.
Abstract

MARDELLI C, Bertail T, Tachibana I, Verhoest G, et al
Refining prognostication in non-muscle-invasive bladder cancer: From clinical models to artificial intelligence.
Urol Oncol. 2026 Mar 13:111047. doi: 10.1016/j.urolonc.2026.111047.
Abstract

ZHANG L, Chen C, Huang W, Dong L, et al
PIN1 suppresses bladder cancer progression by inducing cellular senescence and activating the interferon response pathway.
Cell Signal. 2026;143:112476.
Abstract

PARRAO D, Gallegos H, Ruz K, Lay R, et al
Use of Artificial Intelligence Model Associated with Masson's Trichrome Staining as a Predictor of Muscle Invasion in Bladder Cancer.
Int J Mol Sci. 2026;27:2237.
Abstract

DOMIAN N, Smereczanska M, Mrugacz M, Mlynarczyk G, et al
Comparative Evaluation of HMG Family Proteins and miR-106a-5p in Low-Grade Non-Invasive and High-Grade Muscle-Invasive Papillary Urothelial Carcinoma.
Int J Mol Sci. 2026;27:2089.
Abstract

VENKATESH A, Rodriguez Rosales RD, Kanumuambidi JP, Ishiyama Y, et al
Role of Spatial Heterogeneity in Muscle-Invasive Bladder Cancer on Overall Survival and Immunotherapy Response.
Cancers (Basel). 2026;18:875.
Abstract

KIM T, Shin D, Ahn HK, Moon YJ, et al
Urine-Based cfDNA Ensemble Modeling for Early Detection of Bladder Cancer Using Whole-Genome Methylation Sequencing.
Cancers (Basel). 2026;18:767.
Abstract

MELGAREJO SEGURA MT, Herraez Marcos M, Cano Garcia MC, Zambudio Munuera A, et al
De-Intensification Strategies in Non-Muscle-Invasive Bladder Cancer: Outcomes and Cost Impact of In-Office Bladder Fulguration.
J Clin Med. 2026;15:1939.
Abstract

TANG Y, Wang L, Liu H, Zhu Q, et al
Advances in intravesical therapy for non-muscle-invasive bladder cancer.
Crit Rev Oncol Hematol. 2026;222:105271.
Abstract

BAI J
Impact of physiological ability and surgical stress score on postoperative complications in patients undergoing surgery for non-muscle-invasive bladder cancer.
Medicine (Baltimore). 2026;105:e47699.
Abstract

SABER TANHA A, Sadeghi R, Ghorbani H, Soltani S, et al
Lymphatic mapping and sentinel lymph node biopsy in urinary bladder cancer: A SPECT/CT-based experience.
Ann Nucl Med. 2026 Mar 13. doi: 10.1007/s12149-026-02181.
Abstract

PARIKH M, McMahon P, Eng S, Boateng F, et al
Retrospective, Observational Analysis of Real-World Safety Outcomes in Patients With Locally Advanced/Metastatic Urothelial Cancer Treated With Sacituzumab Govitecan.
Clin Genitourin Cancer. 2026;24:102516.
Abstract

LIU Y, Tang A, Wang H
Toxicogenomic Characterization of Perfluorooctanoic Acid-Associated Bladder Carcinogenesis.
Cell Biol Toxicol. 2026;42:47.
Abstract

ASLANOVA M, Pereanu W, Lawrence A, Wang H, et al
Tumor-Informed Circulating Tumor DNA (ctDNA) in Locally Advanced and Metastatic Urothelial Carcinoma: A Retrospective Single-Center Cohort.
Clin Genitourin Cancer. 2026;24:102512.
Abstract

KOLAHI AZAR H, Beheshtizadeh N, Rezapour R, Pourlak T, et al
p16 positivity as a potent indicator of high-grade histology and its interplay with HER2/neu in urothelial bladder carcinoma.
Tissue Cell. 2026;100:103390.
Abstract

ZHU J, Ma X, Xie F, Wang Y, et al
TNM Stage-Stratified Comparison Between Urachal and Nonurachal Adenocarcinomas of the Bladder: A Single-Center Retrospective Cohort Study.
Clin Genitourin Cancer. 2026;24:102509.
Abstract

LOMBARDO KA, Yoshida T, Johnson E, Fitzgerald K, et al
Molecular characterization of non-muscle invasive tumor from N-methyl-N-nitrosourea (MNU)-induced urothelial carcinoma in a rat model reveals hallmarks of both luminal and basal subtypes.
Exp Mol Pathol. 2026;145:105032.
Abstract

PEARSON M, Engen PA, Green SJ, Emerson J, et al
Microbial profiling of urothelial carcinoma and benign bladder tissue from formalin-fixed specimens.
Urol Oncol. 2026;44:110997.
Abstract

WU DJ, Chan E
Histologic mimics of urothelial carcinoma.
Semin Diagn Pathol. 2026;43:150993.
Abstract

KOMORI M, Ogawa M, Yonezawa T, Momoi Y, et al
Significance of monocyte-to-lymphocyte ratio as a prognostic factor in canine urothelial carcinoma: a retrospective study.
J Vet Med Sci. 2026;88:485-491.
Abstract

BRACARDA S, Mammone G, Mosillo C, Sirgiovanni G, et al
Circulating tumor DNA in urothelial cancer as an intermediate disease state between localized and advanced stages: Moving from risk factors to micrometastatic disease in the perioperative setting.
Urol Oncol. 2026;44:110986.
Abstract

BAS-CUTRINA F, Morales-Alvarado VJ, Gomis-Marti M, Jimenez-Serrano E, et al
Endoscopic vacuum therapy for leaky cavities: is it possible?
Rev Esp Enferm Dig. 2026;118:112-114.
Abstract

ERGUL RB, Kucukgergin C, Cincin ZB, Cakmakoglu B, et al
Genome-wide transcriptional profiling identifies molecular markers associated with early carcinogenesis in high-grade bladder cancer.
Sci Rep. 2026 Mar 26. doi: 10.1038/s41598-026-36530.
Abstract

GONDA M, Kawai N, Ishikawa D, Aoki M, et al
Enhanced magnetic hyperthermia using anti-PD-L1 antibody-conjugated magnetoliposomes in a murine subcutaneous bladder cancer model.
Int J Hyperthermia. 2026;43:2645413.
Abstract

XUE Z, Qie Y, Liang S, Li R, et al
Cost-Effectiveness of Circulating Tumor DNA-Guided Adjuvant Atezolizumab in Muscle-Invasive Bladder Cancer Based on IMvigor011 Trial.
JCO Oncol Pract. 2026 Mar 26:OP2501242. doi: 10.1200/OP-25-01242.
Abstract

FRIESEN MC, Xie S, Locke SJ, Baris D, et al
Enhancing a job exposure matrix with subject-specific information to assess combined exposure to benzene, toluene, and xylene in a case-control study.
Ann Work Expo Health. 2026;70:wxag014.
Abstract

RUAN JL, Lee C, Sharma O, Lovgren N, et al
FLASH radiotherapy enables dose escalation and improves survival in an orthotopic muscle-invasive bladder cancer mouse model.
Br J Radiol. 2026 Mar 26:tqag071. doi: 10.1093.
Abstract

QIAO S, Li Y, Gao Y, Li K, et al
Point-of-Care Detection of Dual Methylation Genes for Rapid Bladder Cancer Diagnosis and Prognosis.
Anal Chem. 2026 Mar 26. doi: 10.1021/acs.analchem.6c00373.
Abstract

CHAN KH, Cen P, Shu T, Canfield S, et al
Consolidation enfortumab vedotin and pembrolizumab after cisplatin induction in metastatic urothelial cancer: Outcomes of complete response and bladder preservation.
J Int Med Res. 2026;54:3000605261430450.
Abstract

LIEDBERG F, Holmberg L, Jarvholm B, Liv P, et al
[Why has bladder cancer incidence not decreased like in lung cancer?].
Lakartidningen. 2026;123:25097.
Abstract

VENHOMAA T, Nikulainen I, Bobjer J, Blackberg M, et al
Radical cystectomy practice patterns in the Nordic countries: results from the prospective NorCys study.
Scand J Urol. 2026;61:72-79.
Abstract

XU MC, Sandberg ML, Childs DD, Cengiz TB, et al
Synergy of PET and MR imaging in the local and regional staging of bladder cancer.
Ther Adv Urol. 2026;18:17562872261430967.
Abstract

XIAO Y, Zhang J, Jia Y, Song H, et al
Cigarette Smoking-Regulated PRKCE Is Involved in Bladder Cancer Susceptibility through cGMP/PKG-Dependent Glycolysis.
Environ Health (Wash). 2025;4:365-378.
Abstract

DE SOUZA RODRIGUES MR, da Silva IM, Leite Vacario BG, Oliveira Rocha LM, et al
Genetic variants in 8-oxoguanine DNA glycosylase 1 (OGG1) and X-ray repair cross-complementing protein 1 (XRCC1) and non-genetic factors are associated with bladder cancer susceptibility and prognosis in a Brazilian population.
J Toxicol Environ Health A. 2026 Mar 25:1-13. doi: 10.1080/15287394.2026.2647858
Abstract

KESSLER ER, Hoover K, Coats H, Fischer SM, et al
Use of a Delphi process to formulate a pragmatic framework for care planning in older adults with advanced bladder cancer.
Support Care Cancer. 2026;34:366.
Abstract

NIEGISCH G, Gakis G, Ohlmann CH, Knuchel-Clarke R, et al
[Perioperative therapy for muscle-invasive bladder cancer-current treatment concepts].
Urologie. 2026 Mar 25. doi: 10.1007/s00120-026-02810.
Abstract

TORNESELLO ML, Piccirillo MC, Tambaro R, Simeon V, et al
Effect of co-occurring mutations in TP53 gene and TERT promoter on the survival of bladder cancer patients.
Front Immunol. 2026;17:1771897.
Abstract

LIU MY, Lin SY
[Caring for a Patient With Rare Urachal Carcinoma and Facilitating Family Medical Decision-Making: A Case Report].
Hu Li Za Zhi. 2026;73:e26213.
Abstract

YAN X, Tang X, Guo L, He Z, et al
Characterization of Immune Infiltrating Cells in Bladder Urothelial Carcinoma and Its Clinical Significance.
Cancer Med. 2026;15:e71737.
Abstract

KOLANUKUDURU KP, Ben-David R, Hug B, Eraky A, et al
Therapeutic efficacy of Gemcitabine/Docetaxel maintenance in patients with non-muscle-invasive bladder cancer receiving initial Bacillus Calmette-Guerin induction.
Urol Oncol. 2026 Mar 23:111078. doi: 10.1016/j.urolonc.2026.111078.
Abstract

SUARTZ CV, de Carvalho PRS, Freitas RA, de Souza AM Neto, et al
The Perioperative Revolution in Muscle-Invasive Bladder Cancer - Progress, Caution, and the Latin American Perspective.
Int Braz J Urol. 2026;52:e20260158.
Abstract

MOLLICA V, Massari F, Fujita K, Giannatempo P, et al
Real-world effectiveness of avelumab, pembrolizumab, and enfortumab vedotin in patients with advanced urothelial carcinoma with squamous differentiation (ARON-2EV).
Cancer Immunol Immunother. 2026;75:119.
Abstract

SALVAGGIO G, Comelli A, Albano D, Galia M, et al
Artificial intelligence and radiomics in bladder cancer MRI: a scoping review of applications, performance, and barriers to clinical translation.
Abdom Radiol (NY). 2026 Mar 24. doi: 10.1007/s00261-026-05457.
Abstract

ARTILES MEDINA A, Aumatell J, Gonzalez-Padilla DA, Pichler R, et al
The updated 2021 EAU risk groups for non-muscle-invasive bladder cancer: what have we learned four years after implementation?
Minerva Urol Nephrol. 2026 Mar 24. doi: 10.23736/S2724-6051.26.06915.
Abstract

PEYTON CC, Dhanda R, Burke T, Tsurutis V, et al
Psychometric Validation of the QLQ-NMIBC24 in Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer.
Res Rep Urol. 2026;18:591097.
Abstract

AVILEZ ND, Tineo RN, Rodrigues JT, Ottaiano AD, et al
Comparison of [(18)F]FDG and [(18)F]PSMA-1007 PET/CT in the Evaluation of Muscle-Invasive Bladder Cancer: A Pilot Feasibility Study.
Mol Imaging Biol. 2026 Mar 23. doi: 10.1007/s11307-026-02085.
Abstract

KOCH J, Xu J, Bormann F, Coutinho Carneiro V, et al
The bladder cancer m(6)A landscape is defined by global methylation dilution and focal 3'-UTR hypermethylation.
EMBO Rep. 2026 Mar 23. doi: 10.1038/s44319-026-00739.
Abstract

SINGH AK, Praharaj M, Lombardo KA, Yoshida T, et al
Retraction Note: Re-engineered BCG overexpressing cyclic di-AMP augments trained immunity and exhibits improved efficacy against bladder cancer.
Nat Commun. 2026;17:2707.
Abstract

LEE NJ, Polverino F, Quarta L, Filzmayer M, et al
Tumor size effect on cancer-specific mortality in T2N0M0 urothelial bladder cancer treated with trimodal therapy.
Urol Oncol. 2026 Mar 22:111076. doi: 10.1016/j.urolonc.2026.111076.
Abstract

NGUYEN ME MD, Cepek J MD, PhD, FRCPC, Charlebois J MD FRCPC, Rosebush P MD, FRCPC, et al
Elevations in serum lithium levels postcystectomy and ileal conduit.
BMJ Case Rep. 2026;19:e267862.
Abstract

XU L, Zeng Z, Zou X, Zhu Z, et al
Construction and evaluation of a bladder cancer prognosis model based on super-enhancer-associated genes.
Discov Oncol. 2026 Mar 23. doi: 10.1007/s12672-026-04851.
Abstract

O'MAHONY CJ, Low E, Lynch OE, Daly K, et al
Investigation of non-visible haematuria in a tertiary urology service.
Ir Med J. 2026;119:41.
Abstract

ZHANG X, Wu X, Du J, Mei J, et al
Gold Nanoparticles in Bladder Cancer Applications: A Paradigm Shift from Diagnostic Tools to Integrated Theranostic Platforms.
Int J Nanomedicine. 2026;21:575926.
Abstract

KLINGENBERG S, Lindgren MS, Jakobsen JK, Jensen JB, et al
DaBlaCa-13 Study: Five-year Follow-up from the Randomized Controlled Trial of Chemoresection with Intravesical Mitomycin C in Recurrent Ta Non-muscle-invasive Bladder Cancer.
Eur Urol Oncol. 2026 Mar 20:S2588-9311(26)00066.
Abstract

ULLAH A, Liu X, Zeng Y, Zhou C, et al
Red ginseng polysaccharide targets the PI3K/AKT/mTOR pathway to induce mitochondrial apoptosis in bladder cancer.
Int J Biol Macromol. 2026 Mar 19:151524. doi: 10.1016/j.ijbiomac.2026.151524.
Abstract

RAIZENNE BL, Koshkin VS, Zhu A, Ben-David R, et al
Prognostic Utility of ctDNA for Trimodality Therapy Outcomes in Muscle Invasive Bladder Cancer.
Clin Genitourin Cancer. 2026;24:102524.
Abstract

KORONICA R, De Leonardis F, Servedio M, Novielli C, et al
Ifosfamide-Induced Encephalopathy in a Very Young Child With Rhabdomyosarcoma: Case Report and Literature Review.
J Pediatr Hematol Oncol. 2026;48:139-141.
Abstract

LU Z, Yang W, Hong Y, Qiao Y, et al
Delivery of Multifunctional Microspheres via Intravesical Instillation for Bladder Carcinoma: Therapeutic Potential and Mechanistic Insights.
Adv Healthc Mater. 2026;15:e04290.
Abstract

TOKUNAGA R, Yamauchi T, Den H, Omotaka S, et al
Epidemiology and treatment patterns of urachal remnants in adult patients with omphalitis: a nationwide claims-based study in Japan.
Surg Today. 2026;56:436-444.
Abstract

HASHIMOTO M, Fukiage K, Minami T, De Velasco MA, et al
Treatment strategies for locally advanced and metastatic urothelial carcinoma based on molecular profiles: A Review.
Histol Histopathol. 2026;41:545-552.
Abstract

SPEZIALE R, Iacovelli V, Leoni G, Anzillotti L, et al
Plasma metabolomic profiling identifies a metabolic signature for non-muscle-invasive bladder cancer independent of hematuria.
Biol Direct. 2026 Apr 3. doi: 10.1186/s13062-026-00766.
Abstract

GRUBA N, Stachurski L, Lesner A
Utility of FRET substrates in bladder cancer diagnosis.
Bioorg Chem. 2026;175:109818.
Abstract

SUN S, Zhang J, Zheng Z, Hao Y, et al
PSMD2-Mediated MAPK Signaling Promotes Bladder Cancer Development and Immune Microenvironment Remodeling.
Oncol Res. 2026;34:30.
Abstract

GIORGIONE R, Grasso D, Gambale E, Scolari F, et al
Serum Biomarkers in Bladder Cancer: NMR Metabolomics for Identification and Monitoring during Platinum-Based Therapy.
Oncol Res. 2026;34:1.
Abstract

SHIBAMORI K, Hashimoto K, Okabe K, Maehana T, et al
Absence of bladder cancer cells in surgical smoke from robot-assisted radical cystectomy: a prospective study.
Front Urol. 2026;6:1714844.
Abstract

MAGNANI CJ, D'Andrea VD, Barros GG, Qian Z, et al
Clinical and genomic profiling of early-onset bladder cancer identifies key alterations and therapeutic targets.
medRxiv [Preprint]. 2026 Mar 24:2025.01.10.25320337.
Abstract

ZHOU L, Chen Y, Yuan X, Guo F, et al
Experiential Aspects in Patients With Permanent Urostomy Following Bladder Cancer Surgery: Meta-Synthesis of Qualitative Studies.
Nurs Open. 2026;13:e70517.
Abstract

HUA X, Huang M, Deng X, Xu J, et al
Correction: The inhibitory effect of compound ChlA-F on human bladder cancer cell invasion can be attributed to its blockage of SOX2 protein.
Cell Death Differ. 2026 Apr 2. doi: 10.1038/s41418-026-01721.
Abstract

GUO X, Wang S, Ma Y, Chen Y, et al
Efficacy and safety of RC48 alone or combined with PD-1 inhibitors in high-risk non-muscle invasive bladder cancer.
Sci Rep. 2026 Apr 2. doi: 10.1038/s41598-026-43393.
Abstract

YAN YC, Guo Q, Xu J, Wei Z, et al
Marked Non-Infectious Elevation of Procalcitonin in a Hemodialysis Patient with Bladder Cancer: A Case Report.
Infect Drug Resist. 2026;19:569356.
Abstract

CAO Y, Li C, Hua Y, Wu T, et al
Multi-omics identification of a programmed cell death-related signature and potential target P4HB for bladder cancer based on a 101-combination machine learning and experimental validation.
Clin Exp Med. 2026;26:214.
Abstract

GOKHALE P, Zapata LV
Immune-Related Adverse Events in Bladder Cancer Patients Treated With Immune Checkpoint Inhibitors: Insights From a FAERS Disproportionality Analysis.
Cancer Med. 2026;15:e71777.
Abstract

KNEZEVIC M, Tomaskovic I, Murgic J, Vrhovec B, et al
Immune landscape of muscle-invasive bladder cancer: role of TIGIT, LAG-3, and PD-L1.
Front Immunol. 2026;17:1777409.
Abstract

FRASCOLLA C, Mastroianni R, Macedo-Silva C, De Menna M, et al
Bridging phenotype and function in bladder cancer using immuno-competent organoids and ex vivo drug screening.
J Exp Clin Cancer Res. 2026 Apr 1. doi: 10.1186/s13046-026-03701.
Abstract

KAMAL AHM, Putluri V, Gandhi T, Ambati CSR, et al
Leveraging untargeted metabolomics in combination with machine learning to uncover novel insights into bladder cancer.
Cancer Metab. 2026;14:8.
Abstract

KABUS M, Aumiller M, Ruhm A, Pongratz T, et al
Combining 5-ALA-PDT with berbamine as an in vitro multimodal therapy approach against bladder cancer cells.
Sci Rep. 2026;16:11228.
Abstract

DURRANI FA, Cacaccio J, Potter W, Dukh M, et al
Anticancer Efficacy of HPPH-PDT Synergies with BCG-Immunotherapy or COX-2 Inhibitor in Treating Bladder Cancer.
Mol Pharm. 2026 Apr 1. doi: 10.1021/acs.molpharmaceut.5c01678.
Abstract

LIU R, Wang J
Recent advances in immunotherapy for bladder cancer: mechanisms, clinical applications, and future perspectives.
Front Oncol. 2026;16:1786965.
Abstract

YI X, Zhao Z, Li J
Development and validation of a risk prediction model for chemical cystitis in patients with non-muscle-invasive bladder cancer undergoing intravesical instillation.
Oncol Rev. 2026;20:1791893.
Abstract

KUSUMOTO H, Inoue M, Shishikura D, Kanzaki Y, et al
Myocardial infarction due to nonbacterial thrombotic endocarditis in a patient with advanced bladder cancer.
Cardiovasc Interv Ther. 2026 Mar 31. doi: 10.1007/s12928-026-01256.
Abstract

LIU X, Chen L, Lin L, Xie Y, et al
PLZ4@SeD-induced ferroptosis sensitizes bladder cancer to chemotherapy and immunotherapy.
Biomater Adv. 2026;185:214842.
Abstract

YUAN Y, Xie T, Hu X, Wei X, et al
Aptamer-Based Discovery of Neuropilin-2 as a Potential Biomarker and Therapeutic Target in Bladder Cancer.
Anal Chem. 2026 Mar 31. doi: 10.1021/acs.analchem.5c07494.
Abstract

BORRELLI A, Novelli S, Messina E, Laschena L, et al
AI-assessed sarcopenia as an independent predictor of neoadjuvant chemotherapy outcomes in muscle-invasive bladder cancer.
Radiol Med. 2026 Mar 31. doi: 10.1007/s11547-026-02203.
Abstract

PRADO S, Ugge H, Vikerfors A, Fall K, et al
Anti-Inflammatory Diet Index (AIDI) and Bladder Cancer Risk by Stage: A 22-Year Prospective Swedish Cohort Study (1998-2020).
Cancer Epidemiol Biomarkers Prev. 2026.
Abstract

HE Y, Gong Y, Wu Y, He S, et al
RBM15 drives bladder cancer progression through YTHDF2-dependent m6A-mediated regulation of ZO2.
J Exp Clin Cancer Res. 2026 Mar 30. doi: 10.1186/s13046-026-03684.
Abstract

YI L, Chen Q, Zeng M, Xiao Z, et al
Elevated intravesical pressure promotes circulating tumor cell release in an orthotopic mouse model of bladder cancer.
In Vitro Cell Dev Biol Anim. 2026 Mar 30. doi: 10.1007/s11626-026-01176.
Abstract

SU ZT, Florissi IS, Geller AE, Johnson Iii BA, et al
Cost-Effectiveness of Perioperative Durvalumab With Neoadjuvant Gemcitabine/Cisplatin in Muscle-Invasive Bladder Cancer Treatment.
J Natl Compr Canc Netw. 2026 Mar 19:1-7. doi: 10.6004/jnccn.2025.7129.
Abstract

OTANI Y, Otani K, Rodden D, Lemieux M, et al
PCO26-275: Single Cell RNA-seq of Circulating Tumor Cells in Recurrent Bladder Cancer After Bladder-Sparing Trimodality Therapy.
J Natl Compr Canc Netw. 2026;24.
Abstract

CHI Q, Xu H, Li H, Ma G, et al
Cx43 modulates malignant phenotypes in bladder cancer cells via the c-Src/PTEN/FAK axis.
J Mol Histol. 2026;57:129.
Abstract

CHEN D, Zhou Z, Wei G, Zhang F, et al
Perioperative and oncological outcomes of thulium laser-ERBT versus conventional TURBT in non-muscle invasive bladder cancer: a meta-analysis of 2,934 patients.
Lasers Med Sci. 2026;41:63.
Abstract

JHA T, Ahuja A, Sharma M, Goel HK, et al
Uncommon but aggressive: A case series on urinary bladder neuroendocrine carcinomas.
J Cancer Res Ther. 2026;22:196-199.
Abstract

AVILA-NIETO C, Jung G, Salih HR, Hagelstein I, et al
Characterization of TROP-2 bispecific T cell engagers for immunotherapy of triple negative breast and bladder cancer.
Front Immunol. 2026;17:1794705.
Abstract

OLUWATOLA O, Bazargan S, Irrera P, Chang D, et al
Transdermal bicarbonate buffer therapy increases intratumoral pH and elicits antitumor responses in bladder cancer.
Front Immunol. 2026;17:1706250.
Abstract

ZHUANG J, Wang H, Chen Z, Wang J, et al
Baicalin chemosensitivity enhancement of cisplatin in bladder cancer via autophagy flux inhibition.
Front Pharmacol. 2026;17:1676788.
Abstract

WANG Q, Wang H, Lan P, Yang B, et al
Integrative Transcriptomics, Machine Learning, and Molecular Dynamics Reveal Honghua Longdan (Gentiana rhodantha)?Modulated Therapeutic Targets in Bladder Cancer.
ACS Omega. 2026;11:17996-18009.
Abstract

RUSSO F, Tripodi L, Caldora F, Pandolfo SD, et al
Identification of a weighted urinary microbial signature for bladder cancer discrimination.
Front Oncol. 2026;16:1784501.
Abstract

URSO L, Feletti F, Lancia F, Canella F, et al
Diagnostic accuracy of (18)F-FDG PET/CT in muscle-invasive bladder cancer: rationale and design of the MIBC-PET study.
Front Med (Lausanne). 2026;13:1792243.
Abstract

HEMMATI GHAVSHOUGH M, Fu MZ, Islam R, Patel D, et al
Sequential Intravesical Gemcitabine and Docetaxel for Non-Muscle Invasive Bladder Cancer: A Narrative Review Across Risk Groups.
Res Rep Urol. 2026;18:584499.
Abstract

SATO T, Hayata N, Hida T, Miura T, et al
[A Case of Asymptomatic Paraganglioma of the Bladder].
Hinyokika Kiyo. 2026;72:1-6.
Abstract

OU J, Ni K, Song H, Li G, et al
The hidden burden: Clinical impact of incidental prostate cancer in bladder cancer patients.
Chin Med J (Engl). 2026 Mar 30. doi: 10.1097/CM9.0000000000004031.
Abstract

BOILLAT S, Goasmat V, Derre L, Domingos-Pereira S, et al
Corrigendum to "Role of myeloid-derived suppressor cells in bladder cancer and targeted therapeutic strategies" [Gene 970 (2025) 149772].
Gene. 2026 Mar 28:150129. doi: 10.1016/j.gene.2026.150129.
Abstract

PATEL KN, Yalla P, Panchal H, Pandya SJ, et al
Is complete TURBT mandatory before radical cystectomy in cases of muscle-invasive bladder cancer?
Urol Oncol. 2026 Mar 28:111080. doi: 10.1016/j.urolonc.2026.111080.
Abstract

RIVES H, Fredette J, Anari F, Ghatalia P, et al
Assessing Treatment Outcomes of Patients Undergoing Enfortumab Vedotin Dose Reduction in Metastatic Bladder Cancer.
Clin Genitourin Cancer. 2026 Mar 3:102525. doi: 10.1016/j.clgc.2026.102525.
Abstract

UGRINOVSKI D, Saidi S, Stankov V, Ambardjieva M, et al
Pan-Cancer Targeted Sequencing Reveals Genomic Heterogeneity and Prognostic Subgroups in Urothelial Bladder Cancer.
Cancers (Basel). 2026;18:1026.
Abstract

KIM DK, Jeon J, Kwon JK, Bang S, et al
Efficacy and Toxicity in Scheduled Intravesical Gemcitabine Versus Bacillus Calmette-Guerin for Bladder Cancer: A Systematic Review and Meta-Analysis.
Cancers (Basel). 2026;18:990.
Abstract

NTOUMAS GN, Kougioumtzopoulou A, Desse D, Fragkoulis C, et al
Bladder Preservation with Concurrent Chemoradiotherapy Following Complete Response to Induction Systemic Therapy in Patients with Muscle-Invasive Bladder Cancer: A Review of the Existing Literature.
Cancers (Basel). 2026;18:961.
Abstract

LILLESAND M, Austdal M, Mroz J, Skaland I, et al
Spatial Immune Profiling and AI-Based Classifiers Identify Predictors of BCG Therapy Outcomes in High-Risk Non-Muscle-Invasive Bladder Cancer.
Cancers (Basel). 2026;18:938.
Abstract

SINGH SP, Liu R, Yan F, Tang Q, et al
Galactokinase 1 Inhibition-Induced Cell Cycle Arrest and Apoptosis in Bladder Cancer Cells Is Associated with AKT Signaling Downregulation.
Int J Mol Sci. 2026;27:2911.
Abstract

BAI J, Yu H, Hu C, Ma Y, et al
Integrating Multi-Omics Atlas to Uncover Genetic and Epigenetic Mechanisms and Reveal Cell State Evolution Across Ecotypes in Male Urological Cancers.
Int J Mol Sci. 2026;27:2712.
Abstract

OLAH C, Juhasz D, Varadi M, Reis H, et al
Molecular subtype concordance and metastatic patterns in muscle-invasive bladder cancer.
J Pathol Clin Res. 2026;12:e70088.
Abstract

LIU Y, Zhao T, Shi R, Xie Y, et al
Cancer-associated fibroblasts in bladder cancer: Immunosuppressive mechanisms and therapeutic targeting.
Semin Oncol. 2026;53:152483.
Abstract

XIAO W, Zhang Z, Wang Y, Zhang W, et al
Enhancing the performance of BP-MRI VI-RADS in detecting muscle-invasive bladder cancer: the potential role of supplementary quantitative parameters.
Jpn J Radiol. 2026 Mar 27. doi: 10.1007/s11604-026-01970.
Abstract

MARWAHA A, Sambhi R, Fernandes R
Dermatomyositis as a Paraneoplastic Syndrome of Metastatic Urothelial Carcinoma.
Curr Oncol. 2026;33:176.
Abstract

VENTO J, Zhang T, Lotan Y, Woldu S, et al
Novel Immune Checkpoint Inhibitor and Antibody-Drug Conjugate Approaches in the Perioperative Management of Muscle-Invasive Bladder Cancer.
Curr Oncol. 2026;33:162.
Abstract

SOUTH N, Mihai IM, Wang V, Agoumi M, et al
Urachal Signet Ring Cell Carcinoma: A Clinicopathological Analysis of 28 Cases.
Curr Oncol. 2026;33:153.
Abstract

HAO Z, Yue S, Yao L, Gong Y, et al
Non-Invasive Urine-Based Diagnostic Technologies for Early Bladder Cancer.
Biosensors (Basel). 2026;16:171.
Abstract

QIAO Q, Guo R, Sun Z, Shi Y, et al
Polyphyllin II regulates ROS levels and promotes ferroptosis in bladder cancer cells.
Mol Med Rep. 2026;33:148.
Abstract

ZHANG Y, Cai L, Chen Y, Bai R, et al
MRI based unsuperviced clustering on MIBC reveals intratumor heterogeneity phenotypes and neoadjuvant chemotherapy efficacy.
Cancer Imaging. 2026;26:48.
Abstract

LUO J, Cheng Z, Chen L, Li X, et al
Correlation analysis of HER2 expression with clinicopathological features and prognosis based on data from 444 patients with urothelial carcinoma.
BMC Urol. 2026;26:86.
Abstract

GUEDES OLIVA P, Jimenez Marrero P, Espino Espino R, Marrero Dominguez R, et al
Urachal adenocarcinoma: Case report, literature review, and therapeutic algorithm proposal.
Actas Urol Esp (Engl Ed). 2026;50:501916.
Abstract

ZHANG Y, Yan R, Wang H, Man J, et al
From macroscopic clearance to molecular eradication: paradigm shift and future perspectives in the detecting of residual lesions after transurethral resection of bladder tumors.
Expert Rev Anticancer Ther. 2026;26:463-477.
Abstract

BONATTI M, Valletta R, D'Erme L, Dolciami M, et al
Preoperative staging of cervical cancer: time to shift from cystoscopy to MRI.
Eur Radiol. 2025 Oct 4. doi: 10.1007/s00330-025-12039.
Abstract

XIONG L, Li J, Jin X, Cao X, et al
An Artificial Intelligence-Based Method for Risk Stratification of Urothelial Carcinoma from Liquid-Based Urine Cytology Whole-Slide Images.
Acta Cytol. 2026;70:211-222.
Abstract

XIAO Y, Yang J, Sun M, Li Y, et al
The tumor-associated fibroblasts regulate urothelial carcinoma progression.
J Mol Cell Biol. 2026;17:mjaf032.
Abstract

TRIPATHY SR, Ayyanar P, Das DK, Barik SK, et al
Plasmacytoid subtype of urothelial carcinoma - Report of two rare cases and unusual features.
Indian J Pathol Microbiol. 2026;69:174-177.
Abstract

OLUMOYIN KD, Aydin AM, Bazargan S, Bunch B, et al
PETIL: Predicting Expansion of Tumor Infiltrating Lymphocytes for the Adoptive Cell Immunotherapy in Bladder Cancers.
bioRxiv [Preprint]. 2026 Mar 13:2025.10.15.682695.
Abstract

ANDERSON HG, Bazargan S, Nusbaum DJ, Poch MA, et al
A virtual cohort framework with applications to adoptive cell therapy in bladder cancer.
bioRxiv [Preprint]. 2026 Mar 10:2026.03.06.710135.
Abstract

LOURENCO C, Constancio V, Tavares NT, Monteiro-Reis S, et al
From cell lines to the clinic: identifying a urinary BlCa-EV signature through comparative proteomics of bladder cancer lysates and extracellular vesicles.
Cell Commun Signal. 2026 Apr 9. doi: 10.1186/s12964-026-02868.
Abstract

ZHAO M, Wang X, Duan X, Wu C, et al
Ferroptosis as a therapeutic vulnerability in ARID1A-deficient bladder cancer.
Commun Biol. 2026 Apr 10. doi: 10.1038/s42003-026-09998.
Abstract

TAN YG, Fong KY, Abern MR, Lim BJH, et al
Evaluating BCG response in primary and metachronous non-muscle invasive bladder cancer following prior upper tract urothelial cancer: A systematic review and meta-analysis.
Urol Oncol. 2026 Apr 8:111091. doi: 10.1016/j.urolonc.2026.111091.
Abstract

ZENG WR, Xu AW, Cheng ZL, Yong JJ, et al
[Clear cell adenocarcinoma of the urinary tract: a clinicopathological analysis of nine cases].
Zhonghua Bing Li Xue Za Zhi. 2026;55:326-332.
Abstract

MOUW KW, Shin KY, Parisi J, Zhai B, et al
Radiation and Avelumab in Cisplatin-Ineligible Patients With Muscle-Invasive Bladder Cancer.
Clin Genitourin Cancer. 2026;24:102548.
Abstract

KAYTAZ M, Degirmenci ME, Kucukgergin C, Aydin AF, et al
Expression of lncRNA-ATB and miR-200c in patients with bladder cancer: a pilot study.
Lab Med. 2026;57:lmag011.
Abstract

DAI Y, Xiao C, Wang L, Zhou W, et al
Efficacy and safety of antibody-drug conjugate based therapy in locally advanced or metastatic urothelial carcinoma: a systematic review and network meta-analysis of emerging clinical evidence.
Front Immunol. 2026;17:1728521.
Abstract

LIU S, Liu X, Liu G, Wang Z, et al
Nuclear hexokinase 2 couples hyperglycemia to MYC-driven glycolytic and stemness programs in bladder cancer.
Cell Death Dis. 2026 Apr 8. doi: 10.1038/s41419-026-08714.
Abstract

VAROL N, Belder N, Cetin S, Durgut SG, et al
Repression of Septin9 inhibits the oncogenic phenotype of bladder cancer.
Urol Oncol. 2026 Apr 7:111097. doi: 10.1016/j.urolonc.2026.111097.
Abstract

SAHOO B, Nayak MK, Ygl K, Aribaskar S, et al
Bleeding ileal conduit varices in a postoperative patient of urinary bladder carcinoma: percutaneous transhepatic variceal embolization to the rescue.
BMJ Case Rep. 2026;19:e266103.
Abstract

SUN M, Wang J, Luo J, Lai S, et al
Assessment of multi-parameter dual-energy CT in predicting muscle invasion in bladder cancer: comparison with VI-RADS.
Insights Imaging. 2026;17:96.
Abstract

YANG G, Wang Y, Fan Z, Wei G, et al
Rapid establishment of KRAS-driven bladder cancer initiation and immune escape models using genetically engineered mice and organoid approaches.
Front Immunol. 2026;17:1726443.
Abstract

DENG Z, Li Y, Shen Y, Zhou M, et al
Comprehensive Analysis Based on the Cancer-Immunity Cycle Identifies a Novel Immunosuppressive Subtype of Bladder Cancer.
Int J Genomics. 2026;2026:9720283.
Abstract

LI W, Xiang C, Xie G, Zhang Y, et al
Postoperative Neutrophil-to-Albumin Ratio as a Prognostic Marker for Patients with Bladder Cancer Undergoing Radical Cystectomy: A Retrospective Observational Cohort Study.
Int J Gen Med. 2026;19:595401.
Abstract

GUO B, Xu C, Fu S, Cheng Q, et al
NQO1-Mediated Anoikis Resistance and Immune Evasion Define a High-Risk Multi-Omic Subtype for Precision Management of T1 High-Grade Bladder Cancer.
Adv Sci (Weinh). 2026 Apr 7:e23605. doi: 10.1002/advs.202523605.
Abstract

OHNO T, Nakajima Y, Yoshikawa Y, Tsujino T, et al
Hypoxia-Induced microRNAs confer survival advantage in bladder cancer by fine-tuning oncogenic Pathways.
Oncology. 2026 Apr 7:1-18. doi: 10.1159/000551754.
Abstract

LIU Y, Shi ZD, Wei YF, Jiang SY, et al
Apigenin Suppresses Bladder Cancer via the SIRT6-NCOA2-PPARalpha Axis.
Int J Biol Sci. 2026;22:3070-3086.
Abstract

ZHENG K, Cui X, Liu Y, Du M, et al
Risk Factors and Predictive Model for Peripherally Inserted Central Catheter Tip Migration in Patients With Bladder Cancer.
Arch Esp Urol. 2026;79:352-361.
Abstract

KAYAR K, Verim L, Sonmez D, Kadihasanoglu M, et al
Distribution of PD-1.5 Gene Variant (rs2227981): A Possible Approach for Risk Assessment in Bladder Cancer.
Arch Esp Urol. 2026;79:233-240.
Abstract

CHERNOBILSKY V, Gonzalez IT, Favre G
Efficacy and Safety of Keyhole Limpet Hemocyanin in Bacillus Calmette-Guerin Unresponsive Non-muscle Invasive Bladder Cancer.
Arch Esp Urol. 2026;79:219-223.
Abstract

VALENCIA NIETO P, Lopez-Campos F, Diezhandino Garcia P, Duque-Santana V, et al
Adjuvant Radiotherapy After Cystectomy in Muscle-Invasive Bladder Cancer: Indications, Benefits and Remaining Challenges.
Arch Esp Urol. 2026;79:160-168.
Abstract

CHENG Y, Chen T, Zheng G, Song Z, et al
PSMD11 stabilizes PGM3 by antagonizing Parkin to promote bladder cancer progression through energy metabolism reprogramming.
Cell Death Dis. 2026 Apr 6. doi: 10.1038/s41419-026-08691.
Abstract

LEITE TFO, Parreira D, Nunes TF
Superselective vesical artery embolisation in the management of haemorrhagic radiation cystitis.
BMJ Case Rep. 2026;19:e270850.
Abstract

ANJUM A, Siddiqui MJ, Ali AMN, Ahmed J, et al
Bladder preservation approach versus radical cystectomy for high-grade non-muscle-invasive bladder cancer: a meta-analysis.
Ann Med Surg (Lond). 2026;88:2661-2668.
Abstract

SANO T, Taoka R, Miki J, Saito R, et al
Comprehensive analysis of oncological outcomes of radical cystectomy for non-muscle invasive bladder cancer.
Sci Rep. 2026 Apr 5. doi: 10.1038/s41598-026-46649.
Abstract

ZENG S, Xing S, Yu X, Liu X, et al
In-Situ Self-Assembling Multifunctional Peptide-Hydrogel Enables Efficient Bladder Cancer Therapy via Sustained Release of Bacillus Calmette-Guerin and Enhanced Immune Response.
ACS Appl Mater Interfaces. 2026 Apr 5. doi: 10.1021/acsami.6c01301.
Abstract

HUANG H, Guo L, Sun H, Liu Y, et al
Saikosaponin D inhibits bladder cancer growth and enhances the synergistic antitumor effect of gemcitabine by targeting PI3K/AKT-mediated ferroptosis.
Biochem Biophys Res Commun. 2026;816:153709.
Abstract

SUN Z, Wang Y, You S, Ji Q, et al
CREB1-ROC1 axis drives bladder cancer progression under hypoxic conditions.
Mol Cell Biochem. 2026 Apr 4. doi: 10.1007/s11010-026-05509.
Abstract

FAN Z, Li D, Chen W, Li Y, et al
Application of transformer-enhanced convolutional neural network: multicenter MRI assessment of muscle invasion in bladder cancer.
Eur Radiol. 2026 Apr 4. doi: 10.1007/s00330-026-12497.
Abstract

MUSHTAQ A, Zabor EC, Adcock B, Dhakal A, et al
Real-World Survival Outcomes and Prognostic Factors in De Novo Stage IV Urothelial Bladder Cancer: A 13-Year Retrospective Cohort Study.
Clin Genitourin Cancer. 2026 Mar 16:102541. doi: 10.1016/j.clgc.2026.102541.
Abstract

BANDO Y, Teishima J, Tobe T, Ueki H, et al
Adequate Bacillus Calmette-Guerin maintenance therapy improves recurrence-free survival in high-risk non-muscle-invasive bladder cancer: A conditional survival study.
Urol Oncol. 2026 Apr 2:111087. doi: 10.1016/j.urolonc.2026.111087.
Abstract

ZAURITO P, Scilipoti P, Longoni M, de Angelis M, et al
Risk stratification of Ta high-grade non-muscle-invasive bladder cancer: Insights from a multicenter cohort study.
Urol Oncol. 2026 Apr 2:111089. doi: 10.1016/j.urolonc.2026.111089.
Abstract

ALRAMADNEH TN, Mutee AF, Kubaev A, Qayumova S, et al
Circulating biomarkers in bladder cancer: emerging evidence and future directions for personalized therapy.
Clin Chim Acta. 2026;588:120992.
Abstract

XU H, Wu J, Qin J, Li Z, et al
Dual-Interface Hierarchical Assembly of Asymmetric ICG-Lipid Conjugates Enables Finite J-type Aggregation and Two-Stage NIR-II Fluorescence Enhancement.
Nano Lett. 2026;26:4296-4305.
Abstract

SHIGEHISA R, Fukata S, Pustimbara A, Yoshimura R, et al
Cytology-stratified evaluation of carcinoma in situ detection using 5-aminolevulinic acid-based photodynamic diagnosis.
Photodiagnosis Photodyn Ther. 2026;58:105431.
Abstract

MULLER DC, Murtha AJ, Bacon JVW, Stephenson M, et al
Prospective multicenter study of ctDNA versus tumor tissue guiding FGFR-targeted therapy in metastatic urothelial cancer.
Nat Commun. 2026;17:3263.
Abstract

DEY P, Muralidaran C
Comparative Evaluation of Transfer Learning Models for Detecting Malignant Cells in Urinary Cytology.
Cytopathology. 2026;37:232-239.
Abstract

HIRAO K, Sano T, Taniguchi H, Yanishi M, et al
Risk factors and management of hypotension and nausea during 5-aminolevulinic acid-assisted transurethral resection of bladder tumors under spinal anesthesia.
Photodiagnosis Photodyn Ther. 2026;58:105365.
Abstract

JHA S, Lobo A, Sangoi AR, Kandukuri SR, et al
Molecular characterization of clear cell adenocarcinoma of the urinary bladder.
Histopathology. 2026;88:1167-1183.
Abstract

CHILD F, Lunj S, Gough J, Humphries MJ, et al
The hypoxic ECM and neutrophils in MIBC immunotherapy resistance.
Nat Rev Urol. 2026;23:236-255.
Abstract

YANG M, Yao Y, Wang K, Qi L, et al
Clinicopathological characteristics and prognostic significance of HER2 status evaluation in patients with urothelial carcinoma: a retrospective single-center experience in China.
Virchows Arch. 2026;488:819-830.
Abstract

DENG H, Mi Y, Zhang L, Tan Y, et al
ARIH2 Ubiquitination Regulates NUPR1 to Inhibit Ferroptosis in Bladder Cancer.
J Cell Mol Med. 2026;30:e71147.
Abstract

HUI K, Gao Y, Huang J, Xu S, et al
Correction: RASAL2, a RAS GTPase-activating protein, inhibits stemness and epithelial-mesenchymal transition via MAPK/SOX2 pathway in bladder cancer.
Cell Death Dis. 2026;17:393.
Abstract

HAO Y, Niu L, Shih YA, Gao P, et al
A nurse-led cross-sectional latent profile analysis of fear of cancer recurrence in patients with non-muscle-invasive bladder cancer.
Medicine (Baltimore). 2026;105:e48370.
Abstract

BJORNSSON O, Geirsson G, Leifsson AS, Nikulasson SThorn, et al
Early recurrence after primary TURBT for non-muscle-invasive bladder cancer in Iceland: the critical role of surgical quality.
Scand J Urol. 2026;61:131-137.
Abstract

MESINOVIC D, Bobjer J, Hagberg O, Aljabery F, et al
Application of the International Bladder Cancer Group prediction model for recurrence-free survival on a national cohort of primary intermediate risk non-muscle invasive bladder cancer.
Scand J Urol. 2026;61:127-130.
Abstract

MAI M, Tran V, Zhu A, Appiah D, et al
Patterns of care and associated social determinants of health in the definitive treatment of localized muscle-invasive bladder cancer patients.
Bladder Cancer. 2026;12:23523735261438727.
Abstract

ZHU YP, Bian XJ, Ye DW, Yao XD, et al
[Expression of Concern] Pseudomonas aeruginosa-mannose-sensitive hema-gglutinin inhibits proliferation and induces apoptosis in a caspase-dependent manner in human bladder cancer cell lines.
Oncol Lett. 2026;31:208.
Abstract

LIU Y, Chen Y, Ye S, Hu J, et al
Microwave-Responsive MnFe-Based Molybdenum Disulfide Nanoflowers for Enhanced Thermal-Dynamic-Chemo Synergistic Therapy in Bladder Cancer.
Int J Nanomedicine. 2026;21:587614.
Abstract

PACINI P, Orecchia L, Asimakopoulos AD, Manfredi M, et al
The role of Bladder EpiCheck((R)) test in predicting residual tumor after transurethral resection of bladder cancer: Results from a pilot study.
Urologia. 2026 Apr 16:3915603261440213. doi: 10.1177/03915603261440213.
Abstract

WANG Y, Gong S, Shen J, Liu G, et al
Integrative analysis of myeloid cell signatures identifies a prognostic risk model and potential mechanisms in bladder cancer.
Biol Direct. 2026 Apr 16. doi: 10.1186/s13062-026-00785.
Abstract

GIATSOGLOU M, Chatzistavrou D, Sopczynski JM, Feng G, et al
Clinical Outcomes in Bacillus Calmette-Guerin-Exposed Non-Muscle-Invasive Bladder Cancer.
JAMA Netw Open. 2026;9:e267470.
Abstract

SYCHEVA IN, Oleynikova NA
[The features of cancer-associated fibroblasts as components of tumor stroma in bladder cancer].
Arkh Patol. 2026;88:87-93.
Abstract

WANG L, Zhang J, Liu Y, Sun Y, et al
Machine learning prediction of postoperative recurrence in bladder cancer using clinical and laboratory indicators.
Sci Rep. 2026 Apr 15. doi: 10.1038/s41598-026-48493.
Abstract

WANG J, Liu H, Li K, Xie Z, et al
Therapeutic potential of asparagus polysaccharide in bladder cancer treatment via modulation of PI3K/AKT/mTOR signaling.
Sci Rep. 2026 Apr 15. doi: 10.1038/s41598-026-47595.
Abstract

UYSAL D, Reible B, Wildner L, Steidler A, et al
Concordance and prognostic value of antibody drug conjugate and checkpoint inhibition targets in matched bladder cancer specimens from transurethral resection of the bladder, radical cystectomy and lymphadenectomy.
Urol Oncol. 2026 Apr 14:111095. doi: 10.1016/j.urolonc.2026.111095.
Abstract

LIANG S, Qie YK, Jia KP, Bai YD, et al
[Efficacy and safety of transvaginal assisted total intracavitary orthotopic neobladder surgery for female urothelial carcinoma of the bladder].
Zhonghua Yi Xue Za Zhi. 2026;106:1484-1488.
Abstract

ZHU L, Liu Y, Lan J, Cai E, et al
Identification of MYC co-expression gene: POLR3G is associated with cell senescence, immunotherapy, chemotherapy responses, and clinical prognosis in bladder cancer patients.
Transl Oncol. 2026;68:102770.
Abstract

ZHAO C, Hou D, Wang K, Chen J, et al
Mucoadhesive tumor-penetrating nanomedicine for intravesical chemo-immunotherapy against bladder cancer.
Sci Adv. 2026;12:eaeb9764.
Abstract

PARK C, Hwangbo H, Hong SH, Jeong HJ, et al
5-Aminoimidazole-4-carboxamide riboside, an AMPK activator, enhances TRAIL-mediated apoptosis in human bladder cancer cells in a p38 MAPK-dependent manner.
Genes Genomics. 2026 Apr 15. doi: 10.1007/s13258-026-01764.
Abstract

KANESVARAN R, Giannatempo P, Filicevas A
Empowering Patients: The Role of Shared Treatment Decision-Making in Advanced Bladder Cancer-A Podcast.
Adv Ther. 2026 Apr 15. doi: 10.1007/s12325-026-03535.
Abstract

ZHANG M, Zhou Y
Bidirectional Longitudinal Associations Among Health-Related Quality of Life, Emotional Expressivity, and Readiness to Return to Work in Patients with Non-Muscle-Invasive Bladder Cancer Receiving Intravesical Therapy: A Three-Wave Cohort Study.
Patient Prefer Adherence. 2026;20:594081.
Abstract

BAJDAK-RUSINEK K, Jankowska K, Sundararajan V, Sieron L, et al
ESRP2 constrains EMT plasticity associated with ZEB1 expression in bladder cancer.
Front Oncol. 2026;16:1764850.
Abstract

PUSTAKE M, Railkar A, Ganiyani MA, Khosla AA, et al
Trends in preferred place of death among patients with bladder cancer in the United States, 2000 to 2020.
Palliat Support Care. 2026;24:e108.
Abstract

ANDRZEJCZAK A, Krajewski W, Jaskula E, Chorbinska J, et al
Soluble immune checkpoints as diagnostic biomarkers in bladder cancer.
Biomark Res. 2026;14:44.
Abstract

PENG S, Liu Y, Huang P, Liu Q, et al
MTHFD1L in muscle invasive bladder cancer: a multi-cohort study on prognosis and therapeutic response.
World J Surg Oncol. 2026 Apr 14. doi: 10.1186/s12957-026-04346.
Abstract

ZHA J, Guo X, Liao W, Wu P, et al
Inhibition of TRPC6 channel suppresses bladder cancer proliferation by disrupting store-operated calcium entry.
Sci Rep. 2026 Apr 14. doi: 10.1038/s41598-026-45219.
Abstract

MUSAEV A, Akpinar C, Ulgen TK, Erkmen S, et al
Impact of Different Surveillance Intervals on Recurrence and Progression in Intermediate-Risk Non-Muscle-Invasive Bladder Cancer.
Clin Genitourin Cancer. 2026;24:102543.
Abstract

SUN X, Qi Q, Ding X, Wang X, et al
The Tumor-Promoting Role of ADM in Bladder Cancer and its Mediated Mechanisms of Cell Death via PKR and STAT1.
Appl Biochem Biotechnol. 2026 Apr 14. doi: 10.1007/s12010-026-05691.
Abstract

CHA JH, Kim KJ, Yun SG, Nam MH, et al
Diagnostic Aspects of a Bacillus Calmette-Guerin (BCG) Infection Following Intravesical Treatment for Bladder Cancer.
Clin Lab. 2026;72.
Abstract

Downregulation of Long Noncoding RNA TUG1 Inhibits Proliferation and Induces Apoptosis Through the TUG1/miR-142/ZEB2 Axis in Bladder Cancer Cells [Retraction].
Onco Targets Ther. 2026;19:614701.
Abstract

LIPKA U, Orywal K, Gudowska-Sawczuk M
Matrix Metalloproteinases and Pro-Inflammatory Cytokines in Bladder Cancer: Diagnostic and Prognostic Perspectives: Narrative Review.
Int J Mol Sci. 2026;27:3218.
Abstract

CANCERS EDITORIAL OFFICE
Expression of Concern: Juengel et al. Mechanisms Behind Temsirolimus Resistance Causing Reactivated Growth and Invasive Behavior of Bladder Cancer Cells In Vitro. Cancers 2019, 11, 777.
Cancers (Basel). 2026;18:1077.
Abstract

ESTEBAN-VILLARRUBIA J, de Velasco G
Targeting metastatic bladder cancer when money is an issue.
Nat Rev Urol. 2026 Apr 13. doi: 10.1038/s41585-026-01142.
Abstract

NIU S, Yang P, Yao Y, Tang X, et al
NT5DC2 inhibits ferroptosis by stabilizing ACSL3 in bladder cancer.
Cell Death Discov. 2026 Apr 14. doi: 10.1038/s41420-026-03091.
Abstract

FAN X, Li Z, Gao Q, Huang P, et al
TRIM28 orchestrates SUMO-ubiquitin crosstalk to stabilize PPARG and drive bladder cancer progression.
Cell Death Dis. 2026 Apr 13. doi: 10.1038/s41419-026-08745.
Abstract

TONG H, Li T, Zhu J, Dou Q, et al
RBM11 drives malignant progression of bladder cancer by regulating GNPDA1-PKM2 axis.
iScience. 2026;29:115402.
Abstract

LIU Q, Zhou P, Tian D
Identification of RNA processing-related gene-based bladder cancer subtypes for prognosis and immune landscape assessment.
Transl Androl Urol. 2026;15:74.
Abstract

OSKARSSON E, Johansson M, Liden O, Alamdari F, et al
Comorbidity alterations between time for diagnosis and radical cystectomy in patients with muscle invasive bladder cancer undergoing neoadjuvant chemotherapy.
Transl Androl Urol. 2026;15:77.
Abstract

MENG H, Wang X, Liu P, Liu Q, et al
Development and feasibility assessment of an automated, synthetic CT-guided plan selection system for bladder cancer adaptive radiotherapy: a retrospective pilot study.
Transl Cancer Res. 2026;15:194.
Abstract

MOLNAR A, Montoya-Cerrillo D, Montgomery EA, Kryvenko ON, et al
The ancillary role of D2-40 in demonstration of muscularis propria invasion vs desmoplastic reaction in invasive urothelial carcinoma of the bladder.
Am J Clin Pathol. 2026;165:aqag025.
Abstract

GUPTA S, Kosari F, Thapa P, Murphy SJ, et al
Sarcomatoid urothelial carcinoma with constitutive PD-L1 overexpression.
Am J Clin Pathol. 2026;165:aqag023.
Abstract

WEN J, Zhou B, Zhang H, Tang Y, et al
Unlocking caspase-8 enables Pt(IV) to trigger robust caspase-3/GSDME-mediated pyroptosis via drug co-delivery in chemoresistant bladder cancer.
J Nanobiotechnology. 2026 Apr 12. doi: 10.1186/s12951-026-04449.
Abstract

LI C, Cheng C, Li S, Wang D, et al
Integration of Node-RADS and Habitat Radiomics for Predicting Occult Nodal Metastasis in Bladder Cancer.
Ann Surg Oncol. 2026 Apr 12. doi: 10.1245/s10434-026-19624.
Abstract

SCILIPOTI P, Zaurito P, Longoni M, Occhi A, et al
The impact of age in patients with non-muscle-invasive bladder cancer treated with Bacillus Calmette-Guerin.
Urol Oncol. 2026 Apr 11:111085. doi: 10.1016/j.urolonc.2026.111085.
Abstract

WANG J, Lu M, Qi N, Zhang M, et al
Integrated machine learning and experimental validation reveal S6K2 as a key target of 6PPD-quinone in bladder cancer.
Ecotoxicol Environ Saf. 2026;316:120085.
Abstract

ANGULO-LOZANO JC, Calvillo-Ramirez A, Noyola-Perez A, Cojuc-Konigsberg G, et al
Unequal Access to Novel Systemic Therapies for Bladder Cancer: A Global Analysis of Clinical Trials of Immune Checkpoint Inhibitors and Antibody-Drug Conjugates.
Curr Urol Rep. 2026;27:21.
Abstract

HAN Y, Zheng Z, Li X, Fan W, et al
Letter to the editor: TGF-beta1 dominates stromal fibroblast-mediated EMT via the FAP/VCAN axis in bladder cancer cells.
J Transl Med. 2026;24:489.
Abstract

CHEN Q, Chen T, Gan L, Lu Y, et al
Mitophagy in bladder cancer: a double-edged sword in tumor progression and therapy.
J Transl Med. 2026;24:523.
Abstract

YAO K, Wang L, Wang J, Liu J, et al
FTO-mediated m6A demethylation inhibits bladder cancer progression via decreasing EMG1 and reducing ribosome biosynthesis.
Biochim Biophys Acta Mol Cell Res. 2026;1873:120147.
Abstract

HAN X, Dong S, Wang Y, Fang X, et al
Grape seed proanthocyanidin extract suppresses bladder cancer by dual blockade of IMPDH1/2-mediated purine and pyrimidine nucleotide biosynthesis.
J Ethnopharmacol. 2026 Apr 8:121663. doi: 10.1016/j.jep.2026.121663.
Abstract

SONG Y, Yang Y, Qin J, Zhang Q, et al
Transformer-Enhanced Joint Information Extraction Framework for Bladder Cancer Medical Dialogue Analysis.
IEEE J Biomed Health Inform. 2026;PP.
Abstract

MENBARI OSKOUIE I, Khatami F, Mesbah G, Baghdadabad LZ, et al
Melatonin enhances the antitumor and immunomodulatory effects of Bacillus Calmette-Guerin immunotherapy in a murine bladder cancer model.
Mol Biol Rep. 2026;53:600.
Abstract

BAO Q, Yoshioka T, Sato S, Goto S, et al
Correlation-Based Morphometric Analysis Reveals Structural Remodeling of Platelet-Bound Circulating Tumor Cells in Urothelial Carcinoma.
Anal Chem. 2026;98:10668-10675.
Abstract

ANDERSEN L, Lindskrog SV, Nordentoft I, Frydendahl A, et al
Cell-Free DNA-Derived Immune Cell Ratios Uncover Cancer-Associated Systemic Changes.
Cancer Res Commun. 2026;6:811-820.
Abstract

MENEGAT ALRS, Menegat BLRS, Braz LDG, Piccoli MVF, et al
Neoadjuvant immune checkpoint inhibitors for muscle-invasive urothelial carcinoma: a systematic review and meta-analysis.
Immunotherapy. 2026;18:139-155.
Abstract

MAHADEVAN KK, Kalluri R
Tumor-restraining fibroblasts emerge after chemotherapy specifically in responders.
Cancer Cell. 2026;44:708-709.
Abstract

LI H, Argani P, Gross JM, Zhu J, et al
Loss of Methylthioadenosine Phosphorylase (MTAP) Expression: A Potentially Useful Tool for Distinguishing Sarcomatoid Urothelial Carcinoma From Inflammatory Myofibroblastic Tumor.
Mod Pathol. 2026;39:100980.
Abstract

LI H, Mou Y, Liu Z, Yu C, et al
Robotic Ureteroileal Bypass Repair for Post-Cystectomy Bricker Ureteroenteric Anastomotic Strictures: Stepwise Approach and Clinic Outcomes.
Ann Surg Oncol. 2026;33:4850-4857.
Abstract

YANG Y, Wu Y, Yang K, Song G, et al
Preliminary Experience of Transurethral Thulium Laser En Bloc Resection of Paraganglioma of the Urinary Bladder.
Ann Surg Oncol. 2026;33:4806-4811.
Abstract

LI C, Cheng C, Li S, Wang D, et al
ASO Author Reflections: Imaging Tumor Heterogeneity to Reveal Occult Nodal Risk in Bladder Cancer.
Ann Surg Oncol. 2026 Apr 24. doi: 10.1245/s10434-026-19699.
Abstract

THAPA BB, Shah AK, Adhikari B, Mishra U, et al
En Bloc Versus Conventional Resection of Primary Bladder Tumor.
Kathmandu Univ Med J (KUMJ). 2025;23:307-311.
Abstract

WU J, Ren X, Zhai Z, Wang L, et al
O-GlcNAcylated TAP1 Impairs Antigen Presentation and Promotes Immune Evasion in Bladder Cancer.
Adv Sci (Weinh). 2026 Apr 24:e19955. doi: 10.1002/advs.202519955.
Abstract

SCHIAVONE N, Finati M, Ricapito A, Fanelli A, et al
Solitary adrenal gland metastasis detected at 24-month follow-up for muscle-invasive bladder cancer.
Urol Case Rep. 2025;65:103334.
Abstract

NUMMI A, Nurminen P, Kesti O, Hogerman M, et al
Impact of asymptomatic bacteriuria on the outcomes and tolerability of Bacillus Calmette-Guerin immunotherapy.
Scand J Urol. 2026;61:148-155.
Abstract

YOSHIDA K, Oka S, Takefuji Y
Re: Jurczok N, Dernbach G, Ebner B, et al. Multiregional immune profiling reveals prognostic patterns in bladder cancer. Eur Urol Oncol. In press. http://dx.doi.org/10.1016/j.euo.2025.12.006.
Eur Urol Oncol. 2026 Apr 22:S2588-9311(26)00095.
Abstract

DAGDEVIREN MA, Oguzkan SB, Ozaslan M, Erturhan MS, et al
Expression levels of miRNA 22-5p and miRNA 337-5p in bladder cancer.
Indian J Med Res. 2026;163:290-294.
Abstract

RESCA S, Morra S, Frego N, Tamburini S, et al
Evolution of survival outcomes in robot-assisted radical cystectomy over 20 years of experience in a high-volume tertiary robotic center.
Minerva Urol Nephrol. 2026;78:249-256.
Abstract

DI TRAPANI E, Lo Giudice A, Mazzone E, Dell'oglio P, et al
Detrimental effect of delayed or incomplete BCG protocols administration after trans-urethral tumor resection in patients with non-muscle-invasive bladder cancer: a systematic review.
Minerva Urol Nephrol. 2026;78:170-176.
Abstract

LEE CH, Shepherd A, Sathianathen N, Hwang JE, et al
Extended versus standard lymph node dissection for urothelial carcinoma of the bladder in people undergoing radical cystectomy.
Cochrane Database Syst Rev. 2026;4:CD013336.
Abstract

DEMIRCI A, Uzel T
Comparative Analysis of Oncological Outcomes between Trimodal Therapy and Radical Cystectomy in Patients with Variant Bladder Cancer.
Indian J Surg Oncol. 2026;17:721-727.
Abstract

TITUS RS, Riveros C, Velasquez EL, Nguyen DD, et al
Addition of immune checkpoint inhibitors to intravesical BCG for high-risk BCG-naive non-muscle invasive bladder cancer: Systematic review and meta-analysis.
BJUI Compass. 2026;7:e70194.
Abstract

YU EY, Wesselius A, Mehrkanoon S, Goosens M, et al
Correction: Vegetable intake and the risk of bladder cancer in the BLadder Cancer Epidemiology and Nutritional Determinants (BLEND) international study.
BMC Med. 2026;24:259.
Abstract

LOBO N, Zuiverloon TCM, Mertens LS
Worse bladder cancer outcomes in women than in men - bias, biology or both?
Nat Rev Urol. 2026 Apr 22. doi: 10.1038/s41585-026-01145.
Abstract

SUN XS, Boustani J, Sun R
Deep Systemic Response in Muscle-invasive Bladder Cancer: Is Radical Cystectomy Still Necessary?
Eur Urol Oncol. 2026 Apr 21:S2588-9311(26)00108.
Abstract

SUN X, Qian L, Jin D, Guo B, et al
Bifunctional DNA multivalent structure integrating stable capture of urothelial carcinoma cells with CRISPR/Cas12a signal amplification for bladder cancer detection.
Biosens Bioelectron. 2026;306:118710.
Abstract

FURRIEL F, Laranjeira P, Pereira M, Silva S, et al
CD39/CD73-mediated immunosuppression and tumor aggressiveness in bladder cancer.
Cancer Immunol Immunother. 2026;75:154.
Abstract

LIANG HQ, Li YJ, Yu JY, Mo QZ, et al
Multi-Omics Analysis Reveals m7G Methylation-Related Genes May Be Involved in TGF-beta Signaling-Mediated Anti-PD-L1 Response in Bladder Cancer.
Immunotargets Ther. 2026;15:583577.
Abstract

CHOI Y, Cho SW, Hong J, Lee J, et al
A Novel Radiomics-based Interpretable Model for Bladder Cancer Grade Prediction Using White-Light Cystoscopy Images.
Eur Urol Open Sci. 2026;87:71-79.
Abstract

YU H, Liu D, Xu J, Li A, et al
Design, synthesis and anti-bladder cancer activity of novel dihydroartemisinin-ibuprofen hybrids.
Bioorg Chem. 2026;176:109893.
Abstract

WILLIAMS S, Cho S, Morrison L, Joshi K, et al
Cost-per-responder analysis of TAR-200 versus other Food and Drug Administration-approved novel and generic treatments among patients with Bacillus Calmette-Guerin-unresponsive, high-risk, non-muscle-invasive bladder cancer with carcinoma in situ in t
J Med Econ. 2026;29:1198-1212.
Abstract

YANG Y, Gong B, Kong X, Guo Y, et al
Habitat-based radiomics-clinical analysis for early prediction of bladder cancer recurrence: a retrospective cohort study.
Abdom Radiol (NY). 2026 Apr 21. doi: 10.1007/s00261-026-05516.
Abstract

ZHANG W, Dai L, Luo M, Shi H, et al
Overexpression of MFAP4 inhibits the proliferation, migration, and invasion of bladder cancer cells.
Discov Oncol. 2026 Apr 20. doi: 10.1007/s12672-026-05056.
Abstract

WANG Y, Yuan J, Guo S, Liu Y, et al
Ubiquitination mediated cisplatin resistance in bladder cancer.
Anticancer Drugs. 2026 Mar 2. doi: 10.1097/CAD.0000000000001816.
Abstract

CAROSINO CM, Olson DJ, Mazahreh RC, Ortiz DJ, et al
An Integrin beta6-targeted antibody-drug conjugate optimized for intravesical delivery to treat non-muscle invasive bladder cancer.
Mol Cancer Ther. 2026 Apr 20. doi: 10.1158/1535-7163.MCT-26-0077.
Abstract

ISHIKAWA D, Naiki T, Naiki-Ito A, Suzuki H, et al
Long-term recurrence-free survival following total penectomy and additional chemotherapy for solitary penile metastasis from muscle invasive bladder cancer.
Urol Case Rep. 2026;66:103433.
Abstract

CALLEGARIN F, Amodeo A, Claps F, Crestani A, et al
A Study to Evaluate Efficacy and Safety of Hydeal Cyst Intravesical Instillations in Non-muscle Invasive Bladder Cancer Patients Treated With Intravesical Chemotherapy or Immunotherapy.
Eur Urol Open Sci. 2026;87:25-30.
Abstract

AHMED HU, Hosen MR, Mostofa MA, Hossain MA, et al
Whole exome sequencing identifies somatically mutated genes in bladder cancer: A pilot study from Bangladesh.
Biochem Biophys Rep. 2026;46:102574.
Abstract

PULANCO MC, Zheng XY, Sankin A, Zheng D, et al
Immune checkpoint B7x promotes immune evasion and resistance to PD-1/PD-L1 blockade in bladder cancer.
Genes Dis. 2025;13:101950.
Abstract

ZHANG X, Wang L, Sun W, Yang X, et al
Therapeutic and prognostic value of repeat transurethral resection for high-grade Ta bladder cancer: a propensity score matching analysis.
Am J Cancer Res. 2026;16:771-795.
Abstract

LI Q, Bai J, Zheng S, Liao J, et al
THAP7-AS1 orchestrates IGF2BP3-m(6)A-dependent CCN2 mRNA stabilization to promote lymphatic metastasis in bladder cancer.
Am J Cancer Res. 2026;16:1215-1230.
Abstract

LI P, Yang E, Zhang X, Shi Y, et al
TIMP1 Derived from Mesenchymal Stem Cells Promotes Bladder Cancer Progression by Regulating the Formation of VDIMs through the RAP1 Pathway.
Int J Biol Sci. 2026;22:3322-3341.
Abstract

CESTA G, Zolfanelli C, Lauciello V, Lorusso V, et al
A molecular landscape tracking the progression of non-muscle invasive bladder cancer.
World J Urol. 2026;44:320.
Abstract

LONGONI M, Falkenbach F, Marmiroli A, Le QC, et al
Correction: Development and external validation of a nomogram predicting cancer-specific mortality-free survival after trimodal therapy in muscle-invasive bladder cancer.
World J Urol. 2026;44:318.
Abstract

AKAND M, Van Weyenbergh T, Moris L, Muilwijk T, et al
Effectiveness of preoperative chemotherapy and radical cystectomy in clinically node-positive and node-negative bladder cancer patients.
World J Urol. 2026;44:319.
Abstract

XIAO X, Lu X, Peng J, Li L, et al
ATAD3A promotes bladder cancer progression by regulating glycolysis through MYC stabilization.
J Transl Med. 2026 Apr 18. doi: 10.1186/s12967-026-08139.
Abstract

SINGH N, Srivastav M
Re: Sebastian C. Schmid, Matthias Jahnen, Kilian Schiller, et al. Radiation Therapy Combined with Immunotherapy Before Radical Cystectomy in Locally Advanced Bladder Cancer: A Prospective, Single-arm, Multicenter, Phase 2 Trial (RACE-IT). Eur Urol Onc
Eur Urol Oncol. 2026 Apr 17:S2588-9311(26)00082.
Abstract

D'ANDREA D, Soria F, Roupret M, Gontero P, et al
Design and Rationale of the ROGUE-1 Registry: A Multicentric Prospective Registry for Primary T1 Nonmuscle-invasive Bladder Cancer.
Eur Urol Oncol. 2026 Apr 18:S2588-9311(26)00096.
Abstract

MITO O, Muto S, Kitamura K, Nagaya N, et al
Prevalence and prognostic impact of cancer cachexia in patients with bladder cancer: a multicenter retrospective study.
Int J Clin Oncol. 2026 Apr 18. doi: 10.1007/s10147-026-03043.
Abstract

CHEN Z, Peng S, Fu S, Lin S, et al
Targeting TPX2-dependent lineage plasticity by CDK4/6 inhibition reverses therapy resistance in neuroendocrine bladder carcinoma.
Cell Rep Med. 2026;7:102712.
Abstract

JIANG L, Li Y, Liu W, Wu S, et al
Harmonizing the adhesion-release dilemma: a bio-based injectable hypertonic hydrogel for bladder perfusion therapy.
J Mater Chem B. 2026;14:4602-4612.
Abstract

OHTSU A, Otani Y, Arai S, Rogachevskaya A, et al
Comparative genomic landscape of primary and metastatic bladder urothelial carcinoma in a large-scale cohort.
Int J Clin Oncol. 2026;31:868-877.
Abstract

DA COSTA RMM JR, Pereira do Nascimento LA, Silva TA, Panhoca R, et al
Comparison between cutaneous ureterostomy and the ileal conduit in patients with urothelial bladder carcinoma undergoing radical cystectomy: Expanding eligibility for the gold standard treatment.
Urol Oncol. 2026;44:111031.
Abstract

WANG B, Davis L, Nizam A, Moningi S, et al
Patterns of local therapy following enfortumab vedotin in advanced urothelial carcinoma.
Urol Oncol. 2026;44:110994.
Abstract

YE J, Li Y, Zhang M, Liao X, et al
Efficacy of disitamab vedotin-based therapy in HER2-negative and HER2-low locally advanced or metastatic urothelial carcinoma: A systematic review and meta-analysis.
Urol Oncol. 2026;44:111034.
Abstract

LI H, Matoso A
S100 expression and SDHB status define distinct biological subsets of bladder paraganglioma.
Hum Pathol. 2026;171:106072.
Abstract

WU DJ, Pacheco R, Chan E, Lowe AC, et al
Prostatic adenocarcinoma identified on transurethral resection of bladder tumor: A clinicopathologic series of a diagnostically relevant potential pitfall.
Hum Pathol. 2026;171:106059.
Abstract

DURSUN F, Akgul B, Gelfond JA, Leach RJ, et al
Surgical operation duration as a predictor of venous thromboembolism risk after radical cystectomy.
Urol Oncol. 2026;44:110983.
Abstract

FILSON CP, Slezak JM, Luong TQ, Aboushwareb T, et al
Real-World Utility of Cxbladder Triage for Patients with Microhematuria: A Matched Cohort Study.
Urol Pract. 2026;13:260-266.
Abstract

PIPITONE S, Vitale MG, Baldessari C, Sabbatini R, et al
Extravasation of enfortumab vedotin: a case report and literature review on antibody-drug conjugates.
Eur J Hosp Pharm. 2026;33:284-286.
Abstract

DUARTE S, Felicio E, Bernardo G, Gaboleiro F, et al
Early complications within 30 days after radical cystectomy: The top seven complications and their predictors.
Investig Clin Urol. 2026;67:254-262.
Abstract

HEO JE, Kim J, Jang WS, Sung HH, et al
Impact of carcinoma in situ of bladder at transurethral resection and radical cystectomy on survival: Retrospective multicenter study.
Investig Clin Urol. 2026;67:246-253.
Abstract

CHOI J, Song W, Nam JK, Lim B, et al
Association of initial transurethral resection staging on survival in radical cystectomy patients.
Investig Clin Urol. 2026;67:237-245.
Abstract

PENG Z, Huang Z, Nan Z, Yan Y, et al
A tumor cell membrane-engineered MXene nanoplatform for chemo-photothermal immunotherapy of bladder cancer.
J Mater Chem B. 2026 Apr 29. doi: 10.1039/d6tb00416.
Abstract

GUBERINA N, Khouya A, Hoffmann C, Fischedick G, et al
Do AI-based contouring algorithms influence physicians in the online adaptive radiotherapy of patients with bladder cancer?
Tech Innov Patient Support Radiat Oncol. 2026;38:100401.
Abstract

SAEED AK, Triantafyllakis P, Gordon NS, James ND, et al
The role of HAI-1 in urothelial bladder cancer: Tissue expression, ectodomain shedding and clinical outcomes.
Biochem Biophys Rep. 2026;46:102600.
Abstract

HAKOZAKI Y, Sugimoto K, Yamada Y, Danno T, et al
Proteogenomic detection of tumor-specific somatic mutant proteins in urinary extracellular vesicles for non-invasive monitoring of bladder cancer.
Front Oncol. 2026;16:1808671.
Abstract

TENG Q, Cheng S, Chen J, Zhu H, et al
An exploration of GuaLouQuMaiWan related novel prognostic model and search for potential compound pachymic acid in bladder cancer.
Front Oncol. 2026;16:1714939.
Abstract

LIM S, Standish L, Liu H, Paul E, et al
Lymph node dissection during cystectomy for non-muscle-invasive bladder cancer: A systematic review.
BJUI Compass. 2026;7:e70201.
Abstract

ZHU C, Liu M, Liu X, Zhang S, et al
The ZIF-8 nanoplatform targeted delivery of IFI44 siRNA to suppress bladder cancer development via modulating the PI3K/AKT signaling pathway.
J Nanobiotechnology. 2026 Apr 30. doi: 10.1186/s12951-026-04419.
Abstract

DER B, Varadi M, Nagy N, Kubik A, et al
Genetic characteristics and targeted treatments of primary bladder and urachal adenocarcinomas: a systematic review with pooled descriptive genomic analyses.
Cancer Metastasis Rev. 2026;45:26.
Abstract

KANG Y, Zhong G, Lv A, Zhang Y, et al
Analysis of factors influencing changes in patient-reported quality of life among patients with bladder cancer.
Eur J Oncol Nurs. 2026;82:103193.
Abstract

GARG T, Lyons T, Rabinowitz K, Gabriel J, et al
Use of Shared Decision-Making in Non-Muscle-Invasive Bladder Cancer: Protocol for a Scoping Review.
JMIR Res Protoc. 2026;15:e90101.
Abstract

WANG Y, Yu X
Development and validation of an interpretable prognostic model for bladder cancer based on lactylation associated genes using SHAP analysis.
Discov Oncol. 2026 Apr 30. doi: 10.1007/s12672-026-05111.
Abstract

PARK C, Cha HJ, Hong SH, Kim HS, et al
Combination Therapy with Betulinic Acid and TRAIL Increases ROS-Dependent Cytotoxicity and Inhibits PI3K/Akt Signaling in Human Bladder Cancer Cells.
Biomol Ther (Seoul). 2026;34:641-651.
Abstract

ZHANG Z, Wang L, An Z, Jiang Y, et al
Hybrid-Driven Bacillus Calmette-Guerin Carrier for Targeted Immuno-Chemo Combo Therapy in Bladder Cancer.
Cyborg Bionic Syst. 2026;7:0492.
Abstract

SINGH G, Kumar A, Kumar L, Mishra N, et al
Urinary exosomal miRNA profiling reveals sensitive non-invasive detection of bladder cancer.
BMC Urol. 2026 Apr 29. doi: 10.1186/s12894-026-02130.
Abstract

KIM D, Ged Y, Grivas P, Singh P, et al
Association Between Proto-Oncogene N-RAS Transcript Level and Overall Survival in Node-Negative Muscle-Invasive Bladder Cancer.
Clin Genitourin Cancer. 2026 Apr 1:102557. doi: 10.1016/j.clgc.2026.102557.
Abstract

KANG J, Lee HJ, Oh SB, Nam JK, et al
Transcriptome-based Deep Learning Model for Predicting Gemcitabine and Cisplatin Chemotherapy Response in Urothelial Carcinoma: Development and External Validation.
Cancer Genomics Proteomics. 2026;23:546-557.
Abstract

CHEN H, Yang G, Wei L, Cui Z, et al
SPI1 inhibits ferroptosis and immune escape of bladder cancer cells by promoting CRYAB expression.
Pathol Res Pract. 2026;283:156487.
Abstract

CASTELLO DIAS CARNEIRO AP, Batista EC, Gomes Bugano DD, Corradi RG, et al
Treatment Patterns and Outcomes in Localized Urothelial Carcinoma in Middle-Income Countries: A Multicenter Real-World Study.
JCO Glob Oncol. 2026;12:e2500324.
Abstract

CORTES J, Trindade Filho JCS, Rogatto SR
The emerging role of the microbiome in bladder cancer: prognostic implications and treatment response.
Braz J Med Biol Res. 2026;59:e15526.
Abstract

HIROSE K, Yoshida S, Chen W, Yajima S, et al
Bayesian reanalysis of the NIAGARA trial using reconstructed individual patient data: perioperative durvalumab in cisplatin-eligible muscle-invasive bladder cancer.
Jpn J Clin Oncol. 2026 Apr 29:hyag072. doi: 10.1093.
Abstract

SHARMA A, Biswal D, Sharma S, Ravani Thrilochana R, et al
Laparoscopic radical cystectomy in patients with bladder cancer: A modified technique with reduced morbidity - A comparative study.
Urologia. 2026 Apr 29:3915603261444885. doi: 10.1177/03915603261444885.
Abstract

GOLOMB D, Atamna F, Avda Y, Leonov Polak M, et al
Tumor site as predictors of pathologic progression in high-grade T1 bladder cancer.
Urologia. 2026 Apr 29:3915603261444890. doi: 10.1177/03915603261444890.
Abstract

ZHAO Q, Qin Z, Liu R, Zuo K, et al
Integrate single-cell and transcriptome analyses to explore the prognostic genes related to TRPM4 in bladder cancer.
Front Bioeng Biotechnol. 2026;14:1773551.
Abstract

MA L, Tao Y, Cheng L, You C, et al
Multilayered analysis of cisplatin resistance mechanisms in bladder cancer: from the cell membrane to organelles.
PeerJ. 2026;14:e21148.
Abstract

ORTIZ-BONILLA CJ, Molony RD, Miyamoto H, Messing E, et al
Bacillus Calmette-Guerin immunotherapy-induced extracellular vesicles promote antitumor immunity in bladder cancer.
Front Immunol. 2026;17:1707754.
Abstract

LI Y, Wei W, Liu C, Lu H, et al
A multidimensional nomogram integrating immune, inflammatory, and coagulation markers for personalized prognosis in bladder cancer.
J Int Med Res. 2026;54:3000605261441388.
Abstract

MOUSAVI SE, Antar RM, Aslani A, Shokri P, et al
Bladder Cancer Incidence Trends in the United States From 2000 to 2020.
Cancer Rep (Hoboken). 2026;9:e70548.
Abstract

KRAVCHUK A, Garzaro JRR, Wirtz R, Wolff I, et al
Digital PCR-Based Uromonitor for Molecular Detection of Bladder Cancer: A Multicenter Validation Study Comparing Quantitative PCR and Urine Cytology.
Clin Genitourin Cancer. 2026 Apr 1:102554. doi: 10.1016/j.clgc.2026.102554.
Abstract

FURUBAYASHI N, Tsujita J, Takayama A, Shiraishi Y, et al
Older Age and Outcomes of Intravesical Bacillus Calmette-Guerin for Non-muscle-invasive Bladder Cancer.
In Vivo. 2026;40:1585-1594.
Abstract

SACCO E, Bizzarri FP
Comment on: "Comparison of long-term survival for muscle-invasive bladder cancer patients who underwent bladder preservation therapy and radical cystectomy: A systematic review and meta-analysis".
Urologia. 2026 Apr 28:3915603261445157. doi: 10.1177/03915603261445157.
Abstract

AHANGAR M, Mischak H, Moulavasilis N, Stravodimos K, et al
Urinary Peptidomic Signatures Predict Overall and Progression-Free Survival in Bladder Cancer.
Proteomics. 2026 Apr 27:e70135. doi: 10.1002/pmic.70135.
Abstract

HSIEH TH, Kuo HP, Pan CH, Lin YC, et al
A cyclin D1-CDK4/6-E2F dependency represents an acquired vulnerability in cisplatin-resistant bladder cancer.
Biol Direct. 2026 Apr 27. doi: 10.1186/s13062-026-00812.
Abstract

ZHONG Z, Wu J, Shang H, Tong Y, et al
Engineered T cell membrane coated nanoparticles reverse thermo-resistance and reprogram tumor microenvironment to synergistically potentiate bladder cancer photothermal immunotherapy.
J Nanobiotechnology. 2026 Apr 27. doi: 10.1186/s12951-026-04455.
Abstract

CHAMGORDANI PR, Taghiyar S, Abedinzadeh M, Shahanipour K, et al
Urinary mRNA profiling of autophagy-related genes ATG5, ATG7, MAP1LC3B, and mTOR in non-muscle invasive bladder cancer (NMIBC).
Cancer Treat Res Commun. 2026;47:101178.
Abstract

HU J, Li B, Xu X, Lin S, et al
Fusobacterium nucleatum Promotes Bladder Cancer Development Through lncRNA IDH1-AS1-Mediated Autophagy.
Arch Immunol Ther Exp (Warsz). 2026;74.
Abstract

REN Y, Wu J, Han F
Predicting Bladder Cancer Prognosis by Integrating Multiple Omics Data through an Adversarial Autoencoder-based Cox proportional hazards Network.
IEEE Trans Comput Biol Bioinform. 2026;PP.
Abstract

STERNER P, Gimbergsson S, Johansson M, Alamdari F, et al
Recurrence Rate After Post-Operative Two-Hour Continuous Bladder Irrigation for Primary Non-Muscle-Invasive Bladder Cancer: A Retrospective Cohort Study.
J Pers Med. 2026;16:175.
Abstract

MEIRELES S, Dias C, Marques A, Silva J, et al
Differentiating Upper Tract Urothelial Carcinoma with Synchronous or Metachronous Bladder Cancer.
Curr Issues Mol Biol. 2026;48:345.
Abstract

RESENDE SALGADO L, Zaytoun O, Rabie A, Murphy N, et al
Radiotherapy for High-Risk Non-Muscle-Invasive Bladder Cancer: Current Evidence and Future Directions.
Curr Oncol. 2026;33:225.
Abstract

HERRMANN S, Gilfrich C, Siepmann S, Rodas Garzaro JR, et al
Robotic Partial Cystectomy and Extended Pelvic Lymph Node Dissection for Node-Positive Urachal Adenocarcinoma in a 34-Year-Old Woman: A Case Report.
Curr Oncol. 2026;33:190.
Abstract

CELLA L, Finocchiaro A, Slusarczyk A, Krajewski W, et al
Mitomycin for intravesical treatment of low-grade intermediate-risk non-muscle invasive bladder cancer.
Future Oncol. 2026 Apr 27:1-9. doi: 10.1080/14796694.2026.2661768.
Abstract

SUN M, Hu D, Li T, Chen Z, et al
Multidimensional transcriptomic analysis and in vitro experiments dissect the landscape of 2',2',4',4'-Tetrabromodiphenyl ether in bladder cancer progression.
Chem Biol Interact. 2026;434:112079.
Abstract

BELSEY J, Chrosny W, Lapon J
Addressing the challenges of health economic modelling in the context of suboptimal evidence base - case study based on a comparison between photodynamic diagnosis and narrow band imaging in non-muscle invasive bladder cancer.
J Med Econ. 2026;29:1341-1354.
Abstract

SEYYEDSALEHI MS, Hadji M, Rashidian H, Naghibzadeh-Tahami A, et al
Fatty Acid Intake and Bladder Cancer Risk: A Multicenter Case-Control Study in Iran.
Nutr Cancer. 2026 Apr 25:1-12. doi: 10.1080/01635581.2026.2658800.
Abstract

XU L, Pi S, Shen Q, Liu Y, et al
[Application of whole-process nutritional management based on IKAP theory in patients undergoing radical cystectomy with ileal conduit diversion].
Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2025;50:2407-2416.
Abstract

LV J, Yang P, Zheng W, Huang D, et al
Predicting muscle-invasive bladder cancer with dual-layer detector spectral CT-derived extracellular volume fraction.
BMC Med Imaging. 2026 Apr 24. doi: 10.1186/s12880-026-02342.
Abstract

LLOYD L
Bladder cancer research is blossoming in Birmingham.
Nat Rev Urol. 2026 Apr 24. doi: 10.1038/s41585-026-01154.
Abstract

SHARIATI S, Mohtadi S, Molavinia S, Salehcheh M, et al
Empagliflozin enhances cisplatin activity in chemo-resistant EJ138 bladder cancer cells: The importance of anti-diabetic medications in cancer treatment.
Sci Rep. 2026 Apr 24. doi: 10.1038/s41598-026-49196.
Abstract

RASCIO L, Borghese O, Minelli F, Sica S, et al
Common femoral artery pseudoaneurysm due to Mycobacterium Bovis infection following intravescical bacillus Calmette-Guerin therapy.
Indian J Tuberc. 2026;73:277-279.
Abstract

SHIGEHISA R, Fukata S, Pustimbara A, Kawada C, et al
Discordant fibroblast growth factor receptor 3 (FGFR3) expression between photodynamic diagnosis-positive and -negative bladder cancer lesions: An intra-patient paired analysis.
Photodiagnosis Photodyn Ther. 2026;59:105488.
Abstract

WU G, Yu W, Yao D, Ma X, et al
A computational framework identifies a matrisome-related gene signature for bladder cancer prognosis and prioritizes candidate compounds.
Comput Biol Chem. 2026;124.
Abstract

YIN L, Wang R, Guo FL, Han X, et al
One-Step Urinary EV Capture-to-SERS on a Temperature-Responsive AuEIH Substrate with Transformer-Based Urologic Cancer Classification.
Anal Chem. 2026;98:12035-12043.
Abstract

XIE F, Xie C, Yue H, Cui J, et al
The association of physical activity with urological cancer risk: a systematic review and meta-analysis.
Nat Commun. 2026;17:3949.
Abstract

LAMMERT SM, Luo W, Zhu AC, Wang P, et al
PAX8-positive conventional urothelial carcinomas of the urinary bladder and their distinct molecular profiles - A clinicopathologic study of 101 consecutive cases with next-generation sequencing in 20 cases.
Histopathology. 2026;88:1315-1323.
Abstract

FARAG MS, Oghbaei N, Hussain J, Lametti A, et al
A minor high-grade component in non-invasive papillary urothelial carcinoma is not associated with a more indolent behaviour.
Histopathology. 2026;88:1430-1442.
Abstract

PICHLER R, van Creij NCH, Mertens LS, Del Giudice F, et al
FGFR1/3 Signaling as an Achilles' Heel of Phenotypic Diversity in Urothelial Carcinoma.
Eur Urol Oncol. 2026;9:220-226.
Abstract

PAN M, Tao T, Kong D, Gong H, et al
Aerobic glycolysis in bladder cancer: research advances and targeted therapy potential.
Front Oncol. 2026;16:1799955.
Abstract

WANG P, Ye F, Wang H, Liu J, et al
Nano-bionic bacteria armed adoptive macrophage therapy against bladder cancer.
Mater Today Bio. 2026;38:103130.
Abstract

AGRAWAL S
A new standard for cisplatin-ineligible muscle-invasive bladder cancer: Landmark results from KEYNOTE-905.
Indian J Urol. 2026;42:172-173.
Abstract

ZHENG Q, Zhao T, Liao E, Cao Z, et al
PTEN-low associated mismatch repair deficiency and nuclear PD-L1 expression in basal-type bladder cancer.
Pathol Res Pract. 2026;283:156509.
Abstract

ZHOU Y, Huang Y, Jian N, Zhu Y, et al
MFAP4 activates PI3K/AKT-NF-kappaB signaling to drive tumor progression and immune evasion in bladder cancer.
Int Immunopharmacol. 2026;182:116719.
Abstract

DIAZ-FUENTES H, Zapot-Martinez JC, Cabrera-Mora NA, Ramos-Arceo E, et al
[Solitary fibrous tumor of the prostate mimicking a tumor of the vesicoprostatic junction. Case report].
Rev Med Inst Mex Seguro Soc. 2026;64:e6779.
Abstract

HUANG T, Xu J, He Y, Shen Y, et al
Fever and leukemoid reaction in bladder cancer: A case report.
Oncol Lett. 2026;31:249.
Abstract

NAFI MMI, Md Rahat Hossain K
DeepBCTPred: deep learning-based prediction of bladder cancer tissues from endoscopic images.
Bioinform Adv. 2026;6:vbag087.
Abstract

AMARA CS, Piyarathna DWB, Kamal AHM, Chan YS, et al
Cigarette smoke induces FASN-dependent fatty acid metabolic rewiring to drive bladder cancer progression.
Cancer Lett. 2026 May 4:218562. doi: 10.1016/j.canlet.2026.218562.
Abstract

HUANG R, Yu J, Bai R, Jiang W, et al
FBXL6 promotes bladder cancer progression by stabilizing ENO1 through K63-linked ubiquitination.
Cell Death Discov. 2026 May 6. doi: 10.1038/s41420-026-03130.
Abstract

CIMADAMORE A, Lopez-Beltran A, Montironi R, Cheng L, et al
Molecular Pathology of Genitourinary Tumors: Diagnostic, Prognostic, and Therapeutic Implications.
Surg Pathol Clin. 2026;19:309-321.
Abstract

WEI Y, Yu Z, Wu S, Li J, et al
In Vivo Metabolic Engineering of Bladder Cancer-Derived Extracellular Vesicles for Noninvasive Cancer Detection.
J Am Chem Soc. 2026 May 6. doi: 10.1021/jacs.6c03124.
Abstract

LIANG H, Huang H, Li Y, Lu Y, et al
Retraction: CircRNA_0058063 functions as a ceRNA in bladder cancer progression via targeting miR-486-3p/FOXP4 axis.
Biosci Rep. 2026;46:BSR20193484.
Abstract

CHENG C, Gao J, Wang R, Wu Y, et al
NOP2-mediated 5-methylcytosine Regulates Lipid Metabolism Reprogramming to Prime Tumors for Ferroptosis in Bladder Cancer Progression.
Int J Biol Sci. 2026;22:4399-4416.
Abstract

ZIMAK Z, Vidovic D, Kulis T, Hauptman D, et al
High feasibility and safety of office-based transurethral laser ablation for recurrent non-muscle invasive bladder cancer: a single-center experience.
Front Oncol. 2026;16:1683009.
Abstract

NYKEL A, Kubiak I, Rutkowska L, Kasprzyk Z, et al
Clinical performance of the urine-based TERT promoter AbsoluteQ Digital PCR for non-invasive detection of bladder cancer.
Mol Oncol. 2026 May 5. doi: 10.1002/1878-0261.70262.
Abstract

O'CALLAGHAN LA, Powell K, Chess-Williams R, McDermott C, et al
The Antipsychotic Aripiprazole Induces Cytotoxicity in Bladder Cancer Cells While Preserving Urothelial and Bladder Function.
Pharmacol Res Perspect. 2026;14:e70260.
Abstract

[Expert consensus on intravesical therapy for non-muscle invasive bladder cancer (2025 edition)].
Zhonghua Zhong Liu Za Zhi. 2026;48:462-475.
Abstract

ARTILES MEDINA A, Subiela JD, Muriel Garcia A, Dominguez Gutierrez A, et al
A systematic review and meta-analysis of clinicopathologic factors associated with adverse oncologic outcomes in bladder cancer patients undergoing radical cystectomy: Evidence from multivariable survival prediction models.
Urol Oncol. 2026 May 4:S1078-1439(26)00113-4. doi: 10.1016/j.urolonc.2026.
Abstract

ZHANG W, Peng X
Genetic evidence against a causal relationship between myocardial infarction and urological malignancies.
Can J Urol. 2026;33:387-401.
Abstract

LIATSOS G, Zioutou K, Avramidis K, Vamvakaris K, et al
Bladder cancer patients hospitalized in a medicine ward including three fuo cases following bacillus calmette-guerin immunotherapy.
Can J Urol. 2026;33:349-360.
Abstract

LEINUM LR, Jensen BT, Lauridsen SV
Factors influencing adherence to intravesical instillation therapies for non-muscle-invasive bladder cancer: a scoping review protocol.
BMJ Open. 2026;16:e116776.
Abstract

SANDIKCI F, Aydin MY, Dogan AE, Yavuz A, et al
Postoperative ileus as a surgical challenge: comparative outcomes of end-to-end and side-to-side ileal anastomosis in radical cystectomy.
Ulus Travma Acil Cerrahi Derg. 2026;32:544-551.
Abstract

MITTAL A, Malhotra K, Panwar V, Kishore S, et al
Targeting Human Epidermal Growth Factor Receptor 2 in Bladder Cancer: Evaluating Its Role as a More Robust Clinicopathological Biomarker Compared to Programmed Death Ligand 1 Expression.
Urol Res Pract. 2026;52:1-6.
Abstract

WU N, He X
FTO promotes bladder cancer progression and stemness-associated phenotypes.
Cytotechnology. 2026;78:103.
Abstract

WANG J, He K, Qi H, Xu J, et al
Icariside II suppresses bladder cancer progression via endoplasmic reticulum stress-mediated autophagy and lysosomal dysfunction.
Eur J Pharmacol. 2026;1025:178924.
Abstract

BROWN RJ, Khan MT, Houston AJ, Niu H, et al
Divergent Macrophage-Regulated T cell States Determine Response to Bacillus Calmette-Guerin vaccine in High-Risk Bladder Cancer.
J Clin Invest. 2026 Apr 21:e200442. doi: 10.1172/JCI200442.
Abstract

SENER TE, de Oliveira TR, Demirkiran ED, Perri D, et al
Face and content validation of TURP and TURB simulation models: an EAU European School of Urology (ESU) Lower Urinary Tract Endoscopy Working Group Study.
World J Urol. 2026;44:339.
Abstract

QIU Z, Xia X, Li X
Comment on "sexual distress in patients after radical cystectomy for bladder cancer: a qualitative study".
Support Care Cancer. 2026;34:491.
Abstract

CARIGNAN L, Alavi R, Millet M, Lavigne M, et al
Assessing the Relationship Between Bladder Cancer cell Contractile Phenotypes and their Invasive Properties.
Cell Mol Bioeng. 2026;19:207-221.
Abstract

CARIGNAN L, Alavi R, Millet M, Lavigne M, et al
Erratum: Publisher Correction: Assessing the Relationship Between Bladder Cancer Cell Contractile Phenotypes and Their Invasive Properties.
Cell Mol Bioeng. 2026;19:223.
Abstract

ISHIZUYA Y, Kawashima A, Yamashita S, Ujike T, et al
Preoperative FAN score predicts survival outcomes after radical cystectomy for bladder cancer.
BJUI Compass. 2026;7:e70221.
Abstract

LUO G, Wang W, Tai S, Yan L, et al
Ribosome biogenesis programs define a three-gene RBscore with prognostic relevance in bladder cancer.
Front Immunol. 2026;17:1810132.
Abstract

CHENG Y, Deng W, Liu Y, Chen G, et al
Research progress in augmentation strategies for PD-1/PD-L1 inhibitors in bladder cancer: from biological determinants to clinical applications.
Front Immunol. 2026;17:1802404.
Abstract

SHEN J, Wang C, Li T, Guan H, et al
Identification of a migrasome-related lncRNA signature and its prognostic and immunological role in bladder cancer.
Front Immunol. 2026;17:1763443.
Abstract

MANTICA G, Esperto F, Malinaric R
Editorial: Microbial biomarkers predicting BCG therapy response in non-muscle invasive bladder cancer.
Front Oncol. 2026;16:1831100.
Abstract

GREENBERG ZF, Hutchinson T, Kahn J, Graim KS, et al
Urinary Extracellular Vesicles for High-Precision Bladder Cancer Subtyping and Prognosis.
J Extracell Biol. 2026;5:e70141.
Abstract

ZHAI Z, Wu F, Sheng G, Jia B, et al
Identification and Functional Analysis of Targets of Dehydrodiisoeugenol in Bladder Cancer Based on Chemoproteomics-Based Profiling.
Pharmaceuticals (Basel). 2026;19:651.
Abstract

FALINSKA H, Witkowska-Patena E, Krzyzanowska K, Dziuk M, et al
Positron Emission Tomography/Computed Tomography in Bladder Cancer: The Role of [(18)F]FDG and Non-FDG Radiotracers.
Medicina (Kaunas). 2026;62:703.
Abstract

GOLOMB D, Simard S, Eisner A, Avda Y, et al
The Burden of Worry: Fear of Cancer Recurrence Across Bladder Cancer Survivorship Phases-A Cross-Sectional Analysis.
J Clin Med. 2026;15:3116.
Abstract

BALTACIOGLU A, Acar O, Sonmez C, Saglican Y, et al
Serum Trimethylamine-N-Oxide and Its Precursors as a Diagnostic Biomarker Panel for Non-Muscle-Invasive Bladder Cancer.
Int J Mol Sci. 2026;27:3591.
Abstract

PACZEK S, Olkowicz M, Kudelski J, Gudowska-Sawczuk M, et al
The Role of Gasdermin B-Mediated Pyroptosis in Bladder Cancer Diagnosis.
Int J Mol Sci. 2026;27:3540.
Abstract

KWON WA, Lee YJ, Song YS
Dynamic Precision Oncology for Real-Time Molecular Monitoring and Management in Urothelial Carcinoma.
Int J Mol Sci. 2026;27:3474.
Abstract

CAO Y, Ma J, Tang X, Cui Y, et al
HCN2 Promotes BGN Transcription via REST to Regulate Ferroptosis and Tumor Progression in Bladder Cancer.
Int J Mol Sci. 2026;27:3433.
Abstract

GRAPSA D, Sassi M, Mikou P
Performance of Urine Fluorescence In Situ Hybridization for Diagnosis of Upper Tract Urothelial Carcinoma: A Comprehensive Review.
Int J Mol Sci. 2026;27:3406.
Abstract

DURMANOVA V, Mikolaskova I, Javor J, Ocenasova A, et al
Association of IL6 rs1800795, TNF rs1800629, CCL2 rs1024611 and VEGFA rs699947 Polymorphisms with Bladder Cancer Risk, Tumor Aggressiveness, and HRV Parameters of Autonomic Nervous System Regulation.
Int J Mol Sci. 2026;27:3361.
Abstract

WU J, Wang Y, Zhao Y, Zheng D, et al
An unusual cause of a vesical mass: Small bowel diverticulum presenting with a bladder fistula: A case report and review of the literature.
Medicine (Baltimore). 2026;105:e48536.
Abstract

ZHANG T, Gao Z, Xiao S, Zou X, et al
Precision Medicine in Bladder Cancer: Redefining Treatment Paradigms Through ADCs, Immunotherapy, and Molecular Subtyping.
Crit Rev Oncol Hematol. 2026 May 1:105348. doi: 10.1016/j.critrevonc.2026.105348
Abstract

KHATRI C, Das PK, Rattan R, Patowary J, et al
Doublet versus triplet therapy in Indian patients with locally advanced & metastatic gall bladder cancer: a randomised trial.
Sci Rep. 2026 May 2. doi: 10.1038/s41598-026-36231.
Abstract

LIANG Z, Wang L, Li D, Chen Y, et al
Targeted inhibition of the H3K27ac/OGT/O-GlcNAcylation axis to overcome gemcitabine-induced chemotherapy resistance in bladder cancer.
Biochim Biophys Acta Mol Basis Dis. 2026 Apr 30:168281.
Abstract

AKIYAMA T, Fukuhara H, Hagiwara Y, Fukata S, et al
Cost-effectiveness analysis of transurethral resection of bladder tumor with photodynamic diagnosis with 5-aminolevulinic acid hydrochloride for non-muscle invasive bladder cancer.
Photodiagnosis Photodyn Ther. 2026 Apr 30:105495.
Abstract

WU P, Chen L, Yang J, Liang Z, et al
STEAP2-associated modulation of PI3K/AKT/mTOR signaling contributes to ginkgetin-induced apoptosis in bladder cancer cells.
Hereditas. 2026 May 1. doi: 10.1186/s41065-026-00686.
Abstract

AGHAYEV A, Durak HM, Hepsen E, Dinc E, et al
Clinical value of VI-RADS score in predicting repeat transurethral resection in primary bladder cancer: a prospective observational study.
BMC Urol. 2026 May 1. doi: 10.1186/s12894-026-02131.
Abstract

ZHANG Y, Zhao K, Du W, Hu L, et al
LC3B promotes bladder cancer cell proliferation via the Sp1-cyclin D1/p27 axis with pan-cancer clinical associations.
Cell Signal. 2026;145:112560.
Abstract

SHIMODA M, Ito H, Aoki T, Karibe J, et al
Comparative Analysis of Risk Stratifications for Non-Muscle-Invasive Bladder Cancer According to the Classifications Provided by the National Comprehensive Cancer Network, European Association of Urology, and Japanese Urological Association Guidelines
Clin Genitourin Cancer. 2026;24:102560.
Abstract

QIN R, Li C, Zhang T, Wang Y, et al
Identification of naringenin chalcone as a key gut metabolite for bladder cancer intervention: An integrated strategy combining network pharmacology and molecular dynamics simulation.
Comput Biol Chem. 2026;124.
Abstract

FICHNA K, Crespo-Cuadrado M, Konuparamban A, Di Carlo V, et al
Nanomotor-Assisted Intravesical Chemotherapy for Bladder Tumor Reduction and Suppression of Early Tumor Regrowth.
Nano Lett. 2026;26:5618-5627.
Abstract

LI X, Liao L
Corynebacterium striatum Infection in Incision and Thoracic Cavity with Concurrent CRKP Colonization Following Lung and Bladder Tumor Resection.
Interdiscip Cardiovasc Thorac Surg. 2026;41:ivag121.
Abstract

GRIFFIN MA, Folk C, Buote NJ
Laparoscopic stapled partial cystectomy with intraoperative cystourethroscopy for urothelial carcinoma in two dogs.
Vet Surg. 2026;55:856-863.
Abstract

BENEDETTI B, Foschi N, Pesaresi C, Tartaglione T, et al
Post-mortem CT detection of fatal air embolism after aerosolized fibrin glue for bladder bleeding.
J Forensic Sci. 2026;71:1507-1512.
Abstract

ERGIN IE, Sanci A, Hepsen E, Sarikaya K, et al
Predictive factors for urethral stricture development in patients with bladder tumor: The role of intravesical BCG therapy.
Actas Urol Esp (Engl Ed). 2026;50:501908.
Abstract

GARG S, Chaurasia JK, Kaushal D, Jayashankar E, et al
High Immunohistochemical Expression of Runt-Related Transcription Factor 2 (RUNX2) Is Associated With High Tumor Grade, Muscle Invasion, Lymph Node Metastasis, and Advanced Stage in Urinary Bladder Cancer.
Cureus. 2026;18:e106976.
Abstract

PIZZI JR, Adhikari I, Prakash P, Shi H, et al
Machine learning-based determination of sex-related bladder cancer biomarkers.
Front Bioinform. 2026;6:1794098.
Abstract

ZOU XC, Xu LY, Yuan YY, Zhang GY, et al
Disitamab vedotin (RC48) combined with PD-1 inhibitors in locally advanced or metastatic urothelial carcinoma: clinical outcomes and prognostic factors from a multicenter real-world study.
Front Immunol. 2026;17:1815591.
Abstract

CONROY S, Gagg H, Quayle LA, Adams JA, et al
Ex vivo drug screening and clustering of bladder cancers for pre-clinical treatment prediction.
Commun Med (Lond). 2026 May 14. doi: 10.1038/s43856-026-01596.
Abstract

YANG M, Li S, Li R, Dong Y, et al
Organoid-Based Transcriptomics Indicate IFIT-Associated Immune Modulation during Cryptotanshinone Treatment in Bladder Cancer.
N Biotechnol. 2026 May 13:S1871-6784(26)00060-9. doi: 10.1016/j.nbt.2026.
Abstract

BROWN JR, Parikh M
Perioperative Systemic Treatment Options for Muscle-Invasive Bladder Cancer.
J Natl Compr Canc Netw. 2026;24:e267034.
Abstract

LAFITTE E, Sfumato P, Walz J, Billon E, et al
Chemotherapy-induced anemia as a prognostic factor for overall survival in patients with bladder cancer treated with neoadjuvant cisplatin-based chemotherapy and cystectomy.
World J Urol. 2026;44:364.
Abstract

ILTZSCHE M, Wetterling N, Jilek L, Nahhas D, et al
PSCA-directed nanosized bio-immune conjugates (NANO:BICs) enable selective uptake of TLR9 agonists in bladder cancer cells.
Front Oncol. 2026;16:1739618.
Abstract

ZHANG D, Li M, Yang B, Yan Z, et al
Plasmon-Enhanced Magnetic Fluorescent Nanoprobe for Ultrasensitive Detection of Urinary miRNA-96 Enabling Early Diagnosis and Risk Stratification of Bladder Cancer.
Anal Chem. 2026 May 13. doi: 10.1021/acs.analchem.6c01055.
Abstract

LI Z, Liu C, Wang H
Exploring the Efficacy of Immunotherapy in Combination with Surgical Resection in High-risk Muscle-invasive Bladder Cancer.
Iran J Allergy Asthma Immunol. 2026;25:317-329.
Abstract

PATIL B, Hadjiiski L, Sun D, Chan HP, et al
Bladder cancer segmentation using u-net-based deep-learning.
Sci Rep. 2026 May 13. doi: 10.1038/s41598-026-52716.
Abstract

COURNEDE M, Gabriel PE, Lottin M, Moschini M, et al
Multi-institutional external validation of the European risk classification for high-grade Ta non-muscle-invasive bladder cancer.
World J Urol. 2026;44:358.
Abstract

TAN WS, Kamat AM, Lewis R, Porta N, et al
Outcomes of Intermediate Risk Non-muscle-invasive Bladder Cancer Receiving Adjuvant Treatment: A Pooled Analysis of Four Randomized Controlled Trials.
Eur Urol Oncol. 2026 May 13:S2588-9311(26)00127.
Abstract

SHIVANI ZA, Puthalath RT
Paraganglioma of the urinary bladder with a novel variant of SDHB mutation.
BMJ Case Rep. 2026;19:e270375.
Abstract

HE Y, Guo H, Wang B, Gao W, et al
Nectin4-targeted molecular imaging for precise endoscopic diagnosis and image-guided surgery in bladder cancer.
Cell Rep Med. 2026 May 12:102795. doi: 10.1016/j.xcrm.2026.102795.
Abstract

YU K, Chen J, Chu YY, Nair S, et al
A Spatial Atlas of Muscle-Invasive Bladder Cancer Reveals Lineage-Specific Vulnerabilities and Immune Architecture.
Cancer Discov. 2026 May 13. doi: 10.1158/2159-8290.CD-26-0099.
Abstract

ALIBEIGINEJAD MH, Esmaielpour A, Tsuboi I, Matsukawa A, et al
The Prognostic Value of Tumor HER2 Expression in Predicting Oncological Outcomes of Patients with Advanced Urothelial Carcinoma: A Systematic Review and Meta-Analysis.
Int J Mol Sci. 2026;27:4130.
Abstract

TARANTINO G, Citro V, Imbimbo C, Crocetto F, et al
The Insulin-Urothelial Axis: Evaluating Insulin Resistance as a Convergent Driver of Bladder Cancer Across Diverse Risk Factor Profiles.
Int J Mol Sci. 2026;27:3919.
Abstract

KOSTAKOPOULOS N, Evmorfopoulos K, Maresca G, Athanasiadis G, et al
Combined Robot-Assisted Radical Cystectomy and Robot-Assisted Nephroureterectomy for Synchronous High-Risk Upper Urinary Tract and Bladder Cancer: A Single-Center Retrospective Study and Review of the Literature.
J Clin Med. 2026;15:3411.
Abstract

HOOPER K, McNall S, Pohl D, Sullivan T, et al
Evidence for a Tumor-Suppressive Role of SHP-1 in EMT Regulation in Bladder Cancer Cells.
Cancers (Basel). 2026;18:1401.
Abstract

POPESCU CG, Chipuc S, Zgura D, Haineala B, et al
Artificial Intelligence-Enhanced Multiparametric MRI and VI-RADS in Bladder Cancer: Current Evidence, Clinical Opportunities and Barriers to Translation.
Cancers (Basel). 2026;18:1322.
Abstract

ZAURITO P, Scilipoti P, Santangelo A, Birtle A, et al
Neoadjuvant Intravesical Therapy for Patients with Non-muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis.
Eur Urol Oncol. 2026 May 12:S2588-9311(26)00119.
Abstract

CUI A, Liu H, Wang K, Wei S, et al
Oleic acid modification enables lysosomal escape of phthalocyanine photosensitizer for effective bladder cancer treatment.
Bioorg Med Chem. 2026;139:118701.
Abstract

HALME ALE, Posa M, Ruotsalainen J, Hallamies S, et al
International Survey of Thromboprophylaxis Practices During Neoadjuvant Therapy for Muscle-Invasive Bladder Cancer.
Clin Genitourin Cancer. 2026 Apr 17:102563. doi: 10.1016/j.clgc.2026.102563.
Abstract

YANG W, Jin Z, Li Z, Xu W, et al
O-GlcNAcylation of KAT2A Enhances Bladder Cancer Proliferation by Inhibiting the KAT2A-TRIM22 Interaction.
Cancer Sci. 2026 May 11. doi: 10.1111/cas.70416.
Abstract

WANG K, Hu Z, Zhu Y, Piao C, et al
LASP1 facilitates bladder cancer progression through binding and downregulating MYH9 to inhibit mitochondrial ROS-induced apoptosis.
Int J Biol Macromol. 2026;366:152483.
Abstract

CHATTERTON K
Fundamentals of bladder cancer nursing: from diagnosis pathways to holistic care.
Br J Nurs. 2026;35:S10-S16.
Abstract

JIANG Z, Yuan C, Yuan H, Qin C, et al
Enhanced detection of bladder cancer using combined circulating tumor cells, urine-derived epithelial cells, and molecular biomarkers.
J Cancer Res Clin Oncol. 2026 May 10. doi: 10.1007/s00432-026-06469.
Abstract

LOTAN Y, Anai S, Kim H, Gin G, et al
Detection of bladder cancer in patients with microscopic hematuria using Oncuria-Detect: results of a prospective, multicenter international study.
J Transl Med. 2026 May 9. doi: 10.1186/s12967-026-08245.
Abstract

FENG X, Sun D, Xu L, Zhu C, et al
Ankaferd versus Immunotherapeutics and Chemotherapeutics in Bladder Cancer.
Arch Esp Urol. 2026;79:504-512.
Abstract

TURAN T, Efiloglu O, Hamidzada I, Ahmadzada J, et al
Predictors of BCG Therapy Complications in Non-Muscle-Invasive Bladder Cancer: A Clavien-Dindo-Based Study.
Arch Esp Urol. 2026;79:495-503.
Abstract

WEI F, Zhao M, Sun X, Ma H, et al
Genetically Predicted Gut Microbiota and Bladder Cancer Risk: A Mendelian Randomisation Analysis.
Arch Esp Urol. 2026;79:431-439.
Abstract

NAVARRO-JIMENEZ S, Carrion-Lopez P, Lorenzo-Sanchez MV, Tarraga-Honrubia MA, et al
Association of Inflammatory and Nutritional Biomarkers with Pathological Response in Patients with Muscle-invasive Bladder Carcinoma Treated with Neoadjuvant Chemotherapy.
Arch Esp Urol. 2026;79:404-414.
Abstract

BAUDET LEON J, Cano Velasco J, Polanco Pujol L, Artero Fullana S, et al
Current Evidence on the Use of Cystoscopy in the Follow-up of Non-Muscle-Invasive Bladder Cancer: Are We Overusing It? Systematic Review of the Literature.
Arch Esp Urol. 2026;79:362-370.
Abstract

JEONG J, Jeong G, Kim Y, Ju H, et al
Machine learning-based integration of transcriptome and digital pathology for predicting chemoresistance in muscle-invasive bladder cancer.
Exp Mol Med. 2026 May 8. doi: 10.1038/s12276-026-01718.
Abstract

GUERRERO-RAMOS F, Gomez-Canizo C, Rodriguez-Izquierdo M, Hernandez-Arroyo M, et al
The combination of atezolizumab and BCG in high-risk non-muscle invasive bladder cancer: results of the phase Ib/II BladderGATE clinical trial.
Oncologist. 2026 May 8:oyag177. doi: 10.1093.
Abstract

VENTURA Y, Morozov A, Chan R, Combat Faria Tavares M, et al
Pathological assessment of morcellated tissue after ERBT: insights from a two-round Delphi survey.
World J Urol. 2026;44:351.
Abstract

LIU D, Zhang QY
Virtual Screening of Traditional Chinese Medicine Natural Product Inhibitors Targeting AQP1 for Bladder Cancer.
Cancer Rep (Hoboken). 2026;9:e70570.
Abstract

WANG J, Liu J, Wang Y, Yan W, et al
Self-Assembled DNA Nanoladder-Based Electrochemical Biosensor for Rapid and Sensitive Detection of Bladder Tumor-Related miRNA in Urine.
Anal Chem. 2026;98:13845-13853.
Abstract

NASRALLAH AA, Evans C, Gu L, Parrish JA, et al
Costs of care and oncologic outcomes associated with blue light cystoscopy in an equal access setting: Results from the BRAVO study.
Urol Oncol. 2026;44:70-79.
Abstract

GHOREIFI A, Hoimes CJ, Ramalingam S, McManus HD, et al
Outcomes of consolidative surgery following enfortumab vedotin plus pembrolizumab for advanced urothelial cancer: A real-world experience.
Urol Oncol. 2026;44:80-85.
Abstract

NOEL ODV, Akgul B, Bhandari M, Ramos F, et al
Clinical trial participation in kidney, bladder, and prostate malignancies in the United States: Sociodemographic distribution and impact on survival.
Urol Oncol. 2026;44:176-188.
Abstract

MA M, Li X, Jing M, Yang Z, et al
Piezo1 Channel Mediates Mechanically Programmable Drug Delivery to Potentiate Intravesical Chemotherapy.
Adv Sci (Weinh). 2026;13:e22936.
Abstract

NGUYEN TTA, Osunkoya AO
Endometriosis Involving the Bladder: A Contemporary Clinicopathologic Analysis of 88 Patients.
Int J Surg Pathol. 2026;34:866-872.
Abstract

DESHWAL A, Kumar H, Khan A, Parwani A, et al
Radiation-Induced Epithelioid Angiosarcoma of the Urinary Bladder Mimicking Sarcomatoid Carcinoma: A Rare Entity and Literature Review.
Int J Surg Pathol. 2026;34:983-989.
Abstract

SHIN Y, Kim S, Rhie SK, An W, et al
HDAC1 has intrinsic protease activity and regulates transcription through clipping histone H3 N-terminal tail.
Cell Death Differ. 2026;33:1036-1049.
Abstract

CHENG T, Hao H, Liu C, Li X, et al
Mapping Patterns of Pelvic Lymph Node Metastasis in Bladder Urothelial Carcinoma: Implications for Personalized Pelvic Radiation Therapy.
Pract Radiat Oncol. 2026;16:e210-e218.
Abstract

DEHGHANPOUR A, Davenport MS, Muglia VF, Nicola R, et al
Vesical Imaging Reporting and Data System: Overcoming Barriers to Global Implementation-AJR Expert Panel Narrative Review.
AJR Am J Roentgenol. 2025 Sep 3. doi: 10.2214/AJR.25.33634.
Abstract

XU W, Gao J, Wu S, Huang J, et al
ELN orchestrates prometastatic and immunosuppressive niche in bladder cancer via TGFB1 autocrine signaling.
JCI Insight. 2026;11:e194700.
Abstract

ALUBAIDY HA, Al-Bdeery AH, Abdul-Adel E, Juda SA, et al
Role of Cyanidin 3-glucoside Extract in the Induction of Cytotoxicity and Apoptosis in a Rat Bladder Cancer Cell Line.
Asian Pac J Cancer Prev. 2026;27:1795-1804.
Abstract

ZHAO X, Qin R, Shen C, Hu D, et al
Integrating machine learning and structural analysis to decipher benzo[a]pyrene-induced bladder cancer networks.
Discov Oncol. 2026 May 21. doi: 10.1007/s12672-026-05207.
Abstract

ZHAO JG, Chen ZY, Pan HQ, Jin Y, et al
ALG1-mediated PDL1 glycosylation drives macrophage m2 polarization to promote bladder cancer progression.
Cell Death Differ. 2026 May 21. doi: 10.1038/s41418-026-01764.
Abstract

ANGULO-LOZANO JC, Posada-Calderon L, Liu H, Blanchard L, et al
Effective PD-1 checkpoint blockade in bladder cancer model requires tumor-draining lymph nodes and lymphocyte trafficking.
Urol Oncol. 2026 May 21:S1078-1439(26)00501.
Abstract

DULF DV, Leo A, Coada CA
Lymphovascular invasion in bladder cancer: from prognostic marker toward a clinical priority.
Expert Rev Anticancer Ther. 2026 May 21. doi: 10.1080/14737140.2026.2679025.
Abstract

SAEED DF, Amer NN, Ismail A, Abdelbary A, et al
Integrative in silico and clinical validation of urinary lncRNAs (SNHG7 & LINC00675) and beta-catenin mRNA as molecular markers for early bladder cancer detection.
Clin Transl Oncol. 2026 May 21. doi: 10.1007/s12094-026-04392.
Abstract

BUCKBY A, Gholami M, Hong M, O'Callaghan M, et al
Androgen Receptor Expression in Urothelial Bladder Cancer-A Systematic Review and Meta-Analysis.
ANZ J Surg. 2026 May 21. doi: 10.1111/ans.70752.
Abstract

Statement of Retraction: Alpha-2 Heremans Schmid Glycoprotein (AHSG) promotes the proliferation of bladder cancer cells by regulating the TGF-beta signalling pathway.
Bioengineered. 2026;17:2667619.
Abstract

PAVALEAN MI, Madan VL, Pavalean MC, Ceafalan LC, et al
The role of CD36 in renal and bladder cancer.
Discoveries (Craiova). 2026;14:e225.
Abstract

LIU X, Bao Y
Meta-analysis of efficacy comparisons between standard- and low-dose Bacillus Calmette-Guerin vaccines in managing non-muscular invasive bladder cancer.
Oncol Lett. 2026;32:288.
Abstract

LIU Z, Tan T, Li S, Wang Y, et al
Bioinformatics analysis and experimental approach identify BRD-family gene DSP as a diagnostic and prognostic indicator in bladder cancer.
Transl Androl Urol. 2026;15:124.
Abstract

YUAN J, Xing S, Sun W, Zeng S, et al
Knowledge mapping of photodynamic therapy in bladder cancer: a bibliometric analysis (2000-2025).
Transl Androl Urol. 2026;15:133.
Abstract

DUQUESNE I, Chakra MA, Myers AA, Boormans JL, et al
Advancing bladder cancer detection: commentary on a urinary DNA methylation diagnostic assay.
Transl Androl Urol. 2026;15:94.
Abstract

XIA Y, Ma B, Huang T, Liu X, et al
Oncologic outcomes of transurethral resection versus laser excision for non-muscle invasive bladder cancer: a SEER retrospective cohort study.
Transl Androl Urol. 2026;15:119.
Abstract

ZHOU X, Weng L, Sun T, Jiang Q, et al
Machine learning-based integration identifies lactylation biomarkers for prognosis prediction and tumor microenvironment modulation in bladder cancer.
Transl Androl Urol. 2026;15:132.
Abstract

CAI S, Ren X, Xia D, Wang M, et al
MDM4 promotes chemoresistance in bladder cancer by attenuating P53-mediated EMT.
Transl Androl Urol. 2026;15:112.
Abstract

BRYAN RT, Goel A, Ward DG
PENK methylation and non-invasive bladder cancer detection.
Transl Androl Urol. 2026;15:96.
Abstract

DELRUE C, Oyaert M, Speeckaert MM
Urinary PENK DNA methylation for bladder cancer diagnosis: methodological rigor, interpretive boundaries, and the evidence required for clinical translation.
Transl Androl Urol. 2026;15:97.
Abstract

ZHAN W, An D, Lei J, Un H, et al
Evaluation of human epidermal growth factor receptor 2 (HER2)-related genes revealed that HER2-antibody-drug conjugate (ADC) drugs confer clinical benefits to Bacillus Calmette-Guerin (BCG)-unresponsive non-muscle invasive bladder cancer patients.
Transl Androl Urol. 2026;15:110.
Abstract

XIE X, Li Z, Qiu T, Li H, et al
TRIM26-Mediated CBX6 Ubiquitination Triggers NETosis to Drive Bladder Cancer Tumor Growth via the CNPY2/NF-kappaB Signaling Pathway.
Drug Dev Res. 2026;87:e70316.
Abstract

CHEN R, Wu D, Wu W, Yang J, et al
H3K18 lactylation promotes glycolysis in bladder cancer via inhibiting GNG7 through regulating PI3K-AKT signaling pathway.
World J Surg Oncol. 2026 May 21. doi: 10.1186/s12957-026-04405.
Abstract

LIANG X, Sun Y, Guo Y, Liu B, et al
Dual-Functional Chitosan-Hyaluronic Acid Dialdehyde Nanoparticles for CD44-Targeted Bcl-2 siRNA Delivery and Photothermal Therapy in Bladder Cancer.
J Biotechnol. 2026 May 19:S0168-1656(26)00162.
Abstract

DING Y, Jin K, Su X, Zhang L, et al
Aberrant p53 fuels macrophage immunoregulatory polarization and refractory clinical outcome in urothelial carcinoma.
J Immunother Cancer. 2026;14:e014408.
Abstract

LIU Y, Khetrapal P, Strafford R, Hadjivasilou A, et al
Artificial Intelligence Remote Patient Monitoring for Predicting Overall Survival for Patients Undergoing Radical Cystectomy for Bladder Cancer: Exploratory Analysis of the Prospective Trial.
JMIR AI. 2026;5:e68994.
Abstract

SUGAWARA D, Mori N
Comments on "Enhancing the performance of bp-MRI VI-RADS in detecting muscle-invasive bladder cancer".
Jpn J Radiol. 2026 May 20. doi: 10.1007/s11604-026-02011.
Abstract

ABUDOUBARI S, Tuersun A, Mutailipu S, Chen W, et al
Interpretable machine learning models for bladder cancer overall survival prediction development and external validation via SEER database and Chinese cohort analysis.
Discov Oncol. 2026 May 20. doi: 10.1007/s12672-026-05099.
Abstract

LI H, Zhu D
Development and verification of cell cycle-related gene markers for prognosis in bladder cancer.
Cancer Biomark. 2026;43:18758592261449024.
Abstract

LI S, Li G, Zhang X
The Prognostic Nutritional Index Serves as a Novel and Independent Predictor of Recurrence in Patients with Non-Muscle-Invasive Bladder Cancer.
Nutr Cancer. 2026 May 19:1-10. doi: 10.1080/01635581.2026.2674944.
Abstract

ZHENG Q, Mei H, Weng X, Yang R, et al
Development and validation of artificial intelligence-based model for bladder cancer immunophenotyping using whole slide images.
NPJ Precis Oncol. 2026 May 19. doi: 10.1038/s41698-026-01443.
Abstract

SQUIRES P, Meng K, Hu X, Turzhitsky V, et al
Perioperative Treatment Patterns for Muscle-Invasive Bladder Cancer Patients Undergoing Radical Cystectomy in the Adjuvant Immunotherapy Era: A Retrospective Analysis of US Community Oncology Practice.
Oncol Ther. 2026 May 19. doi: 10.1007/s40487-026-00441.
Abstract

LI J, Zhang S, Yu S, Shen Y, et al
Mechanistic Insights into Xihuang Wan against Bladder Cancer via PI3K/ AKT/BCL2-Mediated Apoptosis Inhibition: Integrated Network Pharmacology, Molecular Docking, Molecular Dynamics Simulations and Experimental Validation.
Curr Pharm Des. 2026 May 13. doi: 10.2174/0113816128435835260116205839.
Abstract

CHEN J, Zuo J, Zhao J, Zhu X, et al
From fat to tumor: Exploring the inflammatory bridge via CRP in obesity-related bladder cancer.
Medicine (Baltimore). 2026;105:e48851.
Abstract

FIGUERAS M, Ingelmo-Torres M, Roldan FL, Goma E, et al
Role of Bladder EpiCheck((R)) in Bladder cancer: from primary diagnosis to surveillance.
J Transl Med. 2026 May 18. doi: 10.1186/s12967-026-08249.
Abstract

WANG Y, Nai Z, Zhang J
LncRNA HMGA2-AS1 promotes postoperative recurrence in non-muscle-invasive bladder cancer by sponging miR-367-3p to activate YAP1.
World J Surg Oncol. 2026 May 18. doi: 10.1186/s12957-026-04391.
Abstract

WANG B, Zheng X, Hua Q, Zou F, et al
NAA50-mediated SLU7 stabilization promotes cisplatin resistance in bladder cancer via regulating MAP3K3 mRNA nuclear export and p38 MAPK activation.
Cell Oncol (Dordr). 2026 May 18. doi: 10.1007/s13402-026-01219.
Abstract

KAO WH, Liao LZ, Chen YA, Lo UG, et al
Correction: SPHK1 promotes bladder cancer metastasis via PD-L2/c-Src/FAK signaling cascade.
Cell Death Dis. 2026;17:473.
Abstract

CHEN R, Su Y, Chen J, Zhu S, et al
TRIM28-mediated SUMOylation of SREBF1 drives PD?L1 N?glycosylation and immune evasion in bladder cancer.
Cell Death Dis. 2026 May 18. doi: 10.1038/s41419-026-08798.
Abstract

HANNA J, Fu MZ, Inan B, Guevara D, et al
Time toxicity of intravesical BCG versus sequential intravesical gemcitabine and docetaxel for non-muscle-invasive bladder cancer.
BJUI Compass. 2026;7:e70215.
Abstract

JUAN L, Weiping C
Periocular Pigmentation After Gemcitabine Monotherapy for Bladder Cancer: A Rare Case Report.
Clin Case Rep. 2026;14:e72641.
Abstract

COLE A, Shoskes DA, Henderson RJ
Under-reporting of carcinoma in situ in patients with high-grade papillary non-muscle-invasive bladder cancer.
Bladder Cancer. 2026;12:23523735261447111.
Abstract

AKAI T, Yamamichi G, Miyamoto H
Role of androgen receptor signaling in chemoresistance in urothelial cancer: a narrative review.
Chin Clin Oncol. 2026;15:39.
Abstract

ZENG J, Cao Z, Wang C, Xu Y, et al
Intravesical Delivery of P21 mRNA-Loaded Lipid Nanoparticles as a Tumor Suppressor Replacement Therapy for Bladder Cancer.
FASEB J. 2026;40:e71904.
Abstract

LAJARA S, Cuda J, Geisler DL, Staniszewski C, et al
Enhancing urothelial carcinoma diagnosis with artificial intelligence-integrated urine cytology: Biopsy-validated accuracy and efficiency gain.
Cancer Cytopathol. 2026;134:e70110.
Abstract

ZHANG D, Li X, Xu X, Su M, et al
METTL3 promotes the progression of bladder cancer through the METTL3/IGF2BP3/MTA1/PI3K/AKT axis.
Pathol Res Pract. 2026;284:156489.
Abstract

ZHANG X, Shen E, Cheng C, Meng R, et al
Favorable pathological response with enfortumab vedotin plus toripalimab as neoadjuvant therapy for HER2-negative muscle-invasive bladder cancer: a case report.
J Cancer Res Clin Oncol. 2026 May 17. doi: 10.1007/s00432-026-06497.
Abstract

LONGONI M, Falkenbach F, Marmiroli A, Le QC, et al
Years of Life Lost in Patients with Muscle-Invasive and Metastatic Bladder Cancer.
Ann Surg Oncol. 2026 May 17. doi: 10.1245/s10434-026-19790.
Abstract

NADELMANN J, Baca AL, Labagnara K, Dave P, et al
Beyond the Tumor: Exploring the Financial Toxicity of Non-Muscle Invasive Bladder Cancer in a Diverse, Urban Population.
Clin Genitourin Cancer. 2026;24:102564.
Abstract

LIU K, Chen Z, Jin X, Liang H, et al
An integrated molecular classification system identifies distinct prognostic clusters of non-muscle-invasive bladder cancer.
Funct Integr Genomics. 2026;26:103.
Abstract

AKAND M, Nakauma-Gonzalez JA, Jatsenko T, Gevaert T, et al
Transcriptomic profiling across stages of non-muscle-invasive bladder cancer identifies fibroblast activation protein-alpha as a stromal biomarker associated with progression.
Mol Med. 2026 May 15. doi: 10.1186/s10020-026-01497.
Abstract

FLAIG TW, Spiess PE, Abern M, An Y, et al
Bladder Cancer, Version 1.2026, NCCN Clinical Practice Guidelines In Oncology.
J Natl Compr Canc Netw. 2026;24:186-203.
Abstract

DAI YN, Tura B, Yu EY, Zeegers MP, et al
Pro-inflammatory diet predicts poorer survival in bladder cancer: Results from the bladder cancer prognosis programme.
Clin Nutr. 2026;62:106679.
Abstract

FAHEY C, Sud S, Remella A, Milowsky M, et al
Bladder-preserving trimodality therapy for muscle-invasive bladder cancer: current state-of-the-art.
Expert Rev Anticancer Ther. 2026 May 15:1-16. doi: 10.1080/14737140.2026.2673109
Abstract

DE SANTIS M, Milloy N, Walley M, Simpson A, et al
Real-world treatment patterns for metastatic urothelial cancer in 5 European countries: EVEREST 2.
Future Oncol. 2026;22:1429-1437.
Abstract

ZIEMBICKI S, Kirkham TL, Arrandale VH, Navaneelan T, et al
Cancer, chronic obstructive pulmonary disease and ischaemic heart disease in Ontario, Canada workers exposed to diesel engine exhaust.
Occup Environ Med. 2026;83:78-84.
Abstract

TANG F, Liao S, Hou X
Infection-driven bladder carcinogenesis: Molecular mechanisms of pathogen-urothelial cell interactions.
Pathol Res Pract. 2026;283:156488.
Abstract

LASALVIA P, Jaramillo P, Zapata M, Zapata M, et al
Cost of care and budget impact of novel first-line treatments in patients with locally advanced or metastatic urothelial carcinoma from the Colombian healthcare system perspective.
Expert Rev Pharmacoecon Outcomes Res. 2026;26:477-488.
Abstract

SUARTZ CV, de Lima RD, Setoue DND, Brito PHS, et al
Role of Neoadjuvant Therapy in Histological Variant Urothelial Carcinoma.
Clin Genitourin Cancer. 2026;24:102528.
Abstract

DATA S, Trivedi S, Singh Y, Kumar U, et al
HMGB1, An Autophagy-Associated Gene, as a Novel Non-Invasive Diagnostic Biomarker: Clinicopathologic Correlation in Urinary Bladder Carcinoma Patients.
Ann Surg Oncol. 2026;33:5470-5477.
Abstract

POLVERINO F, Catanzaro C, Nicolazzini M, Petix M, et al
Alcohol Use Disorder versus Adverse In-Hospital Outcomes after Radical Cystectomy and Ileal Conduit Urinary Diversion.
Ann Surg Oncol. 2026;33:5847-5853.
Abstract

BOROWCZAK J, Podemska E, Drobnik M, Gawrych A, et al
HSP90beta as a potential prognostic biomarker in urothelial carcinoma: insights from NF-kappaB, IL-8, and heat-shock protein expression.
Clin Transl Oncol. 2026;28:2335-2344.
Abstract

HSIEH CC, Tsai LJ, Lee HY, Juan YS, et al
Arsenic exposure and trend of incidence in urinary cancer from 1979 to 2019: A nationwide population-based study.
J Formos Med Assoc. 2026;125:507-515.
Abstract

LI Y, Ye F, Liu G, Cheng L, et al
Nano-armed bcg delivers Cu-Fe MOF to trigger dual cell death in bladder cancer.
J Nanobiotechnology. 2026 May 29. doi: 10.1186/s12951-026-04590.
Abstract

JUNG M, Park S, Jang I, Han D, et al
Ethnicity-specific molecular subtypes and a machine-learning risk model in Asian patients with non-muscle-invasive bladder cancer.
Sci Rep. 2026 May 29. doi: 10.1038/s41598-026-55438.
Abstract

ZHENG H, Tian Y, Cai Z, Huang G, et al
CircRNA-cZFR is upregulated in bladder cancer and promotes tumorigenesis via UBE2V1 regulation.
Sci Rep. 2026 May 29. doi: 10.1038/s41598-026-48969.
Abstract

GONTERO P, Perry R, Bridge D, Delattre DD, et al
Unmet Treatment Need and Challenges Associated with Comparative Evidence Generation in BCG-unresponsive Non-muscle-invasive Bladder Cancer: An Expert Consensus.
Eur Urol Oncol. 2026 May 29:S2588-9311(26)00134.
Abstract

NECCHI A, Brembilla G, Whiting K, Arita Y, et al
AI-MIRACLE: Artificial Intelligence and MultIpaRAmetric MRI Predict CLinical OutcomEs to Neoadjuvant Immunotherapy in Patients with Muscle-invasive Bladder Cancer Undergoing Radical Cystectomy.
Eur Urol Oncol. 2026 May 29:S2588-9311(26)00133.
Abstract

PALERU G, Singathala GS, Kural S, Kumar L, et al
Emerging role of urinary biomarkers in bladder cancer diagnosis and prognosis.
Urol Oncol. 2026;44:70-81.
Abstract

ZHANG XW, Schlack K, Hartmann A, Steiner T, et al
Genitourinary Oncology Highlights from the European Society for Medical Oncology Annual Meeting 2025: Advances in Renal Cell Carcinoma and Muscle-invasive Bladder Cancer.
Oncol Res Treat. 2026 May 29:1-8. doi: 10.1159/000552743.
Abstract

ZHAO L, Chen HM, Li YT, Zhang T, et al
Comparative efficacy and safety of open, laparoscopic, and robot-assisted radical cystectomy: a systematic review and network meta-analysis.
J Robot Surg. 2026;20:552.
Abstract

NASUTION RFG, Warli SM, Prapiska FF
Prognostic significance of pretreatment hydronephrosis in radiotherapy-based bladder-preserving strategies for muscle-invasive bladder cancer: a systematic review and meta-analysis.
Arch Ital Urol Androl. 2026 May 29:14945. doi: 10.4081/aiua.2026.14945.
Abstract

TANG C, Liu Y, Wang TL, Ma J, et al
Integrated Genomic and Single-Cell Analysis Reveals Heterogeneity, Prognosis, and Treatment Vulnerability in Urothelial Carcinoma.
Hum Mutat. 2026;2026:2797474.
Abstract

LI C, Fang R, Wang J, Wang Y, et al
Urinary DNA methylation biomarkers for bladder cancer diagnosis: a single center case-control study.
Front Oncol. 2026;16:1812094.
Abstract

SAYGIN H, Bolat S, Kablan D, Yavuz H, et al
Metabolic Profiling Reveals Insights Into Bladder Cancer Pathogenesis and Recurrence.
Adv Urol. 2026;2026:6524384.
Abstract

Correction to "Metabolic Profiling Reveals Insights Into Bladder Cancer Pathogenesis and Recurrence".
Adv Urol. 2026;2026:9810919.
Abstract

CHEN IA, Luo HL, Chu CH, Yu CC, et al
Robotic versus laparoscopic radical nephroureterectomy for upper tract urothelial carcinoma: comparable oncologic outcomes with reduced intravesical recurrence in pathological T3 disease.
J Robot Surg. 2026;20:549.
Abstract

WEI W, Xiao X, Ren C, Zhang H, et al
Inhibition of TGM2 enhances cisplatin sensitivity in MSH2-deficient bladder cancer.
Cell Death Discov. 2026 May 28. doi: 10.1038/s41420-026-03182.
Abstract

ZHAO H, Liao J, Wing Sze HV, Liu K, et al
EZH2 Inhibition Remodels Cell States and Enhances EGFRi Sensitization in Bladder Cancer.
Eur Urol Oncol. 2026 May 28:S2588-9311(26)00137.
Abstract

WANG M, Chen J, Wang C, He Y, et al
Progress in the application of combined detection of urinary tumor DNA and exosomes in the classification, staging, and clinical management of bladder cancer: a review.
Front Oncol. 2026;16:1745178.
Abstract

COSKUN A, Sahin AB, Kabul S, Dagtekin ME, et al
Prognostic significance of squamous differentiation in pT2N0 urothelial bladder cancer.
Oncol Lett. 2026;32:299.
Abstract

ZHAO X, Xu X
ARAF regulates malignant progression of bladder cancer through the p38MAPK pathway.
Open Med (Wars). 2026;21:20261422.
Abstract

CHANG Y, Sun N, Liu Y, Jin Z, et al
Lnc00892 enhances cisplatin sensitivity by inducing apoptosis through the BTAF1/MDM2/STAT5B/XIAP axis in bladder cancer cells.
Biol Direct. 2026 May 27. doi: 10.1186/s13062-026-00842.
Abstract

YIM W, Kang H, Kang BH, McGinnis ME, et al
Chemical efflux imaging using an annular nanosensor array for in situ bladder cancer detection.
Nat Nanotechnol. 2026 May 27. doi: 10.1038/s41565-026-02172.
Abstract

HONG X, Hong T, Liu X, Yao P, et al
UBE2C-Mediated CD147-CTLA-4 Axis Promotes T Cell Exhaustion and Immunosuppressive Microenvironment in Bladder Cancer.
Cancer Sci. 2026 May 27. doi: 10.1111/cas.70430.
Abstract

ZHANG N, Liang H, Wang L, Yang T, et al
[Investigating prognostic factors for T1 stage high-grade bladder cancer and developing a multi-marker risk prediction model using immunohistochemistry].
Zhonghua Wai Ke Za Zhi. 2026;64:768-777.
Abstract

ZHONG WL, Zheng HR, Lin TX
[Liquid biopsy empowers precision medicine across the full course of bladder cancer].
Zhonghua Wai Ke Za Zhi. 2026;64:695-700.
Abstract

HAYNE D, Zhang AY, Thomas H, Redfern AD, et al
Reply to Tonghu Liu's Letter to the Editor re: Bacillus Calmette-Guerin Plus Mitomycin Versus Bacillus Calmette-Guerin Alone for Bacillus Calmette Guerin-naive Non-Muscle-Invasive Bladder Cancer: A Randomised Phase 3 Trial (ANZUP 1301). Eur Urol. In p
Eur Urol Focus. 2026 May 27:S2405-4569(26)00088.
Abstract

LIU T, Zhu C, Yan Z
Re: Hayne D, Zhang AY, Thomas H, et al. Bacillus Calmette-Guerin Plus Mitomycin Versus Bacillus Calmette-Guerin Alone for Bacillus Calmette-Guerin-naive Non-muscle-invasive Bladder Cancer: A Randomised Phase 3 Trial (ANZUP 1301). Eur Urol. In press. h
Eur Urol Focus. 2026 May 27:S2405-4569(26)00087.
Abstract

MAMTANI R, Squires P, Mojebi A, Hale B, et al
Neoadjuvant, adjuvant, and perioperative therapy comparisons in muscle-invasive bladder cancer: Clinical and methodological considerations for the interpretation of network meta-analytic findings.
Urol Oncol. 2026 May 27:S1078-1439(26)00495.
Abstract

MA M, Wu H, Zhu D, Sun P, et al
The Mechanistic Role of the lncRNA AC016876.2/miR-133a-3p/SPAG5 Axis in Regulating Autophagy and Malignant Behavior in Bladder Cancer Cells.
Tohoku J Exp Med. 2026 May 28. doi: 10.1620/tjem.2026.
Abstract

RAHMAN SN, Keervani K, Zhao X, Perry CJ, et al
Trends in the diagnosis of variant bladder cancer: a national retrospective cohort analysis.
Front Oncol. 2026;16:1807817.
Abstract

HUANG Z, Wang T, Xia W, Li Q, et al
[Retracted]Oblongifolin C reverses GEM resistance via suppressing autophagy flux in bladder cancer cells.
Exp Ther Med. 2026;32:186.
Abstract

SUN R, Li Y, Zuo L, Tao J, et al
[Myricetin inhibits proliferation and migration of bladder cancer cells by inhibiting HSP90AA1-mediated AKT phosphorylation].
Nan Fang Yi Ke Da Xue Xue Bao. 2026;46:1039-1052.
Abstract

GODLEWSKI D, Aebisher D, Bartusik-Aebisher D, Dynarowicz K, et al
Enhanced Imaging in Bladder Cancer: Fluorescence Cystoscopy and Molecular Diagnostics.
Life (Basel). 2026;16:828.
Abstract

SCHITCU VH, Munteanu VC, Borz MB, Cojocaru I, et al
Systems Biology and Multi-Omics Determinants of Response to Bladder-Preserving Trimodality Therapy in Muscle-Invasive Bladder Cancer.
Life (Basel). 2026;16:826.
Abstract

KARAKAYALI A, Seyyar M, Sanci PC, Sahin E, et al
Prognostic Value of the Prognostic Nutritional Index in Patients with Locally Advanced Bladder Cancer Receiving Perioperative Chemotherapy: A Multicenter Real-World Study.
Medicina (Kaunas). 2026;62:992.
Abstract

KIM KH, Kang BJ, Lee CH, Kim S, et al
Comparison of Long-Term Oncological Outcomes of Intravesical Bacillus Calmette-Guerin Versus Gemcitabine in Treatment-Naive Non-Muscle-Invasive Bladder Cancer with Intermediate and High Risk: A Multicenter Retrospective Analysis.
J Clin Med. 2026;15:3890.
Abstract

KIM SH, Gudlavalleti H, Lerner SP
Narrative Review of Potential Non-Surgical Treatments for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer.
J Clin Med. 2026;15:3830.
Abstract

UN S, Aydin VK, Kurt O, Lengerova G, et al
Time-Dependent Effects of Cisplatin on Autophagy Gene Expression in Bladder Cancer Cells.
Biomedicines. 2026;14:1006.
Abstract

LI W, Liu D, Yin Q, Geng Y, et al
Natural Products Targeting Acetylation in Bladder Cancer: Mechanistic Basis, Therapeutic Potential, and Future Perspectives.
Curr Issues Mol Biol. 2026;48:489.
Abstract

NEWMAN A, Hansel S, Gerrard G, Orton L, et al
Real-World Evaluation of Uromonitor((R)) for Bladder Cancer Detection and Surveillance.
Cancers (Basel). 2026;18:1650.
Abstract

MOHAMED NE, Berry DL, McReynolds J, Korn T, et al
Development and Evaluation of the Personal Patient Profile-Bladder Cancer (P3-BC): A Web-Based Decision Support System for Patients Considering Cystectomy and Urinary Diversion.
Cancers (Basel). 2026;18:1501.
Abstract

ZHENG L, Wang J, Han S, Zhong L, et al
Correction: The KLF16/MYC feedback loop is a therapeutic target in bladder cancer.
J Exp Clin Cancer Res. 2026;45:128.
Abstract

RAMMANT E, Fox L, De Padova S, Liedberg F, et al
Update of the EORTC Health-related Quality of Life Modules for Bladder Cancer: Phase 1-2 of the Development Process.
Eur Urol Oncol. 2026 May 26:S2588-9311(26)00125.
Abstract

KAYAR K, Kayar R, Ozdemir BB, Karabay E, et al
Urinary pH and oncologic outcomes after bacillus calmette-guerin in non-muscle invasive bladder cancer: a retrospective cohort study.
Actas Urol Esp (Engl Ed). 2026 May 25:501995. doi: 10.1016/j.acuroe.2026.501995.
Abstract

CARLSEN B, Klingen TA, Andreassen BK, Beisland C, et al
Tumor cell invasion in blood vessels but not lymphatic vessels in TURBT predicts poor prognosis in bladder cancer.
Urol Oncol. 2026;44:26-35.
Abstract

CHEN J, Ding Z, Lai S, Gan Z, et al
Nanoparticles-mediated dual metabolic-immunological intervention reverses immunosuppression in muscle invasive bladder cancer.
Biomaterials. 2026;335:124335.
Abstract

MOFID B, Jafari A, Simforoosh N, Basiri A, et al
Bladder-sparing chemoradiotherapy following neoadjuvant chemotherapy for muscle-invasive bladder cancer: a retrospective cohort study.
BMC Urol. 2026 May 25. doi: 10.1186/s12894-026-02187.
Abstract

AIZEZI X, Silafu B, Shi H, Huang J, et al
Multi-omics analysis reveals TM4SF19 as a diagnostic and prognostic biomarker in bladder cancer.
Discov Oncol. 2026 May 25. doi: 10.1007/s12672-026-05304.
Abstract

OZALP FR, Ellez HI, Arslan AM, Demirciler E, et al
Integrative in silico transcriptomic and pharmacogenomic analysis of CD276 as a candidate prognostic biomarker and therapeutic target in bladder cancer.
Discov Oncol. 2026 May 25. doi: 10.1007/s12672-026-05310.
Abstract

CAMPO-PEREZ V, Guallar-Garrido S, Cabrera-Rubio R, Herrero-Abadia P, et al
Intravesical mycobacteria reshape bladder and gut microbiota in a murine bladder cancer model.
NPJ Biofilms Microbiomes. 2026 May 25. doi: 10.1038/s41522-026-01002.
Abstract

ZHU C, Lu J, Zhu B, Liu B, et al
ATP13A2 promoted cell stemness, cisplatin resistance, autophagy, and cell progression of bladder cancer.
Front Immunol. 2026;17:1743064.
Abstract

XU Y, Zhao C, Fu S, Wu Y, et al
Spermine oxidase-DOX conjugates reshape tumor microenvironment via carbonyl stress to potentiate bladder cancer chemotherapy.
Mater Today Bio. 2026;38:103222.
Abstract

HU K, Luo L, Li P, Wang X, et al
Fibrinogen-like protein 1 induces the formation of an immunosuppressive microenvironment by upregulating fibronectin 1 to promote immune evasion in bladder cancer.
Cytojournal. 2026;23:25.
Abstract

CHEN L, Hang G, Wen Q, Ren L, et al
Application and challenges of smart responsive multifunctional nanoplatforms in integrated diagnosis and treatment of bladder cancer and overcoming therapeutic resistance.
Front Oncol. 2026;16:1803259.
Abstract

LI Z, Zhong H, Baptista-Hon D, Qiu J, et al
JS-K induces autophagy-dependent ferroptosis in bladder cancer: a multimodal mechanistic and translational study.
Precis Clin Med. 2026;9:pbag012.
Abstract

HAYASHI J, Sugimoto K, Kochi S, Toake M, et al
[A Case of Locally Advanced Colorectal Cancer with Severe Bladder Invasion Successfully Treated with Preoperative Chemotherapy with Anti-EGFR Antibody and Avoiding Total Bladder Resection].
Gan To Kagaku Ryoho. 2026;53:307-309.
Abstract

SHORE ND, Powles TB, Bedke J, Galsky MD, et al
Sasanlimab taken together with Bacillus Calmette-Guerin (BCG) compared with BCG alone in people with high-risk non-muscle invasive bladder cancer: a plain language summary.
Future Oncol. 2026 May 24:1-13. doi: 10.1080/14796694.2026.2671256.
Abstract

WEN J, Wei L, Huang J, Zhou L, et al
Yeast surface display-based screening and preliminary characterization of nectin-4-targeting nanobodies for bladder cancer.
BMC Biotechnol. 2026 May 23. doi: 10.1186/s12896-026-01170.
Abstract

DUCCI G, Ciufolini G, Campioni G, Pasquale V, et al
FGFR3 oncogenic activation drives oxidative metabolic reprogramming in bladder cancer: a systems metabolomics approach.
Commun Biol. 2026 May 23. doi: 10.1038/s42003-026-10356.
Abstract

ELAVARASU SM, Asheem I, M N, S UK, et al
Transcriptomic insights into epigenetic and immunomodulatory roles of nuclear histone genes in bladder cancer: A bioinformatics approach.
Adv Protein Chem Struct Biol. 2026;152:77-101.
Abstract

KOBYLKA P, Murias M, Bakun P, Goslinski T, et al
Cellular responses to morpholinated curcumin derivatives in human muscle-invasive bladder cancer cells.
Toxicol In Vitro. 2026;115:106251.
Abstract

SUN Z, Liu J, Fang Y, Ma L, et al
Ferritin-Based Mild Magnetic Hyperthermia Therapy for Bladder Cancer: A Synergistic Anti-Inflammatory Strategy.
ACS Nano. 2026 May 23. doi: 10.1021/acsnano.6c00407.
Abstract

WANG M, Jia K, Wang Y, Yuan D, et al
The impact of the COVID-19 pandemic in 2020 on the diagnosis, treatment, and cancer-specific survival of major urological cancers: An observational study.
Medicine (Baltimore). 2026;105:e48966.
Abstract

PRADHAN B, Mishra P, Dash P, Niharika, et al
Epigenetic signatures and risk determinants in bladder cancer: Implications for diagnostic and therapeutic interventions.
Urol Oncol. 2026 May 22:S1078-1439(26)00498.
Abstract

WANG S, Tang Y, Xu Y, Wang Y, et al
Discovery of NMP22-Targeting Aptamers for Point-of-Need Test of Bladder Cancer.
Anal Chem. 2026 May 22. doi: 10.1021/acs.analchem.6c00738.
Abstract

ZHANG M, Liu H, Zhang Y, Zhu Z, et al
HIV-related bladder cancer: A ten-year experience.
Int J STD AIDS. 2026 May 22:9564624261449133. doi: 10.1177/09564624261449133.
Abstract

MIYAKE M, Minegishi T, Aikawa T, Fukasawa T, et al
Real-world perioperative systemic treatment patterns and outcomes in patients with urothelial carcinoma undergoing radical surgery.
Cancer Treat Res Commun. 2026;47:101241.
Abstract

MUSANGILE FY, Matsuzaki I, Nishikawa T, Kojima F, et al
Precursor flat urothelial lesions: Molecular landscape, pathogenesis, and biological insights.
Pathol Res Pract. 2026;284:156517.
Abstract

BONNI S, Ramnath NWM, Selten K, Moza A, et al
Bacillus Calmette-Guerin-Related Mycotic Pseudoaneurysm in the Aortic Arch: Clinical and Operative Challenges.
Interdiscip Cardiovasc Thorac Surg. 2026;41:ivag120.
Abstract

NIWA K, Iinuma K, Nakano M, Tomioka M, et al
Secondary primary tumors following iodine-125 low-dose-rate brachytherapy for localized prostate cancer.
Int J Clin Oncol. 2026;31:1008-1016.
Abstract

MORRIS G, Vlachostergios PJ, Rai MP, Scherr D, et al
19q13 amplification with AKT2 and ERCC2 gains in sarcomatoid carcinoma of the urinary bladder.
Cancer Genet. 2026;304-305:51-57.
Abstract

JAN HC, Su YC, Huang SK, Wang CA, et al
HDAC4 overexpression predicts aggressive phenotypes and poor outcomes in urothelial carcinoma.
Cancer Treat Res Commun. 2026;47:101148.
Abstract

QIN X, Zheng B, Liu D, Quan X, et al
A 'two-in-one' tumor-specific-hydrogel-assisted strategy for intravesical chemotherapy and protection of normal tissues.
J Nanobiotechnology. 2026;24:502.
Abstract

CHOI SH, Kim JK, Kim SH, Ryu MO, et al
Recurrent pyuria is associated with shorter progression-free survival in dogs with bladder urothelial carcinoma.
Am J Vet Res. 2026;87:ajvr.
Abstract

WANG Y, An S, Min Y
Crocin-coated zinc-alginate-PEG nanocomposite induces ROS-mediated apoptosis via PI3K/Akt/mTOR suppression in bladder cancer cells.
3 Biotech. 2026;16:248.
Abstract

YILMAZ B, Ataman M, Tuna A
Detection of microplastics in bladder wash fluid obtained after cystoscopy in patients diagnosed with bladder cancer.
Front Public Health. 2026;14:1812477.
Abstract

HE Y, Fang Z, Zhang J, Wei Q, et al
Reversing Bladder Cancer Chemo-resistance through Blocking Cell Senescence by a Combination Therapy.
Theranostics. 2026;16:6827-6842.
Abstract

BELLMUNT J, Xie Y, Juanpere N, Munoz MG, et al
Epigenetic subtypes of high-grade T1 bladder cancer reveal intra-tumor heterogeneity and distinct interactions with tumor microenvironment.
Theranostics. 2026;16:6892-6910.
Abstract

LIU J, Li B, Hou R, Sun J, et al
A five-gene mitochondria-associated prognostic signature for bladder cancer.
Int J Clin Exp Pathol. 2026;19:192-208.
Abstract

YUAN H, Wang T, Peng P, Xu Z, et al
Corrigendum to "Urinary Exosomal miR-17-5p Accelerates Bladder Cancer Invasion by Repressing its Target Gene ARID4B and Regulating the Immune Microenvironment" [Clinical Genitourinary Cancer 22/2 (2024) 569-579.e1].
Clin Genitourin Cancer. 2026 Jun 4:102584. doi: 10.1016/j.clgc.2026.102584.
Abstract

PALMBOS P, Kelleher A, Henderson M, Broses L, et al
TRIM29 is Critical for Bladder Cancer Progression and Modulates the Tumor-Immune Niche.
Res Sq [Preprint]. 2026 May 20:rs.3.rs-9214925. doi: 10.21203/rs.3.rs-9214925.
Abstract

YIM K, Vergara M, Lee J, Reardon B, et al
Genomic analysis of BCG unresponsive non-muscle-invasive bladder cancer identifies drivers of sensitivity to intravesical Gemcitabine/Docetaxel.
bioRxiv [Preprint]. 2026 May 18:2026.05.10.724123.
Abstract

FINI MS, Alley JR, Vensko SP, Karthikeyan D, et al
Immunodominance Hierarchy of Endogenous BBN963 Bladder Cancer Antigens Remains Stable Under Anti-PD1 and Anti-CTLA4 Immunotherapy.
bioRxiv [Preprint]. 2026 May 27:2026.05.20.726664.
Abstract

HUANG Z, Yan Y, Wang X, Li H, et al
Tumor-derived WNT7A reprograms pulmonary fibroblasts to remodel the metastatic niche and promote bladder cancer lung metastasis.
Exp Mol Med. 2026 Jun 3. doi: 10.1038/s12276-026-01735.
Abstract

MACDONALD LP, Kypriotakis G, Karam-Hage M, Minnix JA, et al
Survival Outcomes of a Smoking Cessation Treatment Program After Diagnosis of Bladder Cancer.
Eur Urol Oncol. 2026 Jun 3:S2588-9311(26)00131-8. doi: 10.1016/j.euo.2026.
Abstract

DIAZ GM, Isali I, Davis L, Wang B, et al
Epidemiological Trends and Germline Variant Analysis of Young-Onset Bladder Cancer.
Clin Genitourin Cancer. 2026 May 6:102578. doi: 10.1016/j.clgc.2026.102578.
Abstract

MUNK L, Kumarasegaram V, Hyldgaard JM, Jensen JB, et al
Collecting electronic patient-reported outcomes via smartphone text messages in a bladder cancer RCT: A feasibility study.
Urol Oncol. 2026;44:101-107.
Abstract

ZHANG XJ, Yu HY, Cai YJ, Ke M, et al
Retraction: Lycium barbarum polysaccharides inhibit proliferation and migration of bladder cancer cell lines BIU87 by suppressing Pi3K/AKT pathway.
Oncotarget. 2026;17:193-194.
Abstract

HUANG J, Luo H, Du C, Zhai Q, et al
Antibody-drug conjugate therapy in a renal transplant patient with bladder cancer: A case report.
Clin Nephrol. 2026 Jun 3. doi: 10.5414/CN111972.
Abstract

LIU Z, Yao Z, Hou Y, Liu Z, et al
LGALS1-CD276 Paracrine axis between tumor and endothelial cells promotes tumor angiogenesis and progression in bladder cancer.
Cell Death Differ. 2026 Jun 2. doi: 10.1038/s41418-026-01777.
Abstract

PINTON P, Kawano H, Patschan O, Ravi A, et al
A machine-learning approach to predict additional treatment after Bacillus Calmette-Guerin induction in non-muscle-invasive bladder cancer.
Sci Rep. 2026 Jun 2. doi: 10.1038/s41598-026-55917.
Abstract

LUO Y, Ma J, Wang C, Xiong W, et al
ELK1-YBX1 signaling promotes cisplatin resistance via ferroptosis adaptation in bladder cancer.
Cell Signal. 2026 Jun 1:112633. doi: 10.1016/j.cellsig.2026.112633.
Abstract

NARAYAN A, Leibrandt RC, Lee JS, Dall'Era MA, et al
A Phase I trial of PLZ4-coated paclitaxel-loaded micelles in patients with refractory non-muscle-invasive bladder cancer.
Nanomedicine (Lond). 2026 Jun 1:1-6. doi: 10.1080/17435889.2026.2674162.
Abstract

NIKOLAUS Y
p40-positive metastatic urothelial carcinoma mimicking primary pulmonary squamous cell carcinoma on limited lung biopsy.
BMJ Case Rep. 2026;19:e272914.
Abstract

YANG H, Zhou C, Zhou Z, Zhang F, et al
YBX1 takes actions on triggering M2-like polarization of macrophages and stabilizing CXCL8 mRNA to exhibit its metastatic potential in bladder cancer.
Int Immunopharmacol. 2026;184:116911.
Abstract

KOHLER J, Buck L, Schliesser P, Weische O, et al
Survival association of GLP-1 receptor agonists and SGLT2 inhibitors in bladder cancer patients.
Urol Oncol. 2026;44:92-100.
Abstract

FU L, Huang B, Shi L, Geng Y, et al
DS-MTNet: A dual-stream multi-task network for histopathology localization and histologic risk stratification from small biopsy specimens of bladder cancer.
Comput Methods Programs Biomed. 2026;284:109464.
Abstract

ZHANG W, Wu H, Wang L, Xu H, et al
Antibody-Drug Conjugates for Locally Advanced and Metastatic Urothelial Carcinoma: A Systematic Review and Meta-Analysis.
JAMA Netw Open. 2026;9:e2614764.
Abstract

ZHANG Y, Li R, Shi H, Zhao A, et al
ASO Author Reflections: Benchmarking Large Language Models for Bladder Cancer: Comparative Knowledge Retrieval and Clinical Reasoning of DeepSeek and ChatGPT.
Ann Surg Oncol. 2026 Jun 1. doi: 10.1245/s10434-026-19845.
Abstract

CHEN L, Cao X, Lu Z, Liu L, et al
Artificial intelligence-assisted urine cytology based on the Paris System for Reporting Urothelial Carcinoma.
Cancer Cytopathol. 2026;134:e70120.
Abstract

JIAO B, Xu Y, Wang X, Zhang H, et al
Biomimetic Nanoparticles Based on Tumor Cell Membrane Co-loaded with Vitamin E and Doxorubicin for Targeted Synergistic Treatment of Bladder Cancer.
ACS Appl Bio Mater. 2026 Jun 1. doi: 10.1021/acsabm.6c00552.
Abstract

BOYNE A, Anderson RC, Liu D, Varghese B, et al
Radiogenomic analysis of muscle-invasive bladder cancer using CT-based texture analysis.
Bladder Cancer. 2026;12:23523735261455396.
Abstract

BOLT MJ, Oceguera J, Tostado AR, Candler CD, et al
A phenotypic screen identifies xanthohumol and other flavonoids as killers of bladder cancer.
Pharmacol Res Nat Prod. 2025;7:100236.
Abstract

SELVARAJU A, Dwivedi DK, Patbamniya NK, Kumar M, et al
Multiparametric MRI Radiomics for the Prediction of Histologic Grade in Bladder Cancer.
Indian J Surg Oncol. 2026;17:1057-1064.
Abstract

FERNANDES C, Brito C, Ferreira C, Botelho F, et al
Ensuring Timely Detection of Bladder Cancer: The Role of a Screening for Haematuria Consultations.
Indian J Surg Oncol. 2026;17:964-969.
Abstract

YANG J, You Z, Mo H, Pu J, et al
Identification of succinylation-related genes in bladder cancer: integration of single-cell and transcriptomic data.
Front Immunol. 2026;17:1797389.
Abstract

HANSEN MS, Dyrskjot L, Heide-Jorgensen U, Jensen JB, et al
Aspirin or non-steroidal anti-inflammatory drug initiation and subsequent bladder cancer evaluation.
J Intern Med. 2026 Jun 1. doi: 10.1111/joim.70115.
Abstract

ICHIYAMA T, Narita T, Sekine Y, Shinohara M, et al
Visualizing eligibility gaps between muscle-invasive bladder cancer trials and real-world patients.
Jpn J Clin Oncol. 2026 May 31:hyag087. doi: 10.1093.
Abstract

GUTTI JR, Clarke DM, Saba C, Nagata K, et al
Incorporating Hypofractionated Radiotherapy Improves Management of Canine Urothelial Carcinoma: A Retrospective Study.
Vet Radiol Ultrasound. 2026;67:e70196.
Abstract

ABOU CHAKRA M, Duquesne I, O'Donnell MA
Decoding Immune Mechanisms in BCG-unresponsive Non-muscle Invasive Bladder Cancer.
Front Biosci (Landmark Ed). 2026;31:47606.
Abstract

GUPTA A, Chandra S, Verma T, Gupta A, et al
The Paris System for Urine Cytology: Prospective Assessment of Reproducibility, Diagnostic Accuracy, and Malignancy Risk.
Diagn Cytopathol. 2026;54:506-518.
Abstract

MACH KE, Kornberg Z, Shkolyar E, Long J, et al
Large multicenter validation of urine RNA profile for urothelial carcinoma detection and surveillance.
J Clin Invest. 2026;136:e203094.
Abstract

LEFRANC R, Mathieu C, Ghorbel A, Leger-Vigot A, et al
Consolidative cystectomy after complete response to enfortumab vedotin plus pembrolizumab in metastatic bladder cancer: a case report.
J Surg Case Rep. 2026;2026:rjag435.
Abstract

ERNANDEZ J, Xiang L, Adler R, Hsu J, et al
Dementia and Frailty Impact Postoperative Care Trajectories and Burden among Older Adults Undergoing Radical Cystectomy for Bladder Cancer.
medRxiv [Preprint]. 2026 Jun 6:2026.06.04.26354768.
Abstract

YAP M, Mihai IM, Alanazi MAA, Olteanu GE, et al
Automated H-Scoring in Muscle-Invasive Bladder Cancer IHC: An Internal Validation Study.
Diagnostics (Basel). 2026;16:1673.
Abstract

HJORT PB, Skovhus K, Jensen JB, Ernst A, et al
Study of Bladder Cancer Detection in Standard White Light Versus AI-Supported Endoscopy-02 (RAISE-02)-A Randomized Controlled Non-Inferiority Trial.
Cancers (Basel). 2026;18:1739.
Abstract

CERIA F, Muhammad G, Del Giudice F, Ibrahim Y, et al
Expect the Unexpected: Frequency, Predictors, and Survival Impact of Pathological Upstaging from Non-Muscle-Invasive to Muscle-Invasive Bladder Cancer Following Radical Cystectomy.
Cancers (Basel). 2026;18:1733.
Abstract

SHAH KU, Castro DV, Li X, Zugman M, et al
Evaluating Worldwide Disparities in Bladder Cancer Clinical Trial Availability.
Cancers (Basel). 2026;18:1730.
Abstract

ZHU J, Wang A, Tong H, Sun Y, et al
Abnormal Sialylation Promotes Chemotherapy Resistance in Bladder Cancer via the PI3K-AKT-mTOR Signaling Pathway.
Cancers (Basel). 2026;18:1713.
Abstract

DEGIRMENCI E, Sanli O, Kaytaz M, Kucukgergin C, et al
ZEB1-AS1 and miR-200b-3p Expression in Non-Muscle-Invasive Bladder Cancer: Pathological Correlates.
J Clin Med. 2026;15:4182.
Abstract

SKOVHUS K, Kristensen P, Sindberg DB, Orum M, et al
Preoperative Frailty Assessed by the Record-Based Multidimensional Prognostic Index Predicts 90-Day Days Alive and out of Hospital Following Radical Cystectomy for Bladder Cancer: A Retrospective Cohort Study.
J Clin Med. 2026;15:4057.
Abstract

ANTONOV P, Raycheva G, Eshrefov D, Belov A, et al
FGFR3 Alterations and Nectin-4 Expression as Therapeutic Biomarkers in Bladder Cancer: A Systematic Review and Single-Arm Meta-Analysis.
Int J Mol Sci. 2026;27:5007.
Abstract

CHEN C, Tan Z, Cai L, Chen H, et al
MRI-based deep learning combined with radiomics for the preoperative prediction of lymphovascular invasion in patients with bladder cancer.
Cancer Imaging. 2026 Jun 11. doi: 10.1186/s40644-026-01070.
Abstract

RESEARCH INTERNATIONAL B
RETRACTION: Omega-3 Fatty Acids Inhibit Tumor Growth in a Rat Model of Bladder Cancer.
Biomed Res Int. 2026;2026:e9864535.
Abstract

MUSONE M, Barone B, Chianese S, Conforti P, et al
Beyond the BCG Paradox: Biological Rationale and Clinical Evidence for Combining Intravesical BCG with Immune Checkpoint Inhibitors in High-Risk Non-muscle-Invasive Bladder Cancer.
Oncol Ther. 2026 Jun 11. doi: 10.1007/s40487-026-00445.
Abstract

SIVA J, Jonnalagadda R, Aydogdu C, Diaz GM, et al
External Validation of the International Bladder Cancer Group Intermediate-risk Non-muscle-invasive Bladder Cancer Substratification Model.
Eur Urol Oncol. 2026 Jun 11:S2588-9311(26)00157.
Abstract

KAGENAAR E, Lugo-Palacios DG, Bromley H, Aggarwal A, et al
Surgery or radiotherapy for early-stage cancer study protocol for an emulated target trial of radical radiotherapy versus radical cystectomy, with either following neoadjuvant chemotherapy, for organ-confined muscle-invasive bladder cancer.
BMJ Open. 2026;16:e119596.
Abstract

HE Y, Xie W, Chen W, Dai S, et al
Urine IRF4/PENK/PXDN Methylation Signatures Enable Machine Learning-Driven Bladder Cancer Detection and Microenvironment Dissection.
Technol Cancer Res Treat. 2026;25:15330338261453486.
Abstract

IDIARTE JF, Canclini L, Alem D, Garcia-Lavina CX, et al
Violacein as a multitarget agent in bladder cancer cells.
J Proteomics. 2026 Jun 11:105697. doi: 10.1016/j.jprot.2026.105697.
Abstract

ZENG Y, Gu G, Yang L, Fan B, et al
Ketogenic Diet and beta-Hydroxybutyrate Suppress Bladder Cancer Growth and Enhance Anti-PD-L1 Immunotherapy Efficacy.
Cancer Sci. 2026 Jun 11. doi: 10.1111/cas.70447.
Abstract

MAISCH P, Hamidi Madani M, Koziarz A, Narayan VM, et al
Blue versus white light for transurethral resection of non-muscle invasive bladder cancer.
Cochrane Database Syst Rev. 2026;6:CD013776.
Abstract

Nodal Regulates Bladder Cancer Cell Migration and Invasion via the ALK/Smad Signaling Pathway [Retraction].
Onco Targets Ther. 2026;19:629839.
Abstract

LIAO J, Li X, Li G
Comparative efficacy and safety of carboplatin-based versus cisplatin-based chemotherapy in muscle-invasive and advanced bladder cancer: A systematic review and meta-analysis.
Eur J Clin Pharmacol. 2026;82:168.
Abstract

SANTARELLI V, Asero V, Corvino R, De Berardinis E, et al
Nephroureterectomy for upper tract urothelial carcinoma recurrence in bladder cancer patients treated with radical cystectomy: a multicentric propensity score matched analysis on predictors, practice patterns and survival outcomes.
World J Urol. 2026;44:419.
Abstract

PAN Y, Sun Y, Jiao B, Zhang Y, et al
The international and domestic research trends of targeted therapy in bladder cancer: a bibliometric analysis of the past three decades.
Front Oncol. 2026;16:1850175.
Abstract

DENG C, Soivong P, Akkadechanunt T, Sethabouppha H, et al
Self-Management Experience of Chinese Patients With Nonmuscle-Invasive Bladder Cancer During Intravesical Therapy: A Qualitative Study.
Cancer Nurs. 2026 May 28. doi: 10.1097/NCC.0000000000001598.
Abstract

LIU F, Hu X, Zhu X, Han T, et al
A Retrospective Follow-up Study on the Effects of Different Intravesical Treatments on Recurrence Control and Quality of Life in Patients With Non-Muscle-Invasive Bladder Cancer After Transurethral Resection of Bladder Tumour.
Arch Esp Urol. 2026;79:632-640.
Abstract

YAN D, Zhu W, Tao Y, Huang L, et al
ZRANB1 promotes cell proliferation and lymph node metastasis through SF3B3-mediated alternative splicing of CHEK2 in urothelial bladder cancer.
Cell Death Dis. 2026 Jun 9. doi: 10.1038/s41419-026-08964.
Abstract

SQUIRES P, Meng K, Hu X, Turzhitsky V, et al
Publisher Correction: Perioperative Treatment Patterns for Muscle-Invasive Bladder Cancer Patients Undergoing Radical Cystectomy in the Adjuvant Immunotherapy Era: A Retrospective Analysis of US Community Oncology Practice.
Oncol Ther. 2026 Jun 9. doi: 10.1007/s40487-026-00451.
Abstract

HUANG S, Zhou Z, Xie Q, Wang Z, et al
KRT14 Drives Basal Muscle-Invasive Bladder Cancer Progression and Lung Metastasis by Directly Binding to and Stabilizing IGF2BP1.
Adv Sci (Weinh). 2026 Jun 9:e75900. doi: 10.1002/advs.75900.
Abstract

ALASKER A, Alghafees M, Nammor T, Alanazi N, et al
Immunotherapy in bladder cancer: a systematic review of clinical trials and therapeutic advances.
BMC Urol. 2026 Jun 8. doi: 10.1186/s12894-026-02209.
Abstract

PENG J, Zhu Q, Li S, Xiang B, et al
Cis-3-hexen-1-ol suppresses bladder cancer progression by inducing mitophagy via the PCK2/AMPK/mTOR signaling pathway.
Cell Oncol (Dordr). 2026 Jun 8. doi: 10.1007/s13402-026-01233.
Abstract

NUSRAT NB, Imtiaz S, Aslam A, Rehman AU, et al
Clinical and pathological factors associated with recurrence after radical cystectomy for bladder cancer: A single-center retrospective study.
Pak J Med Sci. 2026;42:932-937.
Abstract

MALIK T, Denfhy J, Theinkha Lin H, Mohammed L, et al
Multicentre real-world evaluation of the Haematuria Cancer Risk Score to risk-stratify the detection of bladder cancer in patients referred from primary care.
BJUI Compass. 2026;7:e70233.
Abstract

DA ANUNCIACAO KF, Roquete Amparo T, Dutra Sousa LR, Xavier VF, et al
Mucoadhesive Nanoemulsion Enhances the Antineoplastic Potential of Naringenin in Bladder Cancer Cell Lines.
ACS Omega. 2026;11:30606-30616.
Abstract

LYU G, Li D
Unraveling the Role of miR-33a-5p in Bladder Cancer Progression: Clinical Significance and Functional Pathways.
Comb Chem High Throughput Screen. 2026.
Abstract

FENG W, He W
Integrative multi-omics identifies a glycosylation-based prognostic framework and nominates ALG3 for targeted therapy in bladder cancer.
Discov Oncol. 2026 Jun 7. doi: 10.1007/s12672-026-05387.
Abstract

HU D, Shen C, Liu C, Xie F, et al
NOTCH3 regulates myofibroblastic CAF differentiation via the P62-ROS signaling axis to promote bladder cancer progression.
J Exp Clin Cancer Res. 2026 Jun 6. doi: 10.1186/s13046-026-03751.
Abstract

ZHAO H, Li K, Xu H, Liao J, et al
Multi-dimensional profiling of lactylation-related signatures for prognostic and therapeutic insights in bladder cancer.
Cancer Cell Int. 2026 Jun 6. doi: 10.1186/s12935-026-04364.
Abstract

PETIX M, Polverino F, Quarta L, Filzmayer M, et al
Effect of marital status on years of life lost from metastatic bladder cancer according to sex and race/ethnicity.
Urol Oncol. 2026;44:132-137.
Abstract

SYED P, Islam MK, Kekki H, Terava J, et al
Glycovariant-based diagnosis of bladder cancer using urinary mucin 1 and carcinoembryonic antigen.
J Pharm Biomed Anal. 2026;280:117589.
Abstract

DU R, Yu Z, Liu D
Nanosensor-coated catheters for bladder cancer detection.
Nat Nanotechnol. 2026 Jun 5. doi: 10.1038/s41565-026-02173.
Abstract

TOUMA SAWAYA R, Nasrallah O, El Hajj A, Abdessater M, et al
Impact of CKD on perioperative outcomes following TURBT: a national NSQIP analysis.
World J Urol. 2026;44:411.
Abstract

YAJIMA S, Yoshida S, Chen W, Fukushima H, et al
Mixture cure model analysis of event-free survival in the NIAGARA Trial: Quantifying the cure fraction benefit of perioperative durvalumab in muscle-invasive bladder cancer.
Urol Oncol. 2026;44:120-126.
Abstract

SUGAHARA D, Murofushi KN, Yamashita H, Ogo E, et al
Real-world outcomes of definitive chemoradiotherapy for bladder cancer: a multi-institutional retrospective study in Japan.
Jpn J Clin Oncol. 2026 Jun 5:hyag063. doi: 10.1093.
Abstract

JOHNSON M, Clark M, Whittington C, Newton E, et al
Adverse dermatologic effects of erdafitinib in a patient with metastatic urothelial carcinoma.
Dermatol Online J. 2026;32.
Abstract

SAKAI T, Abe T, Mizuno R, Izumi H, et al
[LYMPH NODE TUBERCULOSIS AFTER INTRAVESICAL BACILLUS CALMETTE-GUERIN THERAPY FOR BLADDER CARCINOMA IN SITU : A CASE REPORT].
Hinyokika Kiyo. 2026;72:171-176.
Abstract

MANGOLD MH, Egen L, Carl N, Renner LV, et al
Radical cystectomy in octogenarians: a propensity score-matched analysis of short-term outcomes.
World J Urol. 2026;44:405.
Abstract

PALAGAN SENOPATI S, Willy Moris N, I Made K, Ida Bagus Oka W, et al
A Case of Urothelial Carcinoma in Situ of the Bladder in Local Dog in Bali, Indonesia.
Arch Razi Inst. 2025;80:1345-1352.
Abstract

METWALLY S, Gil D, Smialek-Bartyzel J, Pabijan J, et al
Matrix Mechanics Governs Mechano-Metabolic Adaptation across Cancer Grades in Bladder Spheroids.
ACS Appl Mater Interfaces. 2026;18:30775-30789.
Abstract

KAN H, Chen M, Hu W, Yang N, et al
Exploring a critical time window for FOXM1-driven bladder injury in chronic arsenic exposure.
Ecotoxicol Environ Saf. 2026;319:120312.
Abstract

WHITE RE, Linscott JA, Pelletier C, Santos E, et al
Optimizing radical cystectomy recovery: The role of modified ERAS in improving postoperative outcomes.
Urol Oncol. 2026;44:316-322.
Abstract

PADICKAKUDY R, Rosa de Pauli L
[Reconstructive aspects of radical cystectomy with orthotopic bladder replacement].
Wien Med Wochenschr. 2026;176.
Abstract

SU X, Duan X, Bai S, Su P, et al
Cellular origins and etiological factors for squamous cell carcinoma and related cancer types of the bladder.
J Pathol. 2026;269:297-313.
Abstract

ZHANG B, Li S, Lv C, Wang W, et al
True Positive 18F-FDG PET/CT and Negative 123I-MIBG SPECT/CT in a Pediatric Patient With Bladder Malignant Paraganglioma.
Clin Nucl Med. 2026 Mar 31. doi: 10.1097/RLU.0000000000006377.
Abstract

ZHENG K, Liu Y, Wang Y, Jing H, et al
An Asymptomatic Urachal Mucinous Adenocarcinoma on FDG PET/CT.
Clin Nucl Med. 2026 Mar 25. doi: 10.1097/RLU.0000000000006357.
Abstract

EICHENAUER R, Johannsen M, Klier J, Konig F, et al
[Current Data from the National Registry for Urothelial Cancer (UroNAT) by d-uo].
Aktuelle Urol. 2026;57:266-269.
Abstract

FREDERIC J, Oladoyin V, Geetha J, Muhammad A, et al
Primary Enteric-type adenocarcinoma of the bladder managed with colon-type chemotherapy: A rare case and literature review.
J Natl Med Assoc. 2026;118:442-445.
Abstract

MAN X, Dong C, Dong A, Song X, et al
FDG PET/CT in a Case of Inflammatory Myofibroblastic Tumor of the Bladder.
Clin Nucl Med. 2026 Feb 13. doi: 10.1097/RLU.0000000000006381.
Abstract

MARTINEZ RODRIGUEZ P, Poza Fernandez A, Garcia Fadrique G, Acedo Gonzalez J, et al
Bladder and rectal cancer development in prostate cancer patients treated with surgery or radiotherapy: A population-based study.
Actas Urol Esp (Engl Ed). 2026;50:501928.
Abstract

BENLIOGLU C, Kalyenci B, Yucel MO, Cift A, et al
A Intravesical Brucella Abortus S19 (BAS19) Vaccine As A Potential Alternative To Bacillus Calmette-Guerin (BCG) Immunotherapy: A Preclinical Study In Rats.
Urol J. 2026;23:12-20.
Abstract

GOMEZ DEL CANIZO C, Fernandez Sanchez N, Gonzalez Ginel I, Hernandez Arroyo M, et al
The use of presurgical urine cytology improves patient selection for a single instillation of MMC.
Actas Urol Esp (Engl Ed). 2026;50:501904.
Abstract

AYTEN A, Ceylan H, Kinik AH, Gelmis M, et al
Is the Modified Frailty Index-5 a reliable predictor of postoperative morbidity in elderly radical cystectomy patients? A comparative study with CCI and G8.
Actas Urol Esp (Engl Ed). 2026;50:501902.
Abstract

YI LIN LEE MC, Camargo JA, Caetano Vilas Boas G, Silva KS, et al
CRISPR/Cas9-mediated miR-21 editing in high-grade urothelial carcinoma cells and its biological effects.
Mol Biol Rep. 2026;53:973.
Abstract

SONG W, Han G, Li Z, Hu J, et al
Single-cell transcriptomics identifies key immune-suppressive cells and their driver genes in the bladder cancer microenvironment with prognostic implications.
Mol Genet Genomics. 2026;301:142.
Abstract

HE YB, Hu J, Liu Z, Xiao ZC, et al
Non-invasive evaluation of muscle invasion and survival prognosis in bladder cancer using enhanced CT-based deep learning radiomics: a multi-center real-world cohort study.
Mil Med Res. 2026;13:100001.
Abstract

KOTOLLOSHI R, Berndt-Paetz M, Lerner E, Najjar G, et al
ZW4864-mediated inhibition of the beta-catenin/BCL9/BCL9L complex reveals therapeutic potential in bladder cancer.
Mol Oncol. 2026 Jun 18. doi: 10.1002/1878-0261.70292.
Abstract

LEI D, Wu JH, Zeng XH, Xu R, et al
Antidiabetic medications and the risk of bladder cancer in patients with diabetes mellitus: A systematic review and meta-analysis.
Urol Oncol. 2026;44:182-194.
Abstract

MUDRAK DA, Ankudavichus VA, Mylnikov AM, Vrabie EE, et al
[Low-grade urothelial carcinoma of the bladder with osteoclast-like differentiation as part of primary multiple malignancies. Case report and literature review].
Arkh Patol. 2026;88:47-53.
Abstract

GU Z, Zhu H, Zhang Y, Jiang J, et al
Harnessing a cRGD-Targeted Schottky Junction MXene Nanocomposite for Potent Bladder Cancer Therapy: Dual-Modal PTT/PDT Effects with Immune Activation and Favorable Comparison to Doxorubicin.
Int J Nanomedicine. 2026;21:597220.
Abstract

MORIWAKE T, Tominaga Y, Ozaki N, Matsumoto Y, et al
Transcystostomal Bladder Tumor Resection in a Transgender Man After Phalloplasty.
Asian J Endosc Surg. 2026;19:e70330.
Abstract

HUANG L, Li H
Steroidogenesis is associated with bladder cancer progression via reprogramming the metabolic landscape of the tumor immune microenvironment.
Discov Oncol. 2026 Jun 17. doi: 10.1007/s12672-026-05445.
Abstract

JOKELAINEN O, Ruotsalainen L, Ikonen E, Nykopp TK, et al
The Paris System for reporting urinary cytology in the follow-up of non-muscle-invasive bladder cancer.
Urol Oncol. 2026;44:173-181.
Abstract

ZHANG H, Li D, Su M, Zheng Z, et al
Lactate-driven H3K18 lactylation promotes cisplatin resistance in bladder cancer via HNRNPF-Parkin mediated mitophagy.
Drug Resist Updat. 2026;88:101435.
Abstract

VULSTEKE C, Ullen A
Perioperative Enfortumab Vedotin and Pembrolizumab in Bladder Cancer. Reply.
N Engl J Med. 2026;394:2383.
Abstract

COLD KM, Vasquez JL
Perioperative Enfortumab Vedotin and Pembrolizumab in Bladder Cancer.
N Engl J Med. 2026;394:2382-2383.
Abstract

BALCI S, Tanriverdi R, Nebioglu A, Yildirim DD, et al
Elevated serum Raftlin levels in non-muscle invasive bladder cancer: diagnostic implications and rs690037 genotype analysis.
Rev Assoc Med Bras (1992). 2026;72:e20251628.
Abstract

ZHAO S, Xu S, Cao K, Shi Y, et al
Deficiency of LIMA1 accelerates bladder cancer progression by disrupting PINK1/Parkin-mediated mitophagy.
Cell Death Discov. 2026 Jun 16. doi: 10.1038/s41420-026-03136.
Abstract

SCILIPOTI P, de Angelis M, Thibault C, Slusarczyk A, et al
Surrogacy of Intermediate Clinical Endpoints for Overall Survival in Patients With Localized Muscle-Invasive Bladder Cancer.
J Natl Compr Canc Netw. 2026 Jun 16:1-8. doi: 10.6004/jnccn.2026.7014.
Abstract

XIONG Y, Xiao J, Jing L, Bian Y, et al
Machine-learning-assisted artificial olfactory colorimetric sensor array for bladder cancer early detection from urinary volatile organic compounds.
Biosens Bioelectron. 2026;311:118926.
Abstract

LI C, Yang Z, Zhang J, Yan X, et al
Filamin C activates MAPK/ERK signaling to facilitate epithelial-mesenchymal transition in bladder cancer.
Clin Transl Oncol. 2026 Jun 16. doi: 10.1007/s12094-026-04460.
Abstract

SHARMA A, Kumar A, Patel P, Kurmi BD, et al
Recent Advances in Intravesical Chemotherapy: Insights into the FDA-Approved Gemcitabine-Releasing TAR-200 System for Bladder Cancer Management.
Anticancer Agents Med Chem. 2026.
Abstract

WANG Z
Spatial profiling in bladder cancer.
Nat Cell Biol. 2026;28:1089.
Abstract

YANG Z, Ma J, Qiang Z, Xie W, et al
ALKBH2 promotes the Warburg effect and bladder cancer progression under hypoxic conditions via the PI3K/AKT pathway.
Clin Exp Med. 2026 Jun 15. doi: 10.1007/s10238-026-02212.
Abstract

WENG M, Wang X, Zhan Y, Guo Y, et al
Machine learning-based identification of basement membrane-related signature to predict recurrence and immunotherapy benefit in bladder cancer.
Immunol Res. 2026;74:59.
Abstract

CITAKKUL I, Temi YB, Baydar E, Sahin E, et al
Percutaneous nephrostomy as a marker of clinical vulnerability in non-metastatic muscle-invasive bladder cancer: prognostic and infectious implications.
Front Oncol. 2026;16:1820805.
Abstract

LI C, Yang Z, Zhang J, Yan X, et al
ADGRD1 promotes bladder cancer progression and angiogenesis via the PI3K/AKT/mTOR-mediated pro-angiogenic secretome.
Front Oncol. 2026;16:1817872.
Abstract

HE Q, Chen Y, Zhang T, Sheng W, et al
TURBT versus RC in T1N0M0 non-urothelial bladder cancer: a population-based study.
Front Oncol. 2026;16:1802962.
Abstract

REICHARD C, Trainer A, Grant K, Asgarisabet P, et al
Analysis of real-world re-induction outcomes with nadofaragene firadenovec in patients with Bacillus Calmette-Guerin (BCG)-unresponsive non-muscle-invasive bladder cancer.
Transl Androl Urol. 2026;15:180.
Abstract

LI Y, Liu Y, Xi J, Li X, et al
Super-selective bladder arterial chemotherapy for muscle invasive bladder cancer.
Transl Androl Urol. 2026;15:172.
Abstract

KOGUCHI D, Shiba I, Shiono Y, Matsumoto K, et al
Diagnostic potential of urinary PENK methylation for bladder cancer in patients with hematuria: insights from a prospective and multi-institutional study.
Transl Androl Urol. 2026;15:145.
Abstract

CHEN Y, Zheng J, Li D, Wu Q, et al
Association between prognostic nutritional index (PNI)/Controlling Nutritional Status (CONUT) score and prognosis in patients with bladder cancer: a systematic review and meta-analysis.
Transl Androl Urol. 2026;15:167.
Abstract

WANG T, Wei B
Site-specific heterogeneity in treatment response among patients with metastatic bladder cancer: implications for oligometastatic disease-a retrospective cohort study.
Transl Androl Urol. 2026;15:153.
Abstract

WU Q, Qing X, Gao W
Dietary patterns and knowledge-attitude-practice factors are associated with late recurrence of non-muscle-invasive bladder cancer: a case-control study.
Front Nutr. 2026;13:1842495.
Abstract

JIN M, Cai Z, Bu M, Liu J, et al
From molecular networks to translational intervention: current progress in the mechanisms of gemcitabine resistance in bladder cancer.
Front Immunol. 2026;17:1860957.
Abstract

PENG L, Zhang Y, Zhao A, Li R, et al
Benchmarking Large Language Models for Bladder Cancer: Comparative Knowledge Retrieval and Clinical Reasoning of DeepSeek and ChatGPT.
Ann Surg Oncol. 2026 Jun 14. doi: 10.1245/s10434-026-19745.
Abstract

CELLA L, Fasulo V, Uleri A, Piccolini A, et al
Xpert bladder cancer detection and monitor in urothelial carcinoma: systematic review and meta-analysis.
Sci Rep. 2026 Jun 14. doi: 10.1038/s41598-026-57805.
Abstract

XIAO K, Zhou B, Feng D, Yang S, et al
Nanotechnology-enabled precision strategies for bladder cancer: from in vitro diagnostics to in vivo therapy.
J Nanobiotechnology. 2026 Jun 13. doi: 10.1186/s12951-026-04635.
Abstract

HU X, Yang Z, Shi Q, Yu T, et al
A NEK2/ZWINT-NDC80 regulatory axis drives bladder cancer progression and chemoresistance.
Discov Oncol. 2026 Jun 13. doi: 10.1007/s12672-026-05435.
Abstract

WANG C, He S, Zhang B, Zhang S, et al
Development and multicohort validation of an interpretable postoperative model for intravesical recurrence after radical nephroureterectomy in upper tract urothelial carcinoma.
World J Urol. 2026;44:425.
Abstract

GAO S, Zhao X, Jiang P, Liu B, et al
Dual MicroRNA Simultaneous One-Step Profiling via Filler-Mediated Quantum Dot DNA Nanospheres for Bladder Cancer Screening.
ACS Nano. 2026 Jun 13. doi: 10.1021/acsnano.6c03179.
Abstract

TRABELSSI M, Lamy PJ, Daures JP, Perriard F, et al
Xpert(R) bladder Cancer monitor urine test for non-muscle-invasive bladder cancer surveillance: a prospective clinical trial.
Clin Chim Acta. 2026 Jun 12:121169. doi: 10.1016/j.cca.2026.121169.
Abstract

SUN D, Han C, Li D, Li P, et al
A blood-urine regulatory axis: Tumor-derived factors reprogram urine-derived stem cells via CXCL2/CXCR2/ERK signaling to drive bladder cancer stemness.
Cancer Lett. 2026;656:218675.
Abstract

HE Z, Liu Y, Jiang Q, Hou F, et al
Application Value of Radiomics-Based Machine Learning for Preoperative Risk Stratification of Bladder Cancer: Systematic Review and Meta-Analysis.
J Med Internet Res. 2026;28:e81084.
Abstract

AHMADI P, Deyhimfar R, Haghani I, Mohammadi A, et al
Citalopram enhances cisplatin-induced cytotoxicity in T24 bladder cancer cells: An in vitro study.
Exp Mol Pathol. 2026;147:105056.
Abstract

ANDRZEJCZAK A, Krajewski W, Jaskula E, Chorbinska J, et al
Polymorphisms in immune checkpoint genes might influence bladder cancer risk and clinical outcome.
Hum Immunol. 2026;87:111783.
Abstract

MUSCO J, Qiao B, Homich A, Kuliszewski MG, et al
Evaluation of Cancer Cases Reported through Inter-Registry Data Exchange in New York State.
J Registry Manag. 2026;53:15-21.
Abstract

SARRIO-SANZ P, Segura-Heras JV, Artes-Artes M, Belda-Ferre M, et al
External Validation of A Decision Tree Model for Predicting Cancer-Specific Mortality After Radical Cystectomy: A Multi-Center Study in South-East Spain.
Arch Esp Urol. 2026;79:567-575.
Abstract

STUCKEY JI, Mertz JA, Wilson JE, Williamson KE, et al
Covalent PPARgamma inverse agonism by FX-909 reveals mechanistic insights into therapeutic targeting of PPARgamma/RXRalpha-activated urothelial carcinoma.
Cell Chem Biol. 2026;33:837-847.
Abstract

ZHANG F, An J, Zhao L, Cao Y, et al
Artificial Intelligence-Powered Cystoscopy Diagnostic Support System: Clinical Application of Multiarchitecture Deep Learning Models.
J Endourol. 2026;40:925-934.
Abstract

MARCHETTI KA, Asees A, Bokil AP, Medich M, et al
Survivor-identified barriers and facilitators to acute phase recovery following radical cystectomy.
Urol Oncol. 2026;44:234-242.
Abstract

ABDELSHAFI A, Mohamed T, Mohamed H, Mohammed YA, et al
Hand-sewn versus stapled ileo-ileal anastomosis following radical cystectomy: A systematic review and meta-analysis.
Urol Oncol. 2026;44:215-224.
Abstract

LIU J, Jiang W, Wang X, Azoitei A, et al
CRISPR and compound screens in a novel ex vivo tissue model identify DDR1 and ETA as regulators of cancer cell invasion.
Cell Mol Biol Lett. 2026;31:84.
Abstract

YORULMAZ EM, Akin Y, Donmez K, Gorgel SN, et al
Predictive value of the HAS-BLED score in the course of radical cystectomy: A pilot study.
Urol Oncol. 2026;44:297-306.
Abstract

LEON P, Levi LI, Long Depaquit T, Audenet F, et al
Guidelines from the cancer (CCAFU) and infection disease (CI-AFU) committees of the French Association of Urology for the management of adverse events and complications of BCG.
Fr J Urol. 2026;36:103105.
Abstract

ERIKSSON P, Cotillas EA, Mattsson CA, Zadoroznyj A, et al
Stage-Independent Real-Time Subtype Classification and Comprehensive Biopsy Profiling of Urothelial Carcinomas by the Lund Taxonomy System.
Mod Pathol. 2026;39:100997.
Abstract

GORAYA DS, Cray M
Partial cystectomy and adjuvant chemotherapy are associated with prolonged survival in dogs and cats with nontrigonal urothelial carcinoma (2010-2014).
J Am Vet Med Assoc. 2026;264:1-7.
Abstract

PERRET RE, Hruby M, Dehner CA, Siegmund SE, et al
Urinary Bladder Leiomyomas: A Clinicopathological Series With Hormone Receptor, HMGA2, 2SC, and Fumarate Hydratase Status Assessment.
Am J Surg Pathol. 2026;50:705-715.
Abstract

SAGAWA T, Ishida T, Jobu K, Sakoda R, et al
Risk factors for intraoperative hypotension associated with the use of oral 5-aminolevulinic acid as a photodynamic diagnostic agent in transurethral resection of bladder tumors: A meta-analysis.
Photodiagnosis Photodyn Ther. 2026;59:105403.
Abstract

INOMATA H, Asatani S, Ikumi N, Uchikawa M, et al
Malignancy-associated Multicentric Reticulohistocytosis Mimicking Dermatomyositis-like Features, with a Significant Ultrasound Finding.
Intern Med. 2025 Nov 6. doi: 10.2169/internalmedicine.6032.
Abstract

KOBAYASHI G, Sekino Y, Hayashi T, Nakahara H, et al
Nectin-4 expression in upper and lower tract urothelial carcinoma: correlation with early-stage disease and prognostic relevance.
Virchows Arch. 2026;488:1227-1242.
Abstract

GONZALGO ML
An Unprecedented Era of Innovation in Non-Muscle-Invasive Bladder Cancer.
Urol Clin North Am. 2026;53:xv-xvi.
Abstract

LOUGHLIN KR
Hubert Humphrey's Bladder Cancer: If He Could Have Time Traveled, Would that Have Changed the Outcome?
Urol Clin North Am. 2026;53:xiii-xiv.
Abstract

HARGIS P, Baker H, Wiesen B, Kukreja J, et al
Key Clinical Trials Shaping the Future of Superficial High-Risk Bladder Cancer Management.
Urol Clin North Am. 2026;53:509-516.
Abstract

JIANG T, Zhao CC, Liao JC
Future Directions: Artificial Intelligence and Digital Tools in Bladder Cancer Care.
Urol Clin North Am. 2026;53:497-508.
Abstract

GUPTA VK, Joyce DD, Wymer KM, Sharma V, et al
Economic Considerations in the Management of Superficial Bladder Cancer.
Urol Clin North Am. 2026;53:487-496.
Abstract

FU MZ, Sykes J, Pfail J, Packiam VT, et al
Patient-Centered Approaches to Non-Muscle-Invasive Bladder Cancer Care.
Urol Clin North Am. 2026;53:475-486.
Abstract

ZHU S, Washington SL 3rd, Sekar R, Chu CE, et al
Impact of Social and Structural Determinants of Health on Bladder Cancer Outcomes: Focus on Non-Muscle-Invasive Disease.
Urol Clin North Am. 2026;53:463-474.
Abstract

TALLMAN JE, Goh AC
Management of High-Risk Non-Muscle-Invasive Bladder Cancer.
Urol Clin North Am. 2026;53:441-452.
Abstract

NOLAZCO JI, Yim K, Salari K
Molecular and Genetic Insights for Personalized Treatment of Non-Muscle-Invasive Bladder Cancer.
Urol Clin North Am. 2026;53:429-440.
Abstract

WANG B, Isali I, Calaway A, Bukavina L, et al
Emerging Intravesical Therapies for Non-Muscle-Invasive Bladder Cancer.
Urol Clin North Am. 2026;53:393-412.
Abstract

CHOU WH, Lechner A, Liu JJ
Role of Enhanced Imaging in Superficial Bladder Cancer Management.
Urol Clin North Am. 2026;53:377-392.
Abstract

HIGGINS MI, Rivera Lopez CA, Lokeshwar SD, Patel SH, et al
Advances in Diagnosis of Non-Muscle-Invasive Bladder Cancer: A Review.
Urol Clin North Am. 2026;53:353-364.
Abstract

AKINSOLA O, Bharadwaj M, Psutka SP
Epidemiology and Risk Factors for Non-Muscle-Invasive Bladder Cancer: Insights into Prevalence, Risk Stratification, and Implications for Early Diagnosis.
Urol Clin North Am. 2026;53:343-352.
Abstract

TAO S, Zhong Y, Ju J, Sun X, et al
Programmable multivalent aptamer-drug conjugates enable stable tumor targeting and enhanced therapy for advanced bladder cancer.
Biomaterials. 2026;335:124396.
Abstract

ABRAHIMI P, Khan JF, Duren-Lubanski A, Cai W, et al
Intravesical mesothelin-based CAR T cells targeting MUC16 effectively control bladder cancer in preclinical models.
J Exp Med. 2026;223:e20250699.
Abstract

BARBOSA GR, Dal Col LSB, Bighetto CC, de Godoy MCX, et al
BCG Induces PD-1 Upregulation on Circulating CD8(+) T Cells and IL-6 and IL-8 Secretion In Vitro.
Oncol Res. 2026;34:20.
Abstract

YIN Z, Zhen X, Li H, Duan H, et al
Germinal Center-Like Tertiary Lymphoid Structures Mark Immune Responsiveness and Enable Checkpoint Immunotherapy in Bladder Cancer.
Oncol Res. 2026;34:25.
Abstract

XI Z, Ge H, Zhu J, Yang Q, et al
Comparison of the efficacy of different orthotopic neobladder reconstruction techniques following radical cystectomy for bladder cancer: a network meta-analysis.
Front Oncol. 2026;16:1857787.
Abstract

BILGETEKIN I, Demir N, Eraslan E, Akdagcik Z, et al
Prognostic Value of the Inflammatory Burden Index (IBI) in Metastatic Urothelial Carcinoma Prior to First-Line Therapy.
Medicina (Kaunas). 2026;62:1027.
Abstract

KLIMCZAK A, Krawczenko A, Stamnitz S, Bielawska-Pohl A, et al
Immunotoxin WPD101a as a Potential Drug Candidate for Targeted Therapy in Muscle Invasive Bladder Cancer Expressing IL-13Ralpha2-In Vitro Study.
Int J Mol Sci. 2026;27:5566.
Abstract

BAEK SW, Yoon SY, Kim SK, Leem SH, et al
Therapy-Driven Molecular Evolution of Bladder Cancer: Roles of Cellular Plasticity and Tumor Microenvironment.
Int J Mol Sci. 2026;27:5152.
Abstract

HUANG A, Waltzer WC, Hung M, Darras FS, et al
Identification of circCIAO1(5) and circMALAT1 as Novel Potential Biomarkers for Bladder Cancer Monitoring Based on the Binding to miR-101-3p.
Cancers (Basel). 2026;18:1968.
Abstract

FENG T, Jiang L, Zhuang J, Cai L, et al
PD-L1+ CTCs Are Associated with Adverse Pathological Features and Unfavorable Prognosis in Bladder Cancer.
Diagnostics (Basel). 2026;16:1776.
Abstract

CHEN J, An Y, Tong A, Kang S, et al
Bacteroides fragilis toxin promotes gall bladder cancer in mice.
Nat Microbiol. 2026 Jun 25. doi: 10.1038/s41564-026-02404.
Abstract

CHEN L, Liang C
Can manual gemcitabine instillation or tumor microenvironment-based selection enhance the efficacy of TAR-200 in bladder cancer?
Transl Oncol. 2026;71:102875.
Abstract

CHENG K, Zhang HB, Xie HR, Wang L, et al
PRDX1 as a novel urinary biomarker for bladder cancer: Development of an integrated fiber optic sensing platform.
Talanta. 2026;311:130162.
Abstract

WEI L, Guo Y, Hao Y, Ji L, et al
FASN Promotes Malignant Progression of Bladder Cancer by Regulating Lipid Metabolism via the ERK/PPAR Pathway.
Cell Biochem Biophys. 2026 Jun 25. doi: 10.1007/s12013-026-02104.
Abstract

SINGH R, Up S, Garg M
Association of Epithelial-to-Mesenchymal Transition Related Markers With Clinical Outcome in Non-Muscle Invasive and Muscle Invasive Bladder Cancer Patients.
Cell Biochem Biophys. 2026 Jun 25. doi: 10.1007/s12013-026-02106.
Abstract

PEREIRA M, Vale N
Repurposing Antiretroviral Drugs for Urological Cancers: Differential Effects of Protease Inhibitors and NNRTIs on Prostate and Bladder Cancer Cells.
Cells. 2026;15:1045.
Abstract

SCILIPOTI P, Slusarczyk A, Thibault C, Domanski P, et al
Evaluating the Surrogacy of Pathological Complete Response at Radical Cystectomy in Neoadjuvant-based Muscle-invasive Bladder Cancer Trials.
Eur Urol Oncol. 2026 Jun 25:S2588-9311(26)00174.
Abstract

SLUSARCZYK A, Moschini M, Krajewski W, Scilipoti P, et al
Predicting the Development of BCG-unresponsive Disease Among Patients with High-grade Non-muscle-invasive Bladder Cancer: An International Multicenter Analysis.
Eur Urol Oncol. 2026 Jun 25:S2588-9311(26)00173.
Abstract

ZHANG Q, Zhang Q, Guo C, Peng C, et al
scTumorDrug: predicting cell-type-specific drug responses for heterogeneous tumors.
Brief Bioinform. 2026;27:bbag337.
Abstract

PENG M, Shen L, Song D, Wen L, et al
Diagnostic Value of Spectral CT-Derived Extracellular Volume Fraction in the Early Detection of Sigmoid Colon Metastasis from Bladder Cancer: A Case Report.
Surg Case Rep. 2026;12:26-0147.
Abstract

JIN ZR, Dong CY, Li YJ, Zou Y, et al
Efficacy of Disitamab Vedotin in Treating HER2 2+/FISH-Bladder Cancer: A Case Report.
Clin Case Rep. 2026;14:e72855.
Abstract

ZHANG S, Zhang H, Dong X, Qi Z, et al
Case Report: early regression and bladder-intact survival after limited-course immunotherapy-based systemic therapy in two patients with clinically staged bulky muscle-invasive bladder cancer.
Front Immunol. 2026;17:1866469.
Abstract

HAQ F, Chinchankar S, Ambite I, Ahmadi S, et al
Identification of alpha1-oleate as a potent regulator of adipokine-dependent metabolism, in bladder cancer tissue.
Cancer Metab. 2026;14:21.
Abstract

CHEN X, Tang Q, Wang Y, Zhang J, et al
LncRNA ACTA2-AS1 acts as a bladder cancer prognostic biomarker and blocks malignant advance via miR-148b-3p/DNAJB4.
World J Surg Oncol. 2026 Jun 23. doi: 10.1186/s12957-026-04447.
Abstract

LI X, Yang J, Cha J, Xie H, et al
Multi-omics integration and clinical validation identify CKAP2 as a diagnostic biomarker for bladder cancer.
World J Surg Oncol. 2026 Jun 23. doi: 10.1186/s12957-026-04464.
Abstract

GRANDE E, Sibai M, Grases D, Andrada E, et al
Spatial architecture contributes to failure of bulk biomarker-guided neoadjuvant immunotherapy selection in bladder cancer: The DUTRENEO study.
Cell Rep Med. 2026 Jun 23:102878. doi: 10.1016/j.xcrm.2026.102878.
Abstract

PINHEIRO LCL, de Souza Martins MAF, Turim MFV, da Silva IM, et al
Interplay between CDH1 polymorphisms, haplotypes, and genomic repetitive elements in urothelial bladder cancer prognosis.
Mol Biol Rep. 2026;53:990.
Abstract

MARI A, Lambertini L, Albisinni S, Contieri R, et al
The old standard still holds up: reading CREST, POTOMAC, and ALBAN in BCG-naive high-risk non-muscle-invasive bladder cancer.
Minerva Urol Nephrol. 2026 Jun 23. doi: 10.23736/S2724-6051.26.07132.
Abstract

LEDDEROSE S, Schwenke J, Eismann L, Rodler S, et al
Ectonucleotidases CD39 and CD73 expression levels are independent and inverse predictors of survival in muscle-invasive bladder cancer.
J Pathol Clin Res. 2026;12:e70102.
Abstract

LI B, Yang Z, Pei Y, Wang Y, et al
Navigating the Evolution of Urothelial Carcinoma Treatment: From Chemotherapy to Immunotherapy.
Cancer Med. 2026;15:e71859.
Abstract

MA L, Zhang YY, Wang L, Yue FK, et al
[MiR-527 targeting Bcl-2 inhibits migration and promotes apoptosis in bladder urothelial cell carcinoma].
Zhonghua Zhong Liu Za Zhi. 2026;48:793-801.
Abstract

YU Z, Zhang J, Wang Z, Wei S, et al
H3K18la-PSMG1 Axis in Bladder Cancer Progression: Curcumin as a Therapeutic Candidate.
Int J Biol Sci. 2026;22:5953-5968.
Abstract

ZHANG K, Ren Y
Bladder-Preserving Platforms for BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer.
Onco Targets Ther. 2026;19:614003.
Abstract

WU J, Liang P, He Y, Zhang M, et al
VSIG2 is associated with an immune-cold microenvironment and reduced response to PD-1 blockade in bladder cancer.
Front Cell Infect Microbiol. 2026;16:1859986.
Abstract

LINEHAN J, Agarwal PK, Penny X, Kates M, et al
Early Efficacy and Exploratory Biomarker Data of Bel-sar in Patients with Intermediate-risk and High-risk Non-muscle-invasive Bladder Cancer.
Eur Urol Open Sci. 2026;89:77-88.
Abstract

TONG Z, Yu T, Li Z, Zhang F, et al
Ultra-sensitive urine DNA methylation test enables early and accurate detection of bladder cancer.
Epigenomics. 2026;18:709-721.
Abstract

AYDOGDU C, Wang B, McSweeney S, Pieretti A, et al
Preoperative Tumor-Informed ctDNA for Prediction of Nodal Metastases at Radical Cystectomy in Bladder Cancer.
Ann Surg Oncol. 2026 Jun 21. doi: 10.1245/s10434-026-20022.
Abstract

XU H, Wu J, Bai Y, Qin J, et al
Bio-inspired indocyanine green supramolecular assemblies for high-contrast NIR-II imaging and cooperative dual-targeting of bladder cancer.
Biomaterials. 2026;335:124397.
Abstract

PARK IW, Uk PM, Lim B, Jeong IG, et al
Nephroureterectomy with ileal cuff for upper tract recurrence after radical cystectomy: oncologic and survival outcomes.
World J Urol. 2026;44:443.
Abstract

PARIZI MK, D'Andrea D, Pradere B, Teoh JY, et al
Prognostic Factors for Recurrence and Survival After Radical Cystectomy for Non-muscle-invasive Bladder Cancer: A Multicenter Analysis of 1032 Patients.
Eur Urol Oncol. 2026 Jun 20:S2588-9311(26)00168.
Abstract

JACKSON-SPENCE F, Aspden D, Chauhan V, Diaz S, et al
Characteristics of Patients With Advanced or Metastatic Urothelial Cancer Unable to Complete Six Cycles Chemotherapy.
Cancer Med. 2026;15:e71873.
Abstract

ROVIELLO G, Gambale E, Giorgione R, Basso U, et al
Clinical and pathological predictors of early recurrence after neoadjuvant cisplatin gemcitabine in muscle invasive bladder cancer in the RealBLADDER study.
Sci Rep. 2026 Jun 19. doi: 10.1038/s41598-026-58269.
Abstract

HOF JP, Galesloot TE, Aben KKH, Bryan RT, et al
Comprehensive genome-wide association study into multiple recurrence and progression risk in non-muscle invasive bladder cancer.
Cancer Genet. 2026;306-307:106-115.
Abstract

ZAHRAN AA, Shokeir AA, Serria MS, Awadalla A, et al
Predictive value of toll-like receptors, myeloid differentiation factor 88, and nuclear factor kappa-B regarding the response to Bacillus Calmette-Guerin intravesical therapy in patients with high-risk non-muscle-invasive bladder cancer: A controlled
Urol Oncol. 2026;44:195-210.
Abstract

ROSENBERG JE, O'Donnell PH, Petrylak DP, Flaig TW, et al
EV-103 dose escalation/cohort A: 5-year follow-up of enfortumab vedotin plus pembrolizumab in previously untreated locally advanced/metastatic urothelial carcinoma.
ESMO Open. 2026;11:107700.
Abstract

HEIDENREICH A
[Non-muscle-invasive urothelial carcinoma of the bladder: time for a de-escalation of treatment and aftercare].
Urologie. 2026;65:710-718.
Abstract

ZOCK JP, Rijs KJ, Peters S, Vlaanderen JJ, et al
Associations between occupational exposure to chromium (VI) and cancers of the oral cavity, small intestine, pancreas, prostate and urinary bladder: systematic review and meta-analyses.
Occup Environ Med. 2026;83:162-169.
Abstract

RAUCH S, Lange F, Hartmann A, Eckstein M, et al
[Diagnostic and predictive molecular pathology of urothelial carcinoma : Current status and outlook for the future].
Pathologie (Heidelb). 2026;47:254-261.
Abstract

SMEULDERS N, Gaze MN, Guerin F, Rogers T, et al
Surgical nodal staging in rhabdomyosarcoma of the bladder and/or prostate with or without nodal or metastatic spread. A report from the European Paediatric Soft-Tissue Sarcoma Study Group (EpSSG).
J Pediatr Surg. 2026;61:163162.
Abstract

BEN KRIDIS W, Khanfir A
Adjuvant PD-1 Inhibitors After Radical Surgery for High-Risk Muscle-Invasive Urothelial Carcinoma: A Systematic Review and Meta-Analysis of Phase 3 Trials.
Urol Pract. 2026;13:450-458.
Abstract

COVOTTA M, Claroni C, Ceccarelli V, Morettini L, et al
Prediction of postoperative complications after robotic radical cystectomy: comparison of four preoperative scores.
J Robot Surg. 2025;20:118.
Abstract

BDIOUI A, Mahmoudi A, Lajmi Z, Krifa M, et al
Prognostic value of tumor budding in muscle-invasive urothelial carcinoma of the bladder.
J Egypt Natl Canc Inst. 2025;37:76.
Abstract

KHALIL Y, Sun YQ, Mai XM
Nonexercise estimated cardiorespiratory fitness in relation to incidence of urinary tract, bladder and kidney cancer in the HUNT study.
Sci Rep. 2025;15:45231.
Abstract

PLYMOTH M, C CW, Harvey R, Crighton T, et al
Disseminated Bacillus Calmette-Guerin infection following concurrent intravesical BCG therapy and immune checkpoint inhibitior therapy: a case report.
BMC Infect Dis. 2025;25:1575.
Abstract

DAGNINO F, Beatrici E, Qian Z, Stelzl D, et al
Robotic versus open radical cystectomy: factors influencing approach Selection, predictors of surgical Conversion and their implications for patient outcomes.
World J Urol. 2025;43:647.
Abstract

CHEN H, Weng Y, Zheng D, Li T, et al
Heterogeneity of urinary system tumors: novel avenues for targeted therapy and precision medicine.
J Adv Res. 2026;85:837-852.
Abstract

GOBINET L, Klein C, Brunelle S, Illy M, et al
Can bladder MRI avoid systematic second TURBT for patients with high-risk NMIBC?
World J Urol. 2025;43:612.
Abstract

BOTROUS S, Elmaghraby A, Achy SE, Mustafa Y, et al
Prophylactic role of artemisinin in modulating FGFR3, HRAS, and TP53 to prevent early-stage urothelial carcinoma in BBN-induced mouse models.
BMC Biotechnol. 2025;25:102.
Abstract

LEE C, Nam W, Kim CW, Yoon YS, et al
Clinical outcomes of neobladder or augmentation after cystectomy in locally advanced colorectal cancer involving urinary tract: case series.
BMC Urol. 2025;25:221.
Abstract

PICCOLINI A, Paciotti M, Korn SM, Qian Z, et al
Time to Treatment Initiation and Survival in Patients With Muscle-Invasive Bladder Cancer (MIBC).
Clin Genitourin Cancer. 2026 Jun 5:102595. doi: 10.1016/j.clgc.2026.102595.
Abstract

AL-ASFORY K, Mortada WI, El-Khawaga OY, Magar RW, et al
Mentha-derived green synthesized ZnO nanoparticles potentiate methotrexate induced molecular and migratory inhibition via gene expression modulation in T24 bladder cancer cells.
Nanomedicine. 2026 Jul 3:102991. doi: 10.1016/j.nano.2026.102991.
Abstract

CHEN N, Chen L, Cai J, Tan M, et al
Extraperitoneal Single-Port Robotic-Assisted Radical Cystectomy with Orthotopic Ne-obladder: Technique and Surgical Considerations.
Int Braz J Urol. 2027;53:e20260422.
Abstract

BIDEGAIN GARBALA E, Arteaga Mazuelas M, Jarne Betran V, Abinzano Guillen ML, et al
[Subacute meningoencephalitis following intravesical BCG instillation immunotherapy].
An Sist Sanit Navar. 2026;49:e1145.
Abstract

YE Z, Cui W, Theodorescu D, Finkelstein J, et al
Estimating Mosaic Loss of the Y Chromosome in Male Bladder Cancer Participants Using "All of Us" Data.
Stud Health Technol Inform. 2026;338:443-447.
Abstract

LAO J, Yuan X, Liang S, Deng K, et al
Targeted Delivery of Indole-3-Pyruvic Acid Suppresses Macrophage Ferroptosis to Enhance CD8(+) T Cell-Mediated Immunotherapy Response in Bladder Cancer.
Adv Sci (Weinh). 2026 Jul 2:e76319. doi: 10.1002/advs.76319.
Abstract

XIE P, Wang Y, Lu L, Chen J, et al
HER2 assessment in urothelial carcinoma: standardization challenges and the path forward.
Cancer Metastasis Rev. 2026;45:44.
Abstract

MOMENAH MA, Al-Qahtani WS
An exploratory study of BLCA-4 expression, STR analysis, and urothelial cytology in smokers versus non-smokers with bladder cancer.
Front Oncol. 2026;16:1851761.
Abstract

ZHANG X, Xin P, Du Y, Wang R, et al
Biomimetic delivery of a STING agonist via tumor antigen-primed dendritic cell membrane nanovesicles for bladder cancer immunotherapy.
Mater Today Bio. 2026;39:103333.
Abstract

GUO E, Chen L, Li Y, Fan P, et al
A Quantitative Modification of VI-RADS for Bladder Cancer at the Ureteral Orifice: A Reader Study on MRI With Varying Experience Levels.
J Magn Reson Imaging. 2026 Jul 2. doi: 10.1002/jmri.70401.
Abstract

CHEN Z, Wang S, Sun Z, Liao H, et al
An AI-Driven Multi-Omics Framework Identifies CASP8 as a Clinically Actionable Pyroptosis Biomarker in Bladder Cancer.
Biofactors. 2026;52:e70130.
Abstract

RODRIGUEZ-PARRAS P, Angel Arrabal-Polo M, Arrabal-Martin M
Circulating Tumor DNA After Radical Cystectomy as a Marker of Minimal Residual Disease in Muscle-Invasive Bladder Cancer: A Literature Review.
Clin Genitourin Cancer. 2026;24:102596.
Abstract

KOHLI M, Goel S, Iqbal A, Aggarwal A, et al
Impact of 18-FDG PET-CT on the preoperative staging and management of Incidental Gall Bladder Cancer (IGBC)- A prospective study from a tertiary care centre in North India.
Eur J Surg Oncol. 2026;52:111982.
Abstract

ODAGIRI K, Tasaki Y, Naiki T, Morikawa T, et al
Elevation of Eosinophil Proportion After Pembrolizumab Increases the Risk of Immune-Related Adverse Events in Patients With Bladder Cancer.
Cancer Med. 2026;15:e72072.
Abstract

BULUT AS, Kizilkan Y
Evaluation and comparison of voided urine and bladder washing cytologies according to the Paris system.
Rev Assoc Med Bras (1992). 2026;72:e20251936.
Abstract

NOVIARDI DEPP, Seputra KP, Daryanto B, Dhani FK, et al
Atypical urothelial cells investigation with automated urinalysis and expert review of microscopic sediment as early parameter for suspected bladder cancer patients.
Arch Ital Urol Androl. 2026;98:15595.
Abstract

QIU H, Du H, Li X, Wang X, et al
Urinary tract infection caused by rare yeast Vanrija humicola in a urothelial carcinoma patient: a case report and literature review.
Front Immunol. 2026;17:1845780.
Abstract

NOHMI RL, Marques FC, Brito HC, Leite LM, et al
Role of Postoperative Radiation Therapy After Radical Cystectomy for Bladder Cancer: A Systematic Review and Meta-Analysis.
Adv Radiat Oncol. 2026;11:102075.
Abstract

SHIRAISHI Y, Furubayashi N, Tsujita J, Takayama A, et al
Ureteral Orifice Stricture After Transurethral Resection of Bladder Tumors Involving the Ureteral Orifice or Adjacent Area: Clinical Course and Outcomes.
In Vivo. 2026;40:2327-2334.
Abstract

KUO YC, Wang HY, Liao TL, Weng YS, et al
A miR-124-3p/PKC-delta Regulatory Axis Restrains Bladder Cancer Growth and Malignant Progression.
In Vivo. 2026;40:1992-2002.
Abstract

ATIA N, Osman Y, Abdel-Aziz AF, Refaat S, et al
Angiotensin Converting Enzyme (ACE) insertion/deletion (rs1799752) gene polymorphism and bladder cancer aggressiveness in Egyptian patients: A pilot case-control study.
Mol Biol Rep. 2026;53:1058.
Abstract

ANING J, Catto JWF, Martin R, Chatterton K, et al
State of the nation: Understanding the current NHS treatment pathway to identify opportunities to advance future care of patients with high-risk non-muscle invasive bladder cancer in the UK (SPAN-UK).
BJUI Compass. 2026;7:e70236.
Abstract

OZCAN L, Boylu A, Polat EC, Culha MG, et al
Is the albumin/globulin ratio a predictor of response to neoadjuvant chemotherapy before cystectomy for muscle-invasive bladder cancer?
Cent European J Urol. 2026;79:103-110.
Abstract

GAMBINA K, Tymm C, Paiola M, Tanji K, et al
Case Report: Immune checkpoint inhibitor-associated myocarditis, myositis, and myasthenia gravis overlap syndrome with flow cytometric phenotyping before and after treatment in a patient with urothelial carcinoma.
Front Immunol. 2026;17:1793351.
Abstract

ZHANG G, Hou J, Guo M, JiamingYan, et al
Integrating whole-genome bisulfite sequencing and TCGA data reveals methylation patterns associated with the MTHFR 677 C > T Variant.
Sci Rep. 2026;16:19756.
Abstract

CONTIERI R, Hurle R
Reply to Yue Chang's Letter to the Editor re: Contieri R, Paciotti M, Uleri A, et al. Second Transurethral Resection of Bladder Tumor Can Be Safely Omitted in Selected Patients with T1 Non-muscle-invasive Bladder Cancer: Results from the Prospective H
Eur Urol Oncol. 2026 Jun 29:S2588-9311(26)00181.
Abstract

ISKENDER B, Sarihan M, Barlak BSR, Akpinar G, et al
Reprogramming-driven Proteomic Shifts Mirror Bladder Cancer Progression and Reveal Biomarker Candidates Across Disease Grades.
Cancer Genomics Proteomics. 2026;23:777-805.
Abstract

PILALA KM, Papadimitriou AM, Papadimitriou MA, Panoutsopoulou K, et al
Epigenetic silencing of miR-141 via core promoter methylation is associated with short-term bladder cancer progression.
J Biol Chem. 2026 Jun 29:113302. doi: 10.1016/j.jbc.2026.113302.
Abstract

ZHANG P, Wu JC, Wang H, You HH, et al
In-situ cascade assembled peptide-drug conjugate for the treatment of bladder cancer by enhancing membrane-entry and lysosome destabilization.
Biomaterials. 2026;335:124405.
Abstract

MAHAPATRA S, Humble RM, Cordeiro-Rudnisky F, Hafez KS, et al
Invasive urothelial carcinoma in association with surface low-grade papillary urothelial carcinoma: clinical and pathologic insights from a rare entity.
Am J Clin Pathol. 2026;165:aqag072.
Abstract

ZHANG J, Wu B, Xie C, Qian X, et al
Treatment-Related Cystitis During Intravesical Chemotherapy: Incidence, Risk Factors, And Nursing-Pathway Associations.
J Vis Exp. 2026;.
Abstract

LONGONI M, Falkenbach F, Marmiroli A, Le QC, et al
ASO Author Reflections: Quantifying the Unseen: Years of Life Lost as a Patient-Centered Metric in Advanced Bladder Cancer.
Ann Surg Oncol. 2026 Jun 29. doi: 10.1245/s10434-026-20051.
Abstract

LIU H, Chu Y, Hou J, Wang Y, et al
Targeting macrophage-associated core genes for prognostic prediction and therapeutic insights in bladder cancer.
Discov Oncol. 2026 Jun 27. doi: 10.1007/s12672-026-05338.
Abstract

ZHAO Z, Liu X, Zhong Q, Liu L, et al
Choosing neoadjuvant therapy for muscle-invasive bladder cancer based on efficacy-safety trade-off: a network meta-analysis.
Front Oncol. 2026;16:1819312.
Abstract

LEITSMANN C, Reese AS, Zigeuner R, Zurl H, et al
Clinically significant tumor histology in suspected primary bladder cancer: is every transurethral resection necessary?
Front Surg. 2026;13:1813017.
Abstract

GHOREIFI A, Dudinec JV, Refugia JM, Zahir M, et al
Complete pathological response in patients with bladder cancer: predictors and outcomes.
Ther Adv Urol. 2026;18:17562872261458110.
Abstract

XIAO X, Jia X, Shen R, Song D, et al
Clinical dose of enoxaparin enhances oncolytic virus M1 infection and antitumor efficacy in human bladder cancer.
iScience. 2026;29:116353.
Abstract

JANG A, Grier AL, Sheng IY, Bari S, et al
Perioperative immune-checkpoint inhibitors for muscle-invasive bladder cancer.
Drugs Context. 2026;15:2025-9-1.
Abstract

MAHMUD S, Dwyer Orr L, Cline M, Mirsalehi A, et al
Biomarker testing patterns among patients newly diagnosed with metastatic non-small cell lung cancer, prostate cancer, and bladder cancer.
Oncologist. 2026 Jun 27:oyag243. doi: 10.1093.
Abstract

CHANG Y
Re: Roberto Contieri, Marco Paciotti, Alessandro Uleri, et al. Second Transurethral Resection of Bladder Tumor Can Be Safely Omitted in Selected Patients with T1 Non-muscle-invasive Bladder Cancer: Results from the Prospective HuNIRe Trial. Eur Urol O
Eur Urol Oncol. 2026 Jun 28:S2588-9311(26)00169.
Abstract

ERICHSEN DW, Kyro C, Schullehner J, Rosthoj S, et al
Source-specific nitrate and nitrite intake and bladder cancer: findings from the Danish Diet, Cancer and Health Cohort.
Environ Int. 2026;214:110387.
Abstract

HEKMATIRAD S, Gholizadeh F, Montazeri S, Sharifi L, et al
Patient-derived organoids as a predictive platform for drug sensitivity in bladder cancer.
Sci Rep. 2026 Jun 27. doi: 10.1038/s41598-026-59564.
Abstract

Z KHAN M, Atta MA, Kotb A, Ismail A, et al
Beyond the Rotisserie: Dispelling the Myths of Intravesical Therapy and Pioneering a Precision Future for Bladder Cancer.
Urol Res Pract. 2026;52:1-8.
Abstract

SAYEGH Y, McNutt B, Le MK, Liao IC, et al
Accurate focal-plane selection is crucial for artificial intelligence assessment of three-dimensional urine cytology specimens for bladder cancer screening and surveillance.
Cancer Cytopathol. 2026;134:e70117.
Abstract

STECKENRIDER H, Delgado J, Ritch C
Surveillance Protocols: Balancing Patient Burden and Cancer Control.
Urol Clin North Am. 2026;53:453-461.
Abstract

TAZEGUL TE, O'Donnell M, Hougen HY
Bacillus Calmette-Guerin Therapy: Optimizing Outcomes amid Challenges.
Urol Clin North Am. 2026;53:413-427.
Abstract

FILON M, Kabra S, Smelser W, Schmidt B, et al
Transurethral Resection of Bladder Tumors: Evolving Standards of Care-Optimizing Resection, Staging Accuracy, and Recurrence Reduction.
Urol Clin North Am. 2026;53:365-376.
Abstract

MOUSA MK, Carvalho LB, Giddey AD, Figueiredo A, et al
Evaluation of FASP for Mass Spectrometry-Based Untargeted Metabolomics Analysis of Urine Samples.
J Proteome Res. 2026;25:3769-3777.
Abstract

JIANG Y, Xue Y, Chen C, Fang T, et al
Self-Supervised Denoising Network for Quantitative Stimulated Raman Scattering Microscopy in Cross-Type Samples.
Anal Chem. 2026;98:18596-18606.
Abstract

KACAN T, Tezcan B, Yildiz AK, Gokkurt Y, et al
Impact of spinal versus general anesthesia on dwell time of early immediate intravesical epirubicin administration following transurethral resection of bladder tumor: an observational study.
World J Urol. 2026;44:325.
Abstract

SUN RM, Yang Y, Lai YD, Wang HN, et al
BCG-trained macrophages promote pan-anti-tumor activity through epigenetic rewiring of NOX2-ROS axis.
J Exp Clin Cancer Res. 2026;45:134.
Abstract

SANO T, Ikeda J, Yoshida T, Nakamoto T, et al
Hydronephrosis modifies the association between ureteroscopy and intravesical recurrence risk after radical nephroureterectomy for upper tract urothelial carcinoma.
Sci Rep. 2026;16:18820.
Abstract

PU C, Lv Z, Chen G
A systematic review and meta-analysis: evaluating the enhanced recovery after surgery protocol for perioperative care in robot-assisted radical cystectomy.
J Robot Surg. 2026;20:449.
Abstract

CRETTENAND F, Papagiannakis A, Stritt K, Grillo N, et al
Impact of continuous local anesthetic wound infiltration on postoperative outcomes following open radical cystectomy: a comprehensive evaluation.
World J Urol. 2026;44:315.
Abstract

RAM P, Merseburger AS, Huabkong M, Tohi Y, et al
Unresolved questions in the sequencing of systemic therapy for advanced urothelial carcinoma.
World J Urol. 2026;44:307.
Abstract

WATANABE R, Koshitani T, Hashidume S, Kasho K, et al
Urinary bladder invasion secondary to dissemination of gallbladder cancer: an unusual presentation.
Clin J Gastroenterol. 2026;19:684-689.
Abstract

HALIS A, Celiker D
Evaluation of large language models for VI-RADS reports: a comparative analysis of zero-shot and few-shot prompting.
BMC Med Imaging. 2026;26:265.
Abstract

LU X, You X, Liu T, Wei Y, et al
The gene mutation pattern of urachal squamous cell carcinoma resembles that of gastrointestinal tumors: a rare case with favorable prognosis following surgery and adjuvant chemotherapy.
World J Surg Oncol. 2026;24:224.
Abstract

CREFFIER CWG, Chemasle C
Learning Curve and Surgeon Experience in En Bloc Transurethral Resection of Bladder Tumour: A Retrospective Cohort Study.
ANZ J Surg. 2026;96:1528-1535.
Abstract

KITNITCHEE M, Sirivisoot S, Siripoonsub J, Chimnakboon N, et al
BRAF(V595E) detection, uroplakin II expression and PAS staining for diagnosing canine urothelial carcinoma.
Vet Res Commun. 2026;50:245.
Abstract

HUNT KS, Cooke S, Kuehm LM, Lobb TA, et al
Reduced Tumor Control in Males Can Result from Impaired CD4+ T-cell Help through the CD40L-CD40 Pathway.
Cancer Immunol Res. 2026;14:1068-1079.
Abstract

FANG C, Dai J, Weng Z, Zhang L, et al
A machine learning-based epigenetic signature reveals YTHDC1 stabilizes POU5F1 to oppose tumor progression.
J Transl Med. 2026;24:608.
Abstract

ALHAMDANI Z, Obrecht F, Sethi K, Bolton D, et al
The modified G8 screening tool to predict post-operative complications and survival after robot-assisted radical cystectomy - a pilot study.
BMC Urol. 2026;26:104.
Abstract

KOSHIBA T, Hakamata M, Tomita Y, Yamagishi I, et al
Aortoesophageal fistula caused by Mycobacterium bovis following intravesical Bacillus Calmette-Guerin therapy: a case report and literature review.
BMC Infect Dis. 2026;26:813.
Abstract

ZHOU Q, Bao G, Liu M, Gong L, et al
Meta-analysis of the association between CTCs and survival outcomes in urothelial carcinoma.
BMC Urol. 2026;26:95.
Abstract

LIU Y, Song Y, Qi N, Han C, et al
Immediate Vs. Delayed single post-operative intravesical instillation of chemotherapy in reducing bladder recurrence rate in upper tract urothelial carcinoma patients after radical nephroureterectomy.
World J Urol. 2026;44:226.
Abstract

ZHANG J, Su S, Liu M, Luo Y, et al
Nanoparticles co-loaded with bacillus Calmette-Guerin pure protein derivative and doxorubicin for bladder tumor therapy.
BMC Biotechnol. 2026;26:39.
Abstract

MASTROIANNI R, Ragusa A, Iannuzzi A, Tuderti G, et al
Impact of transvaginal extraction on continence after robotic cystectomy with orthotopic neobladder.
World J Urol. 2026;44:197.
Abstract

LI Z, Yan R, Zhao K, Xiao X, et al
Global trends in robot-assisted radical cystectomy: a bibliometric and visualization analysis.
J Robot Surg. 2026;20:245.
Abstract

XIN S, Li G, Zhao L, Su J, et al
The BCAA metabolism-related gene BCAT1 promotes the progression of bladder urothelial carcinoma through the PI3K/AKT/mTOR signalling pathway.
Funct Integr Genomics. 2026;26:39.
Abstract

GASPARINI A, Crowther MJ, Schaffer JM
Standardized survival probabilities and contrasts between hierarchical units in multilevel survival models.
BMC Med Res Methodol. 2026;26:45.
Abstract

LIANG P, Chen J, Shen J, Wang Y, et al
Transurethral thulium laser resection via ureterorenoscope for pediatric low-grade urothelial carcinoma of the bladder: a case report.
BMC Surg. 2026;26:172.
Abstract

AKARKEN I, Tarhan H, Karaoz F, Deliktas H, et al
Clinical Features and Treatment Outcomes of Large Bladder Tumors Nearly Filling the Bladder.
Urol J. 2026;23:48-53.
Abstract

FAYYAZ S, Sauer UG, Li Q, Guthmann H, et al
Reassessing the carcinogenic potential of dibutyl hydrogen phosphate: new insight from repeated-dose toxicity studies.
Arch Toxicol. 2026;100:2111-2134.
Abstract

RAN M, Chen X, Xiao G, Huang R, et al
Exploration of neutrophil-associated genes in the prognosis of bladder urothelial carcinoma based on a machine learning and multi-omics data integration framework.
Hum Genomics. 2026;20:37.
Abstract

OZDEN SB, Kalayci A, Gurses I, Ozdemir F, et al
Clinical utility of cell-free urine miR-93-5p, miR-191-5p, miR-31-5p for invasive urothelial carcinoma detection and immune signature-based subtyping.
BMC Urol. 2026;26:41.
Abstract

GUO Z, Wang G
Neoadjuvant immunotherapy combined with HER2-targeted antibody-drug conjugate in bladder urothelial carcinoma: a case report.
BMC Urol. 2026;26:33.
Abstract

GUNER E, Sam E, Fakir AE, Guneren MS, et al
Factors predicting ureteral stenosis after transurethral resection of the ureteral orifice: a two-center, retrospective clinical study.
BMC Urol. 2025;26:24.
Abstract

YUAN S, Yang K, Wu H, Peng L, et al
Diagnostic performance of artificial intelligence in detecting bladder carcinoma.
World J Urol. 2025;44:63.
Abstract

AVELINO ALN, Goncalves FD, Ferreira JNM, Vasconcelos GR, et al
Investigation of androgen receptor expression in urothelial carcinoma of the bladder.
BMC Urol. 2025;25:308.
Abstract

LIU J, Allen RC, Stephens JT Jr, Huang H, et al
Selective Tumor Cytotoxicity via Singlet Oxygen: Investigating Eosinophil Peroxidase and Myeloperoxidase in Cancer Therapy.
Oncology. 2026;104:849-862.
Abstract

MANGOLD MH, Wieland VLS, Grilli M, Studier-Fischer A, et al
Tranexamic acid in radical cystectomy: a systematic review and meta-analysis of efficacy and safety.
World J Urol. 2025;43:560.
Abstract

IMURA S, Ogi Y, Ishimaru K, Koga S, et al
Small Intestinal Adhesion at a Parastomal Hernia of the Ileal Conduit and Hernia Repair with Laparoscopy and Tailored Mesh: A Case Report.
J Nippon Med Sch. 2026;93:279-283.
Abstract

MOYER JA, Ashraf M, Mi L, Zganjar AJ, et al
Comparative effectiveness of intravesical gemcitabine vs. sequential gemcitabine and docetaxel for high-risk nonmuscle-invasive bladder cancer.
Urol Oncol. 2026 Jul 9:S1078-1439(26)00568-5. doi: 10.1016/j.urolonc.2026.
Abstract

STROJNY Z, Kanikowska D, Kanikowska A, Tomczak Z, et al
The significance of vascular endothelial growth factor and systemic inflammatory reaction in bladder cancer patients.
Cytokine. 2026;205:157190.
Abstract

DI LORENZO G
Evolving Therapeutic Landscape in Non-Muscle-Invasive Bladder Cancer (NMIBC).
Oncology. 2026 Jul 9:1-7. doi: 10.1159/000553466.
Abstract

CHEN N, Cai J, Feng J, He Y, et al
A retrospective observational analysis of the global burden of smoking-attributable prostate, bladder, and kidney cancers among adults aged 40 years and older: Based on the global burden of disease study 2021 with projections to 2045.
Sci Prog. 2026;109:368504261466968.
Abstract

ZHANG X, Ge P, Chen Q, Wang S, et al
Liquid-liquid phase separation-associated gene networks link EMT and ferroptosis to define a PDGFRB-centered prognostic signature in bladder cancer.
Front Immunol. 2026;17:1846096.
Abstract

BARTH G, Koch S, Ecke TH
Keratin 17 immunocytochemistry in urine cytology for urothelial carcinoma detection: Diagnostic performance and interobserver agreement in a prospective real-world cohort.
Cancer Cytopathol. 2026;134:e70130.
Abstract

GUAN J, Jiang X, Lv Y, Xue Y, et al
Visualizing NO(2)(-)/NAD(P)H metabolic crosstalk in E. coli-infected bladder cancer via a dual-responsive probe.
Chem Commun (Camb). 2026 Jul 9. doi: 10.1039/d6cc02834.
Abstract

THIBAULT C, Blons H, Allory Y, Harba A, et al
Molecular Profiling of Urothelial Bladder Cancer: Bridging Tumor Biology and Clinical Decision-making.
Eur Urol Oncol. 2026 Jul 8:S2588-9311(26)00182-3. doi: 10.1016/j.euo.2026.
Abstract

GREIDANUS J, van Dijk-de Haan MC, Messina A, Calareso G, et al
MRI-based Response Assessment of Neoadjuvant Systemic Immunotherapy in Muscle-invasive Bladder Cancer: An Analysis of Inter-radiologist Variability and Diagnostic Accuracy in three Prospective Clinical Trials.
Eur Urol Oncol. 2026 Jul 8:S2588-9311(26)00154-9. doi: 10.1016/j.euo.2026.
Abstract

ZHESTKOV I A, Kamalov D M, Oleynikova N A, Nesterova O Y, et al
[Tumor-associated fibroblasts and clinical and morphological features of bladder cancer].
Urologiia. 2025;:90-94.
Abstract

PETERSEN E, Sheldon J, Torgerson H, Kirschenbaum M, et al
The impact of cachexia and sarcopenia in bladder cancer.
Curr Opin Support Palliat Care. 2026 Jul 9. doi: 10.1097/SPC.0000000000000811.
Abstract

PAN CX, Mossanen M, Ellis JL, Ma AH, et al
Phase I first-in-human dose-escalation trial of a bladder cancer-specific nanoparticle in non-muscle-invasive bladder cancer.
Nanomedicine (Lond). 2026 Jul 8:1-7. doi: 10.1080/17435889.2026.2693194.
Abstract

LI A, Tang C, Wei X, Liu F, et al
Endourological autologous bypass-ureteroplasty for anastomotic atresia in orthotopic neobladder: a novel surgical approach and case report.
Can J Urol. 2026;33:643-648.
Abstract

XU H, Yang C, Fu Q, Zeng S, et al
Hypoxia-induced exosomal LNCOC1 orchestrates bladder cancer progression via the YBX1/PIK3CA axis and serves as a potential liquid biopsy biomarker.
Cell Oncol (Dordr). 2026 Jul 7. doi: 10.1007/s13402-026-01257.
Abstract

YU L, Liu T, Cai Y, Gai Y, et al
An Interface-Regulated Electrochemical Biosensing Platform Based on the Cascade Amplification of Primer Exchange Reaction and CRISPR/Cas12a for Noninvasive Bladder Cancer Diagnosis.
Anal Chem. 2026 Jul 7. doi: 10.1021/acs.analchem.6c02591.
Abstract

SU YL, Huang SY, Kuo CW, Xiao LY, et al
Oncogenic PIK3CA mutation enhances tumor immunogenicity through the IRF1-NLRC5-MHC-I axis in urothelial carcinoma.
J Immunother Cancer. 2026;14:e014770.
Abstract

XIANG L, Li Y, Dong X, Yan Y, et al
EIF4A3 facilitates METTL3-mediated m(6)A methylation of circPCMTD1 to drive bladder cancer progression via miR-3681-5p/HPSE axis.
Cell Signal. 2026 Jul 7:112725. doi: 10.1016/j.cellsig.2026.112725.
Abstract

MONSONIS USO R, Ponce Blasco P, Canos Nebot A, Barrios Arnau L, et al
Association Between Perioperative Blood Transfusion and Survival Outcomes After Radical Cystectomy for Bladder Cancer.
Actas Urol Esp (Engl Ed). 2026 Jul 7:502001. doi: 10.1016/j.acuroe.2026.502001.
Abstract

SIM KC, Sung DJ, Han NY, Han YE, et al
Correlation Between the Natural Course and Magnetic Resonance Imaging Features of Bacillus Calmette-Guerin-Related Granulomatous Prostatitis in Patients With Bladder Cancer.
J Korean Med Sci. 2026;41:e178.
Abstract

OTO J, Herreros-Pomares A, Verger P, Herranz R, et al
A comprehensive plasma-based approach to thromboinflammation in bladder cancer: integrating lipidomics, thrombin generation, and NETosis biomarkers.
J Transl Med. 2026 Jul 6. doi: 10.1186/s12967-026-08570.
Abstract

LIU W, Gong B, Zhang G, Guo Y, et al
Development of multiphasic CT-based delta-radiomics model for predicting postoperative recurrence risk in bladder cancer.
BMC Med Imaging. 2026 Jul 7. doi: 10.1186/s12880-026-02554.
Abstract

YIM W, Kang H, Kang BH, McGinnis ME, et al
Publisher Correction: Chemical efflux imaging using an annular nanosensor array for in situ bladder cancer detection.
Nat Nanotechnol. 2026 Jul 6. doi: 10.1038/s41565-026-02239.
Abstract

LI Z, Fu Y, Zhang J, Wang Y, et al
Challenges in postoperative self-management for patients with bladder cancer and urinary stoma: a qualitative study.
Support Care Cancer. 2026;34:740.
Abstract

PETRELLI F, Colombo Zefinetti L, D'Alessio A, Dottorini L, et al
Next-Generation Checkpoint Combinations: Optimizing PD-(L)1-Based Therapy Across the Advanced, Adjuvant, and Neoadjuvant Settings.
Curr Oncol Rep. 2026;28:72.
Abstract

ZOU XC, Yu ZJ, Yuan YY, Chao HC, et al
Interpretable machine learning model of contrast-enhanced CT radiomics for predicting post-BCG recurrence in high-grade non-muscle-invasive bladder cancer.
World J Urol. 2026;44:486.
Abstract

SCHERPING AK, Tomasik B, Luzha J, Schostak M, et al
Keratins and desmosomal proteins: Utility for molecular subtype identification in muscle-invasive bladder cancer.
Virchows Arch. 2026 Jul 6. doi: 10.1007/s00428-026-04639.
Abstract

MARRONE MT, Bagley E, Butler KR, Couper DJ, et al
Proteomic analysis of sphingolipid metabolic enzymes with risk of bladder cancer incidence and mortality in the Atherosclerosis Risk in Communities (ARIC) Study.
Cancer Prev Res (Phila). 2026 Jul 6. doi: 10.1158/1940-6207.CAPR-25-0499.
Abstract

WANG T, Liao X, Zhang J, Xu X, et al
Urinary Small Extracellular Vesicle DNA as a Biomarker for the Non-Invasive Diagnosis of Bladder Cancer.
Cancer Sci. 2026 Jul 6. doi: 10.1111/cas.70455.
Abstract

MUGLIA VF, Reis RB
Editorial for "A Quantitative Modification of VI-RADS for Bladder Cancer at the Ureteral Orifice: A Reader Study on MRI With Varying Experience Levels".
J Magn Reson Imaging. 2026 Jul 6. doi: 10.1002/jmri.70416.
Abstract

FAKHOURI F, Candido P, Pimenta R, Guimaraes VR, et al
The role of microRNAs-23b and 27b in migration, invasion and proliferation of T24 bladder cancer cells.
BMC Urol. 2026 Jul 4. doi: 10.1186/s12894-026-02241.
Abstract

YANG L, Zhang JM, Chen YJ, Wei ZQ, et al
Multi-omics profiling identifies CDK1 as a key mediator of mitosis through the PTN pathway in bladder cancer.
Future Sci OA. 2026;12:2696931.
Abstract

MOUSA MK, Soares NC, Santos HM
LC-MS-Based Metabolomics and Proteomics Sample Preparation of Urine: Methods and Multi-Omics Integration.
Adv Exp Med Biol. 2026;1510:1-20.
Abstract

CHEN Y, Zhuang J, Yu H, Li K, et al
Hypoxia remodels circSTX6 nuclear export through URH49-ALYREF to drive IGF1-mediated bladder cancer progression.
Cell Signal. 2026;147:112723.
Abstract

DOHERTY R, Kiadaliri A, Hajizadeh M
Socioeconomic inequalities in bladder cancer mortality in Canada: Temporal trends over three decades, 1990-2019.
Public Health. 2026;258:106396.
Abstract

SHIRANI F, Lashay A
Cutaneous ureterostomy versus ileal conduit as urinary diversion in patients with muscle-invasive bladder cancer undergoing radical cystectomy: A comparative analysis of high-risk cases.
Urologia. 2026 Jul 4:3915603261461658. doi: 10.1177/03915603261461658.
Abstract

WANG ZQ, Song Q, Liu JY, Peng CY, et al
A Solid-State Near-Infrared Fluorescent Probe by a Synergistic Extended Conjugated System for Detecting Cys with Long-Term Imaging in Orthotopic Bladder Cancer.
Anal Chem. 2026 Jul 4. doi: 10.1021/acs.analchem.6c03199.
Abstract

SINGH V, Aggarwal A, Akhtar MR, Pandey M, et al
Comparison of quality of life and sexual function after ileal vs. sigmoid orthotopic neobladder reconstruction following nerves, vas deferens, and seminal vesicle-sparing radical cystectomy: A prospective randomized study.
Urol Oncol. 2026;44:82-91.
Abstract

CAI LK, Yang X, Cao Q, Tian W, et al
[MRI-based deep learning model for preoperative prediction of urothelial carcinoma with variant histology of bladder: a retrospective, multicenter study].
Zhonghua Wai Ke Za Zhi. 2026;64:752-759.
Abstract

YAJIMA S, Imasato N, Hashimoto T, Kobayashi S, et al
Diagnostic performance of urinary tumor DNA in urothelial carcinoma: A systematic review and network meta-analysis.
Urol Oncol. 2026;44:13-24.
Abstract

GABRIEL PE, Seisen T, Xylinas E, Duquesne H, et al
Robot-Assisted Versus Open Bladder Cuff Excision After Radical Nephroureterectomy: A Multicenter Study by the French Urothelial Cancer Committee.
Ann Surg Oncol. 2026;33:7790-7800.
Abstract

YAPRAK BAYRAK B, Kosemehmetoglu K, Ozbek B, Simsek S, et al
Marked attenuation of P63 expression in plasmacytoid urothelial carcinoma with expanded immunohistochemical framework including E-cadherin, P120, HER2 and TRPS1.
Histopathology. 2026;89:338-346.
Abstract

YONESE I, Koga F, Toide M, Maezawa Y, et al
Lymph node metastasis as a favorable prognostic factor in metastatic urothelial carcinoma with histological variants treated with pembrolizumab: a retrospective multicentric study (YUSHIMA study-04).
Jpn J Clin Oncol. 2026;56:885-893.
Abstract

LIN Y, Xiang N, Yang Y, Huang S, et al
Shared Genetics of Kidney Function Traits and Bladder Cancer: A Genome-Wide Cross-Trait Analysis.
Cancer Med. 2026;15:e72025.
Abstract

ZHANG Z, Zhao Y, Li Z
Multifocal xanthogranulomatous inflammation of the urinary tract mimicking metastatic urothelial carcinoma: A case report.
Medicine (Baltimore). 2026;105:e49724.
Abstract

GRIFFO A
Nanosensor-integrated catheters for chemical mapping of bladder cancer biomarkers.
Nat Biomed Eng. 2026;10:1274.
Abstract

TSUJINO T, Yamazaki S, Sakamoto M, Yoshikawa Y, et al
A ferroptosis-suppressive state drives resistance to bladder-preserving chemoradiotherapy in muscle-invasive bladder cancer.
Signal Transduct Target Ther. 2026;11:299.
Abstract

YANG H, Zhou C, Zhou Z, Zhang F, et al
Corrigendum to "YBX1 takes actions on triggering M2-like polarization of macrophages and stabilizing CXCL8 mRNA to exhibit its metastatic potential in bladder cancer" [Int. Immunopharmacol. 184 (2026) 116911].
Int Immunopharmacol. 2026 Jul 17:117122. doi: 10.1016/j.intimp.2026.117122.
Abstract

MEHMUD I, Peng L, Zhang Y, Liang R, et al
Localized In-Situ Nanomedicine Synthesis Enables Copper-Mediated Cuproptosis for Effective Bladder Cancer Therapy.
Eur J Pharm Sci. 2026 Jul 17:107613. doi: 10.1016/j.ejps.2026.107613.
Abstract

BAO W, Liu Y, Yang J, Ma X, et al
The diagnostic value of biparametric magnetic resonance imaging vesical imaging-reporting and data system combined with tumor contact length for assessing muscle invasion in bladder cancer lesions scored vesical imaging-reporting and data system 3: A
Indian J Urol. 2026;42:225-231.
Abstract

AGRAWAL S, Pal AK, Sharma S, Tanwar R, et al
The immunotherapy paradox in high-risk non-muscle-invasive bladder cancer: A tale of three trials.
Indian J Urol. 2026;42:254-255.
Abstract

NAJMROCKA M, Semeniuk A, Stec R
Adverse effects of systemic therapy in a patient with urothelial bladder cancer and chronic kidney disease - a case report.
Front Oncol. 2026;16:1733345.
Abstract

ZHAO G, Bai Y, Chen X, Li J, et al
Remodeling of the tumor microenvironment in muscle-invasive bladder cancer: insights from single-cell and spatial transcriptomics after neoadjuvant immunochemotherapy.
Mol Cancer. 2026 Jul 17. doi: 10.1186/s12943-026-02738.
Abstract

PRIBUS SJ, Osredek I, Otonicar J, Simovic-Lorenz M, et al
Multiomic profiling links L1 retrotransposition to genomic instability and ecDNA in bladder cancer.
Nat Commun. 2026;17:6384.
Abstract

MAHONEY ME, Jiang DM, Diaz-Mejia N, Atenafu EG, et al
Long-Term Outcomes of Neoadjuvant Chemotherapy (NAC) Prior to Bladder-Sparing Trimodality Therapy (TMT) for Patients With Muscle-Invasive Bladder Cancer (MIBC).
Clin Genitourin Cancer. 2026;24:102599.
Abstract

FARIA EF, Rodrigues A, Pompeo A, Fazoli A, et al
Robot-Assisted Radical Cystectomy: Recommendations from Latin American Experts Consensus on Surgical Strategy, Urinary Reconstruction, and Oncological and Func-tional Outcomes.
Int Braz J Urol. 2026;52:e20260431.
Abstract

ASTUA IF, Suartz CV, Chade DC, Soares DFG, et al
Bladder Cancer Management in Brazil's Supplementary Health System: Real-World Practice Patterns.
Int Braz J Urol. 2026;52:e20260218.
Abstract

ZHANG Q, Xu K, Chen Z, Li Z, et al
Identification of key genes potentially associated with bladder cancer development by common plasticizers: an integrated transcriptomics and network toxicology study.
Front Oncol. 2026;16:1784832.
Abstract

CHEN H, Liu N, Chen X, Xian P, et al
Safety and preliminary efficacy of Disitamab Vedotin combined with Toripalimab and concurrent radiotherapy in bladder-preserving treatment for HER2-positive invasive bladder cancer.
Front Oncol. 2026;16:1880457.
Abstract

ATTYA ME, Sayed HY
The clinicopathological significance of METTL3/SERPINE2 immunoexpression in urothelial carcinoma of the urinary bladder.
Pol J Pathol. 2026;77:53-61.
Abstract

SUZUKI S, Cohen SM
Effects of Nicotine on Urinary Bladder Carcinogenesis.
Pathol Int. 2026;76:e70151.
Abstract

PATTOU M, Roupret M, Kamat A, Boorjian SA, et al
Novel BCG Combination or Modified BCG Regimens in BCG-Naive High-risk Non-muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis.
Eur Urol Focus. 2026 Jul 15:S2405-4569(26)00115.
Abstract

AI Z, Zhou H, Jiang L, Lang Y, et al
YAP1 lactylation confers cisplatin resistance and prognostic value by suppressing ferroptosis via FOSL1 in bladder cancer.
Cell Rep. 2026;45:117692.
Abstract

BAI Z, Wang S, Wang H, Liu Z, et al
Burden of bladder cancer in China from 1990 to 2023: temporal trends, modifiable risk factors, and implications for prevention.
Int J Clin Oncol. 2026 Jul 15. doi: 10.1007/s10147-026-03139.
Abstract

PEIXOTO GA, Salles MP, Amaro Junior E, Korkes F, et al
Rigid cystoscopy versus flexible outpatient cystoscopy: the economic cost behind the epidemiological and social impact.
Einstein (Sao Paulo). 2026;24:eGS1136.
Abstract

GOTO T, Teramoto Y, Elahi Najafi MA, Yasui M, et al
Role of Latrophilin-1 and Latrophilin-2 as Downstream Effectors of Androgen Receptor Signaling in Urothelial Tumorigenesis.
Cancer Rep (Hoboken). 2026;9:e70624.
Abstract

GUGLIELMO P, Perrone E, Ozcan PP, Mapelli P, et al
Shaping the role of FDG PET in bladder cancer: current evidence and ongoing clinical trial.
Q J Nucl Med Mol Imaging. 2026;70:83-88.
Abstract

WANG Z, Zhou Z, Yang S, Zhao Z, et al
Glycolysis-mediated H3K18la modifications drive aggressive bladder cancer through metabolic and epigenetic reprogramming.
Front Immunol. 2026;17:1777092.
Abstract

SUI J, Chen Y, Jiang Y, He Q, et al
Post-IMvigor011 Era: CtDNA-Guided Postoperative Adjuvant Treatment Stratification in Muscle-Invasive Bladder Cancer.
Cancer Manag Res. 2026;18:609903.
Abstract

OZTURK MI, Ekici M, Aydin C, Caglayan MS, et al
Preoperative Platelet-to-Lymphocyte Ratio as a Predictor of Recurrence and Recurrence-Free Survival in Non-Muscle-Invasive Bladder Cancer Across Different Intravesical Therapies.
J Clin Med. 2026;15:5199.
Abstract

CARRIERE PP, Hassanzadeh CJ
Bladder Preservation Therapy in Muscle-Invasive Bladder Cancer: Current Evidence and Future Directions.
J Clin Med. 2026;15:5101.
Abstract

BISSETTE RG, Congress Z, Nomdedeu-Sancho G, Wajih N, et al
Bioprinted Bladder Cancer Organoids Model System for Prediction of Chemotherapy Response and Drug Screening.
Int J Mol Sci. 2026;27:6082.
Abstract

JERSINOVIC S, Vukovic M, Hennenlotter J, Lutfrenk T, et al
Nectin-4 Expression in Muscle-Invasive Bladder Cancer Is Associated with Growth-Related and Inflammatory Signaling Pathways.
Int J Mol Sci. 2026;27:5706.
Abstract

CHEN Y, Cai L, Yang X, Tao Y, et al
An Immunohistochemistry-Based Molecular Subtyping Approach for Capturing Clinical Outcome Heterogeneity in Bladder Cancer.
Diagnostics (Basel). 2026;16:2055.
Abstract

SIM KC, Kim MJ, Sung DJ, Park BJ, et al
Diagnostic and Prognostic Non-Invasive Markers in Bladder Cancer.
Diagnostics (Basel). 2026;16:1948.
Abstract

MORA-GARIJO B, Rahman S, Xu H, Chatzkel J, et al
Histological Subtypes of Bladder Cancer: Epidemiology, Molecular Biology, and Clinical Implications.
Cancers (Basel). 2026;18:2174.
Abstract

PAN Q, Shi Q, Zhao Y, Yu T, et al
MKRN2-Mediated Degradation of IGF2BP3 Suppresses MYC and Enhances CDK4/6 Inhibitor Sensitivity in Bladder Cancer.
Cancers (Basel). 2026;18:2164.
Abstract

YANG MH, Nagisetti Y, Mukundan A, Karmakar R, et al
Early Classification of Bladder Cancer Using Spectrum-Aided Visual Enhancer (SAVE) and Deep Learning Models: A Non-Invasive Technology for Faster Detection.
Cancers (Basel). 2026;18:2147.
Abstract

FIGOLS M, Gonzalez A, Fernandez-Saorin M, Bautista A, et al
Integrating the Neutrophil-to-Lymphocyte Ratio into a Clinicopathological Nomogram for Event-Free Survival Prediction in Cisplatin-Treated Muscle-Invasive Bladder Cancer.
Cancers (Basel). 2026;18:2054.
Abstract

KWINTA L, Konopka K, Okon K, Lobacz M, et al
Pretreatment NPLH as a Potential Predictor of Pathologic Complete Response to Accelerated MVAC Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer: Comparison with NLR and PLR.
Cancers (Basel). 2026;18:2046.
Abstract

KAMI REDDY KR, Putluri V, Piyarathna DWB, Park JH, et al
Oncogenic PIK3CA reprograms glutamine metabolism to drive bladder cancer progression.
Cell Commun Signal. 2026 Jul 14. doi: 10.1186/s12964-026-03058.
Abstract

MALIK M, Sigorski D, Jacyk P, Rozycki M, et al
ddMVAC versus gemcitabine-cisplatin as neoadjuvant treatment for muscle-invasive urothelial bladder cancer: a multicenter real-world study.
Sci Rep. 2026 Jul 14. doi: 10.1038/s41598-026-60676.
Abstract

MCGRATH J, Banerjee I, Ishiyama Y, Balaji KC, et al
Network meta-analysis of immune checkpoint inhibitors in BCG-naive, high-risk non-muscle-invasive bladder cancer.
Urol Oncol. 2026 Jul 14:S1078-1439(26)00565.
Abstract

WU K, Wang B, Chen Y, Zhou J, et al
Corrigendum to "DAB2IP regulates the chemoresistance to pirarubicin and tumor recurrence of non-muscle invasive bladder cancer through STAT3/Twist1/P-glycoprotein signaling" [Cellular Signaling, 2015 Sep 26; 27(12): 2515-2523].
Cell Signal. 2026 Jul 14:112700. doi: 10.1016/j.cellsig.2026.112700.
Abstract

YAJIMA S, Yoshida S, Imasato N, Chen W, et al
Postoperative Management After Pathological Complete Response to Neoadjuvant Therapy for Muscle-Invasive Bladder Cancer: An Exploratory Reconstructed Individual Patient Data Analysis.
Clin Genitourin Cancer. 2026;24:102603.
Abstract

KARABULUT B, Dag O, Kosemehmetoglu K, Guner G, et al
Can We Foresee Grade and Stage Progression in Mixed Low- and High-Grade Noninvasive Papillary Urothelial Carcinomas?
APMIS. 2026;134:e70238.
Abstract

UYSAL E, Yilmaz Y, Akin Y, Gorgel SN, et al
Demographic and histopathological features of patients with primary bladder cancer without recurrence in two-year follow-up.
J Pak Med Assoc. 2026;76:1026-1032.
Abstract

REN J, Lu J, Xiong Z, Zhang Y, et al
Latent profile analysis of health-related quality of life in patients with bladder cancer and abdominal wall stomas: a multicenter cross-sectional study.
BMC Urol. 2026 Jul 13. doi: 10.1186/s12894-026-02253.
Abstract

KONG J, Huang Y, Xing Y, Fang S, et al
Unlocking the prognostic power of pathomics in bladder cancer: a machine learning odyssey across multiple centers.
BMC Med Imaging. 2026;26:266.
Abstract

GUPTA N, Kumar M, Phulware RH
Bladder carcinoma associated with anti-NXP2-positive inflammatory myopathy: a case-based review.
Rheumatol Int. 2026;46:207.
Abstract

ZHUANG J, Yu H, Chen Y, Sun H, et al
HDAC10 suppresses anti-tumour immunity by inhibiting ILF3-CXCL9 axis to block CD8(+) T cell infiltration and activation in bladder cancer.
Cancer Lett. 2026;657:218729.
Abstract

HE X, Zhu H, Huang Y, Deng X, et al
Analysis of the relationship between serum LAMC2, TROAP and clinical stages and prognosis of non-muscle invasive bladder cancer.
Open Med (Wars). 2026;21:20261481.
Abstract

MAJUMDER A, Dwyer Orr L
Racial and ethnic differences in bladder cancer diagnosis, treatment, and specialty care access among Medicare fee-for-service beneficiaries: a cross-sectional study.
Front Oncol. 2026;16:1797699.
Abstract

ABUHASANEIN S
Oncobiotics in urinary bladder cancer. A narrative review of living cancer therapeutics.
Front Oncol. 2026;16:1845015.
Abstract

YU D, Zhang Y, Tang J, Qing J, et al
A machine learning-guided epithelial plasticity score refines prognostication and immune-context stratification in muscle-invasive bladder cancer.
Discov Oncol. 2026 Jul 13. doi: 10.1007/s12672-026-05555.
Abstract

CHEN D, Zhang C, Xue S, Zeng Y, et al
LRG1 Drives Pathological Angiogenesis by Disrupting Neutrophil Mitochondrial Homeostasis in Bladder Cancer.
Adv Sci (Weinh). 2026 Jul 13:e76604. doi: 10.1002/advs.76604.
Abstract

MASTROIANNI R, Tuderti G, Anceschi U, Bove AM, et al
Robotic intracorporeal modified Bordeaux versus Padua ileal bladder: head-to-head surgical technique, perioperative and functional outcomes.
Minerva Urol Nephrol. 2026;78:430-437.
Abstract

LO RE M, Cadenar A, Pezzoli M, Mancon S, et al
Assessing the concordance between ChatGPT-4 and EAU guidelines indications in bladder cancer management: a real-world study.
Minerva Urol Nephrol. 2026;78:411-418.
Abstract

ZHU Q, Wang J, Wei Y, Liu W, et al
Preliminary feasibility of SHURUI single-port robot-assisted radical cystectomy with exploratory comparison to a contemporaneous da Vinci Xi single-port cohort.
Minerva Urol Nephrol. 2026;78:383-388.
Abstract

YALCIN B, Tuncay E, Arslan S, Araci HE, et al
Survival in Synchronous Versus Metachronous Bladder and Prostate Cancer.
Arch Esp Urol. 2026;79:800-807.
Abstract

PEREZ-BARTIVAS L, Leiva-Cepas F, Ponferrada D, Flores-Paco P, et al
Immunohistochemistry-Based Molecular Subtyping in Muscle-Invasive Bladder Cancer: Predicting Response to Neoadjuvant Chemotherapy.
Arch Esp Urol. 2026;79:773-782.
Abstract

XU Y, Xu J, Han C, Li Q, et al
Bioinformatics analysis of PFKFB family in pan-cancer and preliminary exploration of PFKFB4 in bladder cancer.
Cancer Cell Int. 2026 Jul 13. doi: 10.1186/s12935-026-04354.
Abstract

WANG W, Dong F, Lei J, Li L, et al
Soluplus(R)-based solid dispersion enhances oral bioavailability of A10: a cGAS-STING and ICD activator for bladder cancer therapy.
Int J Pharm. 2026;701:127190.
Abstract

ZSCHABITZ S, Bhatti I, Casuscelli J, Pachmayr LO, et al
Effectiveness and safety of enfortumab vedotin and pembrolizumab in a real-world patient population with urothelial carcinoma: results from a multi-institutional cohort (GUARDIANS).
Cancer Immunol Immunother. 2026;75:184.
Abstract

CHEN DN, Wang JM, Zhang FH, Ye HY, et al
KIF26B promotes bladder cancer progression through activating the NF-kappaB signaling pathway.
iScience. 2026;29:116577.
Abstract

ZHANG X, Wang H, Zhou H, Xiao D, et al
An AI-powered diagnostic system for grading and invasion of non-muscle-invasive bladder cancer via TURBT specimens: A multicenter study.
iScience. 2026;29:116651.
Abstract

HAN C, Miao L, Liu Y, Wang Y, et al
Prognostic and immunological implications of a mitophagy-associated gene signature in bladder cancer.
Transl Androl Urol. 2026;15:199.
Abstract

REN W, Yi J, Zeng M, Cheng H, et al
The YTHDC1/HECW1/SMAD7 axis drives cisplatin resistance in bladder cancer.
Transl Androl Urol. 2026;15:201.
Abstract

ABOU CHAKRA M, Myers AA, Marchetti KA, Zakharia Y, et al
Impact of age on the effectiveness of intravesical Bacillus Calmette?Guerin and gemcitabine/docetaxel in treatment-naive high-risk non?muscle?invasive bladder cancer.
Transl Androl Urol. 2026;15:215.
Abstract

GABRIEL PE, Ingles JC, Zhu A, Horowitz A, et al
Artificial intelligence and predictive tools in non-muscle invasive bladder cancer: a narrative review of current insights and advances.
Transl Androl Urol. 2026;15:221.
Abstract

TANG S, Wang X, Chen F, Zhang L, et al
Identification of pyroptosis-related molecular subtypes and development of a subtype-derived six-gene prognostic signature for bladder cancer.
Transl Androl Urol. 2026;15:200.
Abstract

NIELSEN NK, Hjort PB, Hansen EB, Graugaard-Jensen C, et al
Substaging and Stratified Treatment of T1 Bladder Cancer - a Nationwide Register-Based Study.
Eur Urol Open Sci. 2026;90:92-100.
Abstract

GU J, Wang M, Zhou Z, Zhang M, et al
Associations between the intratumoral microbiome and the host transcriptome in bladder cancer and their implications for prognostic prediction.
Sci Rep. 2026 Jul 11. doi: 10.1038/s41598-026-61819.
Abstract

YAJIMA S, Yoshida S, Imasato N, Chen W, et al
Enfortumab vedotin monotherapy, enfortumab vedotin plus pembrolizumab, and immune checkpoint inhibitor-based neoadjuvant therapy for muscle-invasive bladder cancer: A systematic review and meta-analysis.
Urol Oncol. 2026 Jul 11:S1078-1439(26)00566.
Abstract

YAO Y, Yang P, Niu S, Yang J, et al
GLI2 confers ferroptosis resistance in bladder cancer by transcriptionally upregulating PRDX1.
Apoptosis. 2026;31:191.
Abstract

SILVA A, Baltazar F, Afonso J
Metabolic Reprogramming in the Bladder Cancer Microenvironment: Bridging Fundamental Research and Therapeutic Avenues for Cancer-Associated Fibroblasts.
Adv Exp Med Biol. 2026;1501:145-164.
Abstract

MARTIN EW, Aragon-Ching JB
Circulating tumor DNA (ctDNA)-guided adjuvant therapy for muscle-invasive bladder cancer (MIBC): ready for primetime?
Ann Transl Med. 2026;14:42.
Abstract

ABID S, Qasim N, Qaisar A, Nadeem A, et al
FDA approval of mitomycin hydrogel (Zusduri): a new non-surgical era for non-muscle-invasive bladder cancer (NMIBC).
Ann Med Surg (Lond). 2026;88:3930-3934.
Abstract

NIELSEN NK, Milling RV, Hjort PB, Vasquez JL, et al
Histopathological Advantages of En Bloc Resection in Non-muscle-invasive Bladder Cancer: A Multinational Randomised Controlled Clinical Trial.
Eur Urol Open Sci. 2026;90:69-76.
Abstract

KANG Y, Zhong G, Zhang Y, Chang Z, et al
Exploring the response shift effects on patient-reported outcomes among postoperative bladder cancer patients: a qualitative study in China.
BMC Urol. 2026 Jul 10. doi: 10.1186/s12894-026-02247.
Abstract

WANG H, Ji YA, Luo W, Xie Q, et al
Memory B cells in mature follicle-like tertiary lymphoid structures predict BCG response in non-muscle-invasive bladder cancer.
Sci Rep. 2026 Jul 15. doi: 10.1038/s41598-026-60910.
Abstract

GAUCHER C, Vicier C, Guerin M
[Update: Evolution in the management of metastatic urothelial carcinomas].
Bull Cancer. 2026;113.
Abstract

WANG G, Liu F, Chen Z, Davoli T, et al
conMItion: an R package adjusting confounding factors for associations in multi-omics.
Bioinformatics. 2026;42:btag472.
Abstract

WAFA H, van Creij NCH, Guenther M, Noeparast M, et al
Targeting HER2 in urothelial carcinoma: from pathway inhibition to antibody-drug conjugates.
Cancer Treat Rev. 2026;148:103173.
Abstract

LIN L, Li H, Zhou Q, Ding Q, et al
Machine-intelligent multimodal algebot for intracavitary chemotherapy.
Nat Nanotechnol. 2026;21:996-1007.
Abstract

GUO Q, Li L, Beeraka NM, Zhang Y, et al
Sex-specific divergence in global urological cancer trajectories to 2050: A dual-model projection analysis based on GLOBOCAN and GBD databases.
Eur J Surg Oncol. 2026;52:111943.
Abstract

CRUPI E, Cigliola A, Mercinelli C, Piacentini M, et al
Targeting HER2 in Urothelial Carcinoma: Why Histologic Subtypes and Divergent Histologies Matter.
Clin Genitourin Cancer. 2026;24:102583.
Abstract

SYNESI G, Lewis R, Kilburn L, Bliss J, et al
Identifying underrepresented groups in oncology clinical trials using routinely collected data in an English academic trial setting.
Trials. 2026;27:504.
Abstract

ELDESOUKI S, Elmekresh A, Esmaeilpour H, Kumar S, et al
When double-J stents become a risk: bilateral distal ureteric urothelial carcinoma following ureteric instrumentation: a case report.
BMC Urol. 2026;26:166.
Abstract

WANG G, Cheng Y, Zhou X, Guo Y, et al
SEPT9 methylation as a potential biomarker for uncovering latent malignancy in flat urothelial lesions.
Ann Diagn Pathol. 2026;84:152653.
Abstract

D'SOUZA AA, Groshen SG, Tsao-Wei D, Ruel N, et al
Outcomes for females versus males treated with eribulin mesylate for advanced urothelial carcinoma.
Curr Probl Cancer. 2026;63:101294.
Abstract

FUKUMORI Y, Nishimura K, Tohi Y, Osaki Y, et al
Prostatic Abscess Secondary to Postoperative Wound Infection Caused by Mycobacterium mageritense.
Intern Med. 2026;65:1985-1989.
Abstract

OBEROI JK, Ballas LK, Tyson M, Singh P, et al
Ideal candidates for bladder preservation in muscle-invasive bladder cancer.
Urol Oncol. 2026 Jul 24:S1078-1439(26)00584.
Abstract

SCHNABEL MJ, Grimm MO, Goebell PJ, Hellmis E, et al
[Perioperative Treatment with Durvalumab in Combination with Neoadjuvant Chemotherapy in Cisplatin-Eligible Patients with Muscle-Invasive Bladder Cancer].
Aktuelle Urol. 2026 Jul 24. doi: 10.1055/a-2883-3946.
Abstract

MOECKEL C, Ferguson S
Pembrolizumab-Induced Bullous Pemphigoid: Navigating Diagnostic Challenges and Treatment Resistance.
Cutis. 2026;117:E14-E18.
Abstract

FROLOVA A, Vokuev M, Ikhalainen Y, Prosuntsova D, et al
A systematic DoE approach for optimizing urinary LC-HRMS metabolomics: enhancing reliability in bladder cancer profiling.
Anal Bioanal Chem. 2026 Jul 24. doi: 10.1007/s00216-026-06678.
Abstract

FERREIRA VG, Ehlert ME, Pacheco BS, Souza FSS, et al
Preclinical translational screening of palladium(II)-porphyrin photosensitizers across human and Oncopig bladder cancer cell lines.
Front Oncol. 2026;16:1882402.
Abstract

ALHUBAISHY B, Beshawri I, Abulreish I, Alnajar O, et al
Sequential gemcitabine-docetaxel in BCG-naive and BCG-failure non-muscle-invasive bladder cancer: a systematic review and meta-analysis.
Front Oncol. 2026;16:1859461.
Abstract

OUYANG B, Wu Z, Li J, Zhu G, et al
Preliminary study on intravesical instillation of IL-12 mRNA lipid nanoparticles for the treatment of bladder cancer.
Tumori. 2026 Jul 23:3008916261463130. doi: 10.1177/03008916261463130.
Abstract

ZHENG G, Peng Y, DU Y, Xu T, et al
[Expression characteristics and clinical significance of ERBB2 in bladder urothelial carcinoma based on the TCGA database].
Beijing Da Xue Xue Bao Yi Xue Ban. 2026;58:818-826.
Abstract

JI J, Lai C, Wang F, Hu H, et al
[Impact of coexistent low-grade components on the prognosis of high-grade non-muscle invasive bladder cancer].
Beijing Da Xue Xue Bao Yi Xue Ban. 2026;58:803-807.
Abstract

DONG L, Peng Y, Song Y, Li X, et al
[Development of a 36-gene signature for predicting recurrence in non-muscle-invasive bladder cancer and validation in a Chinese cohort].
Beijing Da Xue Xue Bao Yi Xue Ban. 2026;58:794-802.
Abstract

WANG Y, Song H, DU Y, Xu T, et al
[CRISPR-Cas9 activation screening identifies candidate chemokine regulators of ter-tiary lymphoid structure formation in bladder cancer].
Beijing Da Xue Xue Bao Yi Xue Ban. 2026;58:707-715.
Abstract

FILIANOTI A, Costantini M, Rosca V, Mastroianni R, et al
Electronic nose-based urinary volatilome profiling accurately discriminates bladder cancer from healthy controls: A prospective diagnostic study.
Urol Oncol. 2026 Jul 23:S1078-1439(26)00570.
Abstract

LI Y, Wu L, Shi J, Li W, et al
Single-cell and spatial transcriptomics reveal SUV39H1 as a master epigenetic driver of immunosuppressive niche and stemness in bladder cancer.
Transl Oncol. 2026;71:102929.
Abstract

YASUDA K, Tsujino M, Yamasaki H, Kurahashi Y, et al
Rapidly progressive synchronous multifocal gastrointestinal stenoses in bladder cancer: diagnostic challenges and clinical implications.
Int Cancer Conf J. 2026;15:342-348.
Abstract

FAVORITO LA
Editorial Comment: Multiparametric Magnetic Resonance Imaging and Vesical Imaging-Reporting and Data System (VI-RADS) for Bladder Cancer Diagnosis and Staging: A Guide for Clinicians from the American College of Radiology VI-RADS Steering Committee.
Int Braz J Urol. 2026;52:e20269915.
Abstract

QIN J, Zhou H, Li X, Yin H, et al
Efficacy and safety of combining radiotherapy with first-line chemotherapy and immunotherapy for local advanced/metastatic urothelial cancer: a propensity score matching analysis.
Front Immunol. 2026;17:1786952.
Abstract

DONG Y, Su Y
Perspective on the integration of radiomics and spatial omics in the analysis of the tumor microenvironment of bladder cancer and prospects for precision diagnosis and treatment.
Front Immunol. 2026;17:1821743.
Abstract

NIKNAFS AM, Damron LF, Baclig NV, Iliopoulos M, et al
Threading the Needle in Bladder Cancer: A Narrative Review of the Emerging Role of Integrative Oncology in Treatment-Related Adverse Events in the Era of Immunotherapy and Antibody-Drug Conjugates.
Cureus. 2026;18:e111294.
Abstract

PAN M, Tao T, Peng J, Zhang Y, et al
Prognostic value of platelet-to-lymphocyte ratio in bladder cancer: a systematic review and meta-analysis.
Clin Transl Oncol. 2026 Jul 22. doi: 10.1007/s12094-026-04515.
Abstract

LEE DJ, Williams C, Soefje S, Flynn D, et al
BCG at Home: A First-in-kind Trial of Home-based Intravesical Bacillus Calmette-Guerin Delivery for High-risk Non-muscle-invasive Bladder Cancer.
Eur Urol Focus. 2026 Jul 22:S2405-4569(26)00116.
Abstract

DONG C, Fang Z, Han Y, Yin Y, et al
Centrosome-related gene SPHK1 drives bladder cancer progression and therapeutic vulnerability.
Transl Oncol. 2026;71:102926.
Abstract

MAIORANO BA, Maruzzo M, Slusarczyk A, Subiela JD, et al
Comparative efficacy of perioperative systemic therapies for muscle-invasive bladder cancer: a network meta-analysis of randomized trials.
ESMO Open. 2026;11:108329.
Abstract

SRIDHAR SS
A New Standard in Muscle-Invasive Bladder Cancer - The End of the Cisplatin Era?
N Engl J Med. 2026;395:402-404.
Abstract

GALSKY MD, Valderrama BP, Maruzzo M, Font A, et al
Enfortumab Vedotin and Pembrolizumab in Cisplatin-Eligible Bladder Cancer.
N Engl J Med. 2026;395:338-348.
Abstract

ROUANNE M, Chen N, Mariuzza DL, Yang Z, et al
Tumor-specific antibodies elicited by engineered bacteria promote bladder cancer immunotherapy in preclinical mouse models.
Sci Transl Med. 2026;18:eadv7600.
Abstract

GUO M, Zhou Y, Lin X, Xu Z, et al
The prognostic impact of squamous differentiation in bladder cancer after radical cystectomy: a propensity score-matched comparative analysis of pure urothelial carcinoma, urothelial carcinoma with squamous differentiation, and squamous cell carcinoma
Front Oncol. 2026;16:1890852.
Abstract

CHEN X, Sakatani T, Tanaka S, Contreras-Sanz A, et al
A bladder cancer-associated gene signature for exploratory qPCR-based survival stratification in NAC-Treated muscle-invasive bladder cancer.
J Transl Med. 2026 Jul 21. doi: 10.1186/s12967-026-08681.
Abstract

QIN J, Liao K, Huang L, Qiu R, et al
Retraction notice to "Proteome-driven transcriptomic dissection of EMT networks in bladder cancer based on the VIM and CDH2 protein macromolecules influence: From molecular-protein subtyping to therapeutic target prioritization" [Int. J. Biol. Macromo
Int J Biol Macromol. 2026 Jul 22:153573. doi: 10.1016/j.ijbiomac.2026.153573.
Abstract

QIN J, Li Z, Su L, Wen X, et al
Retraction notice to "Expression of transferrin receptor/TFRC protein in bladder cancer cell T24 and its role in inducing iron death in bladder cancer" [Int. J. Biol. Macromol. 274 (2024) 133323].
Int J Biol Macromol. 2026 Jul 22:153488. doi: 10.1016/j.ijbiomac.2026.153488.
Abstract

NOWROOZI MR, Madani MH, Farzin A, Mazdak M, et al
Deep learning approaches for predicting response to neoadjuvant chemotherapy in muscle invasive bladder cancer: A systematic review.
Urol Oncol. 2026 Jul 21:S1078-1439(26)00567.
Abstract

JIN D, Wang H, Jiang C, Zhang F, et al
Non-Invasive Detection of Bladder Cancer via Urinary DNA Mutation and Methylation Profiling Using Modified qPCR.
J Mol Diagn. 2026 Jul 21:S1525-1578(26)00122.
Abstract

SHI T, Wen C, Wang Z, Jiao Y, et al
Celastrol's covalent strike on HK2: Breaking a metabolic-epigenetic circuit to impede bladder cancer.
Pharmacol Res. 2026;231:108349.
Abstract

ZHANG J, Li P, Liu L, Pan Z, et al
Supportive-care burden among bladder cancer survivors in the United States: a nationally representative NHIS study.
Eur J Oncol Nurs. 2026;84:103285.
Abstract

YANG J, Li X, Wang L, Wan S, et al
Single-cell and spatial transcriptomics identify CAPG as a key driver of cisplatin resistance in bladder cancer.
Funct Integr Genomics. 2026;26:197.
Abstract

HUI K, Wu S, Yue Y, Gu Y, et al
Corrigendum to "RASAL2 inhibits tumor angiogenesis via p-AKT/ETS1 signaling in bladder cancer" [Cellular Signaling, 48 (2018) 38-44].
Cell Signal. 2026 Jul 20:112730. doi: 10.1016/j.cellsig.2026.112730.
Abstract

HAMILTON-REEVES JM, Unger JM, Holzbeierlein JM, Lew DL, et al
Immune-Enhancing Nutrition and Outcomes After Radical Cystectomy: A Randomized Clinical Trial.
JAMA Netw Open. 2026;9:e2623622.
Abstract

YANG B, Yang R, Zhang W, Ren X, et al
Multi-DECT image-based intra- and peritumoral interpretable radiomics and artificial intelligence models for preoperative prediction of pathological grading of non-muscle-invasive bladder cancer.
Abdom Radiol (NY). 2026 Jul 20. doi: 10.1007/s00261-026-05679.
Abstract

SUN L, Yuan L
Natural Biopeptide Hirudin Regulates Value-Added Metastasis of Bladder Cancer Cells by Activating PID1 Expression.
Comb Chem High Throughput Screen. 2026.
Abstract

TIAN H, Han X
Sexual experience of urostomy patients with bladder cancer: a qualitative explorative study.
Sci Rep. 2026 Jul 19. doi: 10.1038/s41598-026-62589.
Abstract

MENG XY, Shi MJ, Li S, Liu M, et al
Tobacco's dual genomic footprints in bladder cancer revealed by multi-omics analysis: An SBS4-like LumU-enriched signature and smoking-driven HRD-related genomic instability.
Genes Dis. 2025;13:102001.
Abstract

SAJJADI S, Ramezani A, Alavimanesh S, Alipoor H, et al
Integrative analysis identifies candidate biomarkers for bladder cancer: evidence from genomic and clinical validation.
Mol Biol Rep. 2026;53:1205.
Abstract

EIGNER E, Fazaa N, Nsair A, Atallah M, et al
Risk of second primary malignancies after bladder cancer diagnosed at a young age: a SEER population-based analysis.
Int J Clin Oncol. 2026 Jul 18. doi: 10.1007/s10147-026-03140.
Abstract

NEOLA G, Flauto F, Caso C, Montuori G, et al
The impact of relative dose intensity on pathological complete response in neoadjuvant chemotherapy of muscle-invasive urothelial cancer: a multicenter retrospective study.
Oncologist. 2026;31:oyag256.
Abstract

POWLES T, Madjar K, Balas BI, Carter C, et al
Higher rates of immune-related adverse events in circulating tumor DNA (ctDNA)-negative patients following adjuvant checkpoint inhibitor therapy.
ESMO Open. 2026;11:107701.
Abstract

ARAGON-CHING JB, Gupta S, Grivas P, Park SH, et al
Avelumab first-line maintenance for advanced urothelial carcinoma: long-term outcomes from the JAVELIN Bladder 100 trial in patients with high body mass index or diabetes mellitus.
ESMO Open. 2026;11:107776.
Abstract

ZHOU D, Li Y, Yan Z, Huang J, et al
Recurrence in the chemotherapy regimen of bladder carcinoma originates from quiescent epidermoid-like cells.
Nat Commun. 2026;17:6902.
Abstract

AMRANE K, Campedel L, Moinard-Butot F, Gout M, et al
Real-world efficacy and safety of immune checkpoint blockades in advanced urothelial carcinoma with histologic variant subtypes: the pembroblad study.
Cancer Immunol Immunother. 2026;75:191.
Abstract

SAGLICAN Y, Unlu Y, Behzatoglu K
Approach and nomenclature problems of extracutaneous basaloid neoplasias of visceral organs with three cases of basaloid carcinoma described for the first time in the urinary bladder.
Histol Histopathol. 2026;41:1377-1385.
Abstract

OGUNKEYE J, Shkolyar E, Mach KE, Prendiville S, et al
Performance of Urine Tumor DNA Detection in Patients with High-grade Non-muscle-invasive Bladder Cancer Undergoing Repeat Transurethral Resection.
Eur Urol Focus. 2026 Jul 31:S2405-4569(26)00097.
Abstract

USUI K, Ito H, Muraoka K, Noto N, et al
Oncologic Outcomes of Robot-Assisted Radical Cystectomy for Variant Histology Bladder Cancer: A Multi-institutional Propensity Score-Matched Analysis.
Clin Genitourin Cancer. 2026;24:102618.
Abstract

GAO S, Jiang P, Liu X, Wang J, et al
Cascaded confinement-encapsulated fluorescence nano-immunomachine for noninvasive urinary monitoring of bladder cancer.
Biosens Bioelectron. 2026;312:119076.
Abstract

BOGALE DE
Activation of the PI3K/AKT/mTOR signaling pathway in bladder cancer pathogenesis and its therapeutic significance.
Cancer Treat Res Commun. 2026;48:101340.
Abstract

ABDULLAH OR, Short K, Alomari LHF, Ignatowicz A, et al
Venous thromboembolism in urothelial bladder cancer - scope of the problem and patients' perspectives: VTE-UBC.
Wiad Lek. 2026;79:1169-1178.
Abstract

ZHONG C, Masters M, Donzella SM, Bliwise DL, et al
Risk of bladder cancer among male participants reporting nocturia in the Cancer Prevention Study-II.
Cancer Epidemiol Biomarkers Prev. 2026.
Abstract

NIEGISCH G, Grunewald C
[Perioperative treatment of muscle-invasive bladder cancer : Current treatment concepts].
Urologie. 2026 Jul 31. doi: 10.1007/s00120-026-02900.
Abstract

MO Z, Gai S, Qin X, Meng D, et al
Retraction notice to "Correlation between TCF7 and bladder cancer and feasibility of Erlotinib targeting in bladder cancer: Molecular mechanism and expression of TCF7 recombinant protein" [Int. J. Biol. Macromol. 301 (2025) 140438].
Int J Biol Macromol. 2026 Jul 30:153654. doi: 10.1016/j.ijbiomac.2026.153654.
Abstract

VERMA GK, Saini D, Chaudhary PK, Saha S, et al
Association between heavy metal exposure and epigenetic modifications in patients with urinary bladder cancer.
Gene. 2026 Jul 30:150330. doi: 10.1016/j.gene.2026.150330.
Abstract

CHEVILLE JC, Tekin B, Orme JJ, Jimenez RE, et al
ERBB2 Copy Number Alterations and Protein Expression in Bladder Cancer Treated by Cystectomy.
Hum Pathol. 2026 Jul 30:106217. doi: 10.1016/j.humpath.2026.106217.
Abstract

HENDRI AZ, Robert R, Febriyanto T, Liliana B, et al
Prognostic significance of TOP2A expression in bladder cancer: Systematic review and meta-analysis.
Can Urol Assoc J. 2026 Jul 20. doi: 10.5489/cuaj.9572.
Abstract

SAYED U, Basheer NM, H M, Nayak PP, et al
Kinesins in Bladder Cancer: Integrating Molecular Mechanisms and Treatment Approaches.
Cell Biol Int. 2026;50:e70191.
Abstract

JIN J, Jin Y, Zhang R, Li Y, et al
A novel quinoline and manganese-based carbon monoxide-releasing molecule for intravesical therapy of bladder cancer.
Br J Pharmacol. 2026 Jul 30. doi: 10.1111/bph.70614.
Abstract

FUKUHARA H, Shigehisa R, Yamamoto S, Fukata S, et al
Comparison of 5-aminolevulinic acid-induced hypotension of extending the oral administration period during photodynamic diagnosis-assisted transurethral resection of bladder tumor for non-muscle invasive bladder cancer.
Photodiagnosis Photodyn Ther. 2026 Jul 29:105591.
Abstract

GU T, Gunelli R, Chen T, Wang C, et al
Robotic-assisted intracorporeal radical cystectomy with modified ileal conduit reduces ureteroileal anastomotic stenosis risk: a comparative study with laparoscopic surgery.
Ann Med. 2026;58:2703361.
Abstract

GAN L, Wu J, Li Z, Cao H, et al
Intra-corporeal robot-assisted versus open radical cystectomy: a meta-analysis.
World J Urol. 2026;44:531.
Abstract

SALAH IBRAHIM A, Gamal DA, Hadia A, Hasaballah A, et al
Superiority of Adjuvant Hyperfractionated Radiotherapy Over Chemotherapy Following Radical Cystectomy.
Asian Pac J Cancer Prev. 2026;27:2571-2580.
Abstract

DA SILVA IM, Rocha LMO, de Andrade QG, de Lima LVA, et al
Telomere stability pathway genes as predictors of susceptibility and prognosis in urothelial bladder cancer: review and bioinformatics analyses.
J Toxicol Environ Health B Crit Rev. 2026.
Abstract

ANTONELLI L, Afferi L, Del Giudice F, Bologna E, et al
Discordant Response in Pelvic Lymph Nodes and Cystectomy Specimens After Neoadjuvant Chemotherapy in Muscle-invasive Bladder Cancer.
Eur Urol Focus. 2026 Jul 28:S2405-4569(26)00155.
Abstract

SUARTZ CV, Huber IMT, Brito PHS, de Lima RD, et al
Perioperative Immunotherapy in Muscle-Invasive Bladder Cancer: A Systematic Review and Meta-Analysis of Neoadjuvant and Adjuvant Strategies.
Clin Oncol (R Coll Radiol). 2026;57:104281.
Abstract

DE MIGUEL-GARCIA G, Ruiz de Porras V, Font-Moron M, Font A, et al
Urinary biomarkers in muscle-invasive bladder cancer: Current state and open opportunities for neoadjuvant chemotherapy response prediction and patient stratification.
Biomed Pharmacother. 2026;202:119807.
Abstract

WANG B, Zou J, Gao L, Lou F, et al
Factors associated with help-seeking for urinary symptoms among Chinese patients with bladder cancer: A qualitative study.
Asia Pac J Oncol Nurs. 2026;13:101001.
Abstract

LAINEZ N, Martinez-Kareaga M, Sagastibeltza-Marinalarena N, Sanchez M, et al
Perioperative therapy in muscle-invasive bladder cancer: real-world evidence from the MINOTAURO study.
ESMO Real World Data Digit Oncol. 2026;13:100732.
Abstract

XU J, Xiong Y, Liu C, Sun J, et al
Oncolytic virus OHSV2 induces pyroptosis in bladder cancer cells via the TLR4/NLRP3/Caspase-1/GSDMD pathway.
Mol Biomed. 2026;7:119.
Abstract

HAGE L, Chakra MA, O'Donnell MA, Userovici M, et al
Clinical patterns and pathogenesis of bladder leiomyoma: a multicenter observational study.
World J Urol. 2026;44:526.
Abstract

TANAKA T, Oriyama T, Yamamoto T, Kimura S, et al
Risk factors for chemotherapy-induced dysgeusia in patients receiving dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin therapy: a retrospective observational study.
Support Care Cancer. 2026;34:808.
Abstract

LUO Y, Liu X, Zhu S, Lin P, et al
Clonal evolution and stromal crosstalk drive an invasive epithelial program in bladder cancer.
Front Cell Dev Biol. 2026;14:1809774.
Abstract

LIU T, Li W, Yin Q, Liu D, et al
Preclinical Models of Bladder Cancer: Barrier, Metabolic, and Translational Susceptibility.
Pharmaceuticals (Basel). 2026;19:1116.
Abstract

CANCERS EDITORIAL OFFICE
Expression of Concern: Park et al. Isorhamnetin Induces Cell Cycle Arrest and Apoptosis Via Reactive Oxygen Species-Mediated AMP-Activated Protein Kinase Signaling Pathway Activation in Human Bladder Cancer Cells. Cancers 2019, 11, 1494.
Cancers (Basel). 2026;18:2357.
Abstract

SALA-GONZALEZ N, Chekhun S, Fina C, Vilaseca M, et al
Low-Cost Pathology Signals for Risk Stratification in High-Risk Non-Muscle-Invasive Bladder Cancer: A Narrative Review.
Cancers (Basel). 2026;18:2269.
Abstract

MUKHERJEE N, Ji N, Hassouneh Z, Furman J, et al
Unveiling the Paradoxical Tumor-Suppressive Role of CCL2/CCR2 in Bladder Cancer: A Novel Immunotherapeutic Strategy.
Cancers (Basel). 2026;18:2267.
Abstract

PEREZ M, Lozano JJ, Ingelmo-Torres M, Domenech M, et al
Correction: Perez et al. Biomarker-Based Nomogram to Predict Neoadjuvant Chemotherapy Response in Muscle-Invasive Bladder Cancer. Biomedicines 2025, 13, 740.
Biomedicines. 2026;14:1604.
Abstract

GIMALOVA G, Gilyazova I, Khusnutdinova E, Pavlov V, et al
SnoRNA and SNHG in Bladder Cancer: Molecular Mechanisms and Clinical Significance.
Curr Issues Mol Biol. 2026;48:662.
Abstract

UGUR R, Demiriz B, Nisli O, Keskin ET, et al
Who is at Risk of Residual Tumor and Pathologic Upstaging at a Second TURBT in Non-Muscle-Invasive Bladder Cancer?
Ann Surg Oncol. 2026 Jul 27. doi: 10.1245/s10434-026-20268.
Abstract

TYSON MD 2ND, Nam JK, Joshi SS, Uchio EM, et al
Intravesical cretostimogene grenadenorepvec oncolytic immunotherapy in high-risk, BCG-unresponsive, non-muscle-invasive bladder cancer with carcinoma in situ (BOND-003 Cohort C): a single-arm, phase 3 trial.
Lancet Oncol. 2026;27:983-993.
Abstract

AKPINAR C, Aydog E, Sahin B, Gulsen M, et al
Contemporary Trends in the Surgical and Systemic Management of Muscle-Invasive Bladder Cancer: Insights From a Nationwide Multicenter Cohort in Turkey Over 2 Decades.
Clin Genitourin Cancer. 2026;24:102612.
Abstract

ALI M, Soliman SE, Eldeeb TS, Aboeleuon E, et al
Muscle invasion in bladder cancer is associated with increased expression of ATG5, LC3A and CHOP.
Mol Biol Rep. 2026;53:1281.
Abstract

BEDKE J, Eccleston A, Unsworth M, Brinkmann J, et al
Management of high-risk non-muscle invasive bladder cancer: a real-world study in North America, Europe and Japan.
Future Oncol. 2026 Jul 27:1-14. doi: 10.1080/14796694.2026.2696928.
Abstract

WANG W, Li D, Liu J, Li L, et al
Molecular Construction and Anti-Bladder Cancer Study of Novel TOP1/PARP1 Dual-Target Inhibitors.
J Med Chem. 2026 Jul 27. doi: 10.1021/acs.jmedchem.6c01714.
Abstract

ZHANG Y, Shi X, Yuan Y, Gao X, et al
MoN/Au/cTAT Boosted Sonochemotherapy Post-Intravesical Instillation in Bladder Cancer.
Small. 2026 Jul 27:e11210. doi: 10.1002/smll.202511210.
Abstract

FREY LJ, Lache N, Fischer ND, Rolz N, et al
Immunohistochemical Expression of Novel Therapeutic Targets in Squamous Cell Carcinoma of the Bladder.
Oncol Res. 2026;34:14.
Abstract

WANG YD, Lai YL, Liu CH, Su YT, et al
Epigenomics-Guided Multi-Omics Integration Uncovers a Lipid-Metabolic Signature with Translational Utility in Bladder Cancer.
Comput Struct Biotechnol J. 2026;35:0139.
Abstract

ISHIGAMI Y, Takahashi M, Nakatsukasa H, Shibano M, et al
Clinical impact of opioid use in patients with urothelial carcinoma treated with pembrolizumab: a single center retrospective study.
Immunotherapy. 2026;18.
Abstract

TYAGI B, Tyagi A, Vashishta M, Tyagi N, et al
Integrated analyses of the microbiome, metabolome, and spatial transcriptomics reveal sex-dependent bladder vulnerability to chronic inorganic arsenic.
J Hazard Mater. 2026;514:142653.
Abstract

CAO S, Chen Z, Wang S, Zhou Q, et al
Arsenic induced deubiquitination modification of PLCE1 in a de-SUMO-dependent manner to affect malignant behavior in bladder epithelial cells.
J Hazard Mater. 2026;514:142786.
Abstract

ZHU A, Singh Z, Holt SK, Schade GR, et al
Impact of low levels of arsenic in drinking water with incident urologic cancers in Washington state.
J Hazard Mater. 2026;514:142671.
Abstract

ZHU Y, Hu Q, Zhang R, Zhang G, et al
Advancements in Endoscopic Optical Coherence Tomography for Urothelial Carcinoma: Research Progress and Clinical Applications.
Curr Med Imaging. 2026;22:e15734056434411.
Abstract

DIANA P, Paciotti M, Frego N, Gallioli A, et al
Intraoperative Skills for Transurethral Resection of Bladder Tumor: Objective Assessment and Construct Validity of the ENTRY Metrics.
Eur Urol Focus. 2026;12:377-382.
Abstract

TILKI B, Guler OC, Demirhan B, Hurmuz P, et al
Stereotactic body radiotherapy for bone-only oligometastatic bladder Cancer: a multi-institutional experience.
Clin Transl Radiat Oncol. 2026;60:101246.
Abstract

ELEFTHERIOU C, Zhao Y, Lami M, Boaz RJ, et al
Comparison of postoperative and early oncological outcomes of open versus robotic radical cystectomy.
J Robot Surg. 2026;20:808.
Abstract

DOLEK EK, Biyikoglu M, Cayan S, Senel S, et al
The Effect of Intravesical Bacillus Calmette-Guerin Treatment on Sexual Functions and Mental Health in Male and Female Patients Diagnosed with Non-Muscle Invasive Bladder Cancer.
Urol Res Pract. 2026;52:1-8.
Abstract

XU J, Huang Y, Ni G, Huang Y, et al
Hemostatic Efficacy and Clinical Outcomes of Radiotherapy in Older Adult Patients With Advanced Bladder Cancer and Hematuria Unsuitable for Standard Treatment.
Med Sci Monit. 2026;32:e953113.
Abstract

DEZA I, de Lacy Costello B, Drabinska-Fois N, White P, et al
Urinary volatilomics using liquid-liquid extraction and gas chromatography-mass spectrometry (GC-MS) combined with machine learning algorithms as a tool for diagnosis and surveillance of urothelial bladder cancer.
BJC Rep. 2026;4:42.
Abstract

SFORZA S, Lubbersmeyer F, Mari A
Prognostic Factors After Radical Cystectomy for Non-muscle-invasive Bladder Cancer: From Prognostication to Patient Selection.
Eur Urol Oncol. 2026 Aug 7:S2588-9311(26)00200-2. doi: 10.1016/j.euo.2026.
Abstract

ST-LAURENT MP, Eigl BJ, Tyldesley S, Yuan R, et al
NeoBLAST: A Pilot Randomized Controlled Trial of Active Surveillance Versus Definitive Bladder Treatment Following Clinical Complete Response to Neoadjuvant Therapy in Muscle-invasive Bladder Cancer - Study Protocol.
Eur Urol Oncol. 2026 Aug 7:S2588-9311(26)00198-7. doi: 10.1016/j.euo.2026.
Abstract

YANG X, Cai L, Wang C, Tan Z, et al
The Prognostic Role of HER2 Expression in Patients With Non-Muscle-Invasive Bladder Cancer.
Clin Genitourin Cancer. 2026;24:102624.
Abstract

XU Z, Wang X
Intracorporeal urinary diversion during robot-assisted radical cystectomy: a bibliometric and visualization analysis of research evolution, evidence landscape, learning curves, and clinical outcomes.
J Robot Surg. 2026;20:806.
Abstract

IKEHATA Y, Nishiyama N, Miyake M, Nishimura N, et al
Prognostic significance of non-muscle-invasive late recurrence after intravesical bacillus Calmette-Guerin therapy in bladder cancer: a multicenter, retrospective real-world study (the Japan Urological Oncology Group).
Jpn J Clin Oncol. 2026 Aug 7:hyag124. doi: 10.1093.
Abstract

TYSON MD 2ND, Choudry MM, McKee C, Kalaria S, et al
Health Care Utilization and Costs Associated With Blue-Light vs White-Light Cystoscopy: A Real-World Bladder Cancer Population.
JU Open Plus. 2026;4:e00085.
Abstract

DONG X, Chen Z, Chen Y, Xiao Z, et al
Mechanical stress, metabolic reprogramming and stromal remodeling: an emerging paradigm in the bladder cancer mechano-micro-environment.
Front Genet. 2026;17:1896399.
Abstract

GOH NS
Presumed Simultaneous Intraocular and Extraocular BCG-osis as a Complication of Intravesical Bacillus Calmette-Guerin Treatment for Non-Muscle-Invasive Bladder Cancer: A Case Report.
Cureus. 2026;18:e114020.
Abstract

DIAO X, Che B, Zhai J, Shao B, et al
Decoding the temporal dimension of innate immunity in intravesical BCG therapy.
Front Immunol. 2026;17:1904049.
Abstract

SAAD A, Daraan FM, Barghouth I, Sleiay M, et al
Complete Response to Intravesical BCG for High-Risk pT1 Bladder Cancer With Lymphovascular Invasion: A Case Report.
Case Rep Oncol Med. 2026;2026:7517129.
Abstract

HENSLEY PJ, Teoh JYC, Li R, Gupta S, et al
Integrating clinically actionable biomarkers into bladder cancer care - recommendations from the International Bladder Cancer Group.
Nat Rev Urol. 2026 Aug 5. doi: 10.1038/s41585-026-01179.
Abstract

SAAD MA, Antari A, Taleb I, El Omri S, et al
Bacillus Calmette-Guerin (BCG) with or without immune checkpoint blockade in BCG-naive high-risk non-muscle-invasive bladder cancer: A systematic review and reconstructed individual patient data meta-analysis.
Crit Rev Oncol Hematol. 2026;227:105510.
Abstract

KIEBACH J, Kamps CSAD, Wesselink E, Aben KKH, et al
Lifestyle and dietary inflammation scores and risks of recurrence and progression among patients with non-muscle invasive bladder cancer.
Nutrition. 2026;151:113354.
Abstract

ZUO J, Tan Y, Mu Z, Dong Y, et al
Assembly-formed bioorthogonal chimeric artificial receptors enable high-contrast fluorescence imaging of tumors.
Sci Adv. 2026;12:eaed9403.
Abstract

GAOL LML, Prabaningrum YSK, Andy, Swity AF, et al
Atypical desmoplastic small round cell tumor (DSRCT) mimicking muscle-invasive bladder cancer (MIBC) in a child: Surgical approach using ileal diversion.
Radiol Case Rep. 2026;21:4398-4404.
Abstract

ZHOU L, Zhu J, Liu Y, Xu B, et al
Integrated Immunological Analysis of Interactions Between CXCL13+ T Cells and LAMP3+ DC in the Immunotherapy Response of Bladder Cancer.
Mol Carcinog. 2026 Aug 5. doi: 10.1002/mc.70162.
Abstract

CHEN Y, Jiang Y, Yang Z, Jing M, et al
LAMC2(+) Epithelial Cells Drive Bladder Cancer Progression and Predict Immunotherapy Response via SERPINB3/STAT3/CD44 Axis.
Cancer Sci. 2026 Aug 5:10.1111/cas.70492. doi: 10.1111/cas.70492.
Abstract

AYDIN A, Abdulmajeed AS, Bekiroglu FB, Kocak M, et al
Investigating gender disparities in urological care for non-muscle invasive bladder cancer (NMIBC).
BJUI Compass. 2026;7:e70245.
Abstract

AYDOGDU C, Wang B, McSweeney S, Pieretti A, et al
ASO Visual Abstract: Preoperative Tumor-Informed ctDNA for Prediction of Nodal Metastases at Radical Cystectomy in Bladder Cancer.
Ann Surg Oncol. 2026 Aug 4. doi: 10.1245/s10434-026-20121.
Abstract

HORI J, Tokumitsu M, Yamaguchi S, Ishida H, et al
[Outcome of Eight-Year-Experiences of BCG Intravesical Instillation Therapy in Patients with Non-Muscle Invasive Bladder Cancer in Asahikawa Medical University Hospital].
Gan To Kagaku Ryoho. 2026;53:407-412.
Abstract

ZHANG S, Li M, Wu Y, Kang Y, et al
Circ_0001495 promotes bladder cancer progression by regulating miR-1184 via MAPK signaling pathway.
Mol Biol Rep. 2026;53:1337.
Abstract

TANAKA N, Miyajima A, Kosaka T, Shirotake S, et al
Editor's Note: Cis-dichlorodiammineplatinum Upregulates Angiotensin II Type 1 Receptors through Reactive Oxygen Species Generation and Enhances VEGF Production in Bladder Cancer.
Mol Cancer Ther. 2026;25:1410.
Abstract

SCILIPOTI P, Rosiello G, Salonia A, Briganti A, et al
Beyond surgical technique: modifiable risk factors and evolving treatment paradigms in bladder cancer surgery.
Nat Rev Urol. 2026 Aug 3. doi: 10.1038/s41585-026-01180.
Abstract

MALMSTROM PU, Dragomir A, Gardmark T
Validation of an AI-based Histologic Prognostic Biomarker in Patients with Non-muscle-invasive Bladder Cancer Using the Prospective Swedish National Register of Urinary Bladder Cancer.
Eur Urol Oncol. 2026 Aug 4:S2588-9311(26)00192-6. doi: 10.1016/j.euo.2026.
Abstract

AGHAMIR SMK, Rahimnia R, Taheri D, Ebrahimi M, et al
Prognostic value of different biomarkers in bladder cancer: protocol for an umbrella review of systematic reviews and meta-analyses.
BMJ Open. 2026;16:e118810.
Abstract

HAWEZ L, Bergengren O, Ahlberg M, Garmo H, et al
Suicide risk among urinary bladder cancer patients compared with the standard population: a nationwide study in Sweden.
Scand J Urol. 2025;60:204-208.
Abstract

MORENO-VEGA A, Zambrano M, Estrada-Virrueta L, Meng X, et al
FGFR3-driven gene regulatory network analysis reveals a protumoral role for p63 in luminal bladder tumors.
J Clin Invest. 2026;136:e193280.
Abstract

UGUR R, Demiriz B, Nisli O, Keskin ET, et al
ASO Visual Abstract: Who is at Risk of Residual Tumor and Pathologic Upstaging at Second TURBT in Non-Muscle-Invasive Bladder Cancer?
Ann Surg Oncol. 2026 Aug 1. doi: 10.1245/s10434-026-20351.
Abstract

ZENG Z, Hu C, Li Y, Ding B, et al
Smart nanoplatform targeting the mitochondria-P-gp axis to overcome chemoresistance for synergistic bladder cancer therapy.
Colloids Surf B Biointerfaces. 2026;268.
Abstract

RUTTEN VC, van Rijen NMA, Franckena M, Robbrecht DGJ, et al
Real-world Impact of Integrating Comprehensive Geriatric Assessment into Clinical Treatment Decision-making for Older Patients with Bladder Cancer.
Eur Urol Open Sci. 2026;91:23-31.
Abstract

FUKUHARA H, Shimasaki S, Yamashita E, Kurano Y, et al
Transurethral laser ablation using 980-nm diode laser for recurrent non-muscle invasive bladder cancer.
Explor Target Antitumor Ther. 2026;7:1002386.
Abstract

MUSCATELLO LV, Bacci B, Brigandi E, Tugnoli C, et al
Computer-aided image analysis for PD-L1 assessment in canine urothelial carcinoma.
Vet J. 2026;318:106758.
Abstract

EINERHAND SMH, Ali H, Wong SQ, van Dorp J, et al
Tremelimumab with or without durvalumab in combination with paclitaxel in metastatic urothelial cancer: phase I/II ICRA trial.
Nat Commun. 2026;17:7679.
Abstract

SUARTZ CV, Azevedo MFD, Brito PHS, Setoue DND, et al
Evolution of treatment and oncological outcomes in patients undergoing radical cystectomy: a comparative analysis across two decades at a tertiary center.
BMC Urol. 2026;26:189.
Abstract

YEH CC, Fan CS, Chen LL, Chua KV, et al
Preclinical evaluation of rBCG-h12: an engineered Bacillus Calmette-Guerin with an enhanced activity against bladder and pancreatic cancers.
Cancer Immunol Immunother. 2026;75:202.
Abstract

WOO S, Muglia VF, Luk L, Takeuchi M, et al
What's next for VI-RADS? Updates and future perspectives from the ACR VI-RADS steering committee.
Cancer Imaging. 2026;26:97.
Abstract

THAI KL, Le PND, Nguyen TT, Ngo XT, et al
Clinical and imaging predictors of urachal carcinoma: the role of gross hematuria and calcification in a single-center retrospective study.
BMC Urol. 2026;26:190.
Abstract

MATSUBARA N, Saijo K, Shimizu Y, Okano S, et al
First-In-Human Study: Dose Expansion of E7130 in Urothelial Carcinoma and Squamous Cell Carcinoma of the Head and Neck.
Cancer Sci. 2026;117:2247-2258.
Abstract

VARANASI P, Wengenack N, Steidley DE, Kodali L, et al
Disseminated Mycobacterium bovis-BCG Infection Following Intravesical BCG Administration in Solid Organ Transplant Recipients.
Transpl Infect Dis. 2026;28:e70220.
Abstract

TEH A, Sima T, Shinozaki E, Malik R, et al
A case of canine urothelial carcinoma of the urinary bladder with skull and skeletal metastases.
Aust Vet J. 2026;104:509-514.
Abstract

LEE T, Akgul M, Fernandez-Pol S, Aron M, et al
Immunohistochemical Expression of p63 and GATA3 in Lymphomas of the Urinary Bladder: A Clinicopathologic Study of a Potential Diagnostic Pitfall.
Int J Surg Pathol. 2026;34:1483-1488.
Abstract

MITRA S, Shangloo A, Bhatkule MA, Akif S, et al
Complete Colonic Metaplasia of the Urinary Bladder and Ureters With Primary Signet-Ring Cell Adenocarcinoma of the Urinary Bladder: A Rare Occurrence.
Int J Surg Pathol. 2026;34:1630-1635.
Abstract

BUDINA A, Vergara N, Navarro FE, Morrissette JJD, et al
High-Grade Urothelial Carcinoma with Divergent Prostatic Differentiation Mimicking a Collision Tumor in a Bladder Diverticulum.
Int J Surg Pathol. 2026;34:1570-1578.
Abstract

GRYPARI IM, Pomoni A, Ganetsou D, Kouroukli O, et al
True Papillae and Squamous Features in Prostate Carcinoma Represent a Potential Diagnostic Pitfall: Report of 3 Patients.
Int J Surg Pathol. 2026;34:1610-1615.
Abstract

POLAT UNAL SE, Suren D, Kurtoglu E
Primary Classical Hodgkin Lymphoma of the Urinary Bladder: Expanding the Spectrum of Bladder Lymphoid Neoplasms.
Int J Surg Pathol. 2026;34:1586-1590.
Abstract

ILMIAH K, Parengkuan IL, Rahaju AS, Mastutik G, et al
Bladder Urothelial Neoplasms Profile in Dr. Soetomo General Academic Hospital Surabaya: Retrospective Study during 2013-2023.
Urologia. 2026;93:384-388.
Abstract

ILKTAC A, Dogan B, Gevher F, Akcay M, et al
Hematuria-related readmission after transurethral resection of bladder tumor in patients receiving antiplatelet therapy.
Urologia. 2026;93:370-375.
Abstract

JAVID RAJA IYUB M, Prabhakar P, Pon Avudaiappan A, Sakthivel DK, et al
Postoperative ileus following radical cystectomy in current urological practice: Incidence and risk factors.
Urologia. 2026;93:376-383.
Abstract

KITAHAMA K, Inamura K
Inverted urothelial papilloma: Diagnostic challenges, molecular insights, and clinical implications.
Histol Histopathol. 2026;41:1483-1491.
Abstract

AL ARMASHI AR, Gong J, Barata P, Brown J, et al
Immune checkpoint inhibitors in urothelial carcinoma: a practical framework for patient selection, toxicity management, response assessment, and treatment sequencing.
Expert Rev Anticancer Ther. 2026;26:1003-1017.
Abstract

ZHU H, Tan S, Liu X
Bladder mucosal apoptosis index and quality of life after adjuvant intravesical BCG therapy for non-muscle-invasive bladder cancer: a retrospective propensity-score-matched study.
Front Oncol. 2026;16:1856699.
Abstract

MATSUSHITA Y, Tamura A, Masuda T, Hasegawa O, et al
Deep learning-based automated identification of papillary bladder cancer from endoscopic still images using SE-ResNeXt-50.
World J Urol. 2026;44:566.
Abstract

LI F, Chen C, Ye W, Huang Y, et al
Shikonin inhibits bladder cancer progression by targeting deoxyribonuclease 2 to suppress reticulon 3-dependent endoplasmic reticulum autophagy.
Phytomedicine. 2026;160:158682.
Abstract

BURGESS EF, Brown L, McCormack M, Liu L, et al
Tumor Mutational Burden and Clinical Outcomes in Muscle-Invasive Bladder Cancer Patients Treated with Neoadjuvant Chemotherapy.
Cancer Res Commun. 2026 Aug 13. doi: 10.1158/2767-9764.CRC-26-0255.
Abstract

RASKIN Y, Baekelandt F, Decaestecker K, Seront E, et al
Real-world treatment patterns and clinical outcomes in patients with non-muscle invasive bladder cancer: a nationwide evaluation.
World J Urol. 2026;44:560.
Abstract

TANG X, Liu J, Zhao Q, Yang X, et al
The Diagnostic and Prognostic Value of Immunohistochemical Markers in Bladder Cancer: A Real-World Study of 477 Patients.
J Clin Med. 2026;15:6124.
Abstract

SUN W, Li Y, Xu M, Guan H, et al
Oridonin Suppresses Bladder Cancer Growth and Metastasis by Inducing S-Phase Arrest and Apoptosis.
Int J Mol Sci. 2026;27:6835.
Abstract

SANTINI N, Procino A, Ljubic S, Dermic D, et al
Extracellular Alpha-Satellite DNA in Human Plasma as a Candidate Biomarker for Bladder Cancer Detection: Preliminary Evidence Using Digital PCR.
Int J Mol Sci. 2026;27:6834.
Abstract

AKHMETKALIYEV A, Fritz Garcia JHG, Sonnenberg-Riethmacher E, Riethmacher D, et al
Matricellular Proteins in Bladder Cancer: Context-Dependent Roles in Tumor Promotion and Suppression.
Int J Mol Sci. 2026;27:6807.
Abstract

PINTON P
Structural Misalignment Between Regulatory Definitions of BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer and Real-World Clinical Practice.
Healthcare (Basel). 2026;14:2303.
Abstract

ZHAO F, Vakhrusheva O, Markowitsch SD, Slade KS, et al
Correction: Zhao et al. Artesunate Inhibits Metastatic Potential in Cisplatin-Resistant Bladder Cancer Cells by Altering Integrins. Cells 2025, 14, 570.
Cells. 2026;15:1363.
Abstract

GOMEZ J, Lakew M, Wilkie H, David B, et al
Bladder Cancer Cells Maintain Paracrine IL-1 Signaling and IL-1Ra Sensitivity Following Chronic IL-1 Exposure.
Cells. 2026;15:1376.
Abstract

GABRIEL PE, Zhu A, Karim C, Eraky A, et al
Prognostic Value of Perioperative Circulating Tumor DNA in Pure Urothelial Carcinoma and Histological Subtypes of Bladder Cancer.
Eur Urol Focus. 2026 Aug 12:S2405-4569(26)00122.
Abstract

BEIJERT IJ, Wever BMM, Moldovan N, van den Burgt Y, et al
Integrated Methylation and Copy Number Analysis for Noninvasive Bladder Cancer Detection in Urine.
JCO Precis Oncol. 2026;10:e2500882.
Abstract

SONG L, Meagher M, Saidian A, Salmasi A, et al
Intravesical Recurrence of Upper Tract Urothelial Carcinoma: Strategies for Prevention.
Curr Urol Rep. 2026;27:37.
Abstract

CHEN K, Bai Z, Huang Y
USP5 silencing inhibits the proliferation of bladder cancer cells and induces cell apoptosis and ferroptosis by destabilizing COL14A1 expression.
Transl Androl Urol. 2026;15:232.
Abstract

WATANABE H, Ishikawa G, Watanabe S, Watanabe S, et al
Clinical benefits, tolerability, and risk factors of adjuvant nivolumab for muscle-invasive bladder cancer.
Transl Androl Urol. 2026;15:234.
Abstract

MIYAKE M
Rural-urban disparities in high?risk non-muscle?invasive bladder cancer: lessons from the Canadian Bladder Cancer Information System.
Transl Androl Urol. 2026;15:227.
Abstract

ZHOU Y, Yang X, Tian T, Yang B, et al
Efficacy and safety of combination versus single-agent immunotherapy for BCG-unresponsive non-muscle-invasive bladder cancer.
Front Immunol. 2026;17:1896444.
Abstract

NIE W, Jiang Y, Yao L, Zhu X, et al
Retraction notice to "Prediction of bladder cancer prognosis and immune microenvironment assessment using machine learning and deep learning models" [Heliyon 10 (2024) e39327].
Heliyon. 2025;12:e44476.
Abstract

GORCZYNSKI A, Tarjan B, Neittaanmaki N
Deep learning-assisted detection of lymph node metastases in bladder cancer.
Diagn Pathol. 2026;21:58.
Abstract

SKUPIN PA, Wu S, Orikogbo O, Chadwick SJ, et al
Treatment Type and Mortality for Black Versus White Patients With Muscle-Invasive Bladder Cancer.
Clin Genitourin Cancer. 2026 Jul 17:102626. doi: 10.1016/j.clgc.2026.102626.
Abstract

SCILIPOTI P, Rosiello G, Salonia A, Briganti A, et al
Re: Contieri R, Paciotti M, Uleri A, et al. Second Transurethral Resection of Bladder Tumor Can Be Safely Omitted in Selected Patients with T1 Non-muscle-invasive Bladder Cancer: Results from the Prospective HuNIRe Trial. Eur Urol Oncol 2026;9:404-412
Eur Urol Oncol. 2026 Aug 11:S2588-9311(26)00219.
Abstract

LIU J, Hu M, Chen J, Zu X, et al
Tro-score, a trogocytosis-related transcriptomic signature, identifies CD109 as a therapeutic target for reversing immunosuppression in bladder cancer.
Int Immunopharmacol. 2026;187:117273.
Abstract

GUO Y, Ren X, Zhang Z, Cheng H, et al
The pre-treatment tumor microenvironment immune status determines Bacillus Calmette-Guerin immunotherapy response in early-stage bladder cancer.
Cancer Immunol Res. 2026 Aug 11. doi: 10.1158/2326-6066.CIR-25-1445.
Abstract

TIAN J, Li L, Xu L, Liu L, et al
Effects of self-management interventions on self-care ability and quality of life in patients with urinary ostomy after bladder cancer: a systematic review and meta-analysis.
Front Oncol. 2026;16:1864061.
Abstract

LI Z, Yan T, Hu C, Lu Z, et al
Construction and Validation of a Ubiquitination-Related Gene Signature Based on WGCNA and Single-cell RNA Sequencing in Bladder Cancer.
Curr Med Chem. 2026 Jul 28. doi: 10.2174/0109298673470246260702000813.
Abstract

WU H, Jiang Y, Zhang X, Wang S, et al
[Everolimus inhibits malignant phenotype of erdafitinib-resistant bladder cancer cells through the p70S6K/PI3K/MAPK signaling pathway].
Nan Fang Yi Ke Da Xue Xue Bao. 2026;46:1870-1877.
Abstract

LOTAN Y, Margulis V, Woldu S, Allison D, et al
Development and validation of a computational histology artificial intelligence-powered prognostic biomarker in muscle-invasive bladder cancer.
Urol Oncol. 2026 Aug 10:S1078-1439(26)00601.
Abstract

DING Y, Zhu Y, Li J, Chen X, et al
Mucosa-penetrating NIR-II nanomedicine for precision photoimmunotherapy of bladder cancer.
Biomaterials. 2026;337:124518.
Abstract

CHEN Y, Wang Z, He C, Yu Z, et al
KLF6-driven macrophage-to-myofibroblast transition promotes PD-L1-mediated immune evasion in bladder cancer.
Int Immunopharmacol. 2026;187:117201.
Abstract

MAISCH P, Muhlberger M, Beck A, Schreen W, et al
Evaluation of Stimulated Raman Histology as a Novel Method for Pathologic Examination of Urothelial Carcinoma With Unprocessed, Fresh Bladder Cancer Tissue.
Technol Cancer Res Treat. 2026;25:15330338261464295.
Abstract

HU Y, Csuka J, Rajbhandari P, Huang P, et al
PLA2G2F suppresses ferroptosis through phospholipid remodeling.
Nat Struct Mol Biol. 2026;33:1147-1157.
Abstract

YANG X, Ding Z, Pengwang Y, Wei Y, et al
RBCK1 promotes chemotherapy resistance in bladder carcinoma by targeting HLTF.
Pathol Res Pract. 2026;286:156625.
Abstract

OU M, Ji C, Wen J
A hypervascular perivascular epithelioid cell tumor of the urinary bladder showing TFE3 immunoreactivity clinically misdiagnosed as paraganglioma in an adolescent patient.
BMC Urol. 2026;26:195.
Abstract

FLEGAR L, Eisenmenger N, Reimold P, Koch R, et al
Surgical Management of Urachal Cancer in Germany: A Nationwide Analysis From 2006 to 2022.
Ann Surg Oncol. 2026;33:8630-8635.
Abstract

DI BELLO F, Gallioli A, Palou J, Breda A, et al
Re: Roberto Contieri, Marco Paciotti, Alessandro Uleri, et al. Second Transurethral Resection of Bladder Tumor Can Be Safely Omitted in Selected Patients with T1 Non-muscle-invasive Bladder Cancer: Results from the Prospective HuNIRe Trial. Eur Urol O
Eur Urol Oncol. 2026 Aug 21:S2588-9311(26)00230.
Abstract

KARDOUST PARIZI M, Shariat SF
Reply to Simone Sforza's Letter to the Editor re: Mehdi Kardoust Parizi, David D'Andrea, Benjamin Pradere, et al. Prognostic Factors for Recurrence and Survival After Radical Cystectomy for Non-muscle-invasive Bladder Cancer: A Multicenter Analysis of
Eur Urol Oncol. 2026 Aug 21:S2588-9311(26)00231.
Abstract

VRIELING A, Kiebach J, Balvers M, Aben KK, et al
Fruit and vegetable consumption, dietary and plasma carotenoids and risks of recurrence and progression in patients with non-muscle-invasive bladder cancer.
Eur J Nutr. 2026;65:237.
Abstract

PFAIL J, O'Leary C, Fu M, Kaldany A, et al
The impact of intraoperative ureteral stent omission on postoperative complications during radical cystectomy.
World J Urol. 2026;44:593.
Abstract

ZEMLA J, Smialek-Bartyzel J, Brzuchacz B, Lekka M, et al
Lectin-Micropatterned Biointerfaces Regulate Cytoskeletal Organization and Viscoelastic Phenotypes of Bladder Cancer Cells.
ACS Omega. 2026;11:48215-48229.
Abstract

KHATAMI F, Mohammadi A, Azadmanesh K, Deyhimfar R, et al
Updated oncolytic viruses for the treatment of bladder cancer: a systematic review.
Iran J Microbiol. 2026;18:448-459.
Abstract

SHI Y, Luo X, Huang Y, Tan C, et al
The Impact of Chronic Kidney Disease on Postoperative Outcomes in Patients With Bladder Cancer: A Meta-Analysis.
Clin Med Insights Oncol. 2026;20:11795549261479103.
Abstract

GAN J, Bai X, Zhang A, Lin F, et al
TRIM59 Drives Bladder Cancer Progression Through E3 Ligase-Dependent K48-Linked Degradation of PTRF.
Cancer Sci. 2026 Aug 21. doi: 10.1111/cas.70510.
Abstract

SCARPA RM
Re: Contieri R, Paciotti M, Uleri A, et al. Patients with T1 Non-muscle-invasive Bladder Cancer: Results from the Prospective HuNIRe Trial. Eur Urol Oncol. 2026;9:404-412.
Eur Urol Oncol. 2026 Aug 21:S2588-9311(26)00229.
Abstract

SUNDRIYAL D, Prasath S, Prakash HS, Swamy AM, et al
Accelerated Methotrexate, Vinblastine, Doxorubicin, and Cisplatin for Muscle-Invasive Bladder Cancer: Real-World Feasibility and Safety in a Resource-Constrained Setting.
JCO Glob Oncol. 2026;12:e2600219.
Abstract

PRASATH S, Sundriyal D, Harsha SP, Swamy AM, et al
Feasibility and safety of accelerated MVAC (aMVAC) in geriatric patients with muscle-invasive bladder cancer.
Med Oncol. 2026;43:248.
Abstract

FU X, Liang Y, Xu B, Huang C, et al
A synergistic cascade nanoreactor breaks bladder cancer chemoresistance: Synergizing cholesterol metabolism reprogramming with cGAS-STING-mediated metallotherapy.
Mater Today Bio. 2026;40:103537.
Abstract

AZARI S, Salmasi A, Stewart T
Perioperative enfortumab vedotin plus pembrolizumab in muscle-invasive bladder cancer: unprecedented outcomes from KEYNOTE-B15.
Oncologist. 2026 Aug 19:oyag332. doi: 10.1093.
Abstract

CRANE K, Bhat KRS, Grivas P, Necchi A, et al
Incidence of KRAS G12C mutations in genitourinary malignancies; emerging target in precision medicine.
Oncotarget. 2026;17:381-387.
Abstract

WANG W, He J, Wu J, Li W, et al
Photon-Counting CT With Low-keV Virtual Monoenergetic Images for Detecting Muscle Invasion in Bladder Cancer: A Prospective Study.
AJR Am J Roentgenol. 2026 Aug 19. doi: 10.2214/AJR.26.35310.
Abstract

LI Z, Li S, Liu Z, Sun Y, et al
BACE2 Promotes Bladder Cancer Chemoresistance Through Proteolytic Activation of JAG1-Notch Signaling.
Cancer Innov. 2026;5:e70073.
Abstract

IRANMAHBOUB P, Dave P, Levine J, Wang S, et al
The Contemporary Pattern of Radical Cystectomy in the Treatment of High-Grade Non-Muscle Invasive Bladder Cancer.
Clin Genitourin Cancer. 2026 Jul 24:102627. doi: 10.1016/j.clgc.2026.102627.
Abstract

HILL-MCMANUS D, Lai Y, Bensimon AG, Young J, et al
Cost-effectiveness of perioperative pembrolizumab plus enfortumab vedotin for cisplatin-ineligible or cisplatin-declining patients with muscle-invasive bladder cancer in the United States.
J Med Econ. 2026;29:2161-2176.
Abstract

LUO H, Xu C, Huang S, Wang T, et al
Exploring Long Noncoding RNA CASC11 as a Biomarker for Bladder Cancer Detection.
Asia Pac J Clin Oncol. 2026 Aug 17. doi: 10.1111/ajco.70139.
Abstract

MANORANJAN B, Zeller S, Price H, Reiner AS, et al
Clinical and genomic characterization of brain metastasis in bladder cancer.
J Neurooncol. 2026;179:44.
Abstract

LIU Y, Li Y, Wu T, Hu H, et al
Comparative Analysis of Disease Burden and Risk Factor Attribution for Urological Cancers in Six High-Growth GBD Regions.
Arch Esp Urol. 2026;79:1014-1026.
Abstract

ALFIERI AG, Ramirez F, Favre G, Tobia Gonzalez I, et al
Oncological Outcomes of Intravesical Bacillus Calmette-Guerin Versus Early Radical Cystectomy in Very High-Risk Non-Muscle-Invasive Bladder Cancer: A Retrospective Cohort From a Latin American Referral Center.
Arch Esp Urol. 2026;79:915-921.
Abstract

CONTIERI R, Hurle R
Reply to Pietro scilipoti, Giuseppe Rosiello, Andrea Salonia, Alberto Briganti, Marco Moschini, Francesco Montorsi Letter to the Editor re: Roberto Contieri, Marco Paciotti, Alessandro Uleri, et al. Second Transurethral Resection of Bladder Tumor Can
Eur Urol Oncol. 2026 Aug 17:S2588-9311(26)00218.
Abstract

LIN YH
Beyond Symptom Relief: A Dual-Mechanism Hypothesis Linking Definitive Bladder Outlet Obstruction Relief to Bladder Cancer Control.
World J Mens Health. 2026 Aug 7. doi: 10.5534/wjmh.260171.
Abstract

HE Q, Jiang Z, Jiang C, Tu X, et al
Bladder preservation vs. radical cystectomy for T2N0M0: trends and survival outcomes from SEER.
World J Urol. 2026;44:575.
Abstract

CHEN C, Zheng H, Luo Y, Kong Y, et al
Corrigendum to SUMOylation promotes extracellular vesicle-mediated transmission of lncRNA ELNAT1? ?and lymph node metastasis in bladder cancer.
J Clin Invest. 2026;136:e210810.
Abstract

HUANG CS, Tung KH, Wu YS, Yu CP, et al
Association of Postoperative Antidepressant and Anxiolytic Exposure With Overall Survival Following Radical Cystectomy for Bladder Cancer.
Psychooncology. 2026;35:e70581.
Abstract

LI R, Zhao A, Zhuang Q, Peng L, et al
An Intravesical Akkermansia muciniphila-Based Chemo-Immunotherapeutic Platform for Bladder Cancer.
Adv Sci (Weinh). 2026 Aug 17:e77241. doi: 10.1002/advs.77241.
Abstract

BURGESS EF, Elom H, Brown LC, McCormack M, et al
The impact of ERBB2 alterations in muscle-invasive bladder cancer after neoadjuvant chemotherapy.
BJUI Compass. 2026;7:e70274.
Abstract

XU H, Han X, Zhang Y, Liu X, et al
When uncertainty becomes guilt: The moralisation of home urinary stoma care after bladder cancer surgery in China.
Soc Sci Med. 2026;407:119667.
Abstract

ANDREASEN TG, Strandgaard T, Divita TJ, Young-Halvorsen K, et al
Impact of Photodynamic Diagnosis on Immune Cell Infiltration in BCG-treated Non-muscle-invasive Bladder Cancer.
Eur Urol Open Sci. 2026;91:74-83.
Abstract

WANG X, Li Z, Zhang B
Decoding the role of exosomes in bladder cancer: focusing on tumor progression and immune microenvironment modulation.
Front Oncol. 2026;16:1821922.
Abstract

MERCIER J, Cornillon P, Barthelemy P, Leon P, et al
Squamous cell carcinoma of the bladder: Current evidence, therapeutic challenges, and research perspectives from the French AVENTUR group.
Crit Rev Oncol Hematol. 2026;225:105505.
Abstract

YUAN Q, Xing X, Ma Z, Shang P, et al
Radiotherapy for female non-gynecologic pelvic and adjacent cancers and secondary uterine Cancers: a SEER analysis.
Radiother Oncol. 2026;222:111697.
Abstract

LIU X, Fu K, Xiong L, Liu X, et al
Clinicopathological features and prognosis of plasmacytoid urothelial carcinoma of the bladder: A retrospective analysis of 36 cases.
Urol Oncol. 2026;44:412-421.
Abstract

NANDWANA D, Siva J, Davis L, Sindhani M, et al
Geospatial correlation of industrial plastics emissions with bladder and kidney cancer burden in Ohio.
Urol Oncol. 2026;44:211-222.
Abstract

MOHAMED T, Mohamed H, Deameh MG, Irshid BAB, et al
Ileal conduit vs. orthotopic ileal neobladder after radical cystectomy: Systematic review and meta-analysis of long-term renal function.
Urol Oncol. 2026;44:147-157.
Abstract

FAYOLLE E, Baudot A, Chaneliere-Sauvant AF, Favier E, et al
Effectiveness of a personalised 6-month programme on physical frailty in older patients treated for bladder or kidney cancer - FRAGECO program - multicenter, controlled, randomized study protocol.
BMC Geriatr. 2026;26:1067.
Abstract

UCHINO T, Miura M, Shingu C, Shin T, et al
Ultrasound versus nerve stimulation-guided interadductor approach for obturator nerve block: evaluation of injectate spread into the obturator canal in a randomized controlled trial.
BMC Anesthesiol. 2026;26:501.
Abstract

COLLINS K, Cheng L
FGFR3-Altered Urothelial Carcinoma: Clinicopathologic Observations With Emphasis on Variant Histology.
Lab Invest. 2026;106:106133.
Abstract

XIN S, Li G, Yang X, Su J, et al
Identifying PLAU as a shared pathogenic gene in type 2 diabetes and bladder urothelial carcinoma through integrated transcriptomic analysis and machine learning for diagnostic and therapeutic value.
Clin Exp Med. 2026;26:298.
Abstract

CHENG L, Tan HM, Lopez-Beltran A, Montironi R, et al
Urothelial Carcinoma in Children and Young Adults is Characterized by Higher Frequency of HRAS Mutations and Lower Prevalence of TERT Promoter and FGFR3 Mutations.
Am J Surg Pathol. 2026;50:999-1006.
Abstract

GUTIU AG, Marrah AJ, Voss BB, Cowan BC, et al
Allow Aloe to Do the Work: Aloe vera Constrains Growth of Bladder Cancer Cells and Modulates Expression of Key Costimulatory Molecules.
Anticancer Res. 2026;46:1883-1892.
Abstract

SATO T, Sano T, Adachi H, Ikeda Y, et al
Clinicopathological Characteristics and Clinical Course of Non-muscle-invasive Bladder Cancer Secondary to Radical Nephroureterectomy.
Anticancer Res. 2026;46:2077-2086.
Abstract

SUGIYAMA Y, Naiki T, Morikawa T, Odagiri K, et al
Prognostic Impact of Early GNRI Sustainability in Metastatic Urothelial Carcinoma Receiving Pembrolizumab.
Anticancer Res. 2026;46:2187-2198.
Abstract

LIAO CH, Chang WS, Chang SY, Wang YC, et al
Insights From Matrix Metalloproteinase-2 Genotypes to Decipher the Genetic Architecture of Bladder Cancer Risk.
Anticancer Res. 2026;46:1861-1874.
Abstract

GOTO K, Ando K, Motoi N, Iizuka T, et al
Imbalance Between CD44 and STAT3 Enhances Spheroid Viability and Impairs Pembrolizumab Response in Urothelial Cancer.
Anticancer Res. 2026;46:2445-2453.
Abstract

FURUBAYASHI N, Tsujita J, Takayama A, Shiraishi Y, et al
Real-world Delivery and Outcomes of Intravesical BCG for Non-muscle-invasive Bladder Cancer.
Anticancer Res. 2026;46:2599-2608.
Abstract

THI TN, Nguyen VT, Thanh HD, Kwon SY, et al
Inhibition of AP-1 Reduces CD46-mediated Invasion of Bladder and Colon Cancer Cells.
Anticancer Res. 2026;46:2525-2539.
Abstract

KLATTE T, Hofbauer SL, Ebert J, Ecke TH, et al
Real-world Patterns and Trends of Intravesical Chemotherapy for Non-muscle Invasive Bladder Cancer: Insights from a Large Prospective German Cohort.
Anticancer Res. 2026;46:3333-3342.
Abstract

SABBADINI P, Paganoni E, Galeasso L, Depetris I, et al
Basaloid Urothelial Carcinoma Presenting With Paraneoplastic Hypercalcemia and Leukocytosis: A Case Report and Literature Review.
Anticancer Res. 2026;46:3517-3522.
Abstract

SASAKI Y, Endo Y, Ochiai T, Kin M, et al
Gene Deletion of Microsomal Prostaglandin E Synthase-1 Suppresses Chemical Carcinogen-induced Bladder Cancer.
Anticancer Res. 2026;46:3651-3659.
Abstract

KOBARI Y, Nakajima N, Saito A, Katsurayama N, et al
Effectiveness and Safety of Enfortumab Vedotin Plus Pembrolizumab for Patients Aged 80 Years and Older With Metastatic Urothelial Carcinoma: A Multicenter Retrospective Study.
Anticancer Res. 2026;46:4453-4460.
Abstract

SRIVASTAVA A, Trivedi S, Kumar U, Singh Y, et al
Quality of life and cost-effectiveness of intravesical gemcitabine/docetaxel vs BCG in BCG-naive non-muscle-invasive bladder cancer.
BJU Int. 2025 Dec 23. doi: 10.1111/bju.70126.
Abstract

MENNES J, Akand M, Benijts R, Baekelandt L, et al
Prophylactic urethrectomy at the time of radical cystectomy for bladder cancer: does it really have an effect on oncological outcomes?
BJU Int. 2025 Dec 23. doi: 10.1111/bju.70096.
Abstract

PELLEGRINO F, de Angelis M, Scilipoti P, Longoni M, et al
Temporal trends and clinical determinants of urinary diversion after radical cystectomy.
BJU Int. 2026;137:323-331.
Abstract

SUBIELA JD, de la Parra I, Taborda J, Medina AA, et al
Defining statistical cure in patients with T1 high-grade non-muscle-invasive bladder carcinoma treated with BCG immunotherapy.
BJU Int. 2026;137:270-281.
Abstract

SILVANI C, Santangelo A, Considine J, Tylecki A, et al
Area deprivation and cancer-specific mortality in non-muscle-invasive bladder cancer: a statewide analysis.
BJU Int. 2026 Jan 20. doi: 10.1111/bju.70151.
Abstract

ABOU CHAKRA M, McElree IM, Mott SL, O'Donnell MA, et al
Impact of American Urological Association risk category on outcomes of intravesical BCG vs gemcitabine/docetaxel in high-grade Ta non-muscle-invasive bladder cancer.
BJU Int. 2026 Jan 19. doi: 10.1111/bju.70149.
Abstract

AMER ML, Amer AR, Elnasharty SF, Homouda AA, et al
Impact of perioperative nutrition on recovery after radical cystectomy: a randomised trial.
BJU Int. 2026;137:536-546.
Abstract

HUMAYUN-ZAKARIA N, Tura BJ, van Hemelrijck M, Bryan RT, et al
Aligning bladder cancer research with patient needs: an update on research priorities.
BJU Int. 2026 Feb 27. doi: 10.1111/bju.70206.
Abstract

SCILIPOTI P, Zaurito P, Longoni M, Tremolada G, et al
Impact of BCG failure patterns on efficacy of intravesical gemcitabine/docetaxel in high-risk non-muscle-invasive bladder cancer.
BJU Int. 2026 Feb 25. doi: 10.1111/bju.70182.
Abstract

BARRETTA A, Piazza P, Catanzaro C, Mottaran A, et al
Is there still a role for ureteric frozen section analysis during radical cystectomy?
BJU Int. 2026;137:659-666.
Abstract

BRYAN RT, Patel K, Ward DG
The nascent role of circulating tumour DNA in the management of non-muscle-invasive bladder cancer.
BJU Int. 2026 Mar 3. doi: 10.1111/bju.70217.
Abstract

FERNANDEZ-MARDOMINGO A, Subiela JD, Artiles Medina A, Krajewski W, et al
Impact of re-transurethral resection of bladder staging on risk stratification of high-grade T1 non-muscle-invasive bladder cancer across European Association of Urology 2021 risk groups.
BJU Int. 2026 Mar 3. doi: 10.1111/bju.70207.
Abstract

DAY E, Bizzarri FP, Waine E, Martin R, et al
Contemporary practice patterns in female radical cystectomy: results of a UK and Ireland survey.
BJU Int. 2026;137:708-715.
Abstract

PIAZZA P, Barretta A, Bravi CA, Mottaran A, et al
Impact of cumulative smoking exposure on morbidity after robot-assisted radical cystectomy.
BJU Int. 2026;137:684-689.
Abstract

SLUSARCZYK A, Scilipoti P, Contieri R, Krajewski W, et al
Refining BCG-failure classifications in non-muscle-invasive bladder cancer.
BJU Int. 2026 Mar 19. doi: 10.1111/bju.70231.
Abstract

Correction to "Long-term multicentre analysis of robot-assisted radical cystectomy for non-muscle-invasive bladder cancer".
BJU Int. 2026 Mar 19. doi: 10.1111/bju.70248.
Abstract

SATHIANATHEN N, Perera M, Ischia J, Lawrentschuk N, et al
Use of MRI in the diagnosis of bladder cancer: a health economic analysis.
BJU Int. 2026 Mar 18. doi: 10.1111/bju.70243.
Abstract

ROESSLER N, Miszczyk M, Gontero P, Dematteis A, et al
Clinical complete response as a surrogate for pathological response in bladder cancer: a systematic review and meta-analysis.
BJU Int. 2026 Mar 16. doi: 10.1111/bju.70214.
Abstract

YE T, Tura B, Abbotts B, Zeegers MP, et al
Clinical outcomes of BCG-treated patients with high-risk non-muscle-invasive bladder cancer according to pre- and post-2021 European Association of Urology risk classifications.
BJU Int. 2026 Mar 23. doi: 10.1111/bju.70247.
Abstract

SIVA J, Aydogdu C, Heller N, Jonnalagadda R, et al
Reducing complexity in International Bladder Cancer Group intermediate-risk non-muscle-invasive bladder cancer stratification: a three-factor approach.
BJU Int. 2026 Apr 2. doi: 10.1111/bju.70269.
Abstract

HJORT PB, Jensen JB, Ernst A
Long-term outcomes following a 5-year recurrence-free interval in non-muscle-invasive bladder cancer.
BJU Int. 2026 Mar 28. doi: 10.1111/bju.70267.
Abstract

FU MZ, Packiam VT, Byrne J
Response to comment on 'Drug-releasing intravesical floating technology for sequential gemcitabine and docetaxel in non-muscle-invasive bladder cancer'.
BJU Int. 2026 Apr 8. doi: 10.1111/bju.70271.
Abstract

KUMAR V, Kant R
Comment on 'Drug-releasing intravesical floating technology for sequential gemcitabine and docetaxel in non-muscle-invasive bladder cancer'.
BJU Int. 2026 Apr 6. doi: 10.1111/bju.70268.
Abstract

RUBIO-BRIONES J, Guerrero Ramos F, Mercade Sanchez A, Bezana Abadia I, et al
Digital Uromonitor(R) outperforms quantitative polymerase chain reaction Uromonitor and cytology for non-muscle-invasive bladder cancer surveillance: results from the 'External Validation of Uromonitor as a Biomarker for Optimization of NMIBC Manageme
BJU Int. 2026 Apr 6. doi: 10.1111/bju.70230.
Abstract

VAN HOOGSTRATEN LMC, Vermeulen SH, Hof JP, van der Heijden AG, et al
Surveillance patterns in non-muscle-invasive bladder cancer across risk groups: a real-world analysis.
BJU Int. 2026 Apr 23. doi: 10.1111/bju.70297.
Abstract

ZHANG B, Wang C, Shang P
Comment on 'Reducing complexity in International Bladder Cancer Group intermediate-risk non-muscle-invasive bladder cancer stratification: a three-factor approach'.
BJU Int. 2026 Apr 23. doi: 10.1111/bju.70302.
Abstract

PACKIAM VT, Black PC, Catto JWF, Ghodoussipour S, et al
'BJUI Clinical Dilemma': Recurrent high-grade non-muscle-invasive bladder cancer in 2026.
BJU Int. 2026 Apr 28. doi: 10.1111/bju.70299.
Abstract

CHETHAN GS, Patil NS
Comment on 'Long-term multicentre analysis of robot-assisted radical cystectomy for non-muscle-invasive bladder cancer'.
BJU Int. 2026 May 7. doi: 10.1111/bju.70313.
Abstract

TILLU N, Wiklund P
Response to: 'Comment on long-term multicentre analysis of robot-assisted radical cystectomy for non-muscle-invasive bladder cancer'.
BJU Int. 2026 May 11. doi: 10.1111/bju.70312.
Abstract

CONTIERI R, Martini A, Furrer M, D'Andrea D, et al
Risk stratification and conditional recurrence after radical cystectomy: toward adaptive follow-up.
BJU Int. 2026;137:1058-1066.
Abstract

DIANA P, Di Bello F, Mas L, Gallioli A, et al
Curriculum-based training improves transurethral resection of bladder tumour performance compared to conventional training: the EuropeaN Training in uRologY (ENTRY) project.
BJU Int. 2026;137:1026-1031.
Abstract

ABOU CHAKRA M, Alsamarah I, Hougen HY, Zakharia Y, et al
Computed tomography-derived extracellular volume fraction is associated with high-grade recurrence in non-muscle-invasive bladder cancer treated with intravesical gemcitabine and docetaxel.
BJU Int. 2026 May 28. doi: 10.1111/bju.70319.
Abstract

UROLAGIN D, Sowmya BA, Kavyashree MV
Comment on 'A study of oral metformin for the intravesical treatment of non-muscle-invasive bladder cancer'.
BJU Int. 2026 Jun 10. doi: 10.1111/bju.70296.
Abstract

VAN HATTUM JW, Remmelink MJ, Oddens JR, de Reijke TM, et al
Response letter 'A study of oral metformin for the intravesical treatment of non-muscle-invasive bladder cancer'.
BJU Int. 2026 Jun 9. doi: 10.1111/bju.70295.
Abstract

NOLAZCO JI, Melnick KR, Lee RJ, Efstathiou JA, et al
Alternatives to radical cystectomy: a bladder-sparing approach in appropriately selected patients.
BJU Int. 2026;138:22-32.
Abstract

ORECCHIA L, Gerardi M, Colalillo G, Leonardis F, et al
Impact of audit and feedback on transurethral resection of bladder tumour quality: a monocentric post-completion evaluation of the RESECT trial.
BJU Int. 2026;138:92-99.
Abstract

GHALI F, Tan WS
A call for regimen agnostic circulating tumour DNA-guided adjuvant selection in muscle-invasive bladder cancer.
BJU Int. 2026 Jul 3. doi: 10.1111/bju.70377.
Abstract

AYDOGDU C, Wang B, McSweeney ST, Diaz G, et al
Longitudinal circulating tumour DNA identifies patients at high risk of upstaging and recurrence in non-muscle-invasive bladder cancer.
BJU Int. 2026 Jul 2. doi: 10.1111/bju.70376.
Abstract

SOPUTRO NA, Wang L, Daher K, Al-Bayati A, et al
Intraoperative evaluation of detrusor muscle during transurethral resection of bladder tumour using confocal fluorescent microscopy.
BJU Int. 2026;138 Suppl 1:S49-S55.
Abstract

DUAN Q
Letter to the Editor regarding: reducing complexity in International Bladder Cancer Group intermediate-risk non-muscle-invasive bladder cancer stratification: a three-factor approach.
BJU Int. 2026 Jul 17. doi: 10.1111/bju.70385.
Abstract

LISTER-WHELAN R, Senior E, Kendall J, Oughton JB, et al
INtraVESical immunoTherapy (INVEST) prior to radical cystectomy for bladder cancer: trial protocol.
BJU Int. 2026 Jul 27. doi: 10.1111/bju.70387.
Abstract

CHEN Y, Yue Z
Incidence is not surveillance yield: interpreting metachronous upper tract urothelial carcinoma risk after non-muscle-invasive bladder cancer.
BJU Int. 2026 Aug 11. doi: 10.1111/bju.70429.
Abstract

IBRAHIM Y, Ribeiro L, Spazzapan M, Gad M, et al
Adoption, consistency, and usability of NICE vs EAU guidelines in low- and intermediate-risk NMIBC: a cross-sectional survey of UK urologists.
BJU Int. 2026;138:449-455.
Abstract

CELLA L, Contieri R, Paciotti M, Fasulo V, et al
Artificial intelligence for predicting BCG response in non-muscle-invasive bladder cancer: a systematic review.
BJU Int. 2026 Aug 17. doi: 10.1111/bju.70404.
Abstract

XING Z, Xu H, Lin P, Hong Y, et al
ITGB4 up-regulated by STAT3 reduces the sensitivity of bladder cancer to cisplatin by suppressing p53.
Br J Cancer. 2026 Apr 9. doi: 10.1038/s41416-026-03364.
Abstract

TEKE K, Ozer C, Yaprak Bayrak B, Reyhancan IA, et al
Boron neutron capture therapy (BNCT) for experimental bladder cancer: systemic or intravesical approach.
Br J Cancer. 2026 Apr 17. doi: 10.1038/s41416-026-03418.
Abstract

MURRAY BO, Gao J, Pasquina-Lemonche L, Swarbrick K, et al
An advanced in vitro bladder cancer model integrating bladder cancer spheroids into a healthy human urothelium for preclinical therapeutic testing.
Br J Cancer. 2026 Jun 2. doi: 10.1038/s41416-026-03476.
Abstract

ZHANG L, Liu Z, Ding Y, Sun J, et al
Lethal clinical outcome and immuno-fibrotic contexture in refractory urothelial carcinoma harboring MYC amplification and overexpression.
Br J Cancer. 2026;135:559-567.
Abstract

BHATTACHARYA R, Kponee-Shovein K, Gao Y, Song Y, et al
Event-free survival and complete response rate as surrogate endpoints for overall survival in high-risk non-muscle-invasive bladder cancer: A meta-analysis of bacillus Calmette-Guerin-naive or -remote cases.
Cancer. 2026;132:e70220.
Abstract

WU Z, Cao L, Zeng J, Feng W, et al
Diagnostic performance analysis of two-gene methylation in urothelial carcinoma based on small-volume urine sample.
Cancer. 2026;132:e70373.
Abstract

MEHTA S, Weinfeld M, Hobeika C, Reizine N, et al
The evolving landscape and clinical utility of circulating tumor DNA across the spectrum of urothelial carcinoma: A systematic review and framework for clinical integration.
Cancer. 2026;132:e70448.
Abstract

HUANG S, Jia K, Liang S, Ma B, et al
Magnetic resonance imaging radiomic phenotypes stratify response and define immune states in very high-risk, nonmuscle-invasive bladder cancer treated with tislelizumab plus nanoparticle albumin-bound paclitaxel.
Cancer. 2026;132:e70498.
Abstract

SUN J, Jin K, Ding Y, Wu Y, et al
Proliferative ecotype determines lethal prognosis and therapeutic benefit in urothelial carcinoma.
Cancer. 2026;132:e70515.
Abstract

WALKER CH, Jabalameli N, Rais-Bahrami S
Radiomic phenotypes in nonmuscle-invasive bladder cancer: A precision biomarker guiding therapy.
Cancer. 2026;132:e70563.
Abstract

LUO W, Wang Y, Wang H, Ji YA, et al
CCL5hi-CD4+ T cells Regulate Macrophage Polarization and Promote Immunotherapy Response in Bladder Cancer.
Cancer Res. 2026 Feb 18. doi: 10.1158/0008-5472.CAN-25-2220.
Abstract

GARCIA-RODRIGUEZ JL, Korsgaard U, Ahmadov U, Jarlstad Olesen MT, et al
Spatial Profiling of Circular RNAs in Cancer Reveals High Expression in Muscle and Stromal Cells.
Cancer Res. 2023;83:3340-3353.
Abstract

ROELS J, Ghaedi H, Kancherla J, Yang Y, et al
The Hippo Pathway Is Dysregulated in Cancer-Associated Fibroblasts in Anti-PD-L1-Resistant Cancer.
Cancer Res. 2026;86:2592-2605.
Abstract

CHEVRIER S, Richard C, Adotevi O, Ayyoub M, et al
Circulating transcriptome analysis finds gene signatures and immune cell activation and abundance predict response to immunotherapy in bladder cancer.
Clin Cancer Res. 2026 Jan 13. doi: 10.1158/1078-0432.CCR-25-2306.
Abstract

EPSTEIN IB, Odogiyon A, Berg S, Otani Y, et al
ctDNA dynamics and recurrence patterns after organ-sparing trimodality therapy for bladder cancer.
Clin Cancer Res. 2026 Jan 26. doi: 10.1158/1078-0432.CCR-25-3712.
Abstract

GUERCIO BJ, Pietzak EJ, Ravichandran V, Chen JF, et al
Neoadjuvant nivolumab with or without ipilimumab for cisplatin-ineligible patients with muscle-invasive bladder cancer.
Clin Cancer Res. 2026 Feb 2. doi: 10.1158/1078-0432.CCR-25-3771.
Abstract

MIRKHESHTI N, Kpormegbey DE, Weinstock C, Gao X, et al
FDA Approval Summary: Durvalumab for the Treatment of Adult Patients with Muscle Invasive Bladder Cancer.
Clin Cancer Res. 2026 Feb 12. doi: 10.1158/1078-0432.CCR-25-3609.
Abstract

KATIMS AB, White C, Alam SM, Farha M, et al
Urinary Biomarkers Objectively Measure Minimal Residual Disease in Non-Muscle-Invasive Bladder Cancer.
Clin Cancer Res. 2026 Feb 9. doi: 10.1158/1078-0432.CCR-25-3395.
Abstract

LOTAN Y, Luu M, Liu M, Tikhonekov S, et al
Clinical Validation of a Multiplex Urine Biomarker Assay for Surveillance of Recurrent Bladder Cancer.
Clin Cancer Res. 2026 Jul 2. doi: 10.1158/1078-0432.CCR-26-1407.
Abstract

LI Z, Izadmehr S, Hoffman-Censits J, Maughan B, et al
Gemcitabine plus Nivolumab with Carboplatin or Oxaliplatin in Cisplatin-Ineligible Patients with Metastatic Urothelial Carcinoma: A Randomized Phase II Trial.
Clin Cancer Res. 2026;32:2911-2920.
Abstract

LOPEZ-BELTRAN A, Cimadamore A, Blanca A, Montironi R, et al
Sarcomatoid urothelial carcinoma: advances and challenges.
Curr Opin Urol. 2026;36:147-154.
Abstract

COMPERAT E
Biomarkers and testing in pathology.
Curr Opin Urol. 2026;36:212-216.
Abstract

ERTOY-BAYDAR D
Histologic subtypes of urothelial carcinoma: an update.
Curr Opin Urol. 2026;36:138-146.
Abstract

REIS H, Szarvas T, Paner GP
Urachal cancer: a clinical, diagnostic, and therapeutic update.
Curr Opin Urol. 2026;36:155-160.
Abstract

ST-LAURENT MP, Black PC
The challenge of bladder preservation in muscle invasive bladder cancer: key concepts and future directions.
Curr Opin Urol. 2026 Jan 30. doi: 10.1097/MOU.0000000000001369.
Abstract

PERRI D, Roche JB, Petrut B, Bozzini G, et al
Bladder diverticula management - conservative and surgical outcomes: a narrative review from EAU endourology.
Curr Opin Urol. 2026;36:79-85.
Abstract

GONZALEZ-PADILLA DA, Subiela JD, Guerrero-Ramos F, Pichler R, et al
Latest developments in urinary tumor DNA and its current clinical role in urothelial bladder cancer and upper tract urothelial carcinoma.
Curr Opin Urol. 2026 Mar 4. doi: 10.1097/MOU.0000000000001373.
Abstract

LEE YHA, Wong CM, Liu AQ, Teoh JY, et al
The future of urothelial carcinoma: a 2024-2025 update of early-phase trials of novel therapeutic agents.
Curr Opin Urol. 2026;36:244-249.
Abstract

AHMAD A, Lepiarczyk O, Birtle AJ
Personalised medicine in urothelial carcinoma: where do we stand and what is the way to go?
Curr Opin Urol. 2026;36:250-256.
Abstract

ALIAGA A, Avila C, Fernandez MI
Navigating bladder preservation in Bacillus Calmette-Guerin-unresponsive disease: how much risk is too much?
Curr Opin Urol. 2026;36:235-243.
Abstract

NEUENSCHWANDER A, Uleri A, Grobet-Jeandin E, Contieri R, et al
Impact of a multidisciplinary approach on outcomes in urothelial carcinoma.
Curr Opin Urol. 2026;36:446-452.
Abstract

DEVELTERE D, Tsantoulis P, Olivier T
Censoring patterns and inconsistent results in checkpoint inhibitor and adjuvant BCG trials for high-risk bladder cancer.
Eur J Cancer. 2026;240:116740.
Abstract

PAPADIMITRIOU MA, Pilala KM, Panoutsopoulou K, Soureas K, et al
Liquid biopsy miRNA risk score in bladder cancer: Translational insights from patient-derived xenografts to prognostic stratification.
Eur J Cancer. 2026;246:116987.
Abstract

SCILIPOTI P, Zaurito P, Longoni M, Colecchia M, et al
Efficacy and Safety of Checkpoint Inhibitors Combined with Bacillus Calmette-Guerin (BCG) in BCG-naive High-risk Non-muscle-invasive Bladder Cancer: Synthesis of Evidence from the ALBAN, CREST, and POTOMAC Trials.
Eur Urol. 2025 Dec 31:S0302-2838(25)04877-8. doi: 10.1016/j.eururo.2025.
Abstract

GALLAGHER K, MacLennan S, Bhatt N, Clement K, et al
RESECT: A Randomised Controlled Trial of Audit and Feedback in Non-muscle-invasive Bladder Cancer Surgery.
Eur Urol. 2025 Dec 10:S0302-2838(25)04736-0. doi: 10.1016/j.eururo.2025.09.4174.
Abstract

FILHO AM, Briganti A, Jemal A, Bray F, et al
Bladder Cancer Incidence and Mortality: A Global Overview and Recent Trends.
Eur Urol. 2025 Dec 19:S0302-2838(25)04864-X. doi: 10.1016/j.eururo.2025.
Abstract

HERR H
Re: Oscar Buisan, Pol Servian, Sonia Pedreno-Lopez, et al. A Novel Heterologous Prime-boost Strategy Using RUTI Vaccine to Improve the Bacillus Calmette-Guerin Response in Non-muscle-invasive Bladder Cancer Patients: Phase 1 RUTIVAC-1 Trial. Eur Urol.
Eur Urol. 2026 Jan 12:S0302-2838(25)04897-3. doi: 10.1016/j.eururo.2025.
Abstract

ROVIELLO G, Vascotto IA, Antonuzzo L
Re: ctDNA-guided Adjuvant Atezolizumab in Muscle-invasive Bladder Cancer.
Eur Urol. 2026 Jan 12:S0302-2838(26)00008-4. doi: 10.1016/j.eururo.2026.
Abstract

KITAMURA H, Tsukamoto T, Kakehi Y, Mizusawa J, et al
Active Surveillance Versus Intravesical Bacillus Calmette-Guerin for High-grade T1 Bladder Cancer with Negative Second Transurethral Resection: The Randomized Noninferiority Phase 3 JCOG1019 Trial.
Eur Urol. 2026 Jan 21:S0302-2838(26)00014-X. doi: 10.1016/j.eururo.2026.
Abstract

GARMAN TS, Kates MR
Re: Maria De Santis, Joan Palou Redorta, Hiroyuki Nishiyama, et al. Durvalumab in Combination with BCG for BCG-naive, High-risk, Non-muscle-invasive Bladder Cancer (POTOMAC): Final Analysis of a Randomised, Open-label, Phase 3 trial. Lancet 2025;406:2
Eur Urol. 2026 Jan 19:S0302-2838(26)00016-3. doi: 10.1016/j.eururo.2026.
Abstract

PICHLER R, Subiela JD, Scilipoti P, Rehder P, et al
Regional Node-positive Bladder Cancer: Therapeutic Decisions Based on Trial Results in Perioperative and Advanced Disease Settings.
Eur Urol. 2026 Jan 19:S0302-2838(26)00019-9. doi: 10.1016/j.eururo.2026.
Abstract

NAGUMO Y, Kimura T, Ishikawa H, Sekino Y, et al
Bladder Preservation Therapy in Combination with Atezolizumab and Radiation Therapy (BPT-ART) for Invasive Bladder Cancer: Final Analysis from a Multicentre, Open-label, Prospective Phase 2 Trial.
Eur Urol. 2026 Jan 17:S0302-2838(25)04872-9. doi: 10.1016/j.eururo.2025.
Abstract

CABRERA C, Buisan O, Servian P
Reply to the Harry Herr's Letter to the Editor re: Oscar Buisan, Pol Servian, Sonia Pedreno-Lopez, et al. A Novel Heterologous Prime-boost Strategy Using RUTI Vaccine to Improve the Bacillus Calmette-Guerin Response in Non-muscle-invasive Bladder Canc
Eur Urol. 2026 Jan 23:S0302-2838(26)00018-7. doi: 10.1016/j.eururo.2026.
Abstract

PICHLER R, Subiela JD, Guerrero-Ramos F
Re: Maria De Santis, Joan Palou Redorta, Hiroyuki Nishiyama, et al. Durvalumab in Combination with BCG for BCG-naive, High-risk, Non-muscle-invasive Bladder Cancer (POTOMAC): Final Analysis of a Randomised, Open-label, Phase 3 trial. Lancet 2025;406:2
Eur Urol. 2026 Feb 4:S0302-2838(26)00054-0. doi: 10.1016/j.eururo.2026.
Abstract

GABRIEL PE, Xylinas E
Re: Ding Ding, Lei Qian, Di Jin, et al. Aptamer-based Positron Emission Tomography Imaging Allows Specific Detection of Residual Bladder Cancer: A First-in-Human Study. Eur Urol 2026;89:93-5.
Eur Urol. 2026 Feb 3:S0302-2838(26)00030-8. doi: 10.1016/j.eururo.2026.
Abstract

BABJUK M
Re: Durvalumab in Combination with BCG for BCG-naive, High risk, Non-muscle-invasive Bladder Cancer (POTOMAC): Final Analysis of a Randomised, Open-label, Phase 3 Trial.
Eur Urol. 2026 Feb 3:S0302-2838(26)00027-8. doi: 10.1016/j.eururo.2026.
Abstract

HAYNE D, Zhang AY, Thomas H, Krieger L, et al
Bacillus Calmette-Guerin Plus Mitomycin Versus Bacillus Calmette-Guerin Alone for Bacillus Calmette-Guerin-naive Non-muscle-invasive Bladder Cancer: A Randomised Phase 3 Trial (ANZUP 1301).
Eur Urol. 2026 Feb 2:S0302-2838(26)00015-1. doi: 10.1016/j.eururo.2026.
Abstract

TATEO V, Basile G, Giannatempo P, de Jong JJ, et al
Updated 5-year Survival Results from PURE-01, a Phase 2 Study of Neoadjuvant Pembrolizumab Followed by Radical Cystectomy in Patients with Muscle-invasive Bladder Cancer.
Eur Urol. 2026 Feb 2:S0302-2838(26)00022-9. doi: 10.1016/j.eururo.2026.
Abstract

MYERS AA, Talwar R, Duan Z, Hensley P, et al
Cost-effectiveness Analysis of Treatments for Bacillus Calmette-Guerin-unresponsive Carcinoma in Situ of the Bladder.
Eur Urol. 2026;89:151-162.
Abstract

SCILIPOTI P, Zaurito P, Longoni M, Colecchia M, et al
Corrigendum to "Efficacy and Safety of Checkpoint Inhibitors Combined with Bacillus Calmette-Guerin (BCG) in BCG-naive High-risk Non-muscle-invasive Bladder Cancer: Synthesis of Evidence from the ALBAN, CREST, and POTOMAC Trials" [Eur. Urol. (2025)].
Eur Urol. 2026 Feb 17:S0302-2838(26)00063-1. doi: 10.1016/j.eururo.2026.
Abstract

CLARK PE
Re: Durvalumab in combination with BCG for BCG-naive, high risk, non-muscle-invasive bladder cancer (POTOMAC): final analysis of a randomised, open-label, phase 3 trial.
Eur Urol. 2026 Feb 25:S0302-2838(26)01995-0. doi: 10.1016/j.eururo.2026.
Abstract

NUSBAUM DJ, Li R, Peyton CC, Spiess PE, et al
Less Is More? How Much Bacillus Calmette-Guerin (BCG) Is Enough for BCG-naive High-risk Non-muscle invasive Bladder Cancer?
Eur Urol. 2026 Feb 24:S0302-2838(26)02001-4. doi: 10.1016/j.eururo.2026.
Abstract

LIU P, Chen J, Zhou J
Re: Twelve-month Results from the CISTO Study Comparing Radical Cystectomy Versus Bladder-Sparing Therapy for Recurrent High-grade Non-muscle-invasive Bladder Cancer.
Eur Urol. 2026 Feb 24:S0302-2838(26)01997-4. doi: 10.1016/j.eururo.2026.
Abstract

GUPTA S, Li R, Hensley PJ, Daneshmand S, et al
Optimal Management of Muscle-invasive Bladder Cancer: Recommendations from the International Bladder Cancer Group.
Eur Urol. 2026 Feb 21:S0302-2838(26)00059-X. doi: 10.1016/j.eururo.2026.
Abstract

CONTIERI R, Lazzeri M, Perdona S, Hurle R, et al
Re: Hiroshi Kitamura, Taiji Tsukamoto, Yoshiyuki Kakehi, et al. Active Surveillance Versus Intravesical Bacillus Calmette-Guerin for High-grade T1 Bladder Cancer with Negative Second Transurethral Resection: The Randomized Noninferiority Phase 3 JCOG1
Eur Urol. 2026 Mar 20:S0302-2838(26)02038-5. doi: 10.1016/j.eururo.2026.
Abstract

KITAMURA H, Nishiyama H
Reply to Roberto Contieri, Massimo Lazzeri, Sisto Perdona, and Rodolfo Hurle's Letter to the Editor re: Kitamura, Tsukamoto T, Kakehi Y, et al. Active Surveillance Versus Intravesical Bacillus Calmette-Guerin for High-grade T1 Bladder Cancer with Nega
Eur Urol. 2026 Mar 20:S0302-2838(26)02039-7. doi: 10.1016/j.eururo.2026.
Abstract

ZHOU Q, Ma H
Re: Perioperative Enfortumab Vedotin and Pembrolizumab in Bladder Cancer.
Eur Urol. 2026 Apr 8:S0302-2838(26)02047-6. doi: 10.1016/j.eururo.2026.
Abstract

COLD KM, Vasquez JL
Re: Jethro C.C. Kwong, Zizo Al-Daqqaq, Yashan Chelliahpillai, et al. Development and International Evaluation of an Artificial Intelligence-based Model (PROGRxN-BCa) Using the World Health Organization 2004/2022 Grading System to Predict Progression R
Eur Urol. 2026 Apr 7:S0302-2838(26)02064-6. doi: 10.1016/j.eururo.2026.
Abstract

LI D
Re: Bacillus Calmette-Guerin Plus Mitomycin Versus Bacillus Calmette-Guerin Alone for Bacillus Calmette-Guerin-naive Non-muscle-invasive Bladder Cancer: A Randomised Phase 3 Trial (ANZUP 1301).
Eur Urol. 2026 Apr 2:S0302-2838(26)02045-2. doi: 10.1016/j.eururo.2026.
Abstract

ZHOU J, Liu P
Re: Bladder Preservation Therapy in Combination with Atezolizumab and Radiation Therapy (BPT-ART) for Invasive Bladder Cancer: Final Analysis from a Multicentre, Open-label, Prospective Phase 2 Trial.
Eur Urol. 2026 Apr 2:S0302-2838(26)02051-8. doi: 10.1016/j.eururo.2026.
Abstract

D'ANDREA D, Soria F, Gontero P, Shariat SF, et al
Re: Kitamura H, Tsukamoto T, Kakehi Y, et al. Active Surveillance Versus Intravesical Bacillus Calmette-Guerin for High-grade T1 Bladder Cancer with Negative Second Transurethral Resection: The Randomized Noninferiority Phase 3 JCOG1019 Trial. Eur Uro
Eur Urol. 2026 Apr 22:S0302-2838(26)02069-5. doi: 10.1016/j.eururo.2026.
Abstract

PICCOLINI A, Paciotti M, Buffi NM
Re: Kitamura H, Tsukamoto T, Kakehi Y, et al. Active Surveillance Versus Intravesical Bacillus Calmette-Guerin for High-Grade T1 Bladder Cancer with Negative Second Transurethral Resection: The Randomized Noninferiority Phase 3 JCOG1019 Trial. Eur Uro
Eur Urol. 2026 Apr 22:S0302-2838(26)02071-3. doi: 10.1016/j.eururo.2026.
Abstract

LOBO N, Contieri R, Mertens L, Kamat AM, et al
Re: Kitamura H, Tsukamoto T, Kakehi Y, et al. Active surveillance versus intravesical bacillus Calmette-Guerin for high-grade T1 bladder cancer with negative second transurethral resection: the randomized noninferiority phase 3 JCOG1019 trial. Eur Uro
Eur Urol. 2026 Apr 21:S0302-2838(26)02072-5. doi: 10.1016/j.eururo.2026.
Abstract

LU W, Chen L
Re: Ipilimumab and Nivolumab Followed by Chemoradiotherapy as Bladder-sparing Treatment in Muscle-invasive Bladder Cancer: A Phase 2 Trial.
Eur Urol. 2026 Apr 23:S0302-2838(26)02098-1. doi: 10.1016/j.eururo.2026.
Abstract

ROVIELLO G, Antonuzzo L
Re: Perioperative enfortumab vedotin and pembrolizumab in bladder cancer.
Eur Urol. 2026 Apr 30:S0302-2838(26)02145-7. doi: 10.1016/j.eururo.2026.
Abstract

BASOURAKOS SP, Shoag J, Calaway A
Re: Kitamura et al. Active Surveillance Versus Intravesical Bacillus Calmette-Guerin for High-grade T1 Bladder Cancer with Negative Second Transurethral Resection (JCOG1019). Eur Urol 2026. In press. http://dx.doi.org/10.1016/j.eururo.2026.01.008.
Eur Urol. 2026 May 13:S0302-2838(26)02149-4. doi: 10.1016/j.eururo.2026.
Abstract

HAYNE D, Zhang AY, Thomas H, Redfern AD, et al
Reply to Daoyuan Li's Words of Wisdom re: Bacillus Calmette-Guerin Plus Mitomycin Versus Bacillus Calmette-Guerin Alone for Bacillus Calmette Guerin-naive Non-Muscle-Invasive Bladder Cancer: A Randomised Phase 3 Trial (ANZUP 1301). Eur Urol. In press.
Eur Urol. 2026 May 21:S0302-2838(26)02159-7. doi: 10.1016/j.eururo.2026.
Abstract

MOSCHINI M, Scilipoti P, Longoni M, Montorsi F, et al
Re: Christof Vulsteke, Nabil Adra, Pongwut Danchaivijitr, et al. Perioperative Enfortumab Vedotin and Pembrolizumab in Bladder Cancer. N Engl J Med 2026;394:1257-1269.
Eur Urol. 2026 May 20:S0302-2838(26)02160-3. doi: 10.1016/j.eururo.2026.
Abstract

DI BELLO F, Gallioli A, Diana P, Avesani G, et al
Re: Gallagher et al. RESECT, A Randomised Controlled Trial of Audit and Feedback in Non-muscle-invasive Bladder Cancer Surgery. Eur Urol 2026. In press. http://dx.doi.org/10.1016/j.eururo.2025.09.4174.
Eur Urol. 2026 May 20:S0302-2838(26)02163-9. doi: 10.1016/j.eururo.2026.
Abstract

COMPERAT E
Re: Efficacy and Safety of Checkpoint Inhibitors Combined with Bacillus Calmette-Guerin (BCG) in BCG-naive High-risk Non-muscle-invasive Bladder Cancer: Synthesis of Evidence from the ALBAN, CREST, and POTOMAC Trials.
Eur Urol. 2026 May 15:S0302-2838(26)01994-9. doi: 10.1016/j.eururo.2026.
Abstract

SUBIELA JD, Gonzalez-Padilla DA, Pichler R, Scilipoti P, et al
Combining ctDNA and utDNA as a Dual Biomarker-driven Strategy for Bladder-sparing Therapy in Muscle-invasive Bladder Cancer: Neither Alone Is Sufficient.
Eur Urol. 2026 May 15:S0302-2838(26)02154-8. doi: 10.1016/j.eururo.2026.
Abstract

MAIORANO BA, Dizman N, Necchi A
Contextualizing the Development of Anti-HER2 Therapies for Patients with Advanced Urothelial Carcinoma.
Eur Urol. 2026;89:479-482.
Abstract

BASIN MF, Daneshmand S
Cystectomy Remains Standard of Care Following Neoadjuvant Therapy in Patients with Muscle-Invasive Bladder Cancer.
Eur Urol. 2026 Jun 17:S0302-2838(26)02171-8. doi: 10.1016/j.eururo.2026.
Abstract

MERTENS LS, Mellema JJ, Sridhar S, van der Heijden MS, et al
Re: Neoadjuvant Sacituzumab Govitecan plus Pembrolizumab, Followed by Adjuvant Pembrolizumab, in Patients with Muscle-invasive Bladder Cancer (SURE-02): A Single-arm, Phase 2 Study.
Eur Urol. 2026 Jun 17:S0302-2838(26)02186-X. doi: 10.1016/j.eururo.2026.
Abstract

CONTIERI R, van der Heijden AG, Mertens LS
Re: Twelve-month Results from the CISTO Study Comparing Radical Cystectomy Versus Bladder-sparing Therapy for Recurrent High-grade Non-muscle-invasive Bladder Cancer: Recurrent High-risk NMIBC: One Bladder, Choose Wisely.
Eur Urol. 2026 Jul 2:S0302-2838(26)02181-0. doi: 10.1016/j.eururo.2026.
Abstract

MIAO J, Yi X
Re: Murthy V, Maitre P, Pal M, et al. Bladder Adjuvant Radiotherapy: Phase III Multicenter Randomized Controlled Trial of Adjuvant Radiotherapy or Observation for Postcystectomy Muscle-invasive Bladder Cancer. J Clin Oncol. In press. http://dx.doi.org
Eur Urol. 2026 Jul 9:S0302-2838(26)02241-4. doi: 10.1016/j.eururo.2026.
Abstract

GONTERO P, Mariappan P, Pradere B, Rai BP, et al
EAU Guidelines on Nonmuscle-invasive Bladder Cancer (TaT1 and CIS) - A Summary of the 2026 Guidelines Update.
Eur Urol. 2026 Jul 15:S0302-2838(26)02111-1. doi: 10.1016/j.eururo.2026.
Abstract

DI BELLO F, Gallioli A, Breda A, Palou J, et al
Re: Kitamura H, Tsukamoto T, Kakehi Y, et al. Active Surveillance Versus Intravesical Bacillus Calmette-Guerin for High-grade T1 Bladder Cancer with Negative Second Transurethral Resection: The Randomized Noninferiority Phase 3 JCOG1019 Trial. Eur Uro
Eur Urol. 2026 Jul 23:S0302-2838(26)02275-X. doi: 10.1016/j.eururo.2026.
Abstract

LAZZERI M, Hurle R, Lughezzani G, Buffi NM, et al
Re: Comprehensive Genome-wide Association Study Into Multiple Recurrence and Progression Risk in Non-muscle-invasive Bladder Cancer.
Eur Urol. 2026 Jul 22:S0302-2838(26)02266-9. doi: 10.1016/j.eururo.2026.
Abstract

GALSKY MD, Necchi A
Cystectomy Can Be Spared in Selected Patients with Muscle-invasive Bladder Cancer and Complete Response Following Neoadjuvant Therapy.
Eur Urol. 2026 Jul 27:S0302-2838(26)02271-2. doi: 10.1016/j.eururo.2026.
Abstract

NIEDERSUESS-BEKE D, Mayrhofer K, Krauter J, Franke J, et al
Enfortumab vedotin plus pembrolizumab in treatment-naive metastatic urothelial carcinoma patients: An Austrian real-world analysis.
Int J Cancer. 2026;158:1654-1665.
Abstract

MANGOLD MH, Baumann G, Wieland VLS, Carl N, et al
Indirect Comparison of Neoadjuvant Treatment Strategies for Muscle-Invasive Bladder Cancer: ddMVAC and Perioperative Durvalumab-Gemcitabine-Cisplatin Versus Gemcitabine-Cisplatin: A Systematic Review and Network Meta-Analysis of Randomised Controlled
Int J Cancer. 2026 Apr 28. doi: 10.1002/ijc.70525.
Abstract

DU J, Shen H, Zeng T, Liu W, et al
Targeted therapies for urothelial carcinoma: From FGFR inhibitors to next?generation antibody-drug conjugates (Review).
Int J Oncol. 2026;68:28.
Abstract

TAOKA R, Fukuhara H, Miyake M, Kobayashi K, et al
Predictive Factors for Gastrointestinal and Hepatic Adverse Events During 5-Aminolevulinic Acid-Guided Photodynamic Diagnosis in Bladder Cancer: Exploratory Analysis of the Phase III SPP2C102 Trial.
Int J Urol. 2025 Dec 25. doi: 10.1111/iju.70328.
Abstract

FIORENTINO V
Editorial Comment to "Prediction of Postoperative Intravesical Recurrence Using Urine DNA Monitoring in Non-Muscular-Invasive Urothelial Bladder Cancer".
Int J Urol. 2025 Dec 25. doi: 10.1111/iju.70332.
Abstract

CHEN W, Yoshida S, Ikeda R, Yoshimura R, et al
Oligometastatic Prostate and Bladder Cancer: An Integrative Narrative Review.
Int J Urol. 2025 Dec 24. doi: 10.1111/iju.70324.
Abstract

IWASAWA T, Tsujino T, Tsukahara S, Fukushima H, et al
Translational Advances in Urothelial Carcinoma: From Bench to Bedside.
Int J Urol. 2026;33:e70341.
Abstract

HIRATA H
Editorial Comment on Oligometastatic Prostate and Bladder Cancer: An Integrative Narrative Review.
Int J Urol. 2026;33:e70343.
Abstract

FUJITA N
Editorial Comments to "Real-World Comparison of Survival Outcomes Between Radical Cystectomy and Intravesical Bacillus Calmette-Guerin (BCG) Therapy in BCG-Naive or -Unresponsive Non-Muscle-Invasive Bladder Cancer".
Int J Urol. 2026;33:e70358.
Abstract

SOMA T, Tanaka H, Nakamura Y, Numao N, et al
Clinical Features and Risk Factors of Enfortumab Vedotin-Induced Peripheral Neuropathy in Patients With Metastatic Urothelial Carcinoma: A Multicenter Retrospective Study (YUSHIMA Study).
Int J Urol. 2026;33:e70329.
Abstract

ZAHIR M, Moghadam FS, Ladi-Seyedian SS, Ghoreifi A, et al
Can Urinary Diversion Type Affect Postoperative Complications Following Radical Cystectomy in Female Patients?
Int J Urol. 2026;33:e70330.
Abstract

SHIMIZU S, Osawa T, Sato M, Yamada S, et al
Validation of the 7-Item Quality of Life Disease-Specific Impact Scale in Patients Undergoing Radical Cystectomy for Bladder Cancer: A Cross-Sectional Study.
Int J Urol. 2026;33:e70364.
Abstract

FUKUTA K, Sasaki Y, Daizumoto K, Izumi K, et al
Prognostic Significance of Achieving the Radical Cystectomy-Pentafecta After Neoadjuvant Chemotherapy and Robot-Assisted Radical Cystectomy.
Int J Urol. 2026;33:e70283.
Abstract

ABE Y, Taoka R, Kaji A, Harada S, et al
Efficacy of Photodynamic Diagnosis Is Confined to the Low-Risk Subgroup of Intermediate-Risk Non-Muscle-Invasive Bladder Cancer: A Propensity Score Matched Analysis.
Int J Urol. 2026;33:e70365.
Abstract

YAJIMA S, Yoshida S, Chen W, Fukushima H, et al
Comparison of Perioperative Chemotherapy Regimens for Muscle-Invasive Bladder Cancer: A Reconstructed Individual Patient Data Analysis of Phase 3 Trials.
Int J Urol. 2026;33:e70380.
Abstract

KUSANO S, Tobu S, Yukimoto M, Yamaguchi Y, et al
Palliative Intra-Arterial Chemotherapy Without Radiotherapy for Elderly Patients With Muscle-Invasive Bladder Cancer: A Single-Center Retrospective Comparison With Radical Cystectomy and Best Supportive Care.
Int J Urol. 2026;33:e70386.
Abstract

SANO T, Ohe C, Motoki Y, Nakamoto T, et al
Prognostic Significance of Tertiary Lymphoid Structure-Like Lymphocyte Aggregates in Routine Histopathological Examination in Bladder Cancer.
Int J Urol. 2026;33:e70392.
Abstract

GOTO Y
Editorial Comment on Comparison of Perioperative Chemotherapy Regimens for Muscle-Invasive Bladder Cancer: A Reconstructed Individual Patient Data Analysis of Phase 3 Trials.
Int J Urol. 2026;33:e70405.
Abstract

SHINOHARA M, Yamamoto H, Kawashima Y, Sekine Y, et al
Association of Prophylactic Intravenous Corticosteroid Premedication With Toxicity and Survival in Patients Receiving Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Carcinoma.
Int J Urol. 2026;33:e70425.
Abstract

FUJITA N
Editorial Comments to "Palliative Intra-Arterial Chemotherapy Without Radiotherapy for Elderly Patients With Muscle-Invasive Bladder Cancer: A Single-Center Retrospective Comparison With Radical Cystectomy and Best Supportive Care".
Int J Urol. 2026;33:e70452.
Abstract

USUI A, Hara T, Oka S, Sakaguchi K, et al
Skin Phototoxicity With Aminolevulinic Acid Hydrochloride in Patients With Non-Muscle Invasive Bladder Cancer: Real-World Incidence and Concomitant Medication Effects.
Int J Urol. 2026;33:e70448.
Abstract

HATAKEYAMA S, Yamamoto K, Yamamoto H, Yasui T, et al
Real-World Outcomes After Radical Cystectomy for Muscle-Invasive Bladder Cancer in Japan: A Nationwide Descriptive Study From the National Clinical Database.
Int J Urol. 2026;33:e70450.
Abstract

MUTA R, Fukushima H, Tanaka H, Numao N, et al
Prognostic Significance of Hypoalbuminemia in Maintenance Avelumab Therapy After First-Line Chemotherapy for Metastatic Urothelial Carcinoma: A Multicenter Real-World Study (YUSHIMA Study).
Int J Urol. 2026;33:e70459.
Abstract

MIYAKE M
Editorial Comment to Real-World Outcomes After Radical Cystectomy for Muscle-Invasive Bladder Cancer in Japan: A Nationwide Descriptive Study From the National Clinical Database.
Int J Urol. 2026;33:e70481.
Abstract

LEMES DE, Santos AAS, de Oliveira JL, Roman-Ramos H, et al
Stage-Dependent Changes in Kynurenine Pathway Enzyme Expression Suggest Immune-Related Involvement in Bladder Cancer Progression.
Int J Urol. 2026;33:e70491.
Abstract

KAWAHARA T, Nagumo Y, Tanuma K, Hamada K, et al
Impact of European Association of Urology Combination and Platinum Eligibility on Real-World Treatment Sequences and Survival in Japanese Patients With Metastatic Urothelial Carcinoma.
Int J Urol. 2026;33:e70403.
Abstract

LONGONI M, Marmiroli A, Falkenbach F, Le QC, et al
Extent of Pelvic Lymph Node Dissection at Partial Cystectomy: Effect on Cancer-Specific Mortality.
Int J Urol. 2026;33:e70483.
Abstract

MATSUYAMA H
Reviewer's Comment on Skin Phototoxicity With Aminolevulinic Acid Hydrochloride in Patients With Non-Muscle Invasive Bladder Cancer.
Int J Urol. 2026;33:e70499.
Abstract

NISHIMURA N, Miyake M, Iwao T, Oda Y, et al
Sarcopenia Weakens the Benefit of Bacillus Calmette-Guerin in Non-Muscle-Invasive Bladder Cancer: A Computed Tomography-Based Cohort Study.
Int J Urol. 2026;33:e70526.
Abstract

KOBAYASHI G, Sekino Y, Miyamoto S, Kobatake K, et al
Comprehensive Genomic Characterization Between Urothelial Carcinoma Subtypes/Divergent Differentiation (S/DD) and Pure Urothelial Carcinoma Using a Large-Scale Japanese Genomic Panel Dataset.
Int J Urol. 2026;33:e70538.
Abstract

ENDO Y, Sakura Y, Kaneko G, Hayakawa N, et al
Impact of Early Relative Dose Intensity on Survival in Patients Receiving Enfortumab Vedotin for Metastatic Urothelial Carcinoma: A Japanese Real-World Multicenter Study.
Int J Urol. 2026;33:e70523.
Abstract

IGARASHI A, Kinoshita T, Fujita M, Obayashi R, et al
Intraoperative Hypotension During Photodynamic Diagnosis-Guided TURBT Under Spinal Anesthesia: A Propensity Score-Matched and Logistic Regression Analysis.
Int J Urol. 2026;33:e70540.
Abstract

KIKUCHI E, Kobayashi T, Shono M, Hoffman J, et al
Real-World Use of Avelumab First-Line Maintenance for Locally Advanced or Metastatic Urothelial Carcinoma in Japan: Treatment Patterns, Effectiveness, and Safety.
Int J Urol. 2026;33:e70558.
Abstract

TAOKA R, Hayakawa N, Kimura T, Kikuchi E, et al
Consensus-Based Development of a Surgical Checklist for Transurethral Resection of Bladder Tumor: An Initiative of the Japanese Society of Urologic Oncology.
Int J Urol. 2026;33:e70570.
Abstract

MATSUSHITA Y, Kita Y, Mukai S, Joraku A, et al
Oncological Outcomes and Prognostic Factors of Platinum-Based Chemotherapy Followed by Avelumab Maintenance Therapy Compared With Platinum-Based Chemotherapy Alone: A Propensity Score-Matched Analysis in a Real-World Population.
Int J Urol. 2026;33:e70584.
Abstract

KIKUCHI E, Tokumaru J, Kawai D, Ide R, et al
Perioperative Systemic Treatment Patterns and Postoperative Mortality Among Patients With Muscle-Invasive Bladder Cancer Undergoing Radical Cystectomy in Japan: WAKKA-MIBC Study.
Int J Urol. 2026;33:e70565.
Abstract

WATANABE R
Editorial Comment to "Perioperative Systemic Treatment Patterns and Postoperative Mortality Among Patients With Muscle-Invasive Bladder Cancer Undergoing Radical Cystectomy in Japan: WAKKA-MIBC Study".
Int J Urol. 2026;33:e70604.
Abstract

WAKITA N, Hara T, Tobe T, Ueki H, et al
Efficacy and Safety of Enfortumab Vedotin by Trial Eligibility in Advanced Urothelial Carcinoma: A Multicenter Real-World Study.
Int J Urol. 2026;33:e70614.
Abstract

ALMULLA AF, Zhang Y, Maes M
Editorial Comment on "Stage-Dependent Changes in Kynurenine Pathway Enzyme Expression Suggest Immune-Related Involvement in Bladder Cancer Progression": Rethinking the Tryptophan-Kynurenine Pathway in Urological Cancer Immunotherapy.
Int J Urol. 2026;33:e70606.
Abstract

CHAI Y, Zhou Y, Peng H, Jiang Y, et al
Comparative efficacy of hyperthermic chemotherapy and BCG instillation in non-muscle invasive bladder cancer: a systematic review and meta-analysis.
Int Urol Nephrol. 2026 Jan 11. doi: 10.1007/s11255-026-05008.
Abstract

OZDEN SB, Bulbul E, Ilki Y, Vural A, et al
Effect of frailty status and histopathological features on upstaging of non-muscle-invasive bladder cancer: a critical analysis based on machine learning.
Int Urol Nephrol. 2026 Jan 26. doi: 10.1007/s11255-026-05021.
Abstract

AYKAC A, Kaya C, Sungur M, Aydin ME, et al
Holmium laser en?bloc vs bipolar and conventional monopolar TURBT for non?muscle?invasive bladder cancer.
Int Urol Nephrol. 2026 Jan 24. doi: 10.1007/s11255-026-05023.
Abstract

PELLEGRINO P, Scherer TP, Wettstein MS, Baumgartner M, et al
Development of a nomogram for prediction of postoperative bleeding after transurethral resection of bladder tumors.
Int Urol Nephrol. 2026;58:921-929.
Abstract

NISHIMURA F, Oniki K, Yamashita A, Honda K, et al
Prognostic role of intramuscular adipose tissue content in patients with urothelial carcinoma treated with pembrolizumab.
Int Urol Nephrol. 2026;58:861-871.
Abstract

ZHENG Q, Liao E, Chen D, Shan G, et al
Bladder cancer organoids: bridging pathological features and drug response for precision oncology.
Int Urol Nephrol. 2026 Mar 8. doi: 10.1007/s11255-026-05081.
Abstract

THAKKER PU, Refugia JM, Casals R, Able C, et al
Stent-free rates in cutaneous ureterostomy urinary diversion after radical cystectomy.
Int Urol Nephrol. 2023;55:2809-2814.
Abstract

SRIVASTAVA A, Trivedi S, Singh Y, Kumar U, et al
Prospective comparative evaluation of clinical efficacy and safety of Intravesical gemcitabine-docetaxel versus BCG in adjuvant management of BCG-naive non-muscle invasive urothelial bladder cancer in Indian population.
Int Urol Nephrol. 2026 Mar 17. doi: 10.1007/s11255-026-05067.
Abstract

TANG C, Wang T, Luo H, Xue J, et al
Liquid biopsy based on multi-targeted capture of urinary tumor DNA combined with machine learning to detect urothelial carcinoma: a multicenter prospective study.
Int Urol Nephrol. 2026;58:1291-1306.
Abstract

GUO C, Wei J, Wang Y, Zhang L, et al
Stage-specific associations of HER2 overexpression with clinical and pathological features in bladder cancer: a systematic review and meta-analysis.
Int Urol Nephrol. 2026 Mar 25. doi: 10.1007/s11255-026-05110.
Abstract

RUSSO P, Foschi N, Lentini N, Bizzarri FP, et al
Perioperative outcomes following open radical cystectomy in the setting of locally advanced bladder cancer.
Int Urol Nephrol. 2026 Apr 9. doi: 10.1007/s11255-026-05127.
Abstract

SAKTHIVEL DK, Prabhakar P, Raja Iyub MJ, Garje R, et al
Signet ring cell carcinoma of the urachus: survival and pathologic outcomes from the national cancer database.
Int Urol Nephrol. 2026;58:1745-1751.
Abstract

MCMASTER T, Hoskin G, Homewood D, Attwell-Heap A, et al
A comparative analysis of variant histology and urothelial bladder cancer following radical cystectomy.
Int Urol Nephrol. 2026 Jun 10. doi: 10.1007/s11255-026-05234.
Abstract

CONTIERI R, Jannello LMI, Vartolomei MD, Roth B, et al
Defining the optimal duration of maintenance mitomycin C in intermediate-risk Ta NMIBC: a multicenter retrospective landmark analysis.
Int Urol Nephrol. 2026;58:2463-2471.
Abstract

DENG S, Jiang R, Wu S, Xiao Y, et al
Bladder tumors in patients initially diagnosed with interstitial cystitis: a ten-year retrospective study.
Int Urol Nephrol. 2026;58:2503-2511.
Abstract

SANDBERG M, Thole D, Bissette R, Wolff D, et al
Comparing benign to malignant cystectomy: complications, emergency department utilization, readmissions, and socioeconomic status.
Int Urol Nephrol. 2026;58:2429-2436.
Abstract

WANG Y, Zhao T, Liang B, Zhen L, et al
Multiparametric MRI-derived radiomic signatures enable noninvasive prediction of HER2 expression in bladder cancer.
Int Urol Nephrol. 2026 Jul 3. doi: 10.1007/s11255-026-05256.
Abstract

GAO M, Liu F, Wen J, Shen Y, et al
Beyond VI-RADS: incremental value of quantitative mpMRI measurements for identifying muscle-invasive bladder cancer.
Int Urol Nephrol. 2026 Jul 10. doi: 10.1007/s11255-026-05267.
Abstract

ZHANG B, Wang C, Yang S, Li X, et al
A comparison of efficacy and prognosis between RC48 combined immunotherapy and gemcitabine-cisplatin combined immunotherapy in bladder-preserving multimodal therapy for muscle-invasive bladder cancer.
Int Urol Nephrol. 2026 Jul 25. doi: 10.1007/s11255-026-05275.
Abstract

KAMAT AM, Hensley PJ, Maiorano BA, Li R, et al
Bacillus Calmette-Guerin (BCG) and Beyond: Is Systemic Immunotherapy for BCG-Naive Non-Muscle-Invasive Bladder Cancer Progress or Overreach?
J Clin Oncol. 2026 Mar 2:JCO2502670. doi: 10.1200/JCO-25-02670.
Abstract

Body Size and Bladder Cancer Risk: A Pooled Analysis of Prospective Studies From the National Cancer Institute Cohort Consortium.
J Clin Oncol. 2026 Apr 17:JCO2502155. doi: 10.1200/JCO-25-02155.
Abstract

MURTHY V, Maitre P, Pal M, Arora A, et al
Bladder Adjuvant Radiotherapy: Phase III Multicenter Randomized Controlled Trial of Adjuvant Radiotherapy or Observation for Postcystectomy Muscle-Invasive Bladder Cancer.
J Clin Oncol. 2026 May 21:JCO2502093. doi: 10.1200/JCO-25-02093.
Abstract

CATHOMAS R, Petrausch U, Hayoz S, Spahn M, et al
Addition of Intravesical Recombinant BCG to Perioperative Chemo-Immunotherapy in Muscle-Invasive Bladder Cancer: Primary Analysis of the Single-Arm Phase 2 Trial SAKK 06/19.
J Clin Oncol. 2026 May 29:101200JCO2600845. doi: 10.1200/JCO-26-00845.
Abstract

NECCHI A, de Jong JJ, Maiorano BA, Proudfoot JA, et al
Neoadjuvant Sacituzumab Govitecan in Patients With Muscle-Invasive Bladder Cancer: Primary Results of the SURE-01 Trial.
J Clin Oncol. 2026 May 31:JCO2600142. doi: 10.1200/JCO-26-00142.
Abstract

THIBAULT C, Bennamoun M, Flechon A, Gravis G, et al
Neoadjuvant Durvalumab +/- Tremelimumab in Combination With Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Muscle-Invasive Bladder Carcinoma: Results of the Phase I/II NEMIO Study.
J Clin Oncol. 2026;44:1921-1932.
Abstract

REZAEE ME, Higgins MI, Su ZT, Sepehri S, et al
Results from the ERAS for Ambulatory TURBT: Enhancing Bladder Cancer Care (EMBRACE) Randomized Controlled Trial.
J Urol. 2026 Feb 9:101097JU0000000000004983. doi: 10.1097/JU.0000000000004983.
Abstract

ANDERSON CB, Sfakianos JP
Circulating Tumor DNA in Bladder Cancer: A New Treatment Paradigm?
J Urol. 2026;215:256-257.
Abstract

LAZAROVICH A, Nusbaum DJ, Agarwal PK, Modi PK, et al
Clinical Trial Design for Bacillus Calmette-Guerin-Unresponsive Non-Muscle Invasive Bladder Cancer-Single-Arm Design Was Necessary, Randomized Trials Are Now Essential.
J Urol. 2026 Feb 11:101097JU0000000000004960. doi: 10.1097/JU.0000000000004960.
Abstract

ZHAO D, Khatri VM, Nakashima JY, Chadha J, et al
Early Detection of Metastatic Progression by Circulating Tumor DNA in Patients Undergoing Bladder-Preserving Trimodality Therapy.
J Urol. 2026;215:305-315.
Abstract

ELIAS R, Aragaki AK, Hoffman-Censits JH, Hahn NM, et al
Intratumoral Expression of a Composite B Cell / CD8 T Cell Biomarker Stratifies Overall Survival by Circulating Tumor DNA Status and Benefit From Adjuvant Immunotherapy in High-Risk Muscle-Invasive Urothelial Carcinoma.
J Urol. 2026;215:294-304.
Abstract

RITCH C, Anderson CB
Cystoscopic Fulguration for Patients with Recurrent Low-Grade Bladder Cancer.
J Urol. 2026 Feb 18:101097JU0000000000004974. doi: 10.1097/JU.0000000000004974.
Abstract

ZHANG S, Li T, Li D, Yin Y, et al
Efficacy, Safety, and Biomarker Analysis of Toripalimab Monoclonal Antibody Combined with Gemcitabine and Cisplatin Chemotherapy as Neoadjuvant Treatment in Muscle-Invasive Bladder Cancer: A Phase II Clinical Trial.
J Urol. 2026 Feb 17:101097JU0000000000004993. doi: 10.1097/JU.0000000000004993.
Abstract

UDEDIBIA E, Solosky K, Macdonald EJ, Gaines J, et al
Critical Analysis of the AUA 2020/2025 Microscopic Hematuria Guidelines to Predict Urothelial but Not Renal Cortical Neoplasms and Validation of the Individual Clinical Components in Risk Stratification for Urothelial Neoplasms but Not Renal Cortical
J Urol. 2026;215:441-449.
Abstract

BEN-DAVID R, Raizenne BL, Eraky A, Duquesne I, et al
Preoperative ctDNA Predicts Upstaging and Recurrence in High-Risk Non-Muscle Invasive Bladder Cancer Undergoing Radical Cystectomy.
J Urol. 2026 Mar 17:101097JU0000000000005034. doi: 10.1097/JU.0000000000005034.
Abstract

PRASAD SM, Shishkov D, Mihaylov NV, Genov P, et al
UGN-102 for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer: 24-Month Duration of Response Results From the Phase 3 ENVISION Trial.
J Urol. 2026 Mar 25:101097JU0000000000005041. doi: 10.1097/JU.0000000000005041.
Abstract

PEDERSEN GL, Mogensen K, Rosthoj S, Erikson MS, et al
In-Office Laser Coagulation of Ta Bladder Tumor Compared With Transurethral Resection of Bladder Tumor: 12 Months Follow-Up Randomized Clinical Trial.
J Urol. 2026;215:535-543.
Abstract

GHOREIFI A, Lotan Y
Letter: Preoperative ctDNA Predicts Upstaging and Recurrence in High-Risk Non-Muscle-Invasive Bladder Cancer Undergoing Radical Cystectomy.
J Urol. 2026 May 1:101097JU0000000000005078. doi: 10.1097/JU.0000000000005078.
Abstract

LI EV, Sharma V, Boorjian SA
Are ctDNA and utDNA the new PSA for Clinically Localized Muscle Invasive Bladder Cancer in the Enfortumab Vedotin/Pembrolizumab Era?
J Urol. 2026 Apr 29:101097JU0000000000005074. doi: 10.1097/JU.0000000000005074.
Abstract

BAHLBURG H, Maas M, Contreras-Sanz A, Othman D, et al
Urine tumor DNA testing identifies recurrence and monitors therapy response in patients with high-risk non-muscle-invasive bladder cancer receiving intravesical bacillus Calmette-Guerin.
J Urol. 2026 May 20:101097JU0000000000005130. doi: 10.1097/JU.0000000000005130.
Abstract

JOYCE DD, Sharma V, Ratcliff GE, Barocas DA, et al
Cost-Effectiveness of Immune Checkpoint Inhibitor Therapy plus BCG for High-Risk Non-muscle Invasive Bladder Cancer: Analyses of CREST, POTOMAC, and ALBAN.
J Urol. 2026 May 18:101097JU0000000000005126. doi: 10.1097/JU.0000000000005126.
Abstract

PRASAD S
Reply: UGN-102 for Recurrent Low-Grade Intermediate-Risk Non-Muscle-Invasive Bladder Cancer: A 24-Month Duration of Response Results from the Phase 3 ENVISION Trial.
J Urol. 2026 Jun 2:101097JU0000000000005128. doi: 10.1097/JU.0000000000005128.
Abstract

JOYCE DD, Sharma V, Boorjian SA
With great cost comes great responsibility: who will own the rising costs of bladder cancer care?
J Urol. 2026 Jun 26:101097JU0000000000005185. doi: 10.1097/JU.0000000000005185.
Abstract

ST-LAURENT MP, Din S, Moryousef J, Lajkosz K, et al
Oncological Outcomes of Non-Muscle Invasive Bladder Cancer in Patients Aged
J Urol. 2026 Jun 24:101097JU0000000000005183. doi: 10.1097/JU.0000000000005183.
Abstract

GABRIEL PE, Zhu A, Xylinas E, Sfakianos JP, et al
Beyond the NMIBC-MIBC Dichotomy: Integrating Molecular Biomarkers into Bladder Cancer Risk Stratification.
J Urol. 2026 Aug 11:101097JU0000000000005255. doi: 10.1097/JU.0000000000005255.
Abstract

WANG J, Wang J, Meng L, Wang X, et al
Interstitial cystitis-related gene CCDC8 accelerates tumorigenesis by participating in CUL7-mediated degradation of P53 in bladder cancer.
Oncogene. 2026 Feb 5. doi: 10.1038/s41388-026-03688.
Abstract

HU H, Zhan X, Xiong Y, Yuan R, et al
Non-classic deubiquitinase USP13 inhibits bladder cancer metastasis through destabilizing cytoplasmic KDM3A.
Oncogene. 2026 Mar 24. doi: 10.1038/s41388-026-03730.
Abstract

XIAO M, Ma Y, Zhang G, Chen G, et al
SRSF10 promotes cisplatin resistance in bladder cancer via BIN1 Exon 12 retention and ANXA1 activation.
Oncogene. 2026 Apr 6. doi: 10.1038/s41388-026-03735.
Abstract

CHENG Y, Chen Y, Wang J, Shu Z, et al
DTX3 promotes anti-tumor immunity by inducing PD-L1 ubiquitination and is suppressed by p65/miR-222 in bladder cancer.
Oncogene. 2026 Jul 24. doi: 10.1038/s41388-026-03915.
Abstract

SUN L, Yao Y, Gong S, Chen Z, et al
YME1L1 degradation by TRIM21 inhibits bladder cancer proliferation, metastasis, and mitochondrial function.
Oncogene. 2026 Jul 20. doi: 10.1038/s41388-026-03903.
Abstract

GAO Y, Chen C, Sun R, Yao Y, et al
LncRMRP drives bladder cancer invasion via a lactylation-driven positive feedback circuit.
Oncogene. 2026 Jul 30. doi: 10.1038/s41388-026-03927.
Abstract

ZHAN Y, Zhu C, Li Y, Wen C, et al
Transcription factor EN1 governs a lipogenic USP18-ACLY axis to drive bladder cancer malignancy.
Oncogene. 2026 Jul 28. doi: 10.1038/s41388-026-03910.
Abstract

XIONG R, Wang M, Du J, Chai B, et al
USP15-mediated deubiquitination of FIS1 impairs mitochondrial function and sensitizes bladder cancer cells to radiotherapy.
Oncogene. 2026 Jul 27. doi: 10.1038/s41388-026-03918.
Abstract

PAN XW, Li L, Huang Y, Huang H, et al
[Corrigendum] Icaritin acts synergistically with epirubicin to suppress bladder cancer growth through inhibition of autophagy.
Oncol Rep. 2026;55:51.
Abstract

WANG X, Chen E, Yang X, Wang Y, et al
[Expression of Concern] 5?Azacytidine inhibits the proliferation of bladder cancer cells via reversal of the aberrant hypermethylation of the hepaCAM gene.
Oncol Rep. 2026;55:103.
Abstract

YU G, Jia Z, Dou Z
[Retracted] miR?24?3p regulates bladder cancer cell proliferation, migration, invasion and autophagy by targeting DEDD.
Oncol Rep. 2026;55:108.
Abstract

ZHU D, Wan X, Huang H, Chen X, et al
[Corrigendum] Knockdown of Bmi1 inhibits the stemness properties and tumorigenicity of human bladder cancer stem cell?like side population cells.
Oncol Rep. 2026;56:171.
Abstract

WANG Q, Lin Q, Li L, Wei W, et al
The Predictive Value of Urinary Twist1 Methylation and VI-RADS Score for Residual Tumor before Repeat Transurethral Resection of Bladder Tumor in NMIBC Patients.
Urol Int. 2026;110:114-124.
Abstract

SCHEPER V, Berninger L, Schwinger M, Woidich R, et al
Routine Retrograde Conduitography after Radical Cystectomy for Bladder Cancer: Diagnostic Yield and Clinical Impact.
Urol Int. 2026 Apr 28:1-10. doi: 10.1159/000552253.
Abstract

TJIAMAN MP, Zaidan MZ, Ausath ZF, Putri AT, et al
Quality of Life and Postoperative Complications of Single- or Bilateral-stoma Cutaneous Ureterostomy Compared to Ileal Conduit After Radical Cystectomy: A Systematic Review and Meta-analysis.
Urology. 2026;207:287-292.
Abstract

HEARD JR, Pagano I, Rosser C, Tan WS, et al
Hematuria Cancer Risk Score in Combination With Oncuria-Detect for Patients Undergoing Evaluation for Hematuria.
Urology. 2026;207:178-183.
Abstract

SIGUENCIA F, Heard J, Smith SM, Pagano I, et al
Diagnostic performance of urinary biomarker tests in detecting bladder cancer: A systematic review, meta-analysis, and network meta-analysis.
Urology. 2026 Feb 4:S0090-4295(26)00074-9. doi: 10.1016/j.urology.2026.
Abstract

SMITH AB, Gore JL, Chisolm S, Squires P, et al
Treatment Selection for Non-Muscle-Invasive Bladder Cancer in an Emerging Treatment Era: A Patient Preference Study.
Urology. 2026 Feb 11:S0090-4295(26)00092-0. doi: 10.1016/j.urology.2026.
Abstract

HJORT PB, Hyldgaard JM, Young-Halvorsen K, Husch T, et al
Association between Photodynamic diagnosis and risk of recurrence and progression in BCG-treated non-muscle invasive bladder cancer patients: a nationwide follow-up study.
Urology. 2026 Feb 10:S0090-4295(26)00091-9. doi: 10.1016/j.urology.2026.
Abstract

APONTE-COLON DA, Wilcox Vanden Berg R, Tua-Caraccia R, Kim JK, et al
Clinical Characteristics, Recurrence, and Survival for Children and Young Adults With Urothelial Cancer: A Systematic Review.
Urology. 2026;208:135-141.
Abstract

SMELSER WW
Editorial Commentary: "Treatment Selection for Non-Muscle-Invasive Bladder Cancer in an Emerging Treatment Era: A Patient Preference Study.
Urology. 2026 Mar 17:S0090-4295(26)00177-9. doi: 10.1016/j.urology.2026.
Abstract

HINOJOSA-GONZALEZ DE, Salgado-Garza G, Low EL, Saffati-Grunhaus G, et al
Differences in Postoperative Healthcare Utilization After Robotic and Open Radical Cystectomy: A NSQIP Analysis.
Urology. 2026;210:71-75.
Abstract

SRIDALLA K, Nicolas JD, Zhao L, French DD, et al
Contemporary Microhematuria Evaluation in Veterans: Cancer Detection and Resource Utilization.
Urology. 2026;211:29-34.
Abstract

EFENDIOGLU F, Ozcan C, Turkmen V, Ugurlu O, et al
Effect of Catheter Type and Size on Patient Comfort and Complications in Intravesical Bacillus Calmette-Guerin and Chemotherapy Administration: A Randomized Prospective Pilot Study.
Urology. 2026;212:51-56.
Abstract

NATHAN KK, Duke Herrell S, Westerman MB, Bjurlin MA, et al
From Lichtleiter to Laser: A 200-Year Odyssey of Transurethral Resection of Bladder Tumors.
Urology. 2026;212:116-121.
Abstract

MALSHY K, Lim K, Jia Y, Guo W, et al
Utilization and Costs Among Bladder Cancer, Other Cancer, and Non-Cancer Populations in the United States.
Urology. 2026 Jun 14:S0090-4295(26)00373-0. doi: 10.1016/j.urology.2026.
Abstract

ALMOHTASIB J, Scire E, Kaul S, Fleishman A, et al
Extended versus Standard Lymph Node Dissection at the Time of Radical Cystectomy for Bladder Cancer.
Urology. 2026 Jun 26:S0090-4295(26)00420-6. doi: 10.1016/j.urology.2026.
Abstract

MARTIN A, Shi C, Martinez GM, Britton C, et al
Long-term Outcomes of Partial Cystectomy for Urothelial Carcinoma in the Era of Bladder Preservation.
Urology. 2026;213:131-140.
Abstract

KENNEDY-YOON D, Almohtasib J, Kaul S, Fleishman A, et al
Association of Patient, Disease, and Socioeconomic Characteristics With Receipt of Intravesical Bacillus Calmette-Guerin Therapy From 2002-2017 and the Impact of BCG Supply Shortages.
Urology. 2026;213:88-95.
Abstract

SMITH AK
Editorial Comment on "Extended versus Standard Lymph Node Dissection at the Time of Radical Cystectomy for Bladder Cancer".
Urology. 2026 Jul 22:S0090-4295(26)00458-9. doi: 10.1016/j.urology.2026.
Abstract

YANG IN, Liang CA, Wu CC, Xu QS, et al
Comprehensive surveillance of MicroRNA to discriminate between muscle-invasive and non-muscle-invasive urothelial carcinoma based on noninvasive urinary small RNA sequencing in Taiwanese patients.
BMC Cancer. 2025;25:1900.
Abstract

RAO XP, Zou XC, Yu ZJ, Yuan YY, et al
Interpretable machine learning using CT radiomics predicts pathological upgrading after secondary resection in non-muscle-invasive bladder cancer.
BMC Cancer. 2026 Jan 19. doi: 10.1186/s12885-026-15554.
Abstract

ISKENDER B, Sarihan M, Barlak BSR, Akpinar G, et al
Conjoining cell reprogramming and mass spectrometry to identify the proteomic variations in the reprogrammed bladder cancer cells: finding cues of normalisation.
BMC Cancer. 2026 Feb 6. doi: 10.1186/s12885-026-15634.
Abstract

OSAKA K, Kishida T, Umemoto S, Karashima T, et al
Evaluation of variations in urine laminin-gamma2 monomer in non-muscle-invasive bladder cancer before and after transurethral resection of the bladder tumor.
BMC Cancer. 2026 Feb 2. doi: 10.1186/s12885-026-15658.
Abstract

ZEBER-LUBECKA N, Bilski K, Dabrowska M, Goryca K, et al
Sex-related differences in gene expression in early-stage bladder cancer revealed by whole-transcriptome sequencing.
BMC Cancer. 2026 Feb 9. doi: 10.1186/s12885-026-15666.
Abstract

ZHANG L, Cao J, Gao Z, Han C, et al
Correlations between metformin and prognosis and adverse reactions in patients undergoing radical cystectomy followed by adjuvant GC chemotherapy for bladder cancer.
BMC Cancer. 2026 Feb 28. doi: 10.1186/s12885-026-15806.
Abstract

GAO WB, Yu JJ
Celldetect test performance in monitoring bladder cancer recurrence after transurethral resection.
BMC Cancer. 2026 Feb 28. doi: 10.1186/s12885-026-15797.
Abstract

FEKNER Z, Sieracka J, Dabrowski P, Kazmierski L, et al
Mumio and bladder cancer: unlocking its potential in 3D cell culture.
BMC Cancer. 2026 Mar 14. doi: 10.1186/s12885-026-15838.
Abstract

HUO X, Qi J, Zhu Y, Song H, et al
Integrative analysis of adenosine-related RNA modifications defines molecular subtypes of bladder cancer and identifies CES1 as a driver of tumor progression and immunotherapy resistance.
BMC Cancer. 2026 Mar 25. doi: 10.1186/s12885-026-15897.
Abstract

TANUMA K, Shiga M, Sano K, Hamada K, et al
Systemic administration of liposomal trehalose dimycolate induces NK1.1(+) cell mediated antitumor immunity in bladder cancer.
BMC Cancer. 2026 Apr 1. doi: 10.1186/s12885-026-15951.
Abstract

KIM JH, Maeng S, Choi J, Lee CU, et al
The potential antitumor effects of combining intravesical therapy with recombinant bacillus calmette-guerin and an anti-PD-1 inhibitor in bladder cancer.
BMC Cancer. 2026 Mar 29. doi: 10.1186/s12885-026-15890.
Abstract

CHEN C, Liu X, Xu A, Jiang N, et al
Transcriptomic analysis of genes in bladder cancer patients with resistance to neoadjuvant chemoimmunotherapy.
BMC Cancer. 2026 May 26. doi: 10.1186/s12885-026-16165.
Abstract

WU Q, Lu P, Zhang X, Qing X, et al
Persistent follicular cystitis following intravesical gemcitabine: a case series and literature review.
BMC Cancer. 2026;26:680.
Abstract

HU P, Wang C, Zeng X, Jin S, et al
The predictive role of tertiary lymphoid structures in the prognosis and response to immunotherapy of bladder cancer patients: a systematic review and meta-analysis.
BMC Cancer. 2026 Jun 13. doi: 10.1186/s12885-026-16326.
Abstract

RIZZO A, Ciccimarra F, de Casio Zequi S, Bove S, et al
Enfortumab vedotin in ECOG-PS 2 advanced urothelial carcinoma patients: a real-world study from the ARON-2(EV) project.
BMC Cancer. 2026;26:756.
Abstract

YI L, Ma Z, Zhang J, Zhan Y, et al
A stratified urine-based molecular diagnostic and prognostic model for non-muscle-invasive bladder cancer management.
BMC Cancer. 2026 Jun 22. doi: 10.1186/s12885-026-16361.
Abstract

ALTIN E, Dogan C, Arslan AI, Topkac EC, et al
ELF-3 and TSC-1 as potential markers of recurrence in low-risk non-muscle-invasive bladder cancer.
BMC Cancer. 2026 Jun 20. doi: 10.1186/s12885-026-16314.
Abstract

ZHANG J, Cheng X, Huang C, Xu Y, et al
The diagnostic performance of a noninvasive urine-based methylation biomarkers Vimentin/POU4F2 to detect bladder carcinoma.
BMC Cancer. 2025;25:1460.
Abstract

RAHATIJAFARABAD B, Poorkhani A, Esfandiari F, Sedaghat S, et al
Trends in urinary tract cancer incidence in Golestan province, Iran: a 16-year population-based study.
BMC Cancer. 2025;25:1227.
Abstract

HAO X, Ye C, Lai W, Xu J, et al
Urologic malignancy in renal transplant recipients: Analysis of OPTN/UNOS data from 2000 to 2022.
BMC Cancer. 2026;26:805.
Abstract

WANG Y, Ailiyaer A, Chen S, Wang W, et al
Development and internal validation of an explainable machine-learning model to predict 3-year overall survival rate after radical cystectomy.
BMC Cancer. 2026;26:813.
Abstract

MOHANTY P, Subhangini M
Immunohistochemical evaluation of molecular subtypes in muscle invasive bladder cancer with demographic correlation.
BMC Cancer. 2026 Jul 10. doi: 10.1186/s12885-026-16476.
Abstract

KURAL S, Kumar L, Pathak AK, Singh S, et al
Non-invasive diagnostic evaluation of urinary exosomal let-7c cluster expression in bladder cancer using machine learning approaches.
BMC Cancer. 2026 Jul 21. doi: 10.1186/s12885-026-16217.
Abstract

TAMBARO R, Calvanese G, Muto A, Formisano L, et al
Real-world outcomes of second-line pembrolizumab in urothelial carcinoma: a multicenter analysis from the Campania Oncological Network (ROC).
BMC Cancer. 2026;26:956.
Abstract

WANG T, Jiang X
Toripalimab plus disitamab vedotin versus tislelizumab-based combination in advanced urothelial carcinoma: a real-world comparative study.
BMC Cancer. 2026;26:997.
Abstract

GAO X, Yu Y, Sun J, Zhao H, et al
CUL5 E3 ubiquitin ligase regulates the evasion of bladder cancer cells to CD8+ T cell-mediated killing by inhibiting autophagy.
PLoS Biol. 2026;24:e3003647.
Abstract

ZHANG J, Huang L, Wang S, Ding J, et al
Acoustic delivery of indocyanine green via biosynthetic gas vesicles for tumor photothermal therapy.
PLoS Biol. 2026;24:e3003786.
Abstract

FENG C, Chen G, Shu Y, Chen J, et al
Resveratrol inhibits bladder cancer proliferation by targeting the AURKA/STAT3 axis: From computational analysis to experimental validation.
PLoS One. 2026;21:e0342162.
Abstract

SHEN J, Zhao Z, Li Z, Wang R, et al
Bladder cancer-induced CVD mortality: Role of CAPG protein.
PLoS One. 2026;21:e0338101.
Abstract

CHEN J, Li B, Gan Y, Li P, et al
TNFRSF17 as a complementary biomarker to PD-L1 for predicting the response to immunotherapy in urothelial bladder cancer.
PLoS One. 2026;21:e0346131.
Abstract

GUO D, Li X, Xu X, Chen X, et al
The Physicochemical Synergy Effect of Nanosecond Pulsed Electric Fields (nsPEF) and cisplatin on reversing chemoresistance of bladder cancer.
PLoS One. 2026;21:e0346699.
Abstract

YANG Z, Ma J, Qiang Z, Xie W, et al
A new target: AlkBH2 promotes bladder cancer by upregulation of inflammation.
PLoS One. 2026;21:e0348059.
Abstract

WANG H, Liu H, Sun F, Wu J, et al
Integrating multi-omics and machine learning to decipher the molecular pathways of bisphenol a-associated lactylation-related genes driving bladder cancer.
PLoS One. 2026;21:e0347134.
Abstract

Retraction: Does Occupational Exposure to Solvents and Pesticides in Association with Glutathione S-Transferase A1, M1, P1, and T1 Polymorphisms Increase the Risk of Bladder Cancer? The Belgrade Case-Control Study.
PLoS One. 2026;21:e0349169.
Abstract

CHEN X, Wang Z, Rong Y, Zhu Z, et al
Elevated ICAM5 as a promising predictor of poor prognosis in bladder cancer via EMT, immune microenvironment, and therapy resistance.
PLoS One. 2026;21:e0347623.
Abstract

ZHANG Q, He C, Hong Y, Huang T, et al
EP300 promotes bladder cancer cell migration through SNAI2.
PLoS One. 2026;21:e0347209.
Abstract

DARJI S, Qu F, Henager M, Prasad A, et al
Optimizing mRNA delivery with targeted elastin-like polypeptide-based LENN formulations: Insights into the endocytosis mechanism.
Proc Natl Acad Sci U S A. 2026;123:e2502486122.
Abstract

GALSKY MD, Izadmehr S, Yu M, Curtis SD, et al
Monitoring of plasma and urine tumor-derived DNA to inform bladder-sparing approaches for patients with muscle-invasive bladder cancer.
Proc Natl Acad Sci U S A. 2026;123:e2533449123.
Abstract

YE F, Han X, Li W, Huang L, et al
Spatial multiomics profiling reveals ZFP36-mediated immunometabolic reprogramming in bladder cancer.
Proc Natl Acad Sci U S A. 2026;123:e2505125123.
Abstract

Thank you for your interest in scientific medicine.

AMEDEO Bladder Cancer is free of charge.

Privacy / Datenschutzerklärung | Imprint / Impressum

;